GenCore version 5.1.7

OM protein - protein search, using sw model

Run on: February 17, 2006, 16:58:02 ; Search time 23 Seconds
(without alignments)
16.733 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AQGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 4989

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	100.0	12	2	H41946	T-cell receptor ga
2	19	100.0	20	2	S21244	H+-transporting tw
3	16	84.2	23	2	S54339	cytochrome P450 CY
4	15	78.9	11	2	PH1600	Ig H chain V-D-J r
5	15	78.9	12	2	C33099	148K exoantigen -
6	15	78.9	12	2	PH0920	T-cell receptor be
7	15	78.9	12	2	PH1467	T-cell receptor be
8	15	78.9	14	2	S23376	collagen alpha cha
9	15	78.9	14	2	PH0804	T-cell receptor al
10	15	78.9	14	2	A39703	tubulin beta-3 cha
11	15	78.9	15	2	PS0382	Ig heavy chain J r
12	15	78.9	15	2	S05700	insulin-like growt
13	15	78.9	15	2	B56046	urinary tract ston
14	15	78.9	15	2	S05699	insulin-like growt
15	15	78.9	17	2	S28839	RNA-binding protei
16	15	78.9	18	2	A36133	hypothetical prote
17	15	78.9	20	2	PC4385	GroEL protein homo
18	15	78.9	20	2	PC4386	GroEL protein homo
19	15	78.9	20	2	A42865	Ca2+/calmodulin-de
20	15	78.9	20	2	S48746	beta tubulin b-bet
21	15	78.9	20	2	A40198	N-acylneuraminate
22	15	78.9	22	2	JN0911	N4-(beta-N-acetylg
23	15	78.9	22	2	A56868	heat shock protein
24	15	78.9	22	2	A48365	methanol-induced c
25	15	78.9	25	2	A60741	insulin-like growt
26	14	73.7	15	2	I65478	c-Ki-ras - hamster
27	14	73.7	15	2	PH1377	T antigen variant
28	14	73.7	16	2	PH1346	Ig heavy chain DJ
29	14	73.7	18	2	G49037	TcR delta chain V-
30	14	73.7	19	2	PH1624	Ig H chain V-D-J r
31	14	73.7	20	2	S06802	outer membrane pro
32	14	73.7	21	2	S21772	lipoxygenase (EC 1
33	14	73.7	21	2	PQ0257	microbial serine p
34	14	73.7	22	2	S68900	xanthine dehydroge
35	14	73.7	23	2	PX0011	glutamate-ammonia
36	14	73.7	23	2	B61079	listeriolysin O -
37	14	73.7	24	2	S53749	histone H4 - rat
38	13	68.4	4	2	PT0633	T-cell receptor be
39	13	68.4	5	2	PT0572	T-cell receptor be
40	13	68.4	8	2	A35180	neutral proteinase
41	13	68.4	12	2	PH0936	T-cell receptor be
42	13	68.4	12	2	PN0160	ribosomal protein
43	13	68.4	12	2	PQ0786	NADH2 dehydrogenas
44	13	68.4	14	2	S17766	beta-glucosidase (
45	13	68.4	14	2	PS0249	porin - rice (stra

ALIGNMENTS

RESULT 1
H41946
T-cell receptor gamma chain (5t.12) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-May-1999
C;Accession: H41946
R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.
Mol. Cell. Biol. 11, 5902-5909, 1991
A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma ge
A;Reference number: A41946; MUID:92049316; PMID:1658619
A;Accession: H41946
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-12 <WHE>
A;Cross-references: UNIPARC:UPI000017C86B
C;Keywords: T-cell receptor

Query Match 100.0%; Score 19; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 4 AQGV 7

RESULT 2
S21244
H+-transporting two-sector ATPase (EC 3.6.3.14) delta chain - spinach mitochondrion (fra
C;Species: mitochondrion Spinacia oleracea (spinach)
C;Date: 19-Mar-1997 #sequence_revision 01-Aug-1997 #text_change 09-Jul-2004
C;Accession: S21244
R;Hamasur, B.; Glaser, E.
Eur. J. Biochem. 205, 409-416, 1992
A;Title: Plant mitochondrial F(0)F(1) ATP synthase. Identification of the individual sub
A;Reference number: S21204; MUID:92209531; PMID:1313368
A;Accession: S21244
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-20 <HAM>
A;Cross-references: UNIPROT:P80085; UNIPARC:UPI00001262D3
C;Keywords: ATP biosynthesis; hydrolase; membrane-associated complex; mitochondrion

Query Match 100.0%; Score 19; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 78;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 9 AQGV 12

RESULT 3
S54339
cytochrome P450 CYP2A7AS - human
C;Species: Homo sapiens (man)
C;Date: 27-Oct-1995 #sequence_revision 03-Nov-1995 #text_change 07-May-1999
C;Accession: S54339
R;Ding, S.; Lake, B.G.; Friedberg, T.; Wolf, C.R.
Biochem. J. 306, 161-166, 1995
A;Title: Expression and alternative splicing of the cytochrome P-450 CYP2A7.
A;Reference number: S54338; MUID:95169049; PMID:7864805
A;Accession: S54339
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-23 <DIN>
A;Cross-references: UNIPARC:UPI000017C0D9

Query Match 84.2%; Score 16; DB 2; Length 23;
Best Local Similarity 75.0%; Pred. No. 6.7e+02;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
:|||
Db 12 SQGV 15

RESULT 4
PH1600
Ig H chain V-D-J region (wild-type clone 310) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 02-Jun-1994 #sequence_revision 02-Jun-1994 #text_change 17-Mar-1999
C;Accession: PH1600
R;Levinson, D.A.; Campos-Torres, J.; Leder, P.
J. Exp. Med. 178, 317-329, 1993
A;Title: Molecular characterization of transgene-induced immunodeficiency in B-less mice
A;Reference number: PH1580; MUID:93301609; PMID:8315387
A;Accession: PH1600
A;Molecule type: DNA
A;Residues: 1-11 <LEV>
A;Cross-references: UNIPARC:UPI000017C6BD
A;Experimental source: bone marrow pre-B lymphocyte
C;Keywords: immunoglobulin

Query Match 78.9%; Score 15; DB 2; Length 11;
Best Local Similarity 75.0%; Pred. No. 6.5e+02;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
|:||
Db 2 ARGV 5

RESULT 5
C33099
148K exoantigen - malaria parasite (Plasmodium falciparum) (fragments)
C;Species: Plasmodium falciparum
C;Date: 24-Aug-1990 #sequence_revision 24-Aug-1990 #text_change 09-Jun-2000
C;Accession: C33099
R;Nichols, J.H.; Hager, L.P.
submitted to the Protein Sequence Database, May 1990
A;Reference number: A33098
A;Accession: C33099
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-12 <NIC>
A;Cross-references: UNIPARC:UPI000017B5DE

Query Match 78.9%; Score 15; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 QGV 4
|||
Db 3 QGV 5

RESULT 6
PH0920
T-cell receptor beta chain V-D-J region (isolate 6) - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 30-May-1997
C;Accession: PH0920
R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.
J. Exp. Med. 174, 1467-1476, 1991
A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic
A;Reference number: PH0891; MUID:92078857; PMID:1836012
A;Accession: PH0920
A;Molecule type: mRNA
A;Residues: 1-12 <GOL>
A;Cross-references: UNIPARC:UPI000017C9FA
A;Experimental source: concanavalin A-activated lymphoblast
A;Note: the authors translated the codon CAG for residue 12 as Glu
C;Keywords: T-cell receptor

Query Match 78.9%; Score 15; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQG 3
|||
Db 5 AQG 7

RESULT 7
PH1467
T-cell receptor beta chain (clone 223/27) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 15-Mar-2004
C;Accession: PH1467
R;Casanova, J.L.; Martinon, F.; Gournier, H.; Barra, C.; Pannetier, C.; Regnault, A.; Kou
J. Exp. Med. 177, 811-820, 1993
A;Title: T cell receptor selection by and recognition of two class I major histocompatib
A;Reference number: PH1430; MUID:93171821; PMID:8436911
A;Accession: PH1467
A;Molecule type: mRNA
A;Residues: 1-12 <CAS>
A;Cross-references: UNIPARC:UPI000017C794
A;Experimental source: cytolytic T-lymphocyte
C;Keywords: receptor; T-cell

Query Match 78.9%; Score 15; DB 2; Length 12;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 QGV 4
|||
Db 7 QGV 9

RESULT 8
S23376
collagen alpha chain - polychaete (Alvinella pompejana) (fragment)
C;Species: Alvinella pompejana
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 29-May-1998
C;Accession: S23376
R;Gaill, F.; Wiedemann, H.; Mann, K.; Kuehn, K.; Timpl, R.; Engel, J.
J. Mol. Biol. 221, 209-223, 1991
A;Title: Molecular characterization of cuticle and interstitial collagens from worms col
A;Reference number: S17581; MUID:92015209; PMID:1920405
A;Accession: S23376
A;Molecule type: protein
A;Residues: 1-14 <GAI>
A;Cross-references: UNIPARC:UPI000017BD70

Query Match 78.9%; Score 15; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQG 3
              |||
Db          3 AQG 5


RESULT 9
PH0804
T-cell receptor alpha chain (L4) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
C;Accession: PH0804
R;Casanova, J.L.; Romero, P.; Widmann, C.; Kourilsky, P.; Maryanski, J.L.
J. Exp. Med. 174, 1371-1383, 1991
A;Title: T cell receptor genes in a series of class I major histocompatibility complex-r
allelic exclusion and antigen-specific repertoire.
A;Reference number: PH0746; MUID:92078846; PMID:1836010
A;Accession: PH0804
A;Molecule type: mRNA
A;Residues: 1-14 <CAS>
A;Cross-references: UNIPARC:UPI000017C77A; EMBL:X60913
A;Experimental source: T lymphocyte
C;Keywords: T-cell receptor

  Query Match             78.9%;  Score 15;  DB 2;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 8.2e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQG 3
              |||
Db          5 AQG 7


RESULT 10
A39703
tubulin beta-3 chain - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 08-Nov-1991 #sequence_revision 08-Nov-1991 #text_change 09-Jul-2004
C;Accession: A39703
R;Alexander, J.E.; Hunt, D.F.; Lee, M.K.; Shabanowitz, J.; Michel, H.; Berlin, S.C.; Mac
Proc. Natl. Acad. Sci. U.S.A. 88, 4685-4689, 1991
A;Title: Characterization of posttranslational modifications in neuron-specific class II
A;Reference number: A39703; MUID:91271258; PMID:2052551
A;Accession: A39703
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-14 <ALE>
A;Cross-references: UNIPROT:Q7M2L3; UNIPARC:UPI000017C586

  Query Match             78.9%;  Score 15;  DB 2;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 8.2e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQG 3
              |||
Db         10 AQG 12


RESULT 11
PS0382
Ig heavy chain J region 2 - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 09-Oct-1992 #sequence_revision 09-Oct-1992 #text_change 06-Jun-1997
C;Accession: PS0382
R;Lang, P.; Mocikat, R.
Gene 102, 261-264, 1991
A;Title: Immunoglobulin heavy-chain joining genes in the rat: comparison with mouse and
A;Reference number: JH0666; MUID:91340162; PMID:1908401
A;Accession: PS0382
A;Molecule type: DNA
A;Residues: 1-15 <LAN>
A;Cross-references: UNIPARC:UPI000017693B; EMBL:X56791
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin

  Query Match             78.9%;  Score 15;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          7 QGV 9


RESULT 12
S05700
insulin-like growth factor-binding protein, adult - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 18-Jun-1993
C;Accession: S05700
R;Roghani, M.; Hossenlopp, P.; Lepage, P.; Balland, A.; Binoux, M.
FEBS Lett. 255, 253-258, 1989
A;Title: Isolation from human cerebrospinal fluid of a new insulin-like growth factor-bi
A;Reference number: S05699; MUID:90005986; PMID:2551732
A;Accession: S05700
A;Molecule type: protein
A;Residues: 1-15 <ROG>
A;Cross-references: UNIPARC:UPI000017C274

  Query Match             78.9%;  Score 15;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          7 QGV 9


RESULT 13
B56046
urinary tract stone matrix protein 2, 21K - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 12-Apr-1995 #sequence_revision 12-Apr-1995 #text_change 12-Apr-1995
C;Accession: B56046
R;Binette, J.P.; Binette, M.B.; Gawinowicz, M.A.; Kendrick, N.
submitted to the Protein Sequence Database, February 1995
A;Description: Isolation, characterization and sequence of stone proteins.
A;Reference number: A56046
A;Accession: B56046
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-15 <BIN>
A;Cross-references: UNIPARC:UPI000017C408

  Query Match             78.9%;  Score 15;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          5 QGV 7


RESULT 14
S05699
insulin-like growth factor-binding protein, juvenile - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 09-Jul-2004
C;Accession: S05699
R;Roghani, M.; Hossenlopp, P.; Lepage, P.; Balland, A.; Binoux, M.
FEBS Lett. 255, 253-258, 1989
A;Title: Isolation from human cerebrospinal fluid of a new insulin-like growth factor-bi
A;Reference number: S05699; MUID:90005986; PMID:2551732
A;Accession: S05699
A;Molecule type: protein
A;Residues: 1-15 <ROG>
```

```
A;Cross-references: UNIPROT:P24592; UNIPARC:UPI000017C276

  Query Match             78.9%;  Score 15;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 8.7e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          7 QGV 9


RESULT 15
S28839
RNA-binding protein, 28K - garden pea (fragment)
C;Species: Pisum sativum (garden pea)
C;Date: 19-Mar-1997 #sequence_revision 10-Oct-1997 #text_change 09-Jul-2004
C;Accession: S28839
R;Subbaiah, C.C.; Tewari, K.K.
Eur. J. Biochem. 211, 171-179, 1993
A;Title: Purification and characterization of ribonucleoproteins from pea chloroplasts.
A;Reference number: S28837; MUID:93145944; PMID:8425527
A;Accession: S28839
A;Molecule type: protein
A;Residues: 1-17 <SUB>
A;Cross-references: UNIPROT:Q9T2K3; UNIPARC:UPI0000096D45
A;Experimental source: cv. Arkel
C;Function:
A;Description: may be involved in post-transcriptional regulation of plastid genes
C;Keywords: chloroplast; transcription regulation

  Query Match             78.9%;  Score 15;  DB 2;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 9.9e+02;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQG 3
              |||
Db          2 AQG 4


Search completed: February 17, 2006, 17:03:28
Job time : 24 secs
```

GenCore version 5.1.7

OM protein - protein search, using sw model

Run on: February 17, 2006, 16:53:37 ; Search time 144.5 Seconds
(without alignments)
19.530 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AQGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 21620

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05.80:*
1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	100.0	20	1	ATP4_SPIOL	P80085 spinacia ol
2	18	94.7	15	2	O65177_MESCR	O65177 mesembryant
3	18	94.7	20	2	Q9R4C7_MYCAV	Q9r4c7 mycobacteri
4	18	94.7	22	2	Q9TRB1_BOVIN	Q9trb1 bos taurus
5	16	84.2	10	2	Q75SW3_ECOLI	Q75sw3 escherichia
6	16	84.2	18	2	Q6LCE8_MOUSE	Q6lce8 mus musculu
7	16	84.2	19	2	Q9PS70_CHICK	Q9ps70 gallus gall
8	16	84.2	20	2	P82666_BOVIN	P82666 bos taurus
9	16	84.2	23	2	Q9UCS1_HUMAN	Q9ucs1 homo sapien
10	15	78.9	8	2	Q28866_MEGNO	Q28866 megaptera n
11	15	78.9	10	1	TRP5_LEUMA	P81737 leucophaea
12	15	78.9	11	2	Q9X9S6_STRLI	Q9x9s6 streptomyce
13	15	78.9	11	2	Q62207_MOUSE	Q62207 mus musculu
14	15	78.9	12	2	Q7Y7W2_9CARY	Q7y7w2 suaeda pros
15	15	78.9	12	2	Q7Y7W3_9CARY	Q7y7w3 suaeda sals
16	15	78.9	12	2	Q7Y7W4_9CARY	Q7y7w4 suaeda ifni
17	15	78.9	12	2	Q7Y7W5_9CARY	Q7y7w5 suaeda hete
18	15	78.9	12	2	Q7Y7W6_9CARY	Q7y7w6 suaeda frut
19	15	78.9	12	2	Q7Y7W7_9CARY	Q7y7w7 suaeda corn
20	15	78.9	12	2	Q7Y7W8_SALEU	Q7y7w8 salicornia
21	15	78.9	12	2	Q7YNG6_9CARY	Q7yng6 salicornia
22	15	78.9	12	2	Q7YNG9_9CARY	Q7yng9 sclerostegi
23	15	78.9	12	2	Q7YNH1_TECAU	Q7ynh1 tecticornia
24	15	78.9	12	2	Q7YNH5_ALLOC	Q7ynh5 allenrolfea
25	15	78.9	12	2	Q7YNH7_9CARY	Q7ynh7 kalidium fo
26	15	78.9	12	2	Q7YNH9_9CARY	Q7ynh9 bienertia c
27	15	78.9	12	2	Q7YNI2_BORAR	Q7yni2 borszczowia
28	15	78.9	12	2	Q7YNI5_9CARY	Q7yni5 suaeda para
29	15	78.9	12	2	Q7YNI8_9CARY	Q7yni8 suaeda lini
30	15	78.9	12	2	Q7YNJ1_9CARY	Q7ynj1 suaeda sp.
31	15	78.9	12	2	Q7YNJ4_9CARY	Q7ynj4 suaeda vera
32	15	78.9	12	2	Q7YNJ7_9CARY	Q7ynj7 suaeda pala
33	15	78.9	12	2	Q7YNK0_9CARY	Q7ynk0 suaeda diva
34	15	78.9	12	2	Q7YNK3_9CARY	Q7ynk3 suaeda foli
35	15	78.9	12	2	Q7YNK6_9CARY	Q7ynk6 suaeda arti
36	15	78.9	12	2	Q7YNK9_9CARY	Q7ynk9 suaeda mono
37	15	78.9	12	2	Q7YNL2_9CARY	Q7ynl2 suaeda dend
38	15	78.9	12	2	Q7YNL5_9CARY	Q7ynl5 suaeda micr
39	15	78.9	12	2	Q7YNL8_9CARY	Q7ynl8 suaeda arcu
40	15	78.9	12	2	Q7YNM1_9CARY	Q7ynm1 suaeda aegy
41	15	78.9	12	2	Q7YNM4_9CARY	Q7ynm4 suaeda verm
42	15	78.9	12	2	Q7YNM7_9CARY	Q7ynm7 suaeda asph
43	15	78.9	12	2	Q7YNN0_9CARY	Q7ynn0 suaeda alti
44	15	78.9	12	2	Q7YNN3_9CARY	Q7ynn3 suaeda micr
45	15	78.9	12	2	Q7YNN6_9CARY	Q7ynn6 suaeda acum

ALIGNMENTS

RESULT 1
ATP4_SPIOL
ID ATP4_SPIOL STANDARD; PRT; 20 AA.
AC P80085;
DT 01-MAY-1992 (Rel. 22, Created)
DT 01-MAY-1992 (Rel. 22, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE ATP synthase delta' chain, mitochondrial (EC 3.6.3.14) (Fragment).
OS Spinacia oleracea (Spinach).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC Caryophyllales; Amaranthaceae; Spinacia.
OX NCBI_TaxID=3562;
RN [1]
RP PROTEIN SEQUENCE.
RC STRAIN=cv. Medania; TISSUE=Leaf mesophyll;
RX MEDLINE=92209531; PubMed=1313368;
RA Hamasur B., Glaser E.;
RT "Plant mitochondrial F0F1 ATP synthase. Identification of the
RT individual subunits and properties of the purified spinach leaf
RT mitochondrial ATP synthase.";
RL Eur. J. Biochem. 205:409-416(1992).
CC -!- FUNCTION: Produces ATP from ADP in the presence of a proton
CC gradient across the membrane.
CC -!- FUNCTION: This is one of the 5 chains of the enzymatic component
CC (coupling factor CF(1)) of the mitochondrial ATPase complex.
CC -!- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(In) = ADP + phosphate +
CC H(+)(Out).
CC -!- SUBUNIT: F-type ATPases have 2 components, CF(1) - the catalytic
CC core - and CF(0) - the membrane proton channel. CF(1) has five
CC subunits: alpha(3), beta(3), gamma(1), delta(1), epsilon(1). CF(0)
CC has three main subunits: a, b and c.
CC -!- SUBCELLULAR LOCATION: Mitochondrial.
CC -!- SIMILARITY: Belongs to the ATPase epsilon chain family.
CC --

CC --
DR PIR; S21244; S21244.
KW ATP synthesis; CF(1); Direct protein sequencing;
KW Hydrogen ion transport; Hydrolase; Ion transport; Mitochondrion;
KW Transport.
FT NON_TER 20 20
SQ SEQUENCE 20 AA; 1968 MW; 2025A964C4B991A3 CRC64;

Query Match 100.0%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||

```
Db          9 AQGV 12


RESULT 2
O65177_MESCR
ID   O65177_MESCR PRELIMINARY;      PRT;    15 AA.
AC   O65177;
DT   01-AUG-1998 (TrEMBLrel. 07, Created)
DT   01-AUG-1998 (TrEMBLrel. 07, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Turgor responsive protein homolog (Fragment).
OS   Mesembryanthemum crystallinum (Common ice plant).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC   Caryophyllales; Aizoaceae; Mesembryanthemum.
OX   NCBI_TaxID=3544;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Root;
RA   Michalowski C.B., Bohnert H.J.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF054444; AAC14178.1; -; mRNA.
FT   NON_TER       1      1
SQ   SEQUENCE   15 AA;  1607 MW;  4137ED0DF9B3FC21 CRC64;

  Query Match             94.7%;  Score 18;  DB 2;  Length 15;
  Best Local Similarity   75.0%;  Pred. No. 9.9e+02;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          9 AQGI 12


RESULT 3
Q9R4C7_MYCAV
ID   Q9R4C7_MYCAV  PRELIMINARY;      PRT;    20 AA.
AC   Q9R4C7;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-MAY-2000 (TrEMBLrel. 13, Last annotation update)
DE   35 kDa EGF-binding protein (Fragment).
OS   Mycobacterium avium.
OC   Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC   Corynebacterineae; Mycobacteriaceae; Mycobacterium;
OC   Mycobacterium avium complex (MAC).
OX   NCBI_TaxID=1764;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=96333319; PubMed=8757813;
RA   Bermudez L.E., Petrofsky M., Shelton K.;
RT   "Epidermal growth factor-binding protein in mycobacterium avium and
RT   mycobacterium tuberculosis: a possible role in the mechanism of
RT   infection.";
RL   Infect. Immun. 64:2917-2922(1996).
SQ   SEQUENCE   20 AA;  2174 MW;  BEA6563671F69778 CRC64;

  Query Match             94.7%;  Score 18;  DB 2;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 1.3e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          1 AQGI 4


RESULT 4
Q9TRB1_BOVIN
ID   Q9TRB1_BOVIN  PRELIMINARY;      PRT;    22 AA.
AC   Q9TRB1;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE   ATP-dependent 20 S proteasome activator (Fragment).
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=94342244; PubMed=8063704;
RA   DeMartino G.N., Moomaw C.R., Zagnitko O.P., Proske R.J., Chu-Ping M.,
RA   Afendis S.J., Swaffield J.C., Slaughter C.A.;
RT   "PA700, an ATP-dependent activator of the 20 S proteasome, is an
RT   ATPase containing multiple members of a nucleotide-binding protein
RT   family.";
RL   J. Biol. Chem. 269:20878-20884(1994).
SQ   SEQUENCE   22 AA;  2195 MW;  FE139D0ACF4AE9BE CRC64;

  Query Match             94.7%;  Score 18;  DB 2;  Length 22;
  Best Local Similarity   75.0%;  Pred. No. 1.4e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          6 AQGI 9


RESULT 5
Q75SW3_ECOLI
ID   Q75SW3_ECOLI PRELIMINARY;      PRT;    10 AA.
AC   Q75SW3;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE   Sigma F factor (Fragment).
GN   Name=fliA;
OS   Escherichia coli.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=562;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=E480-68, E223-69, and Bi7327-41;
RX   PubMed=15056931; DOI=10.1266/ggs.79.1;
RA   Tominaga A.;
RT   "Characterization of six flagellin genes in the H3, H53 and H54
RT   standard strains of Escherichia coli.";
RL   Genes Genet. Syst. 79:1-8(2004).
DR   EMBL; AB128920; BAD14981.1; -; Genomic_DNA.
DR   EMBL; AB128921; BAD14982.1; -; Genomic_DNA.
DR   EMBL; AB128919; BAD14979.1; -; Genomic_DNA.
FT   NON_TER       10     10
SQ   SEQUENCE   10 AA;  1084 MW;  8161421DC1BB5735 CRC64;

  Query Match             84.2%;  Score 16;  DB 2;  Length 10;
  Best Local Similarity   75.0%;  Pred. No. 2.5e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |:||
Db          7 AEGV 10


RESULT 6
Q6LCE8_MOUSE
ID   Q6LCE8_MOUSE PRELIMINARY;      PRT;    18 AA.
AC   Q6LCE8;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   TATA-binding protein (Fragment).
GN   Name=Tbp;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=C57BL/6;
RA   Trachtulec Z., Vincek V., Forejt J., Klein J.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; U63729; AAB80845.1; -; Genomic_DNA.
FT   NON_TER      18     18
SQ   SEQUENCE   18 AA;  1931 MW;  CC4051C3EDABCC6F CRC64;

  Query Match             84.2%;  Score 16;  DB 2;  Length 18;
  Best Local Similarity   75.0%;  Pred. No. 4.4e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db         11 AQGL 14


RESULT 7
Q9PS70_CHICK
ID   Q9PS70_CHICK PRELIMINARY;      PRT;    19 AA.
AC   Q9PS70;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE   LOW density lipoprotein receptor-related protein (Fragment).
OS   Gallus gallus (Chicken).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC   Gallus.
OX   NCBI_TaxID=9031;
RN   [1]
RP   PROTEIN SEQUENCE.
RX   MEDLINE=92011685; PubMed=1918027;
RA   Stifani S., Barber D.L., Aebersold R., Steyrer E., Shen X., Nimpf J.,
RA   Schneider W.J.;
RT   "The laying hen expresses two different low density lipoprotein
RT   receptor-related proteins.";
RL   J. Biol. Chem. 266:19079-19087(1991).
FT   NON_TER       1      1
FT   NON_TER      19     19
SQ   SEQUENCE   19 AA;  1861 MW;  4EEC931205620608 CRC64;

  Query Match             84.2%;  Score 16;  DB 2;  Length 19;
  Best Local Similarity   75.0%;  Pred. No. 4.7e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          3 AQGL 6


RESULT 8
P82666_BOVIN
ID   P82666_BOVIN PRELIMINARY;      PRT;    20 AA.
AC   P82666;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Mitochondrial 28S ribosomal protein S23 (MRP-S23) (Fragments).
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   MEDLINE=20490686; PubMed=10938081; DOI=10.1074/jbc.M003596200;
RA   Koc E.C., Burkhart W., Blackburn K., Moseley A., Koc H.,
RA   Spremulli L.L.;
RT   "A proteomics approach to the identification of mammalian
RT   mitochondrial small subunit ribosomal proteins.";
RL   J. Biol. Chem. 275:32585-32591(2000).
CC   -!- SUBCELLULAR LOCATION: Mitochondrial.
DR   GO; GO:0005739; C:mitochondrion; IEA.
DR   GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW   Mitochondrion; Ribosomal protein.
FT   NON_CONS     10     11
FT   NON_TER       1      1
FT   NON_TER      20     20
SQ   SEQUENCE   20 AA;  2249 MW;  EC7FE3CA50071EE4 CRC64;

  Query Match             84.2%;  Score 16;  DB 2;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 4.9e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |:||
Db          4 AEGV 7


RESULT 9
Q9UCS1_HUMAN
ID   Q9UCS1_HUMAN PRELIMINARY;      PRT;    23 AA.
AC   Q9UCS1;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE   TROPOMYOSIN=33 kDa calcium binding protein fragment A (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PROTEIN SEQUENCE.
RA   Crabos M., Yamakado T., Heizmann C.W., Cerletti N., Buhler F.R.,
RA   Erne P.;
RT   "The calcium binding protein tropomyosin in human platelets and
RT   cardiac tissue: elevation in hypertensive cardiac hypertrophy.";
RL   Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.
FT   NON_TER       1      1
FT   NON_TER      23     23
SQ   SEQUENCE   23 AA;  2475 MW;  EBD4B463017E7716 CRC64;

  Query Match             84.2%;  Score 16;  DB 2;  Length 23;
  Best Local Similarity   75.0%;  Pred. No. 5.6e+03;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db         20 AQGL 23


RESULT 10
Q28866_MEGNO
ID   Q28866_MEGNO PRELIMINARY;      PRT;     8 AA.
AC   Q28866;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-MAY-1999 (TrEMBLrel. 10, Last annotation update)
DE   Actin protein (Fragment).
GN   Name=actin;
OS   Megaptera novaeangliae (Humpback whale).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Cetacea;
OC   Mysticeti; Balaenopteridae; Megaptera.
OX   NCBI_TaxID=9773;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=94285813; PubMed=7912407;
RA   Palumbi S.R., Baker C.S.;
```

```
RT   "Contrasting population structure from nuclear intron sequences and
RT   mtDNA of humpback whales.";
RL   Mol. Biol. Evol. 11:426-435(1994).
DR   EMBL; S73467; AAD14118.1; -; Genomic_DNA.
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;  906 MW;  69C866D1F4177408 CRC64;

  Query Match             78.9%;  Score 15;  DB 2;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+06;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          6 QGV 8


RESULT 11
TRP5_LEUMA
ID   TRP5_LEUMA     STANDARD;      PRT;    10 AA.
AC   P81737;
DT   30-MAY-2000 (Rel. 39, Created)
DT   30-MAY-2000 (Rel. 39, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Tachykinin-related peptide 5 (LemTRP 5).
OS   Leucophaea maderae (Madeira cockroach).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
OC   Blaberidae; Leucophaea.
OX   NCBI_TaxID=6988;
RN   [1]
RP   PROTEIN SEQUENCE.
RC   TISSUE=Midgut;
RX   MEDLINE=97053012; PubMed=8897641;
RA   Muren J.E., Naessel D.R.;
RT   "Isolation of five tachykinin-related peptides from the midgut of the
RT   cockroach Leucophaea maderae: existence of N-terminally extended
RT   isoforms.";
RL   Regul. Pept. 65:185-196(1996).
RN   [2]
RP   PROTEIN SEQUENCE, AND MASS SPECTROMETRY.
RC   TISSUE=Brain;
RX   MEDLINE=97269266; PubMed=9114447; DOI=10.1016/S0196-9781(96)00243-4;
RA   Muren J.E., Naessel D.R.;
RT   "Seven tachykinin-related peptides isolated from the brain of the
RT   madeira cockroach; evidence for tissue-specific expression of
RT   isoforms.";
RL   Peptides 18:7-15(1997).
CC   -!- FUNCTION: Myoactive peptide. Increases the amplitude and frequency
CC       of spontaneous contractions and tonus of hindgut muscle.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Midgut and brain.
CC   -!- MASS SPECTROMETRY: MW=1033.2; METHOD=MALDI; RANGE=1-10;
CC       NOTE=Ref.2.
CC   ---------------------------------------------------------------------
CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
CC   between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC   the European Bioinformatics Institute. There are no restrictions on its
CC   use as long as its content is in no way modified and this statement is not
CC   removed.
CC   ---------------------------------------------------------------------
KW   Amidation; Direct protein sequencing; Neuropeptide; Tachykinin.
FT   MOD_RES      10     10       Arginine amide.
SQ   SEQUENCE   10 AA;  1033 MW;  C452CD66D9C8769D CRC64;

  Query Match             78.9%;  Score 15;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          7 QGV 9


RESULT 12
Q9X9S6_STRLI
ID   Q9X9S6_STRLI PRELIMINARY;      PRT;    11 AA.
AC   Q9X9S6;
DT   01-NOV-1999 (TrEMBLrel. 12, Created)
DT   01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein ORF9 (Fragment).
GN   Name=ORF9;
OS   Streptomyces lividans.
OC   Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC   Streptomycineae; Streptomycetaceae; Streptomyces.
OX   NCBI_TaxID=1916;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=TK21;
RX   MEDLINE=99328982; PubMed=10400594;
RA   Martinez-Costa O.H., Martin-Triana A.J., Martinez E.,
RA   Fernandez-Moreno M.A., Malpartida F.;
RT   "An additinal regulatory gene for actinorhodin production in
RT   Streptomyces lividans involves a LysR-type transcriptional
RT   regulator.";
RL   J. Bacteriol. 181:4353-4364(1999).
DR   EMBL; Y18818; CAB51138.1; -; Genomic_DNA.
KW   Hypothetical protein.
FT   NON_TER       1      1
SQ   SEQUENCE   11 AA;  1160 MW;  D1BABA8EC1EDC412 CRC64;

  Query Match             78.9%;  Score 15;  DB 2;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db          2 QGV 4


RESULT 13
Q62207_MOUSE
ID   Q62207_MOUSE PRELIMINARY;      PRT;    11 AA.
AC   Q62207;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Schwannomin (Fragment).
GN   Name=Nf2; Synonyms=NF2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain;
RX   MEDLINE=95072570; PubMed=7981675;
RA   Huynh D.P., Nechiporuk T., Pulst S.M.;
RT   "Alternative transcripts in the mouse neurofibromatosis type 2 (NF2)
RT   gene are conserved and code for schwannomins with distinct C-terminal
RT   domains.";
RL   Hum. Mol. Genet. 3:1075-1079(1994).
DR   EMBL; L28838; AAA57151.1; -; mRNA.
DR   PIR; I54368; I54368.
DR   MGI; MGI:97307; Nf2.
DR   GO; GO:0005912; C:adherens junction; IMP.
DR   GO; GO:0005515; F:protein binding; IPI.
DR   GO; GO:0045216; P:intercellular junction assembly and/or main. . .; IMP.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA.
DR   GO; GO:0042127; P:regulation of cell proliferation; IMP.
FT   NON_TER       1      1
SQ   SEQUENCE   11 AA;  1238 MW;  C51FA05774140866 CRC64;

  Query Match             78.9%;  Score 15;  DB 2;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+03;
```

```
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQG 3
              |||
Db          3 AQG 5


RESULT 14
Q7Y7W2_9CARY
ID   Q7Y7W2_9CARY PRELIMINARY;      PRT;    12 AA.
AC   Q7Y7W2;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE   Photosystem II CP47 protein (Fragment).
GN   Name=psbB;
OS   Suaeda prostrata.
OG   Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC   Caryophyllales; Amaranthaceae; Suaeda.
OX   NCBI_TaxID=224187;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Schuetze P., Freitag H., Weising K.;
RT   "An integrated molecular and morphological study of the subfamily
RT   Suaedoideae Ulbr. (Chenopodiaceae).";
RL   Plant Syst. Evol. 239:257-286(2003).
DR   EMBL; AY181894; AAO66039.1; -; Genomic_DNA.
DR   EMBL; AY181895; AAO66042.1; -; Genomic_DNA.
DR   EMBL; AY181896; AAO66045.1; -; Genomic_DNA.
DR   EMBL; AY181897; AAO66048.1; -; Genomic_DNA.
DR   EMBL; AY181898; AAO66051.1; -; Genomic_DNA.
DR   GO; GO:0009507; C:chloroplast; IEA.
KW   Chloroplast.
FT   NON_TER       1      1
SQ   SEQUENCE   12 AA;  1328 MW;  26CBA7B1B311B1B7 CRC64;

  Query Match             78.9%;  Score 15;  DB 2;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db         10 QGV 12


RESULT 15
Q7Y7W3_9CARY
ID   Q7Y7W3_9CARY PRELIMINARY;      PRT;    12 AA.
AC   Q7Y7W3;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE   Photosystem II CP47 protein (Fragment).
GN   Name=psbB;
OS   Suaeda salsa.
OG   Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC   Caryophyllales; Amaranthaceae; Suaeda.
OX   NCBI_TaxID=126914;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Schuetze P., Freitag H., Weising K.;
RT   "An integrated molecular and morphological study of the subfamily
RT   Suaedoideae Ulbr. (Chenopodiaceae).";
RL   Plant Syst. Evol. 239:257-286(2003).
DR   EMBL; AY181887; AAO66018.1; -; Genomic_DNA.
DR   EMBL; AY181888; AAO66021.1; -; Genomic_DNA.
DR   GO; GO:0009507; C:chloroplast; IEA.
KW   Chloroplast.
FT   NON_TER       1      1
SQ   SEQUENCE   12 AA;  1328 MW;  26CBA7B1B311B1B7 CRC64;

  Query Match             78.9%;  Score 15;  DB 2;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+03;
  Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 QGV 4
              |||
Db         10 QGV 12


Search completed: February 17, 2006, 17:02:36
Job time : 145.5 secs
```

GenCore version 5.1.7

OM protein - protein search, using sw model

Run on: February 17, 2006, 17:18:43 ; Search time 10.5 Seconds
(without alignments)
5.415 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AQGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 107819 seqs, 14214640 residues

Total number of hits satisfying chosen parameters: 59776

Minimum DB seq length: 0
Maximum DB seq length: 25

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA_New:*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	100.0	19	6	US-10-503-575-304	Sequence 304, App
2	19	100.0	24	7	US-11-054-515-2176	Sequence 2176, Ap
3	19	100.0	24	7	US-11-054-515-2969	Sequence 2969, Ap
4	18	94.7	16	6	US-10-939-890-111	Sequence 111, App
5	18	94.7	20	7	US-11-127-601-29	Sequence 29, Appl
6	18	94.7	20	7	US-11-127-601-30	Sequence 30, Appl
7	18	94.7	20	7	US-11-127-601-31	Sequence 31, Appl
8	18	94.7	20	7	US-11-127-601-32	Sequence 32, Appl
9	18	94.7	20	7	US-11-127-601-33	Sequence 33, Appl
10	18	94.7	20	7	US-11-127-601-34	Sequence 34, Appl
11	18	94.7	20	7	US-11-127-601-35	Sequence 35, Appl
12	18	94.7	20	7	US-11-127-601-36	Sequence 36, Appl
13	16	84.2	8	7	US-11-045-024-1476	Sequence 1476, Ap
14	16	84.2	8	7	US-11-045-024-1478	Sequence 1478, Ap
15	16	84.2	8	7	US-11-045-024-1479	Sequence 1479, Ap
16	16	84.2	8	7	US-11-045-024-1765	Sequence 1765, Ap
17	16	84.2	8	7	US-11-045-024-5309	Sequence 5309, Ap
18	16	84.2	8	7	US-11-045-024-6482	Sequence 6482, Ap
19	16	84.2	8	7	US-11-045-024-7882	Sequence 7882, Ap
20	16	84.2	8	7	US-11-045-024-7944	Sequence 7944, Ap
21	16	84.2	8	7	US-11-045-024-9347	Sequence 9347, Ap
22	16	84.2	8	7	US-11-045-024-9458	Sequence 9458, Ap
23	16	84.2	8	7	US-11-202-330-33	Sequence 33, Appl
24	16	84.2	9	7	US-11-045-024-1498	Sequence 1498, Ap
25	16	84.2	9	7	US-11-045-024-1502	Sequence 1502, Ap
26	16	84.2	9	7	US-11-045-024-5267	Sequence 5267, Ap
27	16	84.2	9	7	US-11-045-024-6454	Sequence 6454, Ap
28	16	84.2	9	7	US-11-045-024-6468	Sequence 6468, Ap
29	16	84.2	9	7	US-11-045-024-6768	Sequence 6768, Ap
30	16	84.2	10	7	US-11-045-024-1523	Sequence 1523, Ap
31	16	84.2	10	7	US-11-045-024-2201	Sequence 2201, Ap
32	16	84.2	10	7	US-11-045-024-5376	Sequence 5376, Ap
33	16	84.2	10	7	US-11-045-024-7412	Sequence 7412, Ap
34	16	84.2	10	7	US-11-045-024-7890	Sequence 7890, Ap
35	16	84.2	10	7	US-11-045-024-7987	Sequence 7987, Ap
36	16	84.2	11	7	US-11-045-024-1552	Sequence 1552, Ap
37	16	84.2	11	7	US-11-045-024-2440	Sequence 2440, Ap
38	16	84.2	11	7	US-11-045-024-3432	Sequence 3432, Ap
39	16	84.2	11	7	US-11-045-024-5408	Sequence 5408, Ap
40	16	84.2	11	7	US-11-045-024-5409	Sequence 5409, Ap
41	16	84.2	11	7	US-11-045-024-7897	Sequence 7897, Ap
42	16	84.2	11	7	US-11-045-024-7948	Sequence 7948, Ap
43	16	84.2	11	7	US-11-045-024-7988	Sequence 7988, Ap
44	16	84.2	11	7	US-11-045-024-9342	Sequence 9342, Ap
45	16	84.2	11	7	US-11-045-024-10140	Sequence 10140, A

ALIGNMENTS

RESULT 1
US-10-503-575-304
; Sequence 304, Application US/10503575
; Publication No. US20050244823A1
; GENERAL INFORMATION:
; APPLICANT: Drijfhout, Jan Wouter
; APPLICANT: van Veelen, Petrus Antonius
; APPLICANT: Koning, Frits
; TITLE OF INVENTION: NOVEL EPITOPES FOR CELIAC DISEASE AND AUTOIMMUNE DISEASES, METHOD
; TITLE OF INVENTION: DETECTING THOSE AND NOVEL NON-ANTIGENIC FOOD COMPOUNDS
; FILE REFERENCE: 2799/72843-PCT-US
; CURRENT APPLICATION NUMBER: US/10/503,575
; CURRENT FILING DATE: 2004-08-04
; PRIOR APPLICATION NUMBER: PCT/NL03/00077
; PRIOR FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: EP 02075456.0
; PRIOR FILING DATE: 2002-02-04
; NUMBER OF SEQ ID NOS: 340
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 304
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-503-575-304

Query Match 100.0%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 9 AQGV 12

RESULT 2
US-11-054-515-2176
; Sequence 2176, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18

```
;  PRIOR APPLICATION NUMBER: 10/293,418
;  PRIOR FILING DATE: 2002-11-14
;  PRIOR APPLICATION NUMBER: 60/331,469
;  PRIOR FILING DATE: 2001-11-16
;  PRIOR APPLICATION NUMBER: 60/340,817
;  PRIOR FILING DATE: 2001-12-19
;  PRIOR APPLICATION NUMBER: 09/880,748
;  PRIOR FILING DATE: 2001-06-15
;  PRIOR APPLICATION NUMBER: 60/293,499
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 60/277,379
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/276,248
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 60/240,816
;  PRIOR FILING DATE: 2000-10-17
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2176
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-054-515-2176

  Query Match             100.0%;  Score 19;  DB 7;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 3
US-11-054-515-2969
; Sequence 2969, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
;  FILE REFERENCE: PF523P3
;  CURRENT APPLICATION NUMBER: US/11/054,515
;  CURRENT FILING DATE:  2005-02-10
;  PRIOR APPLICATION NUMBER: 60/543,296
;  PRIOR FILING DATE: 2004-02-11
;  PRIOR APPLICATION NUMBER: 60/580,347
;  PRIOR FILING DATE: 2004-06-18
;  PRIOR APPLICATION NUMBER: 10/293,418
;  PRIOR FILING DATE: 2002-11-14
;  PRIOR APPLICATION NUMBER: 60/331,469
;  PRIOR FILING DATE: 2001-11-16
;  PRIOR APPLICATION NUMBER: 60/340,817
;  PRIOR FILING DATE: 2001-12-19
;  PRIOR APPLICATION NUMBER: 09/880,748
;  PRIOR FILING DATE: 2001-06-15
;  PRIOR APPLICATION NUMBER: 60/293,499
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 60/277,379
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/276,248
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 60/240,816
;  PRIOR FILING DATE: 2000-10-17
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2969
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-054-515-2969

  Query Match             100.0%;  Score 19;  DB 7;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 4
US-10-939-890-111
; Sequence 111, Application US/10939890
; Publication No. US20050250700A1
; GENERAL INFORMATION:
;  APPLICANT: Sato, Aaron K.
;  APPLICANT:  Sexton, Daniel J.
;  APPLICANT:  Dransfield, Daniel T.
;  APPLICANT:  Ladner, Robert C.
;  APPLICANT:  Arbogast, Christophe
;  APPLICANT:  Bussat, Philippe
;  APPLICANT:  Fan, Hong
;  APPLICANT:  Khurana, Sudha
;  APPLICANT:  Linder, Karen E.
;  APPLICANT:  Marinelli, Edmund R.
;  APPLICANT:  Nanjappan, Palaniappa
;  APPLICANT:  Nunn, Adrian D.
;  APPLICANT:  Pillai, Radhakrishna
;  APPLICANT:  Pochon, Sibylle
;  APPLICANT:  Ramalingam, Kondareddiar
;  APPLICANT:  Shrivastava, Ajay
;  APPLICANT:  Song, Bo
;  APPLICANT:  Swenson, Rolf E.
;  APPLICANT:  Von Wronski, Mathew A.
;  TITLE OF INVENTION: KDR AND VEGF/KDR BINDING PEPTIDES
;  FILE REFERENCE: D0617.70014US00
;  CURRENT APPLICATION NUMBER: US/10/939,890
;  CURRENT FILING DATE:  2004-09-13
;  PRIOR APPLICATION NUMBER: US 10/661,156
;  PRIOR FILING DATE: 2003-09-11
;  PRIOR APPLICATION NUMBER: US 10/382,082
;  PRIOR FILING DATE: 2003-03-03
;  PRIOR APPLICATION NUMBER: PCT/US03/06731
;  PRIOR FILING DATE: 2003-03-03
;  PRIOR APPLICATION NUMBER: US 60/440,411
;  PRIOR FILING DATE: 2003-01-15
;  PRIOR APPLICATION NUMBER: US 60/360,851
;  PRIOR FILING DATE: 2002-03-01
;  NUMBER OF SEQ ID NOS: 883
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 111
;   LENGTH: 16
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Library Isolate
US-10-939-890-111

  Query Match             94.7%;  Score 18;  DB 6;  Length 16;
  Best Local Similarity   75.0%;  Pred. No. 26;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          7 AQGI 10


RESULT 5
US-11-127-601-29
; Sequence 29, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
;  APPLICANT: Compton, Teresa
;  APPLICANT:  Feire, Adam
;  TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
;  FILE REFERENCE: 09820.380
```

; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-29

Query Match 94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||| :
Db 6 AQGI 9

RESULT 6
US-11-127-601-30
; Sequence 30, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-30

Query Match 94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||| :
Db 6 AQGI 9

RESULT 7
US-11-127-601-31
; Sequence 31, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-31

Query Match 94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||| :
Db 6 AQGI 9

RESULT 8
US-11-127-601-32
; Sequence 32, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-32

Query Match 94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||| :
Db 6 AQGI 9

RESULT 9
US-11-127-601-33
; Sequence 33, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
; APPLICANT: Compton, Teresa
; APPLICANT: Feire, Adam
; TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
; FILE REFERENCE: 09820.380
; CURRENT APPLICATION NUMBER: US/11/127,601
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 60/570,260
; PRIOR FILING DATE: 2004-05-12
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Human cytomegalovirus
US-11-127-601-33

Query Match 94.7%; Score 18; DB 7; Length 20;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||| :
Db 6 AQGI 9

RESULT 10
US-11-127-601-34
; Sequence 34, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:

```
;  APPLICANT: Compton, Teresa
;  APPLICANT:  Feire, Adam
;  TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
;  FILE REFERENCE: 09820.380
;  CURRENT APPLICATION NUMBER: US/11/127,601
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 60/570,260
;  PRIOR FILING DATE: 2004-05-12
;  NUMBER OF SEQ ID NOS: 54
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Human cytomegalovirus
US-11-127-601-34

  Query Match             94.7%;  Score 18;  DB 7;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 34;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          6 AQGI 9


RESULT 11
US-11-127-601-35
; Sequence 35, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
;  APPLICANT: Compton, Teresa
;  APPLICANT:  Feire, Adam
;  TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
;  FILE REFERENCE: 09820.380
;  CURRENT APPLICATION NUMBER: US/11/127,601
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 60/570,260
;  PRIOR FILING DATE: 2004-05-12
;  NUMBER OF SEQ ID NOS: 54
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 35
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Human cytomegalovirus
US-11-127-601-35

  Query Match             94.7%;  Score 18;  DB 7;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 34;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          6 AQGI 9


RESULT 12
US-11-127-601-36
; Sequence 36, Application US/11127601
; Publication No. US20050260199A1
; GENERAL INFORMATION:
;  APPLICANT: Compton, Teresa
;  APPLICANT:  Feire, Adam
;  TITLE OF INVENTION: CYTOMEGALOVIRUS DISINTEGRIN-LIKE PEPTIDES
;  FILE REFERENCE: 09820.380
;  CURRENT APPLICATION NUMBER: US/11/127,601
;  CURRENT FILING DATE:  2005-05-12
;  PRIOR APPLICATION NUMBER: US 60/570,260
;  PRIOR FILING DATE: 2004-05-12
;  NUMBER OF SEQ ID NOS: 54
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Human cytomegalovirus
US-11-127-601-36

  Query Match             94.7%;  Score 18;  DB 7;  Length 20;
  Best Local Similarity   75.0%;  Pred. No. 34;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |||:
Db          6 AQGI 9


RESULT 13
US-11-045-024-1476
; Sequence 1476, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
;  APPLICANT: Sette, Alessandro
;  APPLICANT:  Sidney,John
;  APPLICANT:  Southwood, Scott
;  APPLICANT:  Livingston, Brian
;  APPLICANT:  Chesnut, Robert
;  APPLICANT:  Baker, Denise Marie
;  APPLICANT:  Celis, Esteban
;  APPLICANT:  Kubo, Ralph
;  APPLICANT:  Grey, Howard M.
;  APPLICANT:  Epimmune Inc.
;  TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
;  TITLE OF INVENTION:  Virus-1 Using Peptide and Nucleic Acid Compositions
;  FILE REFERENCE: 2060.0040007
;  CURRENT APPLICATION NUMBER: US/11/045,024
;  CURRENT FILING DATE:  2005-01-28
;  PRIOR APPLICATION NUMBER: US 09/412,863
;  PRIOR FILING DATE: 1999-10-05
;  PRIOR APPLICATION NUMBER: US 08/027,146
;  PRIOR FILING DATE: 1993-03-05
;  PRIOR APPLICATION NUMBER: US 08/073,205
;  PRIOR FILING DATE: 1993-06-04
;  PRIOR APPLICATION NUMBER: US 08/103,396
;  PRIOR FILING DATE: 1993-08-06
;  PRIOR APPLICATION NUMBER: US 08/159,184
;  PRIOR FILING DATE: 1993-11-29
;  PRIOR APPLICATION NUMBER: US 08/159,339
;  PRIOR FILING DATE: 1993-11-29
;  PRIOR APPLICATION NUMBER: US 08/205,713
;  PRIOR FILING DATE: 1994-03-04
;  PRIOR APPLICATION NUMBER: US 08/347,610
;  PRIOR FILING DATE: 1994-12-01
;  NUMBER OF SEQ ID NOS: 14528
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1476
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-1476

  Query Match             84.2%;  Score 16;  DB 7;  Length 8;
  Best Local Similarity   75.0%;  Pred. No. 7.7e+04;
  Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              |:||
Db          3 AEGV 6


RESULT 14
US-11-045-024-1478
; Sequence 1478, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
;  APPLICANT: Sette, Alessandro
;  APPLICANT:  Sidney,John
;  APPLICANT:  Southwood, Scott
```

; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
; TITLE OF INVENTION: Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1478
; LENGTH: 8
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-1478

Query Match 84.2%; Score 16; DB 7; Length 8;
Best Local Similarity 75.0%; Pred. No. 7.7e+04;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              |:||
Db          2 AEGV 5
```

RESULT 15
US-11-045-024-1479
; Sequence 1479, Application US/11045024
; Publication No. US20050271676A1
; GENERAL INFORMATION:
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney,John
; APPLICANT: Southwood, Scott
; APPLICANT: Livingston, Brian
; APPLICANT: Chesnut, Robert
; APPLICANT: Baker, Denise Marie
; APPLICANT: Celis, Esteban
; APPLICANT: Kubo, Ralph
; APPLICANT: Grey, Howard M.
; APPLICANT: Epimmune Inc.
; TITLE OF INVENTION: Inducing Cellular Responses to Human Immunodeficiency
; TITLE OF INVENTION: Virus-1 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0040007
; CURRENT APPLICATION NUMBER: US/11/045,024
; CURRENT FILING DATE: 2005-01-28
; PRIOR APPLICATION NUMBER: US 09/412,863
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/103,396
; PRIOR FILING DATE: 1993-08-06
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/159,339
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/347,610
; PRIOR FILING DATE: 1994-12-01
; NUMBER OF SEQ ID NOS: 14528
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1479
; LENGTH: 8
; TYPE: PRT
; ORGANISM: HUMAN IMMUNODEFICIENCY VIRUS
US-11-045-024-1479

Query Match 84.2%; Score 16; DB 7; Length 8;
Best Local Similarity 75.0%; Pred. No. 7.7e+04;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              |:||
Db          2 AEGV 5
```

Search completed: February 17, 2006, 17:22:50
Job time : 11.5 secs

OM protein - protein search, using sw model

Run on: February 21, 2006, 09:03:03 ; Search time 119 Seconds
(without alignments)
14.045 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AQGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 6317

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 500 summaries

Database : Published_Applications_AA_Main:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	100.0	4	4	US-10-028-075B-2	Sequence 2, Appli
2	19	100.0	4	4	US-10-029-206A-2	Sequence 2, Appli
3	19	100.0	4	4	US-10-262-522A-15	Sequence 15, Appl
4	19	100.0	4	4	US-10-409-630-2	Sequence 2, Appli
5	19	100.0	4	4	US-10-409-027-2	Sequence 2, Appli
6	19	100.0	4	4	US-10-409-032-2	Sequence 2, Appli
7	19	100.0	4	4	US-10-409-642-2	Sequence 2, Appli
8	19	100.0	4	4	US-10-409-654-2	Sequence 2, Appli
9	19	100.0	4	4	US-10-409-659-2	Sequence 2, Appli
10	19	100.0	4	4	US-10-409-671-2	Sequence 2, Appli
11	19	100.0	4	4	US-10-409-694-2	Sequence 2, Appli
12	19	100.0	4	4	US-10-409-657-2	Sequence 2, Appli
13	19	100.0	4	4	US-10-409-668-2	Sequence 2, Appli
14	19	100.0	4	4	US-10-753-510-2	Sequence 2, Appli
15	19	100.0	4	5	US-10-821-240A-2	Sequence 2, Appli
16	19	100.0	4	5	US-10-817-756A-12	Sequence 12, Appl
17	19	100.0	4	5	US-10-821-256-2	Sequence 2, Appli
18	19	100.0	9	5	US-10-946-647-184	Sequence 184, App
19	19	100.0	9	5	US-10-946-647-558	Sequence 558, App
20	19	100.0	9	5	US-10-946-647-855	Sequence 855, App
21	19	100.0	9	5	US-10-946-647-954	Sequence 954, App
22	19	100.0	10	4	US-10-122-675-28	Sequence 28, Appl
23	19	100.0	13	3	US-09-957-806A-115	Sequence 115, App
24	19	100.0	19	4	US-10-394-980-6	Sequence 6, Appli
25	19	100.0	19	5	US-10-952-557-6	Sequence 6, Appli
26	19	100.0	20	3	US-09-397-945-430	Sequence 430, App
27	19	100.0	20	4	US-10-280-066-401	Sequence 401, App
28	19	100.0	20	4	US-10-653-595-430	Sequence 430, App
29	19	100.0	20	4	US-10-241-814-13	Sequence 13, Appl
30	19	100.0	21	4	US-10-377-134-8	Sequence 8, Appli
31	19	100.0	21	5	US-10-872-770-12	Sequence 12, Appl
32	19	100.0	23	4	US-10-097-065-597	Sequence 597, App
33	19	100.0	23	4	US-10-372-876-597	Sequence 597, App
34	19	100.0	24	3	US-09-880-748-2176	Sequence 2176, Ap
35	19	100.0	24	3	US-09-880-748-2969	Sequence 2969, Ap
36	19	100.0	24	4	US-10-293-418-2176	Sequence 2176, Ap
37	19	100.0	24	4	US-10-293-418-2969	Sequence 2969, Ap
38	19	100.0	25	3	US-09-864-761-45997	Sequence 45997, A
39	19	100.0	25	4	US-10-269-806-80	Sequence 80, Appl
40	19	100.0	25	4	US-10-029-386-33755	Sequence 33755, A
41	19	100.0	29	4	US-10-424-599-169158	Sequence 169158,
42	19	100.0	29	4	US-10-424-599-281150	Sequence 281150,
43	19	100.0	30	5	US-10-800-023-1	Sequence 1, Appli
44	19	100.0	33	4	US-10-424-599-261845	Sequence 261845,
45	19	100.0	34	4	US-10-425-115-199464	Sequence 199464,
46	19	100.0	35	4	US-10-424-599-242322	Sequence 242322,
47	19	100.0	37	4	US-10-252-773-11	Sequence 11, Appl
48	19	100.0	38	4	US-10-120-319-22	Sequence 22, Appl
49	19	100.0	38	4	US-10-189-977-22	Sequence 22, Appl
50	19	100.0	38	4	US-10-392-098-22	Sequence 22, Appl
51	19	100.0	38	4	US-10-029-386-33511	Sequence 33511, A
52	19	100.0	40	4	US-10-425-115-195035	Sequence 195035,
53	19	100.0	41	4	US-10-282-122A-45229	Sequence 45229, A
54	19	100.0	41	4	US-10-425-115-257966	Sequence 257966,
55	19	100.0	41	5	US-10-773-446-115	Sequence 115, App
56	19	100.0	43	4	US-10-425-115-280416	Sequence 280416,
57	19	100.0	44	4	US-10-425-115-256443	Sequence 256443,
58	19	100.0	48	3	US-09-397-945-424	Sequence 424, App
59	19	100.0	48	4	US-10-424-599-203996	Sequence 203996,
60	19	100.0	48	4	US-10-424-599-216178	Sequence 216178,
61	19	100.0	48	4	US-10-653-595-424	Sequence 424, App
62	19	100.0	48	4	US-10-425-115-339468	Sequence 339468,
63	19	100.0	49	4	US-10-029-386-27682	Sequence 27682, A
64	19	100.0	49	4	US-10-424-599-225119	Sequence 225119,
65	19	100.0	51	3	US-09-866-066-35	Sequence 35, Appl
66	19	100.0	51	4	US-10-424-599-193989	Sequence 193989,
67	19	100.0	51	5	US-10-969-677-35	Sequence 35, Appl
68	19	100.0	52	4	US-10-425-115-314288	Sequence 314288,
69	19	100.0	53	3	US-09-925-302-824	Sequence 824, App
70	19	100.0	53	3	US-09-925-302-824	Sequence 824, App
71	19	100.0	54	4	US-10-016-768-3	Sequence 3, Appli
72	19	100.0	55	3	US-09-764-877-1474	Sequence 1474, Ap
73	19	100.0	55	4	US-10-242-515-1474	Sequence 1474, Ap
74	19	100.0	55	4	US-10-425-115-279298	Sequence 279298,
75	19	100.0	56	3	US-09-864-761-44380	Sequence 44380, A
76	19	100.0	56	4	US-10-116-255-32	Sequence 32, Appl
77	19	100.0	56	4	US-10-264-049-3884	Sequence 3884, Ap
78	19	100.0	56	4	US-10-424-599-279039	Sequence 279039,
79	19	100.0	56	4	US-10-425-115-263648	Sequence 263648,
80	19	100.0	57	4	US-10-424-599-182978	Sequence 182978,
81	19	100.0	57	4	US-10-424-599-249716	Sequence 249716,
82	19	100.0	58	4	US-10-029-386-33617	Sequence 33617, A
83	19	100.0	58	4	US-10-425-115-192059	Sequence 192059,
84	19	100.0	58	4	US-10-425-115-219711	Sequence 219711,
85	19	100.0	58	4	US-10-425-115-336290	Sequence 336290,
86	19	100.0	59	3	US-09-925-298-590	Sequence 590, App
87	19	100.0	59	4	US-10-102-806-590	Sequence 590, App
88	19	100.0	59	4	US-10-029-386-28279	Sequence 28279, A
89	19	100.0	59	4	US-10-425-115-278273	Sequence 278273,
90	19	100.0	60	3	US-09-864-408A-2276	Sequence 2276, Ap
91	19	100.0	60	4	US-10-424-599-198924	Sequence 198924,
92	19	100.0	62	4	US-10-424-599-189118	Sequence 189118,
93	19	100.0	62	4	US-10-424-599-189377	Sequence 189377,
94	19	100.0	62	4	US-10-425-114-71256	Sequence 71256, A
95	19	100.0	62	4	US-10-425-115-188418	Sequence 188418,
96	19	100.0	63	4	US-10-029-386-31780	Sequence 31780, A
97	19	100.0	63	4	US-10-424-599-262885	Sequence 262885,
98	19	100.0	63	4	US-10-424-599-270368	Sequence 270368,
99	19	100.0	63	4	US-10-425-115-251637	Sequence 251637,
100	19	100.0	63	5	US-10-450-763-56831	Sequence 56831, A

101	19	100.0	64	4	US-10-424-599-177860	Sequence 177860,
102	19	100.0	64	4	US-10-425-115-197187	Sequence 197187,
103	19	100.0	64	4	US-10-425-115-219280	Sequence 219280,
104	19	100.0	65	4	US-10-437-963-106625	Sequence 106625,
105	19	100.0	65	4	US-10-425-115-240290	Sequence 240290,
106	19	100.0	65	4	US-10-425-115-357026	Sequence 357026,
107	19	100.0	66	4	US-10-424-599-257517	Sequence 257517,
108	19	100.0	67	4	US-10-437-963-106620	Sequence 106620,
109	19	100.0	67	4	US-10-437-963-158436	Sequence 158436,
110	19	100.0	67	4	US-10-425-115-200989	Sequence 200989,
111	19	100.0	67	4	US-10-425-115-231718	Sequence 231718,
112	19	100.0	67	6	US-11-097-143-39966	Sequence 39966, A
113	19	100.0	68	4	US-10-425-115-354448	Sequence 354448,
114	19	100.0	69	3	US-09-782-142-1	Sequence 1, Appli
115	19	100.0	69	4	US-10-300-257-1	Sequence 1, Appli
116	19	100.0	69	4	US-10-424-599-255403	Sequence 255403,
117	19	100.0	69	4	US-10-437-963-191908	Sequence 191908,
118	19	100.0	69	4	US-10-767-701-34429	Sequence 34429, A
119	19	100.0	69	4	US-10-425-115-324687	Sequence 324687,
120	19	100.0	70	4	US-10-424-599-242839	Sequence 242839,
121	19	100.0	70	4	US-10-437-963-134195	Sequence 134195,
122	19	100.0	70	4	US-10-425-115-321591	Sequence 321591,
123	19	100.0	71	5	US-10-926-683-1548	Sequence 1548, Ap
124	19	100.0	72	4	US-10-131-406-6	Sequence 6, Appli
125	19	100.0	72	4	US-10-424-599-182197	Sequence 182197,
126	19	100.0	72	4	US-10-424-599-234373	Sequence 234373,
127	19	100.0	72	4	US-10-425-115-202113	Sequence 202113,
128	19	100.0	72	4	US-10-425-115-348682	Sequence 348682,
129	19	100.0	72	5	US-10-989-992-6	Sequence 6, Appli
130	19	100.0	74	3	US-09-864-408A-2882	Sequence 2882, Ap
131	19	100.0	74	4	US-10-424-599-178691	Sequence 178691,
132	19	100.0	75	3	US-09-867-550-1124	Sequence 1124, Ap
133	19	100.0	75	4	US-10-424-599-154365	Sequence 154365,
134	19	100.0	75	4	US-10-437-963-147518	Sequence 147518,
135	19	100.0	75	4	US-10-425-115-222854	Sequence 222854,
136	19	100.0	76	4	US-10-029-386-30198	Sequence 30198, A
137	19	100.0	76	4	US-10-425-115-221278	Sequence 221278,
138	19	100.0	76	4	US-10-425-115-292142	Sequence 292142,
139	19	100.0	76	4	US-10-425-115-355384	Sequence 355384,
140	19	100.0	77	4	US-10-425-115-271573	Sequence 271573,
141	19	100.0	77	4	US-10-425-115-289812	Sequence 289812,
142	19	100.0	77	4	US-10-425-115-319654	Sequence 319654,
143	19	100.0	77	4	US-10-425-115-330336	Sequence 330336,
144	19	100.0	78	4	US-10-425-115-243630	Sequence 243630,
145	19	100.0	78	5	US-10-450-763-56828	Sequence 56828, A
146	19	100.0	79	4	US-10-437-963-195350	Sequence 195350,
147	19	100.0	79	4	US-10-425-115-264068	Sequence 264068,
148	19	100.0	81	4	US-10-424-599-277301	Sequence 277301,
149	19	100.0	81	4	US-10-437-963-137515	Sequence 137515,
150	19	100.0	81	4	US-10-425-115-263146	Sequence 263146,
151	19	100.0	81	4	US-10-425-115-306230	Sequence 306230,
152	19	100.0	82	4	US-10-424-599-163460	Sequence 163460,
153	19	100.0	82	4	US-10-424-599-227097	Sequence 227097,
154	19	100.0	82	4	US-10-425-115-236419	Sequence 236419,
155	19	100.0	83	4	US-10-424-599-270384	Sequence 270384,
156	19	100.0	83	4	US-10-437-963-180416	Sequence 180416,
157	19	100.0	83	4	US-10-425-115-205887	Sequence 205887,
158	19	100.0	83	4	US-10-425-115-241912	Sequence 241912,
159	19	100.0	83	4	US-10-425-115-289244	Sequence 289244,
160	19	100.0	84	3	US-09-731-872-330	Sequence 330, App
161	19	100.0	84	3	US-09-876-997-330	Sequence 330, App
162	19	100.0	84	4	US-10-425-115-364443	Sequence 364443,
163	19	100.0	84	5	US-10-643-836-330	Sequence 330, App
164	19	100.0	84	5	US-10-450-763-35681	Sequence 35681, A
165	19	100.0	84	6	US-11-097-143-21975	Sequence 21975, A
166	19	100.0	85	4	US-10-425-114-68442	Sequence 68442, A
167	19	100.0	85	4	US-10-363-616-365	Sequence 365, App
168	19	100.0	85	4	US-10-335-977-8250	Sequence 8250, Ap
169	19	100.0	85	4	US-10-425-115-368000	Sequence 368000,
170	19	100.0	86	3	US-09-955-502-4	Sequence 4, Appli
171	19	100.0	86	3	US-09-864-408A-2696	Sequence 2696, Ap
172	19	100.0	86	4	US-10-335-977-8249	Sequence 8249, Ap
173	19	100.0	86	5	US-10-799-514-13	Sequence 13, Appl
174	19	100.0	87	4	US-10-424-599-283838	Sequence 283838,
175	19	100.0	87	4	US-10-437-963-123960	Sequence 123960,
176	19	100.0	88	3	US-09-989-920-196	Sequence 196, App
177	19	100.0	88	4	US-10-437-963-148963	Sequence 148963,
178	19	100.0	88	4	US-10-425-115-199844	Sequence 199844,
179	19	100.0	88	4	US-10-425-115-353524	Sequence 353524,
180	19	100.0	89	4	US-10-424-599-173797	Sequence 173797,
181	19	100.0	89	4	US-10-693-367-14	Sequence 14, Appl
182	19	100.0	89	4	US-10-425-115-232359	Sequence 232359,
183	19	100.0	90	4	US-10-425-115-221841	Sequence 221841,
184	19	100.0	91	4	US-10-424-599-282611	Sequence 282611,
185	19	100.0	91	4	US-10-767-701-58893	Sequence 58893, A
186	19	100.0	91	4	US-10-425-115-215363	Sequence 215363,
187	19	100.0	91	5	US-10-450-763-35010	Sequence 35010, A
188	19	100.0	92	4	US-10-424-599-152428	Sequence 152428,
189	19	100.0	92	4	US-10-425-115-255856	Sequence 255856,
190	19	100.0	92	5	US-10-509-055-4	Sequence 4, Appli
191	19	100.0	93	4	US-10-424-599-176284	Sequence 176284,
192	19	100.0	93	4	US-10-425-115-245408	Sequence 245408,
193	19	100.0	93	4	US-10-425-115-280821	Sequence 280821,
194	19	100.0	93	5	US-10-484-148-23	Sequence 23, Appl
195	19	100.0	94	4	US-10-425-115-341122	Sequence 341122,
196	19	100.0	95	4	US-10-156-761-11115	Sequence 11115, A
197	19	100.0	95	4	US-10-425-115-298069	Sequence 298069,
198	19	100.0	95	4	US-10-425-115-314568	Sequence 314568,
199	19	100.0	95	4	US-10-425-115-348114	Sequence 348114,
200	19	100.0	96	4	US-10-424-599-220040	Sequence 220040,
201	19	100.0	96	4	US-10-437-963-186534	Sequence 186534,
202	19	100.0	96	4	US-10-767-701-48980	Sequence 48980, A
203	19	100.0	96	4	US-10-425-115-220279	Sequence 220279,
204	19	100.0	97	4	US-10-437-963-198150	Sequence 198150,
205	19	100.0	97	4	US-10-425-115-358132	Sequence 358132,
206	19	100.0	97	5	US-10-501-282-1482	Sequence 1482, Ap
207	19	100.0	98	4	US-10-424-599-189929	Sequence 189929,
208	19	100.0	98	4	US-10-424-599-194380	Sequence 194380,
209	19	100.0	99	5	US-10-617-320-5200	Sequence 5200, Ap
210	19	100.0	100	4	US-10-080-170-56	Sequence 56, Appl
211	19	100.0	100	4	US-10-080-170-56	Sequence 56, Appl
212	19	100.0	100	4	US-10-468-356-56	Sequence 56, Appl
213	19	100.0	100	4	US-10-425-115-222178	Sequence 222178,
214	19	100.0	100	4	US-10-425-115-289173	Sequence 289173,
215	19	100.0	101	3	US-09-864-408A-2992	Sequence 2992, Ap
216	19	100.0	101	4	US-10-437-963-121960	Sequence 121960,
217	19	100.0	101	5	US-10-450-763-32365	Sequence 32365, A
218	19	100.0	101	5	US-10-450-763-54297	Sequence 54297, A
219	19	100.0	102	4	US-10-101-464A-699	Sequence 699, App
220	19	100.0	102	4	US-10-080-170-301	Sequence 301, App
221	19	100.0	102	4	US-10-424-599-159264	Sequence 159264,
222	19	100.0	102	4	US-10-080-170-301	Sequence 301, App
223	19	100.0	102	4	US-10-468-356-301	Sequence 301, App
224	19	100.0	102	4	US-10-425-115-265628	Sequence 265628,
225	19	100.0	102	5	US-10-864-252-699	Sequence 699, App
226	19	100.0	103	4	US-10-424-599-179799	Sequence 179799,
227	19	100.0	103	4	US-10-424-599-261546	Sequence 261546,
228	19	100.0	104	4	US-10-424-599-198118	Sequence 198118,
229	19	100.0	104	4	US-10-424-599-244826	Sequence 244826,
230	19	100.0	104	4	US-10-425-115-205212	Sequence 205212,
231	19	100.0	104	4	US-10-425-115-273311	Sequence 273311,
232	19	100.0	105	4	US-10-424-599-258231	Sequence 258231,
233	19	100.0	105	4	US-10-437-963-187330	Sequence 187330,
234	19	100.0	106	4	US-10-424-599-207947	Sequence 207947,
235	19	100.0	106	4	US-10-437-963-124557	Sequence 124557,
236	19	100.0	106	4	US-10-425-115-197558	Sequence 197558,
237	19	100.0	106	4	US-10-425-115-354333	Sequence 354333,
238	19	100.0	106	5	US-10-775-481A-55	Sequence 55, Appl
239	19	100.0	107	3	US-09-800-095A-104	Sequence 104, App
240	19	100.0	107	3	US-09-833-245-1848	Sequence 1848, Ap
241	19	100.0	107	4	US-10-424-599-161119	Sequence 161119,
242	19	100.0	107	4	US-10-424-599-177891	Sequence 177891,
243	19	100.0	107	4	US-10-425-115-291289	Sequence 291289,
244	19	100.0	108	4	US-10-425-115-294264	Sequence 294264,
245	19	100.0	109	4	US-10-437-963-180999	Sequence 180999,
246	19	100.0	109	4	US-10-425-115-260668	Sequence 260668,

247	19	100.0	109	4	US-10-425-115-280327	Sequence 280327,
248	19	100.0	109	4	US-10-425-115-361658	Sequence 361658,
249	19	100.0	110	4	US-10-424-599-164976	Sequence 164976,
250	19	100.0	110	4	US-10-425-115-352048	Sequence 352048,
251	19	100.0	111	4	US-10-424-599-193076	Sequence 193076,
252	19	100.0	111	4	US-10-335-977-6860	Sequence 6860, Ap
253	19	100.0	111	4	US-10-767-701-52353	Sequence 52353, A
254	19	100.0	111	4	US-10-425-115-350889	Sequence 350889,
255	19	100.0	112	4	US-10-767-701-35668	Sequence 35668, A
256	19	100.0	112	4	US-10-425-115-287837	Sequence 287837,
257	19	100.0	113	4	US-10-156-761-11142	Sequence 11142, A
258	19	100.0	113	4	US-10-080-170-8	Sequence 8, Appli
259	19	100.0	113	4	US-10-424-599-203422	Sequence 203422,
260	19	100.0	113	4	US-10-424-599-258239	Sequence 258239,
261	19	100.0	113	4	US-10-080-170-8	Sequence 8, Appli
262	19	100.0	113	4	US-10-437-963-191861	Sequence 191861,
263	19	100.0	113	4	US-10-468-356-8	Sequence 8, Appli
264	19	100.0	113	4	US-10-425-115-211125	Sequence 211125,
265	19	100.0	113	4	US-10-425-115-316206	Sequence 316206,
266	19	100.0	114	4	US-10-437-963-167613	Sequence 167613,
267	19	100.0	114	4	US-10-767-701-46385	Sequence 46385, A
268	19	100.0	114	4	US-10-425-115-230329	Sequence 230329,
269	19	100.0	114	4	US-10-425-115-269209	Sequence 269209,
270	19	100.0	114	5	US-10-732-923-6358	Sequence 6358, Ap
271	19	100.0	114	5	US-10-450-763-38060	Sequence 38060, A
272	19	100.0	115	3	US-09-833-245-709	Sequence 709, App
273	19	100.0	115	4	US-10-230-331-34	Sequence 34, Appl
274	19	100.0	115	4	US-10-437-963-106605	Sequence 106605,
275	19	100.0	115	4	US-10-437-963-130842	Sequence 130842,
276	19	100.0	115	4	US-10-437-963-154724	Sequence 154724,
277	19	100.0	115	4	US-10-437-963-163186	Sequence 163186,
278	19	100.0	115	4	US-10-425-115-358687	Sequence 358687,
279	19	100.0	116	4	US-10-108-260A-4532	Sequence 4532, Ap
280	19	100.0	116	4	US-10-424-599-250303	Sequence 250303,
281	19	100.0	116	4	US-10-437-963-134757	Sequence 134757,
282	19	100.0	117	4	US-10-437-963-135657	Sequence 135657,
283	19	100.0	118	4	US-10-424-599-253142	Sequence 253142,
284	19	100.0	118	4	US-10-425-115-311566	Sequence 311566,
285	19	100.0	119	4	US-10-190-435-241	Sequence 241, App
286	19	100.0	119	4	US-10-425-115-292750	Sequence 292750,
287	19	100.0	119	4	US-10-425-115-337575	Sequence 337575,
288	19	100.0	120	3	US-09-867-550-634	Sequence 634, App
289	19	100.0	120	4	US-10-437-963-133900	Sequence 133900,
290	19	100.0	120	4	US-10-425-115-299755	Sequence 299755,
291	19	100.0	120	4	US-10-425-115-326962	Sequence 326962,
292	19	100.0	120	5	US-10-856-499-2171	Sequence 2171, Ap
293	19	100.0	121	3	US-09-974-879-484	Sequence 484, App
294	19	100.0	121	3	US-09-305-736-485	Sequence 485, App
295	19	100.0	121	3	US-09-818-683-485	Sequence 485, App
296	19	100.0	121	3	US-09-818-683-485	Sequence 485, App
297	19	100.0	121	4	US-10-424-599-260152	Sequence 260152,
298	19	100.0	121	4	US-10-621-401-484	Sequence 484, App
299	19	100.0	122	4	US-10-291-172-305	Sequence 305, App
300	19	100.0	122	4	US-10-424-599-212313	Sequence 212313,
301	19	100.0	122	4	US-10-221-278-305	Sequence 305, App
302	19	100.0	122	4	US-10-425-114-38922	Sequence 38922, A
303	19	100.0	122	4	US-10-408-765A-2161	Sequence 2161, Ap
304	19	100.0	122	4	US-10-437-963-183338	Sequence 183338,
305	19	100.0	122	4	US-10-767-701-58817	Sequence 58817, A
306	19	100.0	122	4	US-10-425-115-312000	Sequence 312000,
307	19	100.0	123	4	US-10-276-774-2424	Sequence 2424, Ap
308	19	100.0	123	4	US-10-767-701-54912	Sequence 54912, A
309	19	100.0	124	4	US-10-289-762-1155	Sequence 1155, Ap
310	19	100.0	124	4	US-10-425-115-310342	Sequence 310342,
311	19	100.0	125	4	US-10-425-115-255481	Sequence 255481,
312	19	100.0	126	4	US-10-282-122A-77481	Sequence 77481, A
313	19	100.0	126	4	US-10-424-599-274218	Sequence 274218,
314	19	100.0	126	4	US-10-767-701-37075	Sequence 37075, A
315	19	100.0	127	4	US-10-424-599-215284	Sequence 215284,
316	19	100.0	127	4	US-10-437-963-160818	Sequence 160818,
317	19	100.0	127	4	US-10-437-963-192729	Sequence 192729,
318	19	100.0	127	4	US-10-466-242-7	Sequence 7, Appli
319	19	100.0	127	4	US-10-425-115-217543	Sequence 217543,
320	19	100.0	127	4	US-10-425-115-289211	Sequence 289211,
321	19	100.0	127	5	US-10-450-763-53377	Sequence 53377, A
322	19	100.0	128	3	US-09-925-299-898	Sequence 898, App
323	19	100.0	128	3	US-09-925-299-898	Sequence 898, App
324	19	100.0	128	4	US-10-424-599-176293	Sequence 176293,
325	19	100.0	128	4	US-10-425-114-50582	Sequence 50582, A
326	19	100.0	129	4	US-10-425-115-252447	Sequence 252447,
327	19	100.0	129	4	US-10-425-115-351484	Sequence 351484,
328	19	100.0	129	4	US-10-425-115-352840	Sequence 352840,
329	19	100.0	130	4	US-10-282-122A-61474	Sequence 61474, A
330	19	100.0	131	4	US-10-437-963-136208	Sequence 136208,
331	19	100.0	131	4	US-10-425-115-250272	Sequence 250272,
332	19	100.0	131	4	US-10-425-115-348961	Sequence 348961,
333	19	100.0	131	5	US-10-926-683-1521	Sequence 1521, Ap
334	19	100.0	132	4	US-10-424-599-152396	Sequence 152396,
335	19	100.0	132	4	US-10-424-599-200500	Sequence 200500,
336	19	100.0	132	4	US-10-424-599-202559	Sequence 202559,
337	19	100.0	132	4	US-10-424-599-258234	Sequence 258234,
338	19	100.0	132	4	US-10-437-963-156826	Sequence 156826,
339	19	100.0	132	4	US-10-437-963-165385	Sequence 165385,
340	19	100.0	132	5	US-10-762-107-88	Sequence 88, Appl
341	19	100.0	133	3	US-09-864-761-35106	Sequence 35106, A
342	19	100.0	133	3	US-09-738-626-6551	Sequence 6551, Ap
343	19	100.0	133	4	US-10-424-599-146459	Sequence 146459,
344	19	100.0	133	4	US-10-424-599-279320	Sequence 279320,
345	19	100.0	133	4	US-10-437-963-181680	Sequence 181680,
346	19	100.0	133	4	US-10-425-115-213101	Sequence 213101,
347	19	100.0	134	3	US-09-855-604-120	Sequence 120, App
348	19	100.0	134	3	US-09-855-604-120	Sequence 120, App
349	19	100.0	134	4	US-10-425-115-253088	Sequence 253088,
350	19	100.0	134	4	US-10-425-115-270514	Sequence 270514,
351	19	100.0	134	4	US-10-425-115-359259	Sequence 359259,
352	19	100.0	135	4	US-10-097-065-596	Sequence 596, App
353	19	100.0	135	4	US-10-372-876-596	Sequence 596, App
354	19	100.0	135	4	US-10-424-599-250888	Sequence 250888,
355	19	100.0	135	4	US-10-437-963-155403	Sequence 155403,
356	19	100.0	135	4	US-10-425-115-215369	Sequence 215369,
357	19	100.0	136	4	US-10-282-122A-49569	Sequence 49569, A
358	19	100.0	138	4	US-10-286-421-21	Sequence 21, Appl
359	19	100.0	138	4	US-10-286-421-23	Sequence 23, Appl
360	19	100.0	138	4	US-10-282-122A-60639	Sequence 60639, A
361	19	100.0	138	4	US-10-424-599-159394	Sequence 159394,
362	19	100.0	138	4	US-10-424-599-258721	Sequence 258721,
363	19	100.0	138	4	US-10-437-963-168302	Sequence 168302,
364	19	100.0	140	4	US-10-156-761-7616	Sequence 7616, Ap
365	19	100.0	140	4	US-10-276-774-1424	Sequence 1424, Ap
366	19	100.0	140	5	US-10-450-763-52271	Sequence 52271, A
367	19	100.0	141	4	US-10-040-895-4	Sequence 4, Appli
368	19	100.0	141	4	US-10-029-386-33367	Sequence 33367, A
369	19	100.0	141	4	US-10-108-260A-3939	Sequence 3939, Ap
370	19	100.0	141	4	US-10-282-122A-53067	Sequence 53067, A
371	19	100.0	141	4	US-10-767-701-49530	Sequence 49530, A
372	19	100.0	141	4	US-10-767-701-53785	Sequence 53785, A
373	19	100.0	141	4	US-10-425-115-185028	Sequence 185028,
374	19	100.0	141	6	US-11-097-143-30363	Sequence 30363, A
375	19	100.0	142	3	US-09-789-561-191	Sequence 191, App
376	19	100.0	142	4	US-10-424-599-185556	Sequence 185556,
377	19	100.0	142	4	US-10-425-114-42683	Sequence 42683, A
378	19	100.0	142	4	US-10-425-115-364754	Sequence 364754,
379	19	100.0	142	5	US-10-883-936-191	Sequence 191, App
380	19	100.0	143	4	US-10-282-122A-57897	Sequence 57897, A
381	19	100.0	143	4	US-10-424-599-192151	Sequence 192151,
382	19	100.0	143	4	US-10-296-115-1363	Sequence 1363, Ap
383	19	100.0	143	4	US-10-767-701-41448	Sequence 41448, A
384	19	100.0	143	4	US-10-425-115-257969	Sequence 257969,
385	19	100.0	144	4	US-10-424-599-231893	Sequence 231893,
386	19	100.0	144	4	US-10-425-114-42759	Sequence 42759, A
387	19	100.0	144	5	US-10-450-763-48446	Sequence 48446, A
388	19	100.0	145	4	US-10-425-114-56492	Sequence 56492, A
389	19	100.0	145	4	US-10-425-115-207074	Sequence 207074,
390	19	100.0	145	4	US-10-425-115-300954	Sequence 300954,
391	19	100.0	145	4	US-10-425-115-307850	Sequence 307850,
392	19	100.0	146	4	US-10-424-599-204568	Sequence 204568,

393	19	100.0	146	4	US-10-424-599-204570	Sequence 204570,
394	19	100.0	146	4	US-10-425-114-42380	Sequence 42380, A
395	19	100.0	146	4	US-10-335-977-7336	Sequence 7336, Ap
396	19	100.0	146	4	US-10-437-963-115335	Sequence 115335,
397	19	100.0	146	4	US-10-437-963-202884	Sequence 202884,
398	19	100.0	146	4	US-10-425-115-191100	Sequence 191100,
399	19	100.0	146	4	US-10-425-115-233009	Sequence 233009,
400	19	100.0	146	4	US-10-425-115-240137	Sequence 240137,
401	19	100.0	146	5	US-10-732-923-6396	Sequence 6396, Ap
402	19	100.0	146	5	US-10-450-763-59772	Sequence 59772, A
403	19	100.0	147	4	US-10-012-542-458	Sequence 458, App
404	19	100.0	147	4	US-10-115-123-458	Sequence 458, App
405	19	100.0	147	4	US-10-424-599-225582	Sequence 225582,
406	19	100.0	147	4	US-10-437-963-141415	Sequence 141415,
407	19	100.0	147	4	US-10-437-963-162770	Sequence 162770,
408	19	100.0	147	4	US-10-800-834-458	Sequence 458, App
409	19	100.0	148	3	US-09-738-626-5513	Sequence 5513, Ap
410	19	100.0	148	4	US-10-156-761-9414	Sequence 9414, Ap
411	19	100.0	148	4	US-10-369-493-12669	Sequence 12669, A
412	19	100.0	148	4	US-10-437-963-107135	Sequence 107135,
413	19	100.0	148	4	US-10-425-115-295634	Sequence 295634,
414	19	100.0	148	4	US-10-425-115-312425	Sequence 312425,
415	19	100.0	149	4	US-10-767-701-40218	Sequence 40218, A
416	19	100.0	149	4	US-10-425-115-223420	Sequence 223420,
417	19	100.0	149	4	US-10-425-115-308365	Sequence 308365,
418	19	100.0	149	5	US-10-732-923-6391	Sequence 6391, Ap
419	19	100.0	150	3	US-09-799-777-25	Sequence 25, Appl
420	19	100.0	150	4	US-10-337-699-4	Sequence 4, Appli
421	19	100.0	150	4	US-10-425-114-70920	Sequence 70920, A
422	19	100.0	150	4	US-10-437-963-147629	Sequence 147629,
423	19	100.0	151	4	US-10-424-599-197953	Sequence 197953,
424	19	100.0	151	4	US-10-424-599-236391	Sequence 236391,
425	19	100.0	151	4	US-10-437-963-120202	Sequence 120202,
426	19	100.0	151	4	US-10-767-701-39347	Sequence 39347, A
427	19	100.0	151	4	US-10-767-701-41378	Sequence 41378, A
428	19	100.0	152	3	US-09-925-300-1734	Sequence 1734, Ap
429	19	100.0	152	4	US-10-437-963-198231	Sequence 198231,
430	19	100.0	152	5	US-10-732-923-6357	Sequence 6357, Ap
431	19	100.0	152	5	US-10-450-763-46998	Sequence 46998, A
432	19	100.0	153	3	US-09-939-980-514	Sequence 514, App
433	19	100.0	153	3	US-09-905-176-22	Sequence 22, Appl
434	19	100.0	153	4	US-10-078-929-58	Sequence 58, Appl
435	19	100.0	153	4	US-10-213-880-6	Sequence 6, Appli
436	19	100.0	153	4	US-10-177-293-286	Sequence 286, App
437	19	100.0	153	4	US-10-094-749-2408	Sequence 2408, Ap
438	19	100.0	153	4	US-10-401-403-182	Sequence 182, App
439	19	100.0	153	4	US-10-335-977-6504	Sequence 6504, Ap
440	19	100.0	153	4	US-10-767-701-39142	Sequence 39142, A
441	19	100.0	153	4	US-10-425-115-261370	Sequence 261370,
442	19	100.0	153	5	US-10-739-930-10655	Sequence 10655, A
443	19	100.0	153	5	US-10-732-923-2213	Sequence 2213, Ap
444	19	100.0	153	5	US-10-732-923-2214	Sequence 2214, Ap
445	19	100.0	153	5	US-10-450-763-58009	Sequence 58009, A
446	19	100.0	154	4	US-10-282-122A-50893	Sequence 50893, A
447	19	100.0	154	4	US-10-335-977-4792	Sequence 4792, Ap
448	19	100.0	154	4	US-10-335-977-7337	Sequence 7337, Ap
449	19	100.0	154	4	US-10-437-963-129993	Sequence 129993,
450	19	100.0	154	4	US-10-437-963-143040	Sequence 143040,
451	19	100.0	154	4	US-10-425-115-288937	Sequence 288937,
452	19	100.0	155	4	US-10-425-114-42206	Sequence 42206, A
453	19	100.0	155	4	US-10-335-977-4791	Sequence 4791, Ap
454	19	100.0	155	4	US-10-437-963-197465	Sequence 197465,
455	19	100.0	155	4	US-10-781-014-88	Sequence 88, Appl
456	19	100.0	156	4	US-10-437-963-122605	Sequence 122605,
457	19	100.0	157	4	US-10-080-170-226	Sequence 226, App
458	19	100.0	157	4	US-10-425-114-59233	Sequence 59233, A
459	19	100.0	157	4	US-10-080-170-226	Sequence 226, App
460	19	100.0	157	4	US-10-468-356-226	Sequence 226, App
461	19	100.0	157	4	US-10-425-115-276031	Sequence 276031,
462	19	100.0	157	4	US-10-425-115-322287	Sequence 322287,
463	19	100.0	158	3	US-09-071-035-348	Sequence 348, App
464	19	100.0	158	3	US-09-890-688-12	Sequence 12, Appl
465	19	100.0	158	4	US-10-206-576-348	Sequence 348, App
466	19	100.0	158	4	US-10-043-487-233	Sequence 233, App
467	19	100.0	158	4	US-10-043-487-346	Sequence 346, App
468	19	100.0	158	4	US-10-767-701-62314	Sequence 62314, A
469	19	100.0	158	4	US-10-425-115-256315	Sequence 256315,
470	19	100.0	158	4	US-10-425-115-275635	Sequence 275635,
471	19	100.0	158	5	US-10-912-362-348	Sequence 348, App
472	19	100.0	159	4	US-10-156-761-13786	Sequence 13786, A
473	19	100.0	159	5	US-10-799-514-23	Sequence 23, Appl
474	19	100.0	160	4	US-10-451-467A-62	Sequence 62, Appl
475	19	100.0	161	4	US-10-156-761-11117	Sequence 11117, A
476	19	100.0	161	4	US-10-029-386-32368	Sequence 32368, A
477	19	100.0	161	4	US-10-425-114-43119	Sequence 43119, A
478	19	100.0	161	4	US-10-296-115-968	Sequence 968, App
479	19	100.0	161	4	US-10-437-963-189946	Sequence 189946,
480	19	100.0	161	4	US-10-451-467A-382	Sequence 382, App
481	19	100.0	161	4	US-10-767-701-49916	Sequence 49916, A
482	19	100.0	161	4	US-10-767-701-61985	Sequence 61985, A
483	19	100.0	161	4	US-10-425-115-330445	Sequence 330445,
484	19	100.0	161	4	US-10-425-115-356208	Sequence 356208,
485	19	100.0	162	4	US-10-080-170-243	Sequence 243, App
486	19	100.0	162	4	US-10-461-990-31	Sequence 31, Appl
487	19	100.0	162	4	US-10-080-170-243	Sequence 243, App
488	19	100.0	162	4	US-10-767-701-56786	Sequence 56786, A
489	19	100.0	162	4	US-10-468-356-243	Sequence 243, App
490	19	100.0	162	4	US-10-425-115-251896	Sequence 251896,
491	19	100.0	162	4	US-10-425-115-254077	Sequence 254077,
492	19	100.0	163	4	US-10-094-749-2612	Sequence 2612, Ap
493	19	100.0	163	4	US-10-289-762-103	Sequence 103, App
494	19	100.0	163	4	US-10-424-599-226266	Sequence 226266,
495	19	100.0	163	4	US-10-424-599-256875	Sequence 256875,
496	19	100.0	163	4	US-10-424-599-276381	Sequence 276381,
497	19	100.0	163	4	US-10-437-963-124774	Sequence 124774,
498	19	100.0	163	4	US-10-425-115-215847	Sequence 215847,
499	19	100.0	163	4	US-10-425-115-251012	Sequence 251012,
500	19	100.0	163	6	US-11-097-143-39597	Sequence 39597, A

ALIGNMENTS

RESULT 1
US-10-028-075B-2
; Sequence 2, Application US/10028075B
; Publication No. US20030113733A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Gene regulator
; FILE REFERENCE: 2183-5223US
; CURRENT APPLICATION NUMBER: US/10/028,075B
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: EP 01203748.7
; PRIOR FILING DATE: 2001-10-04
; NUMBER OF SEQ ID NOS: 175
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligopeptide
US-10-028-075B-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 2

US-10-029-206A-2
; Sequence 2, Application US/10029206A
; Publication No. US20030119720A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robert
; TITLE OF INVENTION: Oligopeptide treatment of anthrax
; FILE REFERENCE: 2183-5222US
; CURRENT APPLICATION NUMBER: US/10/029,206A
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 09/821,380
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 175
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligopeptide
US-10-029-206A-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 3
US-10-262-522A-15
; Sequence 15, Application US/10262522A
; Publication No. US20030166556A1
; GENERAL INFORMATION:
; APPLICANT: Khan, Nisar A.
; APPLICANT: Benner, Robbert
; TITLE OF INVENTION: Immunoregulator
; FILE REFERENCE: P52912US00
; CURRENT APPLICATION NUMBER: US/10/262,522A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: PCT/NL01/00259
; PRIOR FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: EP 00201139.3
; PRIOR FILING DATE: 2000-03-29
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (1)..(4)
; OTHER INFORMATION: ALA-replacement in peptide LQGV
US-10-262-522A-15

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 4
US-10-409-630-2
; Sequence 2, Application US/10409630
; Publication No. US20030215434A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBBERT
; TITLE OF INVENTION: TREATMENT OF MULTIPLE SCLEROSIS (MS)
; FILE REFERENCE: 3077-5953US
; CURRENT APPLICATION NUMBER: US/10/409,630
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-630-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 5
US-10-409-027-2
; Sequence 2, Application US/10409027
; Publication No. US20030219425A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR A.
; APPLICANT: BENNER, ROBBERT
; APPLICANT: YZERMANS, JOHANNES N.M.
; TITLE OF INVENTION: TREATMENT OF TRANSPLANT SURVIVAL
; FILE REFERENCE: 3077-5957US
; CURRENT APPLICATION NUMBER: US/10/409,027
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-409-027-2

Query Match 100.0%; Score 19; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 6
US-10-409-032-2
; Sequence 2, Application US/10409032
; Publication No. US20030220257A1
; GENERAL INFORMATION:
; APPLICANT: KHAN, NISAR AHMED
; APPLICANT: BENNER ROBBERT
; TITLE OF INVENTION: TREATMENT OF TRAUMA
; FILE REFERENCE: 3077-5952US
; CURRENT APPLICATION NUMBER: US/10/409,032
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/028,075

```
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-032-2

  Query Match            100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 7
US-10-409-642-2
; Sequence 2, Application US/10409642
; Publication No. US20030220258A1
; GENERAL INFORMATION:
;  APPLICANT: KHAN, NISAR A.
;  APPLICANT:  BENNER, ROBBERT
;  APPLICANT:  JACOBS, BARTHOLOMEUS C.
;  TITLE OF INVENTION: TREATMENT OF ISCHEMIC EVENTS
;  FILE REFERENCE: 3077-5957US
;  CURRENT APPLICATION NUMBER: US/10/409,642
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-642-2

  Query Match            100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 8
US-10-409-654-2
; Sequence 2, Application US/10409654
; Publication No. US20030220259A1
; GENERAL INFORMATION:
;  APPLICANT: KHAN, NISAR A.
;  APPLICANT:  BENNER, ROBBERT
;  APPLICANT:  WENSVOORT, GERT
;  TITLE OF INVENTION: TREATMENT OF NEUROLOGICAL DISORDERS
;  FILE REFERENCE: 3077-5958US
;  CURRENT APPLICATION NUMBER: US/10/409,654
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-654-2

  Query Match            100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 9
US-10-409-659-2
; Sequence 2, Application US/10409659
; Publication No. US20030220260A1
; GENERAL INFORMATION:
;  APPLICANT: KHAN, NISAR A.
;  APPLICANT:  BENNER, ROBBERT
;  TITLE OF INVENTION: PEPTIDE COMPOSITIONS
;  FILE REFERENCE: 3077-5956US
;  CURRENT APPLICATION NUMBER: US/10/409,659
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-659-2

  Query Match            100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 10
US-10-409-671-2
; Sequence 2, Application US/10409671
; Publication No. US20030220261A1
; GENERAL INFORMATION:
;  APPLICANT: KHAN, NISAR A.
;  APPLICANT:  BENNER, ROBBERT
;  TITLE OF INVENTION: TREATMENT OF IATROGENIC DISEASE
;  FILE REFERENCE: 3077-5955US
;  CURRENT APPLICATION NUMBER: US/10/409,671
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-671-2
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 11
US-10-409-694-2
; Sequence 2, Application US/10409694
; Publication No. US20030224995A1
; GENERAL INFORMATION:
;  APPLICANT: KHAN, NISAR A.
;  APPLICANT:  WENSVOORT, GERT
;  APPLICANT:  BENNER, ROBBERT
;  TITLE OF INVENTION: TREATMENT OF BURNS
;  FILE REFERENCE: 3077-5954US
;  CURRENT APPLICATION NUMBER: US/10/409,694
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-694-2

  Query Match           100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 12
US-10-409-657-2
; Sequence 2, Application US/10409657
; Publication No. US20040013661A1
; GENERAL INFORMATION:
;  APPLICANT: WENSVOORT, GERT
;  APPLICANT:  KHAN, NISAR A.
;  APPLICANT:  BENNER, ROBBERT
;  TITLE OF INVENTION: STRATIFICATION
;  FILE REFERENCE: 3077-5960US
;  CURRENT APPLICATION NUMBER: US/10/409,657
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-409-657-2

  Query Match           100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 13
US-10-409-668-2
; Sequence 2, Application US/10409668
; Publication No. US20040202645A1
; GENERAL INFORMATION:
;  APPLICANT: Khan, Nisar A.
;  APPLICANT:  Benner, Robbert
;  TITLE OF INVENTION: Treatment of Transplant Survival
;  FILE REFERENCE: 3077-5959US
;  CURRENT APPLICATION NUMBER: US/10/409,668
;  CURRENT FILING DATE:  2003-04-08
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic peptide
US-10-409-668-2

  Query Match           100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 14
US-10-753-510-2
; Sequence 2, Application US/10753510
; Publication No. US20040208885A1
; GENERAL INFORMATION:
;  APPLICANT: Khan, Nisar A.
;  APPLICANT:  Benner, Robert
;  TITLE OF INVENTION: Gene regulator
;  FILE REFERENCE: 2183-5223US
;  CURRENT APPLICATION NUMBER: US/10/753,510
;  CURRENT FILING DATE:  2004-01-07
;  PRIOR APPLICATION NUMBER: US/10/028,075B
;  PRIOR FILING DATE: 2001-12-21
;  PRIOR APPLICATION NUMBER: EP 01203748.7
;  PRIOR FILING DATE: 2001-10-04
;  NUMBER OF SEQ ID NOS: 175
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: oligopeptide
US-10-753-510-2

  Query Match           100.0%;  Score 19;  DB 4;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 15
US-10-821-240A-2
; Sequence 2, Application US/10821240A
; Publication No. US20050037430A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Khan, Nisar A.
;  APPLICANT:  Benner, Robert
;  TITLE OF INVENTION: Gene regulator
;  FILE REFERENCE: 2183-5223US
;  CURRENT APPLICATION NUMBER: US/10/821,240A
;  CURRENT FILING DATE:  2004-04-08
;  PRIOR APPLICATION NUMBER: 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  PRIOR APPLICATION NUMBER: EP 01203748.7
;  PRIOR FILING DATE: 2001-10-04
;  NUMBER OF SEQ ID NOS: 312
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Derivative of SEQ ID NO:1
US-10-821-240A-2

  Query Match           100.0%;  Score 19;  DB 5;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 16
US-10-817-756A-12
; Sequence 12, Application US/10817756A
; Publication No. US20050214943A1
; GENERAL INFORMATION:
;  APPLICANT: Khan, Nisar A.
;  APPLICANT:  Benner, Robbert
;  APPLICANT:  Erasmus Universiteit Rotterdam
;  TITLE OF INVENTION: Gene regulatory peptides
;  FILE REFERENCE: 2183-6400US
;  CURRENT APPLICATION NUMBER: US/10/817,756A
;  CURRENT FILING DATE:  2004-04-02
;  PRIOR APPLICATION NUMBER: PCT/NL02/00639
;  PRIOR FILING DATE: 2002-10-04
;  PRIOR APPLICATION NUMBER: EP 01203748.7
;  PRIOR FILING DATE: 2001-10-04
;  PRIOR APPLICATION NUMBER: US 10/028,075
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Chemically synthesized peptid
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (1)..(4)
US-10-817-756A-12

  Query Match           100.0%;  Score 19;  DB 5;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 17
US-10-821-256-2
; Sequence 2, Application US/10821256
; Publication No. US20050227925A1
; GENERAL INFORMATION:
;  APPLICANT: Khan, Nisar A
;  APPLICANT:  Benner, Robbert
;  TITLE OF INVENTION: Compositions Capable of Reducing Elevated Blood Urea
;  TITLE OF INVENTION:  Concentration
;  FILE REFERENCE: 3077-6420
;  CURRENT APPLICATION NUMBER: US/10/821,256
;  CURRENT FILING DATE:  2004-04-08
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthesized Peptide
US-10-821-256-2

  Query Match           100.0%;  Score 19;  DB 5;  Length 4;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 18
US-10-946-647-184
; Sequence 184, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
;  APPLICANT: EMERY, DARYLL A.
;  APPLICANT:  STRAUB, DARREN E.
;  APPLICANT:  WONDERLING, LAURA
;  TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
;  FILE REFERENCE: 293.00340101
;  CURRENT APPLICATION NUMBER: US/10/946,647
;  CURRENT FILING DATE:  2004-09-20
;  PRIOR APPLICATION NUMBER: 60/504,119
;  PRIOR FILING DATE: 2003-09-19
;  NUMBER OF SEQ ID NOS: 1448
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Salmonella enterica
US-10-946-647-184

  Query Match           100.0%;  Score 19;  DB 5;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 19
US-10-946-647-558
; Sequence 558, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
;  APPLICANT: EMERY, DARYLL A.
;  APPLICANT:  STRAUB, DARREN E.
;  APPLICANT:  WONDERLING, LAURA
;  TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
;  FILE REFERENCE: 293.00340101
;  CURRENT APPLICATION NUMBER: US/10/946,647
;  CURRENT FILING DATE:  2004-09-20
;  PRIOR APPLICATION NUMBER: 60/504,119
;  PRIOR FILING DATE: 2003-09-19
;  NUMBER OF SEQ ID NOS: 1448
```

```
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 558
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Salmonella enteritidis
US-10-946-647-558

  Query Match            100.0%;  Score 19;  DB 5;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 20
US-10-946-647-855
; Sequence 855, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
;  APPLICANT: EMERY, DARYLL A.
;  APPLICANT:  STRAUB, DARREN E.
;  APPLICANT:  WONDERLING, LAURA
;  TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
;  FILE REFERENCE: 293.00340101
;  CURRENT APPLICATION NUMBER: US/10/946,647
;  CURRENT FILING DATE:  2004-09-20
;  PRIOR APPLICATION NUMBER: 60/504,119
;  PRIOR FILING DATE: 2003-09-19
;  NUMBER OF SEQ ID NOS: 1448
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 855
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Escherichia coli
US-10-946-647-855

  Query Match            100.0%;  Score 19;  DB 5;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 21
US-10-946-647-954
; Sequence 954, Application US/10946647
; Publication No. US20050186217A1
; GENERAL INFORMATION:
;  APPLICANT: EMERY, DARYLL A.
;  APPLICANT:  STRAUB, DARREN E.
;  APPLICANT:  WONDERLING, LAURA
;  TITLE OF INVENTION: COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE
;  FILE REFERENCE: 293.00340101
;  CURRENT APPLICATION NUMBER: US/10/946,647
;  CURRENT FILING DATE:  2004-09-20
;  PRIOR APPLICATION NUMBER: 60/504,119
;  PRIOR FILING DATE: 2003-09-19
;  NUMBER OF SEQ ID NOS: 1448
;  SOFTWARE: PatentIn version 3.3
; SEQ ID NO 954
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Escherichia coli
US-10-946-647-954

  Query Match            100.0%;  Score 19;  DB 5;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 22
US-10-122-675-28
; Sequence 28, Application US/10122675
; Publication No. US20030194712A1
; GENERAL INFORMATION:
;  APPLICANT: Anderson, David
;  APPLICANT:  Li, Weiqun
;  APPLICANT:  Lu, Henry
;  APPLICANT:  Rigel Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Methods for Identifying Polypeptide Factors Interacting
;  TITLE OF INVENTION:  With RNA
;  FILE REFERENCE: 021044-002000US
;  CURRENT APPLICATION NUMBER: US/10/122,675
;  CURRENT FILING DATE:  2002-10-31
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:inosine
;   OTHER INFORMATION: monophosphate dehydrogenase (IMPDH) peptide
US-10-122-675-28

  Query Match            100.0%;  Score 19;  DB 4;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 23
US-09-957-806A-115
; Sequence 115, Application US/09957806A
; Publication No. US20050181446A1
; GENERAL INFORMATION:
;  APPLICANT: Roggen, Erwin
;  APPLICANT:  Ernst, Steffen
;  APPLICANT:  Svendsen, Allan
;  APPLICANT:  Friis, Esben
;  APPLICANT:  Osten, Claus
;  TITLE OF INVENTION: PROTEIN VARIANTS HAVING MODIFIED IMMUNOGENICITY
;  FILE REFERENCE: 10021.204-US
;  CURRENT APPLICATION NUMBER: US/09/957,806A
;  CURRENT FILING DATE:  2001-09-21
;  NUMBER OF SEQ ID NOS: 248
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 115
;   LENGTH: 13
;   TYPE: PRT
;   ORGANISM: Thermomyces
US-09-957-806A-115

  Query Match            100.0%;  Score 19;  DB 3;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 24
US-10-394-980-6
; Sequence 6, Application US/10394980
```

```
; Publication No. US20040005633A1
; GENERAL INFORMATION:
;  APPLICANT: Vandekerckhove, Joel
;  APPLICANT:  Gevaert, Kris
;  TITLE OF INVENTION: METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND
;  TITLE OF INVENTION:  QUANTITATIVE PROTEOME ANALYSIS, AND USES THEREFOR
;  FILE REFERENCE: VBV-001
;  CURRENT APPLICATION NUMBER: US/10/394,980
;  CURRENT FILING DATE:  2003-03-21
;  PRIOR APPLICATION NUMBER: PCT/EP02/03368
;  PRIOR FILING DATE: 2002-03-22
;  PRIOR APPLICATION NUMBER: US60/278,171
;  PRIOR FILING DATE: 2001-03-22
;  PRIOR APPLICATION NUMBER: US60/318,749
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US60/323,999
;  PRIOR FILING DATE: 2001-09-20
;  NUMBER OF SEQ ID NOS: 473
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   OTHER INFORMATION: part of AMBP_HUMAN ((P02760) alphae-1-microglobulin)
US-10-394-980-6

  Query Match             100.0%;  Score 19;  DB 4;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 6.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 25
US-10-952-557-6
; Sequence 6, Application US/10952557
; Publication No. US20050196823A1
; GENERAL INFORMATION:
;  APPLICANT: Vandekerckhove, Joel
;  APPLICANT:  Gevaert, Kris
;  TITLE OF INVENTION: METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND
;  TITLE OF INVENTION:  QUANTITATIVE PROTEOME ANALYSIS, AND USES THEREFOR
;  FILE REFERENCE: VBV-001
;  CURRENT APPLICATION NUMBER: US/10/952,557
;  CURRENT FILING DATE:  2004-09-28
;  PRIOR APPLICATION NUMBER: US/10/394,980
;  PRIOR FILING DATE: 2003-03-21
;  PRIOR APPLICATION NUMBER: PCT/EP02/03368
;  PRIOR FILING DATE: 2002-03-22
;  PRIOR APPLICATION NUMBER: US60/278,171
;  PRIOR FILING DATE: 2001-03-22
;  PRIOR APPLICATION NUMBER: US60/318,749
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US60/323,999
;  PRIOR FILING DATE: 2001-09-20
;  NUMBER OF SEQ ID NOS: 473
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   OTHER INFORMATION: part of AMBP_HUMAN ((P02760) alphae-1-microglobulin)
US-10-952-557-6

  Query Match             100.0%;  Score 19;  DB 5;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 6.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 26
US-09-397-945-430
; Sequence 430, Application US/09397945
; Publication No. US20030065139A1
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc. et al.
;  TITLE OF INVENTION: 95 Human secreted proteins
;  FILE REFERENCE: PZ027P1
;  CURRENT APPLICATION NUMBER: US/09/397,945
;  CURRENT FILING DATE:  1999-09-17
;  PRIOR APPLICATION NUMBER: PCT/US99/05804
;  PRIOR FILING DATE: 1999-03-18
;  PRIOR APPLICATION NUMBER: 60/078,566
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,576
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,573
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,574
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,579
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/080,314
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/080,312
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/078,578
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,581
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,577
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,563
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/080,313
;  PRIOR FILING DATE: 1998-04-01
;  NUMBER OF SEQ ID NOS: 470
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 430
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-397-945-430

  Query Match             100.0%;  Score 19;  DB 3;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 27
US-10-280-066-401
; Sequence 401, Application US/10280066
; Publication No. US20030180718A1
; GENERAL INFORMATION:
;  APPLICANT: Pillutla, Renuka C.
;  APPLICANT:  Brissette, Renee
;  APPLICANT:  Spruyt, Michael
;  APPLICANT:  Dedova, Olga
;  APPLICANT:  Blume, Arthur J.
;  APPLICANT:  Prendergast, John
;  APPLICANT:  Goldstein, Neil I.
;  TITLE OF INVENTION: TARGET SPECIFIC SCREENING AND ITS USE FOR IDENTIFYING TARGET BINDI
;  FILE REFERENCE: 2598-4009US1
```

```
;  CURRENT APPLICATION NUMBER: US/10/280,066
;  CURRENT FILING DATE:  2002-10-24
;  PRIOR APPLICATION NUMBER: 60/345,471
;  PRIOR FILING DATE: 2001-10-24
;  NUMBER OF SEQ ID NOS: 537
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 401
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Eschericia coli
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   OTHER INFORMATION: VEGFR1-20F-3-B6
US-10-280-066-401

  Query Match           100.0%;  Score 19;  DB 4;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 6.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 28
US-10-653-595-430
; Sequence 430, Application US/10653595
; Publication No. US20040048304A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et. al.
;  TITLE OF INVENTION: 95 Human secreted proteins
;  FILE REFERENCE: PZ027P1C1
;  CURRENT APPLICATION NUMBER: US/10/653,595
;  CURRENT FILING DATE:  2003-09-03
;  PRIOR APPLICATION NUMBER: US 09/397945
;  PRIOR FILING DATE: 1999-09-17
;  PRIOR APPLICATION NUMBER: PCT/US99/05804
;  PRIOR FILING DATE: 1999-03-18
;  PRIOR APPLICATION NUMBER: 60/078,566
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,576
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,573
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,574
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,579
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/080,314
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/080,312
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/078,578
;  PRIOR FILING DATE: 1998-03-19
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 470
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 430
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-653-595-430

  Query Match           100.0%;  Score 19;  DB 4;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 6.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 29
US-10-241-814-13
; Sequence 13, Application US/10241814
; Publication No. US20040053391A1
; GENERAL INFORMATION:
;  APPLICANT: Katholieke Universiteit Nijmegen
;  TITLE OF INVENTION: Renal cell carcinoma antigen G-250-derived peptides that
;  TITLE OF INVENTION:  elicit both CD4 and CD8 T-cell responses
;  FILE REFERENCE: 470-021777
;  CURRENT APPLICATION NUMBER: US/10/241,814
;  CURRENT FILING DATE:  2002-09-11
;  NUMBER OF SEQ ID NOS: 16
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-241-814-13

  Query Match           100.0%;  Score 19;  DB 4;  Length 20;
  Best Local Similarity  100.0%;  Pred. No. 6.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 30
US-10-377-134-8
; Sequence 8, Application US/10377134
; Publication No. US20040096938A1
; GENERAL INFORMATION:
;  APPLICANT: XU, Ming-Qun
;  APPLICANT:  EVANS, Thomas C.
;  APPLICANT:  PRADHAN, Sriharsa
;  APPLICANT:  COMB, Donald G.
;  APPLICANT:  PAULUS, Henry
;  APPLICANT:  SUN, Luo
;  APPLICANT:  CHEN, Lixin
;  APPLICANT:  GHOSH, Inca
;  TITLE OF INVENTION: METHOD FOR GENERATING SPLIT, NON-TRANSFERABLE GENES
;  TITLE OF INVENTION:  THAT ARE ABLE TO EXPRESS AN ACTIVE PROTEIN PRODUCT
;  FILE REFERENCE: NEB-219
;  CURRENT APPLICATION NUMBER: US/10/377,134
;  CURRENT FILING DATE:  2003-02-28
;  PRIOR APPLICATION NUMBER: 09/936,588
;  PRIOR FILING DATE: 2002-03-29
;  PRIOR APPLICATION NUMBER: PCT/US00/14122
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 60/135,677
;  PRIOR FILING DATE: 1999-05-24
;  NUMBER OF SEQ ID NOS: 138
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 21
;   TYPE: PRT
;   ORGANISM: Escherichia coli
US-10-377-134-8

  Query Match           100.0%;  Score 19;  DB 4;  Length 21;
  Best Local Similarity  100.0%;  Pred. No. 7.1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 31
US-10-872-770-12
; Sequence 12, Application US/10872770
; Publication No. US20050164362A1
; GENERAL INFORMATION:
;  APPLICANT: EDWARDS, ALED
```

```
;  APPLICANT:  DHARAMSI, AKIL
;  APPLICANT:  DOMAGALIA, MEGAN
;  APPLICANT:  PINDER, BENJAMIN
;  APPLICANT:  ALAM, MUHAMMAD ZAHOO
;  APPLICANT:  VEDADI, MASOUD
;  APPLICANT:  WREZEL, OLGA
;  APPLICANT:  HOUSTON, SIMON
;  APPLICANT:  KIMBER, MATTHEW
;  APPLICANT:  VALLEE, FRANCOIS
;  APPLICANT:  AWREY, DONALD E.
;  APPLICANT:  BEATTIE, BRYAN
;  TITLE OF INVENTION: NOVEL PURIFIED POLYPEPTIDES FROM PSEUDOMONAS AERUGINOSA
;  FILE REFERENCE: IPT-191.01
;  CURRENT APPLICATION NUMBER: US/10/872,770
;  CURRENT FILING DATE:  2004-06-21
;  PRIOR APPLICATION NUMBER: PCT/CA02/01977
;  PRIOR FILING DATE: 2002-12-20
;  PRIOR APPLICATION NUMBER: 60/370,755
;  PRIOR FILING DATE: 2002-04-08
;  PRIOR APPLICATION NUMBER: 60/344,112
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
;   LENGTH: 21
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-10-872-770-12

  Query Match             100.0%;  Score 19;  DB 5;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 7.1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         12 AQGV 15


RESULT 32
US-10-097-065-597
; Sequence 597, Application US/10097065
; Publication No. US20030055236A1
; GENERAL INFORMATION:
;  APPLICANT: Moore, Paul A. et al.
;  TITLE OF INVENTION: 110 Human Secreted Proteins
;  FILE REFERENCE: PZ021P1
;  CURRENT APPLICATION NUMBER: US/10/097,065
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: PCT/US98/27059
;  PRIOR FILING DATE: 1998-12-17
;  PRIOR APPLICATION NUMBER: 60/070,923
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,007
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,057
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,006
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,369
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,367
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,368
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,169
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,053
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,064
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,054
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,008
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,365
;  PRIOR FILING DATE: 1997-12-19
;  NUMBER OF SEQ ID NOS: 672
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 597
;   LENGTH: 23
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-097-065-597

  Query Match             100.0%;  Score 19;  DB 4;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 33
US-10-372-876-597
; Sequence 597, Application US/10372876
; Publication No. US20030204071A1
; GENERAL INFORMATION:
;  APPLICANT: Moore, Paul A. et al.
;  TITLE OF INVENTION: 110 Human Secreted Proteins
;  FILE REFERENCE: PZ021P1
;  CURRENT APPLICATION NUMBER: US/10/372,876
;  CURRENT FILING DATE:  2003-02-26
;  PRIOR APPLICATION NUMBER: 09/334,595
;  PRIOR FILING DATE: 1999-06-17
;  PRIOR APPLICATION NUMBER: PCT/US98/27059
;  PRIOR FILING DATE: 1998-12-17
;  PRIOR APPLICATION NUMBER: 60/070,923
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,007
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,057
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,006
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,369
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,367
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,368
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/068,169
;  PRIOR FILING DATE: 1997-12-19
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 672
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 597
;   LENGTH: 23
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-372-876-597

  Query Match             100.0%;  Score 19;  DB 4;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 34
US-09-880-748-2176
; Sequence 2176, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
;  FILE REFERENCE: PF523
;  CURRENT APPLICATION NUMBER: US/09/880,748
;  CURRENT FILING DATE:  2001-06-15
;  PRIOR APPLICATION NUMBER: 60/212,210
;  PRIOR FILING DATE: 2000-06-15
;  PRIOR APPLICATION NUMBER: 60/240,816
;  PRIOR FILING DATE: 2000-10-17
;  PRIOR APPLICATION NUMBER: 60/276,248
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 60/277,379
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/293,499
;  PRIOR FILING DATE: 2001-05-25
;  NUMBER OF SEQ ID NOS: 3239
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2176
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-880-748-2176

  Query Match             100.0%;  Score 19;  DB 3;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 8.1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 35
US-09-880-748-2969
; Sequence 2969, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
;  FILE REFERENCE: PF523
;  CURRENT APPLICATION NUMBER: US/09/880,748
;  CURRENT FILING DATE:  2001-06-15
;  PRIOR APPLICATION NUMBER: 60/212,210
;  PRIOR FILING DATE: 2000-06-15
;  PRIOR APPLICATION NUMBER: 60/240,816
;  PRIOR FILING DATE: 2000-10-17
;  PRIOR APPLICATION NUMBER: 60/276,248
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 60/277,379
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/293,499
;  PRIOR FILING DATE: 2001-05-25
;  NUMBER OF SEQ ID NOS: 3239
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2969
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-880-748-2969

  Query Match             100.0%;  Score 19;  DB 3;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 8.1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 36
US-10-293-418-2176
; Sequence 2176, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
;  FILE REFERENCE: PF523P2
;  CURRENT APPLICATION NUMBER: US/10/293,418
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: 60/331,469
;  PRIOR FILING DATE: 2001-11-16
;  PRIOR APPLICATION NUMBER: 60/340,817
;  PRIOR FILING DATE: 2001-12-19
;  PRIOR APPLICATION NUMBER: 09/880,748
;  PRIOR FILING DATE: 2001-06-15
;  PRIOR APPLICATION NUMBER: 60/293,499
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 60/277,379
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/276,248
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 60/240,816
;  PRIOR FILING DATE: 2000-10-17
;  PRIOR APPLICATION NUMBER: 60/212,210
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2176
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-293-418-2176

  Query Match             100.0%;  Score 19;  DB 4;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 8.1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 37
US-10-293-418-2969
; Sequence 2969, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Antibodies that Immunospecifically Bind BLyS
;  FILE REFERENCE: PF523P2
;  CURRENT APPLICATION NUMBER: US/10/293,418
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: 60/331,469
;  PRIOR FILING DATE: 2001-11-16
;  PRIOR APPLICATION NUMBER: 60/340,817
;  PRIOR FILING DATE: 2001-12-19
;  PRIOR APPLICATION NUMBER: 09/880,748
;  PRIOR FILING DATE: 2001-06-15
;  PRIOR APPLICATION NUMBER: 60/293,499
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 60/277,379
;  PRIOR FILING DATE: 2001-03-21
;  PRIOR APPLICATION NUMBER: 60/276,248
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 60/240,816
;  PRIOR FILING DATE: 2000-10-17
;  PRIOR APPLICATION NUMBER: 60/212,210
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2969
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-293-418-2969

  Query Match             100.0%;  Score 19;  DB 4;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 8.1e+02;
```

```
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 38
US-09-864-761-45997
; Sequence 45997, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 45997
;   LENGTH: 25
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC012614.3
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.7
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.7
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL =  50
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.7
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.8
US-09-864-761-45997

  Query Match           100.0%;  Score 19;  DB 3;  Length 25;
  Best Local Similarity  100.0%;  Pred. No. 8.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         16 AQGV 19


RESULT 39
US-10-269-806-80
; Sequence 80, Application US/10269806
; Publication No. US20030176352A1
; GENERAL INFORMATION:
;  APPLICANT: Min, Hosung
;  APPLICANT:  Sitney, Karen
;  APPLICANT:  Hartley, Cynthia
;  TITLE OF INVENTION: Peptides and Related Compounds Having Thrombopoietic Activity
;  FILE REFERENCE: A-750
;  CURRENT APPLICATION NUMBER: US/10/269,806
;  CURRENT FILING DATE:  2002-10-10
;  NUMBER OF SEQ ID NOS: 199
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 80
;   LENGTH: 25
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthesized Peptide Sequence
US-10-269-806-80

  Query Match           100.0%;  Score 19;  DB 4;  Length 25;
  Best Local Similarity  100.0%;  Pred. No. 8.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 40
US-10-029-386-33755
; Sequence 33755, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GI
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33755
;   LENGTH: 25
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC007869.2
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.4
US-10-029-386-33755

  Query Match           100.0%;  Score 19;  DB 4;  Length 25;
  Best Local Similarity  100.0%;  Pred. No. 8.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

```
RESULT 41
US-10-424-599-169158
; Sequence 169158, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 169158
;   LENGTH: 29
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_123764C.1.pep
US-10-424-599-169158

  Query Match             100.0%;  Score 19;  DB 4;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 9.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 42
US-10-424-599-281150
; Sequence 281150, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 281150
;   LENGTH: 29
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_95900C.1.pep
US-10-424-599-281150

  Query Match             100.0%;  Score 19;  DB 4;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 9.8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          7 AQGV 10


RESULT 43
US-10-800-023-1
; Sequence 1, Application US/10800023
; Publication No. US20040258688A1
; GENERAL INFORMATION:
;  APPLICANT: Steinman, Ralph
;  APPLICANT:  Nussenzweig, Michel
;  APPLICANT:  Hawiger, Daniel
;  APPLICANT:  Bonifaz, Laura
;  TITLE OF INVENTION: Enhanced Antigen Delivery and Modulation
;  TITLE OF INVENTION:  of the Immune Response Therefrom
;  FILE REFERENCE: 600-1-081CONCIP1
;  CURRENT APPLICATION NUMBER: US/10/800,023
;  CURRENT FILING DATE:  2004-03-14
;  PRIOR APPLICATION NUMBER: 09/925,284
;  PRIOR FILING DATE: 2001-08-09
;  PRIOR APPLICATION NUMBER: 09/586,704
;  PRIOR FILING DATE: 2000-06-05
;  PRIOR APPLICATION NUMBER: PCT/US96/01383
;  PRIOR FILING DATE: 1996-01-31
;  PRIOR APPLICATION NUMBER: 08/381,528
;  PRIOR FILING DATE: 1995-01-31
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-800-023-1

  Query Match             100.0%;  Score 19;  DB 5;  Length 30;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         15 AQGV 18


RESULT 44
US-10-424-599-261845
; Sequence 261845, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 261845
;   LENGTH: 33
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_78469C.1.pep
US-10-424-599-261845

  Query Match             100.0%;  Score 19;  DB 4;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         26 AQGV 29


RESULT 45
US-10-425-115-199464
; Sequence 199464, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
```

```
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 199464
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(34)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_113486C.1.pep
US-10-425-115-199464

  Query Match            100.0%;  Score 19;  DB 4;  Length 34;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         14 AQGV 17


RESULT 46
US-10-424-599-242322
; Sequence 242322, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 242322
;   LENGTH: 35
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_60845C.1.pep
US-10-424-599-242322

  Query Match            100.0%;  Score 19;  DB 4;  Length 35;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 47
US-10-252-773-11
; Sequence 11, Application US/10252773
; Publication No. US20030131383A1
; GENERAL INFORMATION:
;  APPLICANT: EVERETT, NICHOLAS P.
;  APPLICANT:  LI, QUNIGSHUN
;  APPLICANT:  LAWRENCE, CHRISTOPHER
;  APPLICANT:  DAVIES, MAELOR H.
;  TITLE OF INVENTION: PEPTIDES WITH ENHANCED STABILITY TO PROTEASE
;  TITLE OF INVENTION:  DEGRADATION
;  FILE REFERENCE: INTERLINK 3.0-003
;  CURRENT APPLICATION NUMBER: US/10/252,773
;  CURRENT FILING DATE:  2002-09-23
;  PRIOR APPLICATION NUMBER: 60/106,373
;  PRIOR FILING DATE: 1998-10-30
;  PRIOR APPLICATION NUMBER: 60/106,573
;  PRIOR FILING DATE: 1998-11-02
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 37
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: antimicrobial peptide
US-10-252-773-11

  Query Match            100.0%;  Score 19;  DB 4;  Length 37;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 48
US-10-120-319-22
; Sequence 22, Application US/10120319
; Publication No. US20020164749A1
; GENERAL INFORMATION:
;  APPLICANT: Taylor, Diane E.
;  APPLICANT:  Ge, Zhongming
;  TITLE OF INVENTION: ALPHA-1, 3-FUCOSYLTRANFERASE
;  FILE REFERENCE: 07254/049001
;  CURRENT APPLICATION NUMBER: US/10/120,319
;  CURRENT FILING DATE:  2002-04-09
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/092,315
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/048,857
;  PRIOR FILING DATE: EARLIER FILING DATE: 1997-06-06
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 38
;   TYPE: PRT
;   ORGANISM: Helicobacter pylori
US-10-120-319-22

  Query Match            100.0%;  Score 19;  DB 4;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         35 AQGV 38


RESULT 49
US-10-189-977-22
; Sequence 22, Application US/10189977
; Publication No. US20030166211A1
; GENERAL INFORMATION:
;  APPLICANT: Taylor, Diane E.
;  APPLICANT:  Ge, Zhongming
;  TITLE OF INVENTION: ALPHA-1, 3-FUCOSYLTRANFERASE
;  FILE REFERENCE: 07254/049001
;  CURRENT APPLICATION NUMBER: US/10/189,977
;  CURRENT FILING DATE:  2002-07-03
;  PRIOR APPLICATION NUMBER: US/09/092,315
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: US 60/048,857
;  PRIOR FILING DATE: 1997-06-06
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 38
```

```
;   TYPE: PRT
;   ORGANISM: Helicobacter pylori
US-10-189-977-22

  Query Match             100.0%;  Score 19;  DB 4;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         35 AQGV 38


RESULT 50
US-10-392-098-22
; Sequence 22, Application US/10392098
; Publication No. US20030166212A1
; GENERAL INFORMATION:
;  APPLICANT: Taylor, Diane E.
;  APPLICANT:  Ge, Zhongming
;  TITLE OF INVENTION: NUCLEIC ACIDS ENCODING ALPHA-1,3
;  TITLE OF INVENTION:  FUCOSYLTRANSFERASES AND EXPRESSION SYSTEMS FOR MAKING AND
;  TITLE OF INVENTION:  EXPRESSING THEM (amended)
;  FILE REFERENCE: 07254-049002
;  CURRENT APPLICATION NUMBER: US/10/392,098
;  CURRENT FILING DATE:  2003-03-17
;  PRIOR APPLICATION NUMBER: US/09/733,524A
;  PRIOR FILING DATE: 2000-12-07
;  PRIOR APPLICATION NUMBER: US 09/092,315
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: US 60/048,857
;  PRIOR FILING DATE: 1997-06-06
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 22
;   LENGTH: 38
;   TYPE: PRT
;   ORGANISM: Helicobacter pylori
US-10-392-098-22

  Query Match             100.0%;  Score 19;  DB 4;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         35 AQGV 38


RESULT 51
US-10-029-386-33511
; Sequence 33511, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33511
;   LENGTH: 38
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC003955.1
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.43
US-10-029-386-33511

  Query Match             100.0%;  Score 19;  DB 4;  Length 38;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 52
US-10-425-115-195035
; Sequence 195035, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 195035
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_109461C.1.pep
US-10-425-115-195035

  Query Match             100.0%;  Score 19;  DB 4;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         22 AQGV 25


RESULT 53
US-10-282-122A-45229
; Sequence 45229, Application US/10282122A
; Publication No. US20040029129A1
; GENERAL INFORMATION:
;  APPLICANT: Wang, Liangsu
;  APPLICANT:  Zamudio, Carlos
;  APPLICANT:  Malone, Cheryl
;  APPLICANT:  Haselbeck, Robert
;  APPLICANT:  Ohlsen, Kari
;  APPLICANT:  Zyskind, Judith
;  APPLICANT:  Wall, Daniel
;  APPLICANT:  Trawick, John
;  APPLICANT:  Carr, Grant
;  APPLICANT:  Yamamoto, Robert
;  APPLICANT:  Forsyth, R.
;  APPLICANT:  Xu, H.
;  TITLE OF INVENTION: Identification of Essential Genes in Microorganisms
;  FILE REFERENCE: ELITRA.034A
;  CURRENT APPLICATION NUMBER: US/10/282,122A
;  CURRENT FILING DATE:  2003-02-20
;  PRIOR APPLICATION NUMBER: 60/191,078
;  PRIOR FILING DATE: 2000-03-21
;  PRIOR APPLICATION NUMBER: 60/206,848
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 60/207,727
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/230,335
;  PRIOR FILING DATE: 2000-09-06
;  PRIOR APPLICATION NUMBER: 60/230,347
;  PRIOR FILING DATE: 2000-09-09
;  PRIOR APPLICATION NUMBER: 60/242,578
```

```
;  PRIOR FILING DATE: 2000-10-23
;  PRIOR APPLICATION NUMBER: 60/253,625
;  PRIOR FILING DATE: 2000-11-27
;  PRIOR APPLICATION NUMBER: 60/257,931
;  PRIOR FILING DATE: 2000-12-22
;  PRIOR APPLICATION NUMBER: 60/267,636
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/269,308
;  PRIOR FILING DATE: 2001-02-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 78614
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 45229
;   LENGTH: 41
;   TYPE: PRT
;   ORGANISM: Acinetobacter baumannii
US-10-282-122A-45229

  Query Match           100.0%;  Score 19;  DB 4;  Length 41;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 54
US-10-425-115-257966
; Sequence 257966, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 257966
;   LENGTH: 41
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_166852C.1.pep
US-10-425-115-257966

  Query Match           100.0%;  Score 19;  DB 4;  Length 41;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         26 AQGV 29


RESULT 55
US-10-773-446-115
; Sequence 115, Application US/10773446
; Publication No. US20050176662A1
; GENERAL INFORMATION:
;  APPLICANT: INANA, GEORGE
;  APPLICANT:  McLAREN, MARGARET
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETECTING AND TREATING RETINAL
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 39532-192229
;  CURRENT APPLICATION NUMBER: US/10/773,446
;  CURRENT FILING DATE:  2004-02-09
;  NUMBER OF SEQ ID NOS: 131
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 115
;   LENGTH: 41
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-773-446-115

  Query Match           100.0%;  Score 19;  DB 5;  Length 41;
  Best Local Similarity  100.0%;  Pred. No. 1.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         12 AQGV 15


RESULT 56
US-10-425-115-280416
; Sequence 280416, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 280416
;   LENGTH: 43
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_18840C.1.pep
US-10-425-115-280416

  Query Match           100.0%;  Score 19;  DB 4;  Length 43;
  Best Local Similarity  100.0%;  Pred. No. 1.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         31 AQGV 34


RESULT 57
US-10-425-115-256443
; Sequence 256443, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 256443
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_165468C.1.pep
US-10-425-115-256443

  Query Match           100.0%;  Score 19;  DB 4;  Length 44;
  Best Local Similarity  100.0%;  Pred. No. 1.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db         15 AQGV 18


RESULT 58
US-09-397-945-424
; Sequence 424, Application US/09397945
; Publication No. US20030065139A1
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc. et al.
;  TITLE OF INVENTION: 95 Human secreted proteins
;  FILE REFERENCE: PZ027P1
;  CURRENT APPLICATION NUMBER: US/09/397,945
;  CURRENT FILING DATE:  1999-09-17
;  PRIOR APPLICATION NUMBER: PCT/US99/05804
;  PRIOR FILING DATE: 1999-03-18
;  PRIOR APPLICATION NUMBER: 60/078,566
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,576
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,573
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,574
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,579
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/080,314
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/080,312
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/078,578
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,581
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,577
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,563
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/080,313
;  PRIOR FILING DATE: 1998-04-01
;  NUMBER OF SEQ ID NOS: 470
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 424
;   LENGTH: 48
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-397-945-424

  Query Match             100.0%;  Score 19;  DB 3;  Length 48;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         33 AQGV 36


RESULT 59
US-10-424-599-203996
; Sequence 203996, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 203996
;   LENGTH: 48
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_26235C.1.pep
US-10-424-599-203996

  Query Match             100.0%;  Score 19;  DB 4;  Length 48;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         12 AQGV 15


RESULT 60
US-10-424-599-216178
; Sequence 216178, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 216178
;   LENGTH: 48
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_37238C.1.pep
US-10-424-599-216178

  Query Match             100.0%;  Score 19;  DB 4;  Length 48;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         10 AQGV 13


RESULT 61
US-10-653-595-424
; Sequence 424, Application US/10653595
; Publication No. US20040048304A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et. al.
;  TITLE OF INVENTION: 95 Human secreted proteins
;  FILE REFERENCE: PZ027P1C1
;  CURRENT APPLICATION NUMBER: US/10/653,595
;  CURRENT FILING DATE:  2003-09-03
;  PRIOR APPLICATION NUMBER: US 09/397945
;  PRIOR FILING DATE: 1999-09-17
;  PRIOR APPLICATION NUMBER: PCT/US99/05804
;  PRIOR FILING DATE: 1999-03-18
;  PRIOR APPLICATION NUMBER: 60/078,566
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,576
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,573
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,574
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/078,579
```

```
;  PRIOR FILING DATE: 1998-03-19
;  PRIOR APPLICATION NUMBER: 60/080,314
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/080,312
;  PRIOR FILING DATE: 1998-04-01
;  PRIOR APPLICATION NUMBER: 60/078,578
;  PRIOR FILING DATE: 1998-03-19
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 470
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 424
;    LENGTH: 48
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-10-653-595-424

  Query Match             100.0%;  Score 19;  DB 4;  Length 48;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         33 AQGV 36


RESULT 62
US-10-425-115-339468
; Sequence 339468, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 339468
;    LENGTH: 48
;    TYPE: PRT
;    ORGANISM: Zea mays
;    FEATURE:
;    OTHER INFORMATION: Clone ID: MRT4577_72766C.1.pep
US-10-425-115-339468

  Query Match             100.0%;  Score 19;  DB 4;  Length 48;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 63
US-10-029-386-27682
; Sequence 27682, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 27682
;    LENGTH: 49
;    TYPE: PRT
;    ORGANISM: Homo sapiens
;    FEATURE:
;    OTHER INFORMATION: MAP TO AL139135.2
;    OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.3
;    OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.3
;    OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.9
;    OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.2
;    OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 2.3
;    OTHER INFORMATION: SWISSPROT HIT: P70213, EVALUE 1.00e-07
US-10-029-386-27682

  Query Match             100.0%;  Score 19;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47


RESULT 64
US-10-424-599-225119
; Sequence 225119, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 225119
;    LENGTH: 49
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_45312C.1.pep
US-10-424-599-225119

  Query Match             100.0%;  Score 19;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         25 AQGV 28


RESULT 65
US-09-866-066-35
; Sequence 35, Application US/09866066
; Publication No. US20030113888A1
; GENERAL INFORMATION:
;  APPLICANT: Benjamin, Christopher
;  APPLICANT:  Roberds, Steve
;  APPLICANT:  Ruble, Cara
;  APPLICANT:  Gotow, Lisa
;  APPLICANT:  Karnovsky, Alla
;  TITLE OF INVENTION: Human Ion Channels
;  FILE REFERENCE: 00229.US1
;  CURRENT APPLICATION NUMBER: US/09/866,066
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: 60/207,152
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/207,257
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/207,119
```

```
;  PRIOR FILING DATE: 2000-05-26
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
;   LENGTH: 51
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-866-066-35

  Query Match           100.0%;  Score 19;  DB 3;  Length 51;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 66
US-10-424-599-193989
; Sequence 193989, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 193989
;   LENGTH: 51
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_17199C.1.pep
US-10-424-599-193989

  Query Match           100.0%;  Score 19;  DB 4;  Length 51;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 67
US-10-969-677-35
; Sequence 35, Application US/10969677
; Publication No. US20050176098A1
; GENERAL INFORMATION:
;  APPLICANT: Benjamin, Christopher
;  APPLICANT:  Roberds, Steve
;  APPLICANT:  Ruble, Cara
;  APPLICANT:  Gotow, Lisa
;  APPLICANT:  Karnovsky, Alla
;  TITLE OF INVENTION: Human Ion Channels
;  FILE REFERENCE: 00229.US1
;  CURRENT APPLICATION NUMBER: US/10/969,677
;  CURRENT FILING DATE:  2004-10-20
;  PRIOR APPLICATION NUMBER: US/09/866,066
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: 60/207,152
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/207,257
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/207,119
;  PRIOR FILING DATE: 2000-05-26
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
;   LENGTH: 51
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-969-677-35

  Query Match           100.0%;  Score 19;  DB 5;  Length 51;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 68
US-10-425-115-314288
; Sequence 314288, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 314288
;   LENGTH: 52
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_49690C.1.pep
US-10-425-115-314288

  Query Match           100.0%;  Score 19;  DB 4;  Length 52;
  Best Local Similarity  100.0%;  Pred. No. 1.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         40 AQGV 43


RESULT 69
US-09-925-302-824
; Sequence 824, Application US/09925302
; Patent No. US20020044941A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PA104
;  CURRENT APPLICATION NUMBER: US/09/925,302
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: PCT/US00/05918
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: 60/124,270
;  PRIOR FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 896
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 824
;   LENGTH: 53
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (16)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
```

```
;   LOCATION: (46)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (47)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (52)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (53)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-925-302-824

  Query Match            100.0%;  Score 19;  DB 3;  Length 53;
  Best Local Similarity  100.0%;  Pred. No. 1.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 70
US-09-925-302-824
; Sequence 824, Application US/09925302
; Publication No. US20030064072A9
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PA104
;  CURRENT APPLICATION NUMBER: US/09/925,302
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: PCT/US00/05918
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: 60/124,270
;  PRIOR FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 896
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 824
;   LENGTH: 53
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (16)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (46)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (47)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (52)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (53)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-925-302-824

  Query Match            100.0%;  Score 19;  DB 3;  Length 53;
  Best Local Similarity  100.0%;  Pred. No. 1.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 71
US-10-016-768-3
; Sequence 3, Application US/10016768
; Publication No. US20020142443A1
; GENERAL INFORMATION:
;  APPLICANT: Baehrecke, Eric  H.
;  TITLE OF INVENTION: GENES REGULATING PROGRAMMED CELL DEATH
;  FILE REFERENCE: 4115-131
;  CURRENT APPLICATION NUMBER: US/10/016,768
;  CURRENT FILING DATE:  2001-10-29
;  NUMBER OF SEQ ID NOS: 12
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 54
;   TYPE: PRT
;   ORGANISM: T. nigroviridis
US-10-016-768-3

  Query Match            100.0%;  Score 19;  DB 4;  Length 54;
  Best Local Similarity  100.0%;  Pred. No. 1.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         36 AQGV 39


RESULT 72
US-09-764-877-1474
; Sequence 1474, Application US/09764877
; Patent No. US20020147140A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC005
;  CURRENT APPLICATION NUMBER: US/09/764,877
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - refer to PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 4031
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1474
;   LENGTH: 55
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-764-877-1474

  Query Match            100.0%;  Score 19;  DB 3;  Length 55;
  Best Local Similarity  100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 73
US-10-242-515-1474
; Sequence 1474, Application US/10242515
; Publication No. US20040009488A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC005C1
;  CURRENT APPLICATION NUMBER: US/10/242,515
;  CURRENT FILING DATE:  2002-09-13
;  PRIOR APPLICATION NUMBER: 09/764,877
;  PRIOR FILING DATE: 2001-01-17
;  PRIOR APPLICATION NUMBER: 60/179,065
;  PRIOR FILING DATE: 2000-01-31
;  PRIOR APPLICATION NUMBER: 60/180,628
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: 60/214,886
;  PRIOR FILING DATE: 2000-06-28
;  PRIOR APPLICATION NUMBER: 60/217,487
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 60/225,758
;  PRIOR FILING DATE: 2000-08-14
```

```
;  PRIOR APPLICATION NUMBER: 60/220,963
;  PRIOR FILING DATE: 2000-07-26
;  PRIOR APPLICATION NUMBER: 60/217,496
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 60/225,447
;  PRIOR FILING DATE: 2000-08-14
;  PRIOR APPLICATION NUMBER: 60/218,290
;  PRIOR FILING DATE: 2000-07-14
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4031
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1474
;    LENGTH: 55
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-10-242-515-1474

  Query Match             100.0%;  Score 19;  DB 4;  Length 55;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 74
US-10-425-115-279298
; Sequence 279298, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 279298
;    LENGTH: 55
;    TYPE: PRT
;    ORGANISM: Zea mays
;    FEATURE:
;    OTHER INFORMATION: Clone ID: MRT4577_18629C.1.pep
US-10-425-115-279298

  Query Match             100.0%;  Score 19;  DB 4;  Length 55;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         49 AQGV 52


RESULT 75
US-09-864-761-44380
; Sequence 44380, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 44380
;    LENGTH: 56
;    TYPE: PRT
;    ORGANISM: Homo sapiens
;    FEATURE:
;    OTHER INFORMATION: MAP TO AC004816.1
;    OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.2
;    OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.3
;    OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.2
;    OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.2
;    OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.4
;    OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.4
;    OTHER INFORMATION: EST_HUMAN HIT: BE727589.1, EVALUE 1.20e+00
;    OTHER INFORMATION: SWISSPROT HIT: P08325, EVALUE 4.60e+00
US-09-864-761-44380

  Query Match             100.0%;  Score 19;  DB 3;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 76
US-10-116-255-32
; Sequence 32, Application US/10116255
; Publication No. US20030036646A1
; GENERAL INFORMATION:
;  APPLICANT: Ni et al.
;  TITLE OF INVENTION: Uncoupling Protein Polynucleotides, Polypeptides, and
;  TITLE OF INVENTION:  Antibodies
;  FILE REFERENCE: PT009P1
;  CURRENT APPLICATION NUMBER: US/10/116,255
;  CURRENT FILING DATE:  2002-04-05
```

```
;  PRIOR APPLICATION NUMBER: 09/685,897
;  PRIOR FILING DATE: 2000-10-11
;  PRIOR APPLICATION NUMBER: PCT/US00/09534
;  PRIOR FILING DATE: 2000-04-06
;  PRIOR APPLICATION NUMBER: 60/128,701
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: 60/142,821
;  PRIOR FILING DATE: 1999-07-08
;  PRIOR APPLICATION NUMBER: 60/149,448
;  PRIOR FILING DATE: 1999-08-18
;  PRIOR APPLICATION NUMBER: 60/164,751
;  PRIOR FILING DATE: 1999-11-12
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
;   LENGTH: 56
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-116-255-32

  Query Match             100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 77
US-10-264-049-3884
; Sequence 3884, Application US/10264049
; Publication No. US20040005579A1
; GENERAL INFORMATION:
;  APPLICANT: Birse et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PA133P1
;  CURRENT APPLICATION NUMBER: US/10/264,049
;  CURRENT FILING DATE:  2002-10-04
;  PRIOR APPLICATION NUMBER: PCT/US01/18569
;  PRIOR FILING DATE: 2001-06-07
;  PRIOR APPLICATION NUMBER: US 60/209,467
;  PRIOR FILING DATE: 2000-06-07
;  NUMBER OF SEQ ID NOS: 4360
;  SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 3884
;   LENGTH: 56
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (3)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (6)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (7)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (19)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (22)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (37)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (43)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (54)
;   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
US-10-264-049-3884

  Query Match             100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         28 AQGV 31


RESULT 78
US-10-424-599-279039
; Sequence 279039, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 279039
;   LENGTH: 56
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_93996C.1.pep
US-10-424-599-279039

  Query Match             100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         47 AQGV 50


RESULT 79
US-10-425-115-263648
; Sequence 263648, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 263648
;   LENGTH: 56
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_172059C.1.pep
US-10-425-115-263648
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity  100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47


RESULT 80
US-10-424-599-182978
; Sequence 182978, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 182978
;   LENGTH: 57
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(57)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_136242C.1.pep
US-10-424-599-182978

  Query Match           100.0%;  Score 19;  DB 4;  Length 57;
  Best Local Similarity  100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 81
US-10-424-599-249716
; Sequence 249716, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 249716
;   LENGTH: 57
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(57)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_67522C.1.pep
US-10-424-599-249716

  Query Match           100.0%;  Score 19;  DB 4;  Length 57;
  Best Local Similarity  100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         19 AQGV 22


RESULT 82
US-10-029-386-33617
; Sequence 33617, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33617
;   LENGTH: 58
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO CHR7.1
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.47
;   OTHER INFORMATION: SWISSPROT HIT: Q14168, EVALUE 7.00e-20
US-10-029-386-33617

  Query Match           100.0%;  Score 19;  DB 4;  Length 58;
  Best Local Similarity  100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         31 AQGV 34


RESULT 83
US-10-425-115-192059
; Sequence 192059, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 192059
;   LENGTH: 58
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_106743C.1.pep
US-10-425-115-192059

  Query Match           100.0%;  Score 19;  DB 4;  Length 58;
  Best Local Similarity  100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

```
RESULT 84
US-10-425-115-219711
; Sequence 219711, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 219711
;   LENGTH: 58
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_131965C.1.pep
US-10-425-115-219711

  Query Match            100.0%;  Score 19;  DB 4;  Length 58;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         31 AQGV 34


RESULT 85
US-10-425-115-336290
; Sequence 336290, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 336290
;   LENGTH: 58
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(58)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_69805C.1.pep
US-10-425-115-336290

  Query Match            100.0%;  Score 19;  DB 4;  Length 58;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 86
US-09-925-298-590
; Sequence 590, Application US/09925298
; Publication No. US20020039764A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PA103
;  CURRENT APPLICATION NUMBER: US/09/925,298
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: PCT/US00/05881
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: 60/124,270
;  PRIOR FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 846
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 590
;   LENGTH: 59
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-925-298-590

  Query Match            100.0%;  Score 19;  DB 3;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 87
US-10-102-806-590
; Sequence 590, Application US/10102806
; Publication No. US20030054421A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PA103P1C1
;  CURRENT APPLICATION NUMBER: US/10/102,806
;  CURRENT FILING DATE:  2002-03-22
;  PRIOR APPLICATION NUMBER: 09/925,298
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: PCT/US00/05881
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: 60/124,270
;  PRIOR FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 846
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 590
;   LENGTH: 59
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-102-806-590

  Query Match            100.0%;  Score 19;  DB 4;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 88
US-10-029-386-28279
; Sequence 28279, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GE
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
```

```
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 28279
;    LENGTH: 59
;    TYPE: PRT
;    ORGANISM: Homo sapiens
;    FEATURE:
;    OTHER INFORMATION: MAP TO CHR22_184_2.0
;    OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.1
;    OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.61
;    OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.1
;    OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.2
;    OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.95
;    OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.98
;    OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.1
;    OTHER INFORMATION: SWISSPROT HIT: P13463, EVALUE 6.10e+00
US-10-029-386-28279

  Query Match             100.0%;  Score 19;  DB 4;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         52 AQGV 55


RESULT 89
US-10-425-115-278273
; Sequence 278273, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 278273
;    LENGTH: 59
;    TYPE: PRT
;    ORGANISM: Zea mays
;    FEATURE:
;    OTHER INFORMATION: Clone ID: MRT4577_18535C.1.pep
US-10-425-115-278273

  Query Match             100.0%;  Score 19;  DB 4;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 90
US-09-864-408A-2276
; Sequence 2276, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Shimkets, Richard A.
;  TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Encc
;  FILE REFERENCE: 21402-012
;  CURRENT APPLICATION NUMBER: US/09/864,408A
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: 60/206,690
;  PRIOR FILING DATE: 2000-05-24
;  NUMBER OF SEQ ID NOS: 9068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2276
;    LENGTH: 60
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-09-864-408A-2276

  Query Match             100.0%;  Score 19;  DB 3;  Length 60;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 91
US-10-424-599-198924
; Sequence 198924, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 198924
;    LENGTH: 60
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_21653C.1.pep
US-10-424-599-198924

  Query Match             100.0%;  Score 19;  DB 4;  Length 60;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 92
US-10-424-599-189118
; Sequence 189118, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 189118
;    LENGTH: 62
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    NAME/KEY: unsure
;    LOCATION: (1)..(62)
;    OTHER INFORMATION: unsure at all Xaa locations
;    FEATURE:
```

```
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_141789C.1.pep
US-10-424-599-189118

  Query Match            100.0%;  Score 19;  DB 4;  Length 62;
  Best Local Similarity  100.0%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 93
US-10-424-599-189377
; Sequence 189377, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 189377
;   LENGTH: 62
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_142023C.1.pep
US-10-424-599-189377

  Query Match            100.0%;  Score 19;  DB 4;  Length 62;
  Best Local Similarity  100.0%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         18 AQGV 21


RESULT 94
US-10-425-114-71256
; Sequence 71256, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
;  APPLICANT: Liu, Jingdong
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Screen, Steven E
;  APPLICANT:  Tabaska, Jack E
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53313)B
;  CURRENT APPLICATION NUMBER: US/10/425,114
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 71256
;   LENGTH: 62
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: LIB3067-051-E1_FLI.pep
US-10-425-114-71256

  Query Match            100.0%;  Score 19;  DB 4;  Length 62;
  Best Local Similarity  100.0%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 95
US-10-425-115-188418
; Sequence 188418, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 188418
;   LENGTH: 62
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_103429C.1.pep
US-10-425-115-188418

  Query Match            100.0%;  Score 19;  DB 4;  Length 62;
  Best Local Similarity  100.0%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         55 AQGV 58


RESULT 96
US-10-029-386-31780
; Sequence 31780, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GE
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 31780
;   LENGTH: 63
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AF172277.1
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.3
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL =   1
;   OTHER INFORMATION: SWISSPROT HIT: Q01635, EVALUE 1.00e-20
US-10-029-386-31780

  Query Match            100.0%;  Score 19;  DB 4;  Length 63;
  Best Local Similarity  100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         41 AQGV 44
```

```
RESULT 97
US-10-424-599-262885
; Sequence 262885, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 262885
;   LENGTH: 63
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_79406C.1.pep
US-10-424-599-262885

  Query Match             100.0%;  Score 19;  DB 4;  Length 63;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         34 AQGV 37


RESULT 98
US-10-424-599-270368
; Sequence 270368, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 270368
;   LENGTH: 63
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_86160C.1.pep
US-10-424-599-270368

  Query Match             100.0%;  Score 19;  DB 4;  Length 63;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         45 AQGV 48


RESULT 99
US-10-425-115-251637
; Sequence 251637, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 251637
;   LENGTH: 63
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(63)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_161079C.1.pep
US-10-425-115-251637

  Query Match             100.0%;  Score 19;  DB 4;  Length 63;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         58 AQGV 61


RESULT 100
US-10-450-763-56831
; Sequence 56831, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 790CIP3/US
;  CURRENT APPLICATION NUMBER: US/10/450,763
;  CURRENT FILING DATE:  2003-06-11
;  PRIOR APPLICATION NUMBER: PCT/US01/08631
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 09/540,217
;  PRIOR FILING DATE: 2000-03-31
;  PRIOR APPLICATION NUMBER: 09/649,167
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 60736
;  SOFTWARE: Custom
; SEQ ID NO 56831
;   LENGTH: 63
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(63)
;   OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-56831

  Query Match             100.0%;  Score 19;  DB 5;  Length 63;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         34 AQGV 37


RESULT 101
US-10-424-599-177860
; Sequence 177860, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
```

```
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 177860
;   LENGTH: 64
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_131623C.1.pep
US-10-424-599-177860

  Query Match             100.0%;  Score 19;  DB 4;  Length 64;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         18 AQGV 21


RESULT 102
US-10-425-115-197187
; Sequence 197187, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 197187
;   LENGTH: 64
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_111417C.1.pep
US-10-425-115-197187

  Query Match             100.0%;  Score 19;  DB 4;  Length 64;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         38 AQGV 41


RESULT 103
US-10-425-115-219280
; Sequence 219280, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 219280
;   LENGTH: 64
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_131575C.1.pep
US-10-425-115-219280

  Query Match             100.0%;  Score 19;  DB 4;  Length 64;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         25 AQGV 28


RESULT 104
US-10-437-963-106625
; Sequence 106625, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 106625
;   LENGTH: 65
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_11051C.1.pep
US-10-437-963-106625

  Query Match             100.0%;  Score 19;  DB 4;  Length 65;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         48 AQGV 51


RESULT 105
US-10-425-115-240290
; Sequence 240290, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 240290
;   LENGTH: 65
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_150727C.1.pep
US-10-425-115-240290
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 65;
  Best Local Similarity  100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 106
US-10-425-115-357026
; Sequence 357026, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 357026
;   LENGTH: 65
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_88777C.1.pep
US-10-425-115-357026

  Query Match           100.0%;  Score 19;  DB 4;  Length 65;
  Best Local Similarity  100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 107
US-10-424-599-257517
; Sequence 257517, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 257517
;   LENGTH: 66
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_74561C.1.pep
US-10-424-599-257517

  Query Match           100.0%;  Score 19;  DB 4;  Length 66;
  Best Local Similarity  100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         23 AQGV 26


RESULT 108
US-10-437-963-106620
; Sequence 106620, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 106620
;   LENGTH: 67
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_11047C.1.pep
US-10-437-963-106620

  Query Match           100.0%;  Score 19;  DB 4;  Length 67;
  Best Local Similarity  100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         25 AQGV 28


RESULT 109
US-10-437-963-158436
; Sequence 158436, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 158436
;   LENGTH: 67
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_57911C.1.pep
US-10-437-963-158436

  Query Match           100.0%;  Score 19;  DB 4;  Length 67;
  Best Local Similarity  100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 110
```

```
US-10-425-115-200989
; Sequence 200989, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 200989
;   LENGTH: 67
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(67)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_11488C.1.pep
US-10-425-115-200989

  Query Match             100.0%;  Score 19;  DB 4;  Length 67;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         35 AQGV 38


RESULT 111
US-10-425-115-231718
; Sequence 231718, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 231718
;   LENGTH: 67
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_142922C.1.pep
US-10-425-115-231718

  Query Match             100.0%;  Score 19;  DB 4;  Length 67;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 112
US-11-097-143-39966
; Sequence 39966, Application US/11097143
; Publication No. US20050208558A1
; GENERAL INFORMATION:
;  APPLICANT: Venter, J. Craig
;  APPLICANT:  et al.
;  TITLE OF INVENTION: DETECTION KIT, SUCH AS NUCLEIC ACID
;  TITLE OF INVENTION:  ARRAYS, FOR DETECTING EXPRESSION OF 10,000 OR MORE
;  TITLE OF INVENTION:  DROSOPHILA GENES.
;  FILE REFERENCE: CL000728
;  CURRENT APPLICATION NUMBER: US/11/097,143
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: 60/157,832
;  PRIOR FILING DATE: 1999-10-05
;  PRIOR APPLICATION NUMBER: 60/160,191
;  PRIOR FILING DATE: 1999-10-19
;  PRIOR APPLICATION NUMBER: 60/161,932
;  PRIOR FILING DATE: 1999-10-28
;  PRIOR APPLICATION NUMBER: 60/164,769
;  PRIOR FILING DATE: 1999-11-12
;  PRIOR APPLICATION NUMBER: 60/173,383
;  PRIOR FILING DATE: 1999-12-28
;  PRIOR APPLICATION NUMBER: 60/175,693
;  PRIOR FILING DATE: 2000-01-12
;  PRIOR APPLICATION NUMBER: 60/184,831
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: 60/191,637
;  PRIOR FILING DATE: 2000-03-23
;  NUMBER OF SEQ ID NOS: 43008
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 39966
;   LENGTH: 67
;   TYPE: PRT
;   ORGANISM: DROSOPHILA
US-11-097-143-39966

  Query Match             100.0%;  Score 19;  DB 6;  Length 67;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          9 AQGV 12


RESULT 113
US-10-425-115-354448
; Sequence 354448, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 354448
;   LENGTH: 68
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(68)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_86428C.1.pep
US-10-425-115-354448

  Query Match             100.0%;  Score 19;  DB 4;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
```

```
Db         39 AQGV 42


RESULT 114
US-09-782-142-1
; Sequence 1, Application US/09782142
; Patent No. US20020001827A1
;   GENERAL INFORMATION:
;        APPLICANT: Bandman, Olga
;                   Hawkins, Phillip R.
;                   Murry, Lynn E.
;                   Goli, Surya K.
;        TITLE OF INVENTION: NOVEL HUMAN CYTOKINES
;        NUMBER OF SEQUENCES: 7
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Incyte Pharmaceuticals, Inc.
;             STREET: 3174 Porter Drive
;             CITY: Palo Alto
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94304
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/782,142
;             FILING DATE: 12-Feb-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/792,013
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Billings, Lucy J.
;             REGISTRATION NUMBER: 36,749
;             REFERENCE/DOCKET NUMBER: PF-0205 US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-855-0555
;             TELEFAX: 415-845-4166
;   INFORMATION FOR SEQ ID NO: 1:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 69 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        IMMEDIATE SOURCE:
;             LIBRARY: SINTBST01
;             CLONE: 1431384
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-782-142-1

  Query Match             100.0%;  Score 19;  DB 3;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 115
US-10-300-257-1
; Sequence 1, Application US/10300257
; Publication No. US20030096371A1
;   GENERAL INFORMATION:
;        APPLICANT: Bandman, Olga
;                   Hawkins, Phillip R.
;                   Murry, Lynn E.
;                   Goli, Surya K.
;        TITLE OF INVENTION: HUMAN CYTOKINES
;        NUMBER OF SEQUENCES: 7
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Incyte Pharmaceuticals, Inc.
;             STREET: 3174 Porter Drive
;             CITY: Palo Alto
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94304
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/300,257
;             FILING DATE: 19-No. US20030096371A1-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: <Unknown>
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Billings, Lucy J.
;             REGISTRATION NUMBER: 36,749
;             REFERENCE/DOCKET NUMBER: PF-0205 US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-855-0555
;             TELEFAX: 415-845-4166
;   INFORMATION FOR SEQ ID NO: 1:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 69 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        IMMEDIATE SOURCE:
;             LIBRARY: SINTBST01
;             CLONE: 1431384
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-300-257-1

  Query Match             100.0%;  Score 19;  DB 4;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 116
US-10-424-599-255403
; Sequence 255403, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 255403
;   LENGTH: 69
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_72650C.1.pep
US-10-424-599-255403

  Query Match             100.0%;  Score 19;  DB 4;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db         21 AQGV 24


RESULT 117
US-10-437-963-191908
; Sequence 191908, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 191908
;   LENGTH: 69
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(69)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_88183C.1.pep
US-10-437-963-191908

  Query Match             100.0%;  Score 19;  DB 4;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         23 AQGV 26


RESULT 118
US-10-767-701-34429
; Sequence 34429, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
;  APPLICANT: Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof For Plant Improvement
;  FILE REFERENCE: 38-21(53535)B
;  CURRENT APPLICATION NUMBER: US/10/767,701
;  CURRENT FILING DATE:  2004-01-29
;  NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 34429
;   LENGTH: 69
;   TYPE: PRT
;   ORGANISM: Sorghum bicolor
;   FEATURE:
;   OTHER INFORMATION: Clone ID: SORBI-28MAY03-C48184_1.pep
US-10-767-701-34429

  Query Match             100.0%;  Score 19;  DB 4;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         59 AQGV 62


RESULT 119
US-10-425-115-324687
; Sequence 324687, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 324687
;   LENGTH: 69
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_59186C.1.pep
US-10-425-115-324687

  Query Match             100.0%;  Score 19;  DB 4;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         29 AQGV 32


RESULT 120
US-10-424-599-242839
; Sequence 242839, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 242839
;   LENGTH: 70
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_61312C.1.pep
US-10-424-599-242839

  Query Match             100.0%;  Score 19;  DB 4;  Length 70;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         10 AQGV 13


RESULT 121
US-10-437-963-134195
; Sequence 134195, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
```

```
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 134195
;   LENGTH: 70
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_35993C.1.pep
US-10-437-963-134195

  Query Match           100.0%;  Score 19;  DB 4;  Length 70;
  Best Local Similarity  100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 122
US-10-425-115-321591
; Sequence 321591, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 321591
;   LENGTH: 70
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_56356C.1.pep
US-10-425-115-321591

  Query Match           100.0%;  Score 19;  DB 4;  Length 70;
  Best Local Similarity  100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 123
US-10-926-683-1548
; Sequence 1548, Application US/10926683
; Publication No. US20050106595A1
; GENERAL INFORMATION:
;  APPLICANT: Dumas Milne Edwards, J.B.
;  APPLICANT:  Duclert A.
;  APPLICANT:  Giordano, J.Y.
;  TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
;  FILE REFERENCE: GENSET.025CP1
;  CURRENT APPLICATION NUMBER: US/10/926,683
;  CURRENT FILING DATE:  2004-08-25
;  PRIOR APPLICATION NUMBER: US/09/471,276
;  PRIOR FILING DATE: 1999-12-21
;  PRIOR APPLICATION NUMBER: 09/057,719
;  PRIOR FILING DATE: 1998-04-09
;  PRIOR APPLICATION NUMBER: 09/069,047
;  PRIOR FILING DATE: 1998-04-28
;  PRIOR APPLICATION NUMBER: PCT/IB99/00712
;  PRIOR FILING DATE: 1999-04-09
;  NUMBER OF SEQ ID NOS: 1622
;  SOFTWARE: Patent.pm
; SEQ ID NO 1548
;   LENGTH: 71
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-926-683-1548

  Query Match           100.0%;  Score 19;  DB 5;  Length 71;
  Best Local Similarity  100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         59 AQGV 62


RESULT 124
US-10-131-406-6
; Sequence 6, Application US/10131406
; Publication No. US20030013104A1
;  GENERAL INFORMATION:
;       APPLICANT: LEVY, STUART B.
;       TITLE OF INVENTION: MULTIPLE ANTIBIOTIC RESISTANCE OPERON
;                           ASSAYS
;       NUMBER OF SEQUENCES: 7
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
;            STREET: 600 ATLANTIC AVENUE
;            CITY: BOSTON
;            STATE: MA
;            COUNTRY: USA
;            ZIP: 02210
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/131,406
;            FILING DATE: 22-Apr-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/225,480
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: US 07/938,085
;            FILING DATE: 28-AUG-1992
;       ATTORNEY/AGENT INFORMATION:
;            NAME: GATES, EDWARD R.
;            REGISTRATION NUMBER: 31,616
;            REFERENCE/DOCKET NUMBER: T0359/7003
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 617-720-3500
;            TELEFAX: 617-720-2441
;  INFORMATION FOR SEQ ID NO: 6:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 72 amino acids
;            TYPE: amino acid
;            TOPOLOGY: linear
;       MOLECULE TYPE: protein
;       SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-131-406-6

  Query Match           100.0%;  Score 19;  DB 4;  Length 72;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 125
US-10-424-599-182197
; Sequence 182197, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 182197
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_135537C.1.pep
US-10-424-599-182197

  Query Match             100.0%;  Score 19;  DB 4;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 126
US-10-424-599-234373
; Sequence 234373, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 234373
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_53667C.1.pep
US-10-424-599-234373

  Query Match             100.0%;  Score 19;  DB 4;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         52 AQGV 55


RESULT 127
US-10-425-115-202113
; Sequence 202113, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 202113
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_115914C.1.pep
US-10-425-115-202113

  Query Match             100.0%;  Score 19;  DB 4;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 128
US-10-425-115-348682
; Sequence 348682, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 348682
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_81163C.1.pep
US-10-425-115-348682

  Query Match             100.0%;  Score 19;  DB 4;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         40 AQGV 43


RESULT 129
US-10-989-992-6
; Sequence 6, Application US/10989992
; Publication No. US20050136460A1
;   GENERAL INFORMATION:
;        APPLICANT: LEVY, STUART B.
;        TITLE OF INVENTION: MULTIPLE ANTIBIOTIC RESISTANCE OPERON
;                            ASSAYS
;        NUMBER OF SEQUENCES: 7
;        CORRESPONDENCE ADDRESS:
```

```
;               ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
;               STREET: 600 ATLANTIC AVENUE
;               CITY: BOSTON
;               STATE: MA
;               COUNTRY: USA
;               ZIP: 02210
;          COMPUTER READABLE FORM:
;               MEDIUM TYPE: Floppy disk
;               COMPUTER: IBM PC compatible
;               OPERATING SYSTEM: PC-DOS/MS-DOS
;               SOFTWARE: PatentIn Release #1.0, Version #1.25
;          CURRENT APPLICATION DATA:
;               APPLICATION NUMBER: US/10/989,992
;               FILING DATE: 15-Nov-2004
;               CLASSIFICATION: <Unknown>
;          PRIOR APPLICATION DATA:
;               APPLICATION NUMBER: US/10/131,406
;               FILING DATE: 22-Apr-2002
;               APPLICATION NUMBER: US/08/225,480
;               FILING DATE: <Unknown>
;               APPLICATION NUMBER: US 07/938,085
;               FILING DATE: 28-AUG-1992
;          ATTORNEY/AGENT INFORMATION:
;               NAME: GATES, EDWARD R.
;               REGISTRATION NUMBER: 31,616
;               REFERENCE/DOCKET NUMBER: T0359/7003
;          TELECOMMUNICATION INFORMATION:
;               TELEPHONE: 617-720-3500
;               TELEFAX: 617-720-2441
;     INFORMATION FOR SEQ ID NO: 6:
;          SEQUENCE CHARACTERISTICS:
;               LENGTH: 72 amino acids
;               TYPE: amino acid
;               TOPOLOGY: linear
;          MOLECULE TYPE: protein
;          SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-989-992-6

  Query Match             100.0%;  Score 19;  DB 5;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 130
US-09-864-408A-2882
; Sequence 2882, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Shimkets, Richard A.
;  TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Encc
;  FILE REFERENCE: 21402-012
;  CURRENT APPLICATION NUMBER: US/09/864,408A
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: 60/206,690
;  PRIOR FILING DATE: 2000-05-24
;  NUMBER OF SEQ ID NOS: 9068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2882
;   LENGTH: 74
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-864-408A-2882

  Query Match             100.0%;  Score 19;  DB 3;  Length 74;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         48 AQGV 51


RESULT 131
US-10-424-599-178691
; Sequence 178691, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 178691
;   LENGTH: 74
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_132375C.1.pep
US-10-424-599-178691

  Query Match             100.0%;  Score 19;  DB 4;  Length 74;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         61 AQGV 64


RESULT 132
US-09-867-550-1124
; Sequence 1124, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Mehraban, Fuad,
;  APPLICANT:  Conley, Pamela
;  APPLICANT:  Law, Debbie
;  APPLICANT:  Topper, James
;  TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
;  TITLE OF INVENTION:  Thereby
;  FILE REFERENCE: 21402-013 (Cura-313)
;  CURRENT APPLICATION NUMBER: US/09/867,550
;  CURRENT FILING DATE:  2001-09-20
;  PRIOR APPLICATION NUMBER: USSN 60/208,427
;  PRIOR FILING DATE: 2000-05-30
;  NUMBER OF SEQ ID NOS: 2125
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1124
;   LENGTH: 75
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-867-550-1124

  Query Match             100.0%;  Score 19;  DB 3;  Length 75;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 133
US-10-424-599-154365
; Sequence 154365, Application US/10424599
```

```
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 154365
;   LENGTH: 75
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_110412C.1.pep
US-10-424-599-154365

  Query Match           100.0%;  Score 19;  DB 4;  Length 75;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          7 AQGV 10


RESULT 134
US-10-437-963-147518
; Sequence 147518, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 147518
;   LENGTH: 75
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(75)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_48038C.1.pep
US-10-437-963-147518

  Query Match           100.0%;  Score 19;  DB 4;  Length 75;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         64 AQGV 67


RESULT 135
US-10-425-115-222854
; Sequence 222854, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 222854
;   LENGTH: 75
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(75)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_134833C.1.pep
US-10-425-115-222854

  Query Match           100.0%;  Score 19;  DB 4;  Length 75;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 136
US-10-029-386-30198
; Sequence 30198, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GE
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 30198
;   LENGTH: 76
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO CHR13.1
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.9
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL =   1
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.94
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 0.85
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.75
;   OTHER INFORMATION: SWISSPROT HIT: P40182, EVALUE 2.50e+00
US-10-029-386-30198

  Query Match           100.0%;  Score 19;  DB 4;  Length 76;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         59 AQGV 62


RESULT 137
US-10-425-115-221278
```

```
; Sequence 221278, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 221278
;   LENGTH: 76
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(76)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_133398C.1.pep
US-10-425-115-221278

  Query Match           100.0%;  Score 19;  DB 4;  Length 76;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         38 AQGV 41


RESULT 138
US-10-425-115-292142
; Sequence 292142, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 292142
;   LENGTH: 76
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(76)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_2951C.1.pep
US-10-425-115-292142

  Query Match           100.0%;  Score 19;  DB 4;  Length 76;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         16 AQGV 19


RESULT 139
US-10-425-115-355384
; Sequence 355384, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 355384
;   LENGTH: 76
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(76)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_87277C.1.pep
US-10-425-115-355384

  Query Match           100.0%;  Score 19;  DB 4;  Length 76;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         68 AQGV 71


RESULT 140
US-10-425-115-271573
; Sequence 271573, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 271573
;   LENGTH: 77
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_179269C.1.pep
US-10-425-115-271573

  Query Match           100.0%;  Score 19;  DB 4;  Length 77;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         32 AQGV 35


RESULT 141
US-10-425-115-289812
; Sequence 289812, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
```

```
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 289812
;   LENGTH: 77
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(77)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_27398C.1.pep
US-10-425-115-289812

  Query Match            100.0%;  Score 19;  DB 4;  Length 77;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         61 AQGV 64


RESULT 142
US-10-425-115-319654
; Sequence 319654, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 319654
;   LENGTH: 77
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_54595C.1.pep
US-10-425-115-319654

  Query Match            100.0%;  Score 19;  DB 4;  Length 77;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 143
US-10-425-115-330336
; Sequence 330336, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 330336
;   LENGTH: 77
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_64366C.1.pep
US-10-425-115-330336

  Query Match            100.0%;  Score 19;  DB 4;  Length 77;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         32 AQGV 35


RESULT 144
US-10-425-115-243630
; Sequence 243630, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 243630
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_153773C.1.pep
US-10-425-115-243630

  Query Match            100.0%;  Score 19;  DB 4;  Length 78;
  Best Local Similarity  100.0%;  Pred. No. 2.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         66 AQGV 69


RESULT 145
US-10-450-763-56828
; Sequence 56828, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 790CIP3/US
;  CURRENT APPLICATION NUMBER: US/10/450,763
;  CURRENT FILING DATE:  2003-06-11
;  PRIOR APPLICATION NUMBER: PCT/US01/08631
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 09/540,217
;  PRIOR FILING DATE: 2000-03-31
;  PRIOR APPLICATION NUMBER: 09/649,167
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 60736
;  SOFTWARE: Custom
; SEQ ID NO 56828
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Homo sapiens
```

```
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(78)
;   OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-56828

  Query Match           100.0%;  Score 19;  DB 5;  Length 78;
  Best Local Similarity  100.0%;  Pred. No. 2.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         55 AQGV 58


RESULT 146
US-10-437-963-195350
; Sequence 195350, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 195350
;   LENGTH: 79
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_91307C.1.pep
US-10-437-963-195350

  Query Match           100.0%;  Score 19;  DB 4;  Length 79;
  Best Local Similarity  100.0%;  Pred. No. 2.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         50 AQGV 53


RESULT 147
US-10-425-115-264068
; Sequence 264068, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 264068
;   LENGTH: 79
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_172445C.1.pep
US-10-425-115-264068

  Query Match           100.0%;  Score 19;  DB 4;  Length 79;
  Best Local Similarity  100.0%;  Pred. No. 2.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         22 AQGV 25


RESULT 148
US-10-424-599-277301
; Sequence 277301, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 277301
;   LENGTH: 81
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_92426C.1.pep
US-10-424-599-277301

  Query Match           100.0%;  Score 19;  DB 4;  Length 81;
  Best Local Similarity  100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         56 AQGV 59


RESULT 149
US-10-437-963-137515
; Sequence 137515, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 137515
;   LENGTH: 81
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_38992C.1.pep
US-10-437-963-137515

  Query Match           100.0%;  Score 19;  DB 4;  Length 81;
  Best Local Similarity  100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db         18 AQGV 21


RESULT 150
US-10-425-115-263146
; Sequence 263146, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 263146
;   LENGTH: 81
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_171600C.1.pep
US-10-425-115-263146

  Query Match             100.0%;  Score 19;  DB 4;  Length 81;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         53 AQGV 56


RESULT 151
US-10-425-115-306230
; Sequence 306230, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 306230
;   LENGTH: 81
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_42347C.1.pep
US-10-425-115-306230

  Query Match             100.0%;  Score 19;  DB 4;  Length 81;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 152
US-10-424-599-163460
; Sequence 163460, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 163460
;   LENGTH: 82
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_118623C.1.pep
US-10-424-599-163460

  Query Match             100.0%;  Score 19;  DB 4;  Length 82;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         22 AQGV 25


RESULT 153
US-10-424-599-227097
; Sequence 227097, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 227097
;   LENGTH: 82
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_47099C.1.pep
US-10-424-599-227097

  Query Match             100.0%;  Score 19;  DB 4;  Length 82;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         70 AQGV 73


RESULT 154
US-10-425-115-236419
; Sequence 236419, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
```

```
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 236419
;   LENGTH: 82
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_147196C.1.pep
US-10-425-115-236419

  Query Match            100.0%;  Score 19;  DB 4;  Length 82;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 155
US-10-424-599-270384
; Sequence 270384, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 270384
;   LENGTH: 83
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_86175C.1.pep
US-10-424-599-270384

  Query Match            100.0%;  Score 19;  DB 4;  Length 83;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          9 AQGV 12


RESULT 156
US-10-437-963-180416
; Sequence 180416, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 180416
;   LENGTH: 83
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_77786C.1.pep
US-10-437-963-180416

  Query Match            100.0%;  Score 19;  DB 4;  Length 83;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 157
US-10-425-115-205887
; Sequence 205887, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 205887
;   LENGTH: 83
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_119352C.1.pep
US-10-425-115-205887

  Query Match            100.0%;  Score 19;  DB 4;  Length 83;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         60 AQGV 63


RESULT 158
US-10-425-115-241912
; Sequence 241912, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 241912
;   LENGTH: 83
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(83)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_152202C.1.pep
US-10-425-115-241912
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 83;
  Best Local Similarity  100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 159
US-10-425-115-289244
; Sequence 289244, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 289244
;   LENGTH: 83
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_26880C.1.pep
US-10-425-115-289244

  Query Match           100.0%;  Score 19;  DB 4;  Length 83;
  Best Local Similarity  100.0%;  Pred. No. 2.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         50 AQGV 53


RESULT 160
US-09-731-872-330
; Sequence 330, Application US/09731872
; Patent No. US20020102604A1
; GENERAL INFORMATION:
;  APPLICANT: Dumas Milne Edwards, Jean Baptiste
;  APPLICANT:  Bougueleret, Lydie
;  APPLICANT:  Jobert, Severin
;  TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
;  FILE REFERENCE: 78.US3.REG
;  CURRENT APPLICATION NUMBER: US/09/731,872
;  CURRENT FILING DATE:  2000-12-07
;  PRIOR APPLICATION NUMBER: US 60/169,629
;  PRIOR FILING DATE: 1999-12-08
;  PRIOR APPLICATION NUMBER: US 60/187,470
;  PRIOR FILING DATE: 2000-03-06
;  NUMBER OF SEQ ID NOS: 482
;  SOFTWARE: Patent.pm
; SEQ ID NO 330
;   LENGTH: 84
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SIGNAL
;   LOCATION: -20..-1
US-09-731-872-330

  Query Match           100.0%;  Score 19;  DB 3;  Length 84;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 161
US-09-876-997-330
; Sequence 330, Application US/09876997
; Publication No. US20030152921A1
; GENERAL INFORMATION:
;  APPLICANT: Dumas Milne Edwards, Jean Baptiste
;  APPLICANT:  Bougueleret, Lydie
;  APPLICANT:  Jobert, Severin
;  TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
;  FILE REFERENCE: 78.US4.CIP
;  CURRENT APPLICATION NUMBER: US/09/876,997
;  CURRENT FILING DATE:  2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/731,872
;  PRIOR FILING DATE: 2000-12-07
;  PRIOR APPLICATION NUMBER: US 60/187,470
;  PRIOR FILING DATE: 2000-03-06
;  PRIOR APPLICATION NUMBER: US 60/169,629
;  PRIOR FILING DATE: 1999-12-08
;  NUMBER OF SEQ ID NOS: 482
;  SOFTWARE: Patent.pm
; SEQ ID NO 330
;   LENGTH: 84
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SIGNAL
;   LOCATION: -20..-1
US-09-876-997-330

  Query Match           100.0%;  Score 19;  DB 3;  Length 84;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 162
US-10-425-115-364443
; Sequence 364443, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 364443
;   LENGTH: 84
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_95540C.1.pep
US-10-425-115-364443

  Query Match           100.0%;  Score 19;  DB 4;  Length 84;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         73 AQGV 76
```

```
RESULT 163
US-10-643-836-330
; Sequence 330, Application US/10643836
; Publication No. US20050096458A1
; GENERAL INFORMATION:
;  APPLICANT: Dumas Milne Edwards, Jean Baptiste
;  APPLICANT:  Bougueleret, Lydie
;  APPLICANT:  Jobert, Severin
;  TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
;  FILE REFERENCE: 78.US3.REG
;  CURRENT APPLICATION NUMBER: US/10/643,836
;  CURRENT FILING DATE:  2003-08-19
;  PRIOR APPLICATION NUMBER: US/09/731,872
;  PRIOR FILING DATE: 2000-12-07
;  PRIOR APPLICATION NUMBER: US 60/169,629
;  PRIOR FILING DATE: 1999-12-08
;  PRIOR APPLICATION NUMBER: US 60/187,470
;  PRIOR FILING DATE: 2000-03-06
;  NUMBER OF SEQ ID NOS: 482
;  SOFTWARE: Patent.pm
; SEQ ID NO 330
;   LENGTH: 84
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SIGNAL
;   LOCATION: -20..-1
US-10-643-836-330

  Query Match             100.0%;  Score 19;  DB 5;  Length 84;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 164
US-10-450-763-35681
; Sequence 35681, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 790CIP3/US
;  CURRENT APPLICATION NUMBER: US/10/450,763
;  CURRENT FILING DATE:  2003-06-11
;  PRIOR APPLICATION NUMBER: PCT/US01/08631
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 09/540,217
;  PRIOR FILING DATE: 2000-03-31
;  PRIOR APPLICATION NUMBER: 09/649,167
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 60736
;  SOFTWARE: Custom
; SEQ ID NO 35681
;   LENGTH: 84
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(84)
;   OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-35681

  Query Match             100.0%;  Score 19;  DB 5;  Length 84;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 165
US-11-097-143-21975
; Sequence 21975, Application US/11097143
; Publication No. US20050208558A1
; GENERAL INFORMATION:
;  APPLICANT: Venter, J. Craig
;  APPLICANT:  et al.
;  TITLE OF INVENTION: DETECTION KIT, SUCH AS NUCLEIC ACID
;  TITLE OF INVENTION:  ARRAYS, FOR DETECTING EXPRESSION OF 10,000 OR MORE
;  TITLE OF INVENTION:  DROSOPHILA GENES.
;  FILE REFERENCE: CL000728
;  CURRENT APPLICATION NUMBER: US/11/097,143
;  CURRENT FILING DATE:  2005-04-04
;  PRIOR APPLICATION NUMBER: 60/157,832
;  PRIOR FILING DATE: 1999-10-05
;  PRIOR APPLICATION NUMBER: 60/160,191
;  PRIOR FILING DATE: 1999-10-19
;  PRIOR APPLICATION NUMBER: 60/161,932
;  PRIOR FILING DATE: 1999-10-28
;  PRIOR APPLICATION NUMBER: 60/164,769
;  PRIOR FILING DATE: 1999-11-12
;  PRIOR APPLICATION NUMBER: 60/173,383
;  PRIOR FILING DATE: 1999-12-28
;  PRIOR APPLICATION NUMBER: 60/175,693
;  PRIOR FILING DATE: 2000-01-12
;  PRIOR APPLICATION NUMBER: 60/184,831
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: 60/191,637
;  PRIOR FILING DATE: 2000-03-23
;  NUMBER OF SEQ ID NOS: 43008
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21975
;   LENGTH: 84
;   TYPE: PRT
;   ORGANISM: DROSOPHILA
US-11-097-143-21975

  Query Match             100.0%;  Score 19;  DB 6;  Length 84;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         50 AQGV 53


RESULT 166
US-10-425-114-68442
; Sequence 68442, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
;  APPLICANT: Liu, Jingdong
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Screen, Steven E
;  APPLICANT:  Tabaska, Jack E
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53313)B
;  CURRENT APPLICATION NUMBER: US/10/425,114
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 68442
;   LENGTH: 85
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: LIB3136-058-H12_FLI.pep
US-10-425-114-68442
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 85;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 167
US-10-363-616-365
; Sequence 365, Application US/10363616
; Publication No. US20040044181A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 21272-113 (793)
;  CURRENT APPLICATION NUMBER: US/10/363,616
;  CURRENT FILING DATE:  2003-03-03
;  PRIOR APPLICATION NUMBER: 09/654,935
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 490
; SEQ ID NO 365
;   LENGTH: 85
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-363-616-365

  Query Match           100.0%;  Score 19;  DB 4;  Length 85;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47


RESULT 168
US-10-335-977-8250
; Sequence 8250, Application US/10335977
; Publication No. US20040052799A1
;   GENERAL INFORMATION:
;        APPLICANT: DOUGLAS SMITH et al
;        TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
;                            RELATING TO HELICOBACTER PYLORI FOR
;                            DIAGNOSTICS AND THERAPEUTICS
;        NUMBER OF SEQUENCES: 10031
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: LAHIVE & COCKFIELD
;             STREET: 28 State Street
;             CITY: Boston
;             STATE: Massachusetts
;             COUNTRY: USA
;             ZIP: 02109-1875
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: CD/ROM ISO9660
;             COMPUTER: IBM PC Compatible
;             OPERATING SYSTEM: Windows NT 4.0
;             SOFTWARE: UNIX
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/335,977
;             FILING DATE: 30-Dec-2002
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/993,002
;             FILING DATE: 17-DEC-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Mandragouras, Amy E.
;             REGISTRATION NUMBER: 36,207
;             REFERENCE/DOCKET NUMBER: GTN-018
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (617)227-7400
;             TELEFAX: (617)742-4214
;   INFORMATION FOR SEQ ID NO: 8250:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 85 amino acids
;             TYPE: amino acid
;             TOPOLOGY: linear
;        MOLECULE TYPE: protein
;        HYPOTHETICAL: YES
;        ORIGINAL SOURCE:
;             ORGANISM: Helicobacter pylori
;        FEATURE:
;             NAME/KEY:  misc_feature
;             LOCATION: (B) LOCATION 1...85
;        SEQUENCE DESCRIPTION: SEQ ID NO: 8250:
US-10-335-977-8250

  Query Match           100.0%;  Score 19;  DB 4;  Length 85;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         23 AQGV 26


RESULT 169
US-10-425-115-368000
; Sequence 368000, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 368000
;   LENGTH: 85
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_98789C.1.pep
US-10-425-115-368000

  Query Match           100.0%;  Score 19;  DB 4;  Length 85;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         18 AQGV 21


RESULT 170
US-09-955-502-4
; Sequence 4, Application US/09955502
; Patent No. US20020072118A1
; GENERAL INFORMATION:
;  APPLICANT: Downs, Diana M.
;  APPLICANT:  Gralnick, Jeff A.
;  TITLE OF INVENTION: Method for Preventing Superoxide Damage to Cells and
;  TITLE OF INVENTION:  Oxygen-Labile Proteins
;  FILE REFERENCE: 960296.97559
;  CURRENT APPLICATION NUMBER: US/09/955,502
;  CURRENT FILING DATE:  2001-09-18
;  PRIOR APPLICATION NUMBER: 60/234,588
;  PRIOR FILING DATE: 2000-09-22
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
```

```
;   LENGTH: 86
;   TYPE: PRT
;   ORGANISM: Bordetella bronchiseptica
US-09-955-502-4

  Query Match             100.0%;  Score 19;  DB 3;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         82 AQGV 85


RESULT 171
US-09-864-408A-2696
; Sequence 2696, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Shimkets, Richard A.
;  TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Encc
;  FILE REFERENCE: 21402-012
;  CURRENT APPLICATION NUMBER: US/09/864,408A
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: 60/206,690
;  PRIOR FILING DATE: 2000-05-24
;  NUMBER OF SEQ ID NOS: 9068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2696
;   LENGTH: 86
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-864-408A-2696

  Query Match             100.0%;  Score 19;  DB 3;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         75 AQGV 78


RESULT 172
US-10-335-977-8249
; Sequence 8249, Application US/10335977
; Publication No. US20040052799A1
;   GENERAL INFORMATION:
;        APPLICANT: DOUGLAS SMITH et al
;        TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
;                            RELATING TO HELICOBACTER PYLORI FOR
;                            DIAGNOSTICS AND THERAPEUTICS
;        NUMBER OF SEQUENCES: 10031
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: LAHIVE & COCKFIELD
;             STREET: 28 State Street
;             CITY: Boston
;             STATE: Massachusetts
;             COUNTRY: USA
;             ZIP: 02109-1875
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: CD/ROM ISO9660
;             COMPUTER: IBM PC Compatible
;             OPERATING SYSTEM: Windows NT 4.0
;             SOFTWARE: UNIX
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/335,977
;             FILING DATE: 30-Dec-2002
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/993,002
;             FILING DATE: 17-DEC-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Mandragouras, Amy E.
;             REGISTRATION NUMBER: 36,207
;             REFERENCE/DOCKET NUMBER: GTN-018
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (617)227-7400
;             TELEFAX: (617)742-4214
;   INFORMATION FOR SEQ ID NO: 8249:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 86 amino acids
;             TYPE: amino acid
;             TOPOLOGY: linear
;        MOLECULE TYPE: protein
;        HYPOTHETICAL: YES
;        ORIGINAL SOURCE:
;             ORGANISM: Helicobacter pylori
;        FEATURE:
;             NAME/KEY:  misc_feature
;             LOCATION: (B) LOCATION 1...86
;        SEQUENCE DESCRIPTION: SEQ ID NO: 8249:
US-10-335-977-8249

  Query Match             100.0%;  Score 19;  DB 4;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 173
US-10-799-514-13
; Sequence 13, Application US/10799514
; Publication No. US20040241178A1
; GENERAL INFORMATION:
;  APPLICANT: Spertini, Francois
;  APPLICANT:  Corthesy, Blaise
;  TITLE OF INVENTION: Allergen Peptide Fragments and Use Thereof
;  FILE REFERENCE: 25720-502
;  CURRENT APPLICATION NUMBER: US/10/799,514
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: 60/455,004
;  PRIOR FILING DATE: 2003-03-14
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
;   LENGTH: 86
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: Peptide
US-10-799-514-13

  Query Match             100.0%;  Score 19;  DB 5;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47


RESULT 174
US-10-424-599-283838
; Sequence 283838, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
```

```
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 283838
;   LENGTH: 87
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(87)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_98329C.1.pep
US-10-424-599-283838

  Query Match           100.0%;  Score 19;  DB 4;  Length 87;
  Best Local Similarity  100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         37 AQGV 40


RESULT 175
US-10-437-963-123960
; Sequence 123960, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 123960
;   LENGTH: 87
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(87)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_26744C.1.pep
US-10-437-963-123960

  Query Match           100.0%;  Score 19;  DB 4;  Length 87;
  Best Local Similarity  100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         41 AQGV 44


RESULT 176
US-09-989-920-196
; Sequence 196, Application US/09989920
; Patent No. US20020172957A1
; GENERAL INFORMATION:
;  APPLICANT: Macina, Roberto
;  APPLICANT:  Recipon, Herve
;  APPLICANT:  Chen, Sei-Yu
;  APPLICANT:  Sun, Yongming
;  APPLICANT:  Liu, Chenghua
;  TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific Genes and Prote
;  FILE REFERENCE: DEX-0291
;  CURRENT APPLICATION NUMBER: US/09/989,920
;  CURRENT FILING DATE:  2001-11-21
;  PRIOR APPLICATION NUMBER: 60/252,500
;  PRIOR FILING DATE: 2000-11-22
;  NUMBER OF SEQ ID NOS: 284
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 196
;   LENGTH: 88
;   TYPE: PRT
;   ORGANISM: Homo sapien
US-09-989-920-196

  Query Match           100.0%;  Score 19;  DB 3;  Length 88;
  Best Local Similarity  100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         69 AQGV 72


RESULT 177
US-10-437-963-148963
; Sequence 148963, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 148963
;   LENGTH: 88
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_49342C.1.pep
US-10-437-963-148963

  Query Match           100.0%;  Score 19;  DB 4;  Length 88;
  Best Local Similarity  100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         23 AQGV 26


RESULT 178
US-10-425-115-199844
; Sequence 199844, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
```

```
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 199844
;   LENGTH: 88
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_11384C.1.pep
US-10-425-115-199844

  Query Match             100.0%;  Score 19;  DB 4;  Length 88;
  Best Local Similarity   100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         80 AQGV 83


RESULT 179
US-10-425-115-353524
; Sequence 353524, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 353524
;   LENGTH: 88
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_8558C.1.pep
US-10-425-115-353524

  Query Match             100.0%;  Score 19;  DB 4;  Length 88;
  Best Local Similarity   100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         65 AQGV 68


RESULT 180
US-10-424-599-173797
; Sequence 173797, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 173797
;   LENGTH: 89
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_127958C.1.pep
US-10-424-599-173797

  Query Match             100.0%;  Score 19;  DB 4;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         12 AQGV 15


RESULT 181
US-10-693-367-14
; Sequence 14, Application US/10693367
; Publication No. US20040091992A1
; GENERAL INFORMATION:
;  APPLICANT: The Trustees of Columbia University
;  APPLICANT:  Minden, Audrey
;  TITLE OF INVENTION: PAK4, A NOVEL GENE ENDODING A SERINE/THREONINE KINASE
;  FILE REFERENCE: 575/55311-A-PCT-US
;  CURRENT APPLICATION NUMBER: US/10/693,367
;  CURRENT FILING DATE:  2003-10-24
;  PRIOR APPLICATION NUMBER: US/09/718,032
;  PRIOR FILING DATE: 2000-11-21
;  PRIOR APPLICATION NUMBER: PCT/US99/11341
;  PRIOR FILING DATE: 1999-05-21
;  PRIOR APPLICATION NUMBER: 09/082,737
;  PRIOR FILING DATE: 1998-05-21
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
;   LENGTH: 89
;   TYPE: PRT
;   ORGANISM: mouse
US-10-693-367-14

  Query Match             100.0%;  Score 19;  DB 4;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         78 AQGV 81


RESULT 182
US-10-425-115-232359
; Sequence 232359, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 232359
;   LENGTH: 89
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_143506C.1.pep
US-10-425-115-232359

  Query Match             100.0%;  Score 19;  DB 4;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db         31 AQGV 34


RESULT 183
US-10-425-115-221841
; Sequence 221841, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 221841
;   LENGTH: 90
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(90)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_133910C.1.pep
US-10-425-115-221841

  Query Match             100.0%;  Score 19;  DB 4;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         27 AQGV 30


RESULT 184
US-10-424-599-282611
; Sequence 282611, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 282611
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_97219C.1.pep
US-10-424-599-282611

  Query Match             100.0%;  Score 19;  DB 4;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         23 AQGV 26


RESULT 185
US-10-767-701-58893
; Sequence 58893, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
;  APPLICANT: Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof For Plant Improvement
;  FILE REFERENCE: 38-21(53535)B
;  CURRENT APPLICATION NUMBER: US/10/767,701
;  CURRENT FILING DATE:  2004-01-29
;  NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 58893
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Sorghum bicolor
;   FEATURE:
;   OTHER INFORMATION: Clone ID: 6676508.pep
US-10-767-701-58893

  Query Match             100.0%;  Score 19;  DB 4;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 186
US-10-425-115-215363
; Sequence 215363, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 215363
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_128008C.1.pep
US-10-425-115-215363

  Query Match             100.0%;  Score 19;  DB 4;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         38 AQGV 41


RESULT 187
US-10-450-763-35010
; Sequence 35010, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 790CIP3/US
;  CURRENT APPLICATION NUMBER: US/10/450,763
;  CURRENT FILING DATE:  2003-06-11
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/08631
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 09/540,217
;  PRIOR FILING DATE: 2000-03-31
;  PRIOR APPLICATION NUMBER: 09/649,167
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 60736
;  SOFTWARE: Custom
; SEQ ID NO 35010
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-450-763-35010

  Query Match             100.0%;  Score 19;  DB 5;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 188
US-10-424-599-152428
; Sequence 152428, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 152428
;   LENGTH: 92
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_108666C.1.pep
US-10-424-599-152428

  Query Match             100.0%;  Score 19;  DB 4;  Length 92;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         58 AQGV 61


RESULT 189
US-10-425-115-255856
; Sequence 255856, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 255856
;   LENGTH: 92
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_164933C.1.pep
US-10-425-115-255856

  Query Match             100.0%;  Score 19;  DB 4;  Length 92;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 190
US-10-509-055-4
; Sequence 4, Application US/10509055
; Publication No. US20050227354A1
; GENERAL INFORMATION:
;  APPLICANT: SAGAWA, Hiroaki et al.
;  TITLE OF INVENTION: PROCESS FOR PRODUCING CYTOTOXIC LYMPHOCYTE
;  FILE REFERENCE: 1422-0644PUS1
;  CURRENT APPLICATION NUMBER: US/10/509,055
;  CURRENT FILING DATE:  2004-09-24
;  PRIOR APPLICATION NUMBER: PCT/JP03/03575
;  PRIOR FILING DATE: 2003-03-25
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: Patent-In 3.3
; SEQ ID NO 4
;   LENGTH: 92
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: partial region of fibronectin named III-12
US-10-509-055-4

  Query Match             100.0%;  Score 19;  DB 5;  Length 92;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         84 AQGV 87


RESULT 191
US-10-424-599-176284
; Sequence 176284, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 176284
;   LENGTH: 93
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(93)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_130201C.1.pep
US-10-424-599-176284

  Query Match             100.0%;  Score 19;  DB 4;  Length 93;
```

```
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         14 AQGV 17


RESULT 192
US-10-425-115-245408
; Sequence 245408, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 245408
;   LENGTH: 93
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_155398C.1.pep
US-10-425-115-245408

  Query Match             100.0%;  Score 19;  DB 4;  Length 93;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         37 AQGV 40


RESULT 193
US-10-425-115-280821
; Sequence 280821, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 280821
;   LENGTH: 93
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_1920C.1.pep
US-10-425-115-280821

  Query Match             100.0%;  Score 19;  DB 4;  Length 93;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 194
US-10-484-148-23
; Sequence 23, Application US/10484148
; Publication No. US20040248251A1
; GENERAL INFORMATION:
;  APPLICANT: LAL, Preeti G.; HONCHELL, Cynthia D.;
;  APPLICANT:  FORSYTHE, Ian J.; CHAWLA, Narinder K.;
;  APPLICANT:  TANG, Y. Tom; BOROWSKY, Mark L.; BARROSO, Ines;
;  APPLICANT:  YUE, Henry; WARREN, Bridget A.;
;  APPLICANT:  THANGAVELU, Kavitha; GIETZEN, Kimberly J.;
;  APPLICANT:  AZIMZAI, Yalda; LEE, Ernestine A.;
;  APPLICANT:  BAUGHN, Mariah R.; GORVAD, Ann E.;
;  APPLICANT:  DUGGAN, Brendan M.; TRAN, Bao;
;  APPLICANT:  LI, Joana X.; RICHARDSON, Thomas W.;
;  APPLICANT:  ELLIOTT, Vicki S.; ZEBARJADIAN, Yeganeh
;  APPLICANT:  TRAN, Uyen K.; YAO, Monique G.;
;  APPLICANT:  PETERSON, David P.; LUO, Wen
;  APPLICANT:  LEHR-MASON, Patricia M.
;  TITLE OF INVENTION: RECEPTORS AND MEMBRANE ASSOCIATED PROTEINS
;  FILE REFERENCE: PF-1082 USN
;  CURRENT APPLICATION NUMBER: US/10/484,148
;  CURRENT FILING DATE:  2004-01-15
;  PRIOR APPLICATION NUMBER: PCT/US02/22833
;  PRIOR FILING DATE: 2002-07-16
;  PRIOR APPLICATION NUMBER: US 60/306,020
;  PRIOR FILING DATE: 2001-07-17
;  PRIOR APPLICATION NUMBER: US 60/308,179
;  PRIOR FILING DATE: 2001-07-27
;  PRIOR APPLICATION NUMBER: US 60/309,702
;  PRIOR FILING DATE: 2001-08-02
;  PRIOR APPLICATION NUMBER: US 60/311,476
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: US 60/311,718
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: US 60/311,551
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: US 60/314,798
;  PRIOR FILING DATE: 2001-08-24
;  PRIOR APPLICATION NUMBER: US 60/316,639
;  PRIOR FILING DATE: 2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/317,996
;  PRIOR FILING DATE: 2001-09-07
;  NUMBER OF SEQ ID NOS: 46
;  SOFTWARE: PERL Program
; SEQ ID NO 23
;   LENGTH: 93
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Incyte ID No: 1985321CD1
US-10-484-148-23

  Query Match             100.0%;  Score 19;  DB 5;  Length 93;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         89 AQGV 92


RESULT 195
US-10-425-115-341122
; Sequence 341122, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
```

```
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 341122
;   LENGTH: 94
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_74271C.1.pep
US-10-425-115-341122

  Query Match             100.0%;  Score 19;  DB 4;  Length 94;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         45 AQGV 48


RESULT 196
US-10-156-761-11115
; Sequence 11115, Application US/10156761
; Publication No. US20030119018A1
; GENERAL INFORMATION:
;  APPLICANT: OMURA, SATOSHI
;  APPLICANT:  IKEDA, HARUO
;  APPLICANT:  ISHIKAWA, JUN
;  APPLICANT:  HORIKAWA, HIROSHI
;  APPLICANT:  SHIBA, TADAYOSHI
;  APPLICANT:  SAKAKI, YOSHIYUKI
;  APPLICANT:  HATTORI, MASAHIRA
;  TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES
;  FILE REFERENCE: 249-262
;  CURRENT APPLICATION NUMBER: US/10/156,761
;  CURRENT FILING DATE:  2002-05-29
;  PRIOR APPLICATION NUMBER: JP 2001-204089
;  PRIOR FILING DATE: 2001-05-30
;  PRIOR APPLICATION NUMBER: JP 2001-272697
;  PRIOR FILING DATE: 2001-08-02
;  NUMBER OF SEQ ID NOS: 15109
; SEQ ID NO 11115
;   LENGTH: 95
;   TYPE: PRT
;   ORGANISM: Streptomyces avermitilis
US-10-156-761-11115

  Query Match             100.0%;  Score 19;  DB 4;  Length 95;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         54 AQGV 57


RESULT 197
US-10-425-115-298069
; Sequence 298069, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 298069
;   LENGTH: 95
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(95)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_34909C.1.pep
US-10-425-115-298069

  Query Match             100.0%;  Score 19;  DB 4;  Length 95;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         42 AQGV 45


RESULT 198
US-10-425-115-314568
; Sequence 314568, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 314568
;   LENGTH: 95
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_49944C.1.pep
US-10-425-115-314568

  Query Match             100.0%;  Score 19;  DB 4;  Length 95;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 199
US-10-425-115-348114
; Sequence 348114, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 348114
;   LENGTH: 95
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_80644C.1.pep
US-10-425-115-348114
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 95;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         52 AQGV 55


RESULT 200
US-10-424-599-220040
; Sequence 220040, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 220040
;   LENGTH: 96
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(96)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_40725C.1.pep
US-10-424-599-220040

  Query Match           100.0%;  Score 19;  DB 4;  Length 96;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         73 AQGV 76


RESULT 201
US-10-437-963-186534
; Sequence 186534, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 186534
;   LENGTH: 96
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_83325C.1.pep
US-10-437-963-186534

  Query Match           100.0%;  Score 19;  DB 4;  Length 96;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         77 AQGV 80


RESULT 202
US-10-767-701-48980
; Sequence 48980, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
;  APPLICANT: Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof For Plant Improvement
;  FILE REFERENCE: 38-21(53535)B
;  CURRENT APPLICATION NUMBER: US/10/767,701
;  CURRENT FILING DATE:  2004-01-29
;  NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 48980
;   LENGTH: 96
;   TYPE: PRT
;   ORGANISM: Sorghum bicolor
;   FEATURE:
;   OTHER INFORMATION: Clone ID: LIB3476-024-P1-K1-G11.pep
US-10-767-701-48980

  Query Match           100.0%;  Score 19;  DB 4;  Length 96;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         18 AQGV 21


RESULT 203
US-10-425-115-220279
; Sequence 220279, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 220279
;   LENGTH: 96
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(96)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_13247C.1.pep
US-10-425-115-220279

  Query Match           100.0%;  Score 19;  DB 4;  Length 96;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
```

```
Db         44 AQGV 47


RESULT 204
US-10-437-963-198150
; Sequence 198150, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 198150
;   LENGTH: 97
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_93839C.1.pep
US-10-437-963-198150

  Query Match            100.0%;  Score 19;  DB 4;  Length 97;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         89 AQGV 92


RESULT 205
US-10-425-115-358132
; Sequence 358132, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 358132
;   LENGTH: 97
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(97)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_89784C.1.pep
US-10-425-115-358132

  Query Match            100.0%;  Score 19;  DB 4;  Length 97;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 206
US-10-501-282-1482
; Sequence 1482, Application US/10501282
; Publication No. US20050203280A1
; GENERAL INFORMATION:
;  APPLICANT: MCMICHAEL, JOHN CALHOUN
;  APPLICANT:  ZAGURSKY, ROBERT JOHN
;  APPLICANT:  RUSSELL, DAVID PARRISH
;  APPLICANT:  PLETCHER, LEAH DIANE
;  TITLE OF INVENTION: ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFS) ENCODING
;  TITLE OF INVENTION:  POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF
;  FILE REFERENCE: AM100780 L2
;  CURRENT APPLICATION NUMBER: US/10/501,282
;  CURRENT FILING DATE:  2004-07-09
;  PRIOR APPLICATION NUMBER: 60/333,777
;  PRIOR FILING DATE: 2001-11-29
;  PRIOR APPLICATION NUMBER: 60/426,742
;  PRIOR FILING DATE: 2002-11-18
;  PRIOR APPLICATION NUMBER: PCT/US02/36123
;  PRIOR FILING DATE: 2002-11-25
;  NUMBER OF SEQ ID NOS: 6653
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1482
;   LENGTH: 97
;   TYPE: PRT
;   ORGANISM: Alloiococcus otitidis
US-10-501-282-1482

  Query Match            100.0%;  Score 19;  DB 5;  Length 97;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         43 AQGV 46


RESULT 207
US-10-424-599-189929
; Sequence 189929, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 189929
;   LENGTH: 98
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_142524C.1.pep
US-10-424-599-189929

  Query Match            100.0%;  Score 19;  DB 4;  Length 98;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         15 AQGV 18


RESULT 208
US-10-424-599-194380
```

```
; Sequence 194380, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 194380
;   LENGTH: 98
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_17552C.1.pep
US-10-424-599-194380

  Query Match             100.0%;  Score 19;  DB 4;  Length 98;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         60 AQGV 63


RESULT 209
US-10-617-320-5200
; Sequence 5200, Application US/10617320
; Publication No. US20050136404A1
;   GENERAL INFORMATION:
;        APPLICANT: Lynn A Doucette-Stamm  and David Bush
;        TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID
;                            SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE   FOR DIAGNO
;                            THERAPEUTICS
;        NUMBER OF SEQUENCES: 5206
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: GENOME THERAPEUTICS CORPORATION
;             STREET: 100 Beaver Street
;             CITY: Waltham
;             STATE: Massachusetts
;             COUNTRY: USA
;             ZIP: 02354
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: CD/ROM ISO9660
;             COMPUTER: <Unknown>
;             OPERATING SYSTEM: <Unknown>
;             SOFTWARE: <Unknown>
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/617,320
;             FILING DATE: 10-Jul-2003
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/107,433
;             FILING DATE: 30-Jun-1998
;             APPLICATION NUMBER: 60/ 085131
;             FILING DATE: May 12, 1998
;             APPLICATION NUMBER: 60/051553
;             FILING DATE: July 2, 1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Ariniello, Pamela Deneke
;             REGISTRATION NUMBER: 40,489
;             REFERENCE/DOCKET NUMBER: GTC-011
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (781)893-5007
;             TELEFAX: (781)893-8277
;   INFORMATION FOR SEQ ID NO: 5200:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 99 amino acids
;             TYPE: amino acid
;             TOPOLOGY: linear
;        MOLECULE TYPE: protein
;        HYPOTHETICAL: YES
;        ORIGINAL SOURCE:
;             ORGANISM: Streptococcus pneumoniae
;        FEATURE:
;             NAME/KEY:  misc_feature
;             LOCATION: (B) LOCATION 1...99
;        SEQUENCE DESCRIPTION: SEQ ID NO: 5200:
US-10-617-320-5200

  Query Match             100.0%;  Score 19;  DB 5;  Length 99;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         85 AQGV 88


RESULT 210
US-10-080-170-56
; Sequence 56, Application US/10080170
; Publication No. US20030129601A1
; GENERAL INFORMATION:
;  APPLICANT: COLE, S.T.
;  TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
;  TITLE OF INVENTION:  IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
;  TITLE OF INVENTION:  TREATMENT OF MYCOBACTERIOSES
;  FILE REFERENCE: 03495.0218
;  CURRENT APPLICATION NUMBER: US/10/080,170
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: 60/270,123
;  PRIOR FILING DATE: 2001-02-22
;  NUMBER OF SEQ ID NOS: 652
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 56
;   LENGTH: 100
;   TYPE: PRT
;   ORGANISM: Mycobacterium leprae
US-10-080-170-56

  Query Match             100.0%;  Score 19;  DB 4;  Length 100;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         68 AQGV 71


RESULT 211
US-10-080-170-56
; Sequence 56, Application US/10080170
; Publication No. US20040121322A9
; GENERAL INFORMATION:
;  APPLICANT: COLE, S.T.
;  TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
;  TITLE OF INVENTION:  IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
;  TITLE OF INVENTION:  TREATMENT OF MYCOBACTERIOSES
;  FILE REFERENCE: 03495.0218
;  CURRENT APPLICATION NUMBER: US/10/080,170
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: 60/270,123
;  PRIOR FILING DATE: 2001-02-22
;  NUMBER OF SEQ ID NOS: 652
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 56
;   LENGTH: 100
;   TYPE: PRT
;   ORGANISM: Mycobacterium leprae
US-10-080-170-56
```

```
  Query Match            100.0%;  Score 19;  DB 4;  Length 100;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         68 AQGV 71


RESULT 212
US-10-468-356-56
; Sequence 56, Application US/10468356
; Publication No. US20040197896A1
; GENERAL INFORMATION:
;  APPLICANT: COLE, STEWART
;  TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENEOMICS AS A TOOL FOR
;  TITLE OF INVENTION:  IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
;  TITLE OF INVENTION:  TREATMENT OF MYCOBACTERIOSES
;  FILE REFERENCE: 05394.0019
;  CURRENT APPLICATION NUMBER: US/10/468,356
;  CURRENT FILING DATE:  2003-08-19
;  PRIOR APPLICATION NUMBER: 10/080,170
;  PRIOR FILING DATE: 2002-02-22
;  PRIOR APPLICATION NUMBER: 60/270,123
;  PRIOR FILING DATE: 2001-02-22
;  NUMBER OF SEQ ID NOS: 655
;  SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 56
;   LENGTH: 100
;   TYPE: PRT
;   ORGANISM: Mycobacterium leprae
US-10-468-356-56

  Query Match            100.0%;  Score 19;  DB 4;  Length 100;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         68 AQGV 71


RESULT 213
US-10-425-115-222178
; Sequence 222178, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 222178
;   LENGTH: 100
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_134216C.1.pep
US-10-425-115-222178

  Query Match            100.0%;  Score 19;  DB 4;  Length 100;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         72 AQGV 75


RESULT 214
US-10-425-115-289173
; Sequence 289173, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 289173
;   LENGTH: 100
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_26816C.1.pep
US-10-425-115-289173

  Query Match            100.0%;  Score 19;  DB 4;  Length 100;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         64 AQGV 67


RESULT 215
US-09-864-408A-2992
; Sequence 2992, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Shimkets, Richard A.
;  TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Enco
;  FILE REFERENCE: 21402-012
;  CURRENT APPLICATION NUMBER: US/09/864,408A
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: 60/206,690
;  PRIOR FILING DATE: 2000-05-24
;  NUMBER OF SEQ ID NOS: 9068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2992
;   LENGTH: 101
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-864-408A-2992

  Query Match            100.0%;  Score 19;  DB 3;  Length 101;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         77 AQGV 80


RESULT 216
US-10-437-963-121960
; Sequence 121960, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
```

```
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 121960
;   LENGTH: 101
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(101)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_24934C.1.pep
US-10-437-963-121960

  Query Match            100.0%;  Score 19;  DB 4;  Length 101;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         68 AQGV 71


RESULT 217
US-10-450-763-32365
; Sequence 32365, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 790CIP3/US
;  CURRENT APPLICATION NUMBER: US/10/450,763
;  CURRENT FILING DATE:  2003-06-11
;  PRIOR APPLICATION NUMBER: PCT/US01/08631
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 09/540,217
;  PRIOR FILING DATE: 2000-03-31
;  PRIOR APPLICATION NUMBER: 09/649,167
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 60736
;  SOFTWARE: Custom
; SEQ ID NO 32365
;   LENGTH: 101
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(101)
;   OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-32365

  Query Match            100.0%;  Score 19;  DB 5;  Length 101;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         46 AQGV 49


RESULT 218
US-10-450-763-54297
; Sequence 54297, Application US/10450763
; Publication No. US20050196754A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc
;  TITLE OF INVENTION: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
;  FILE REFERENCE: 790CIP3/US
;  CURRENT APPLICATION NUMBER: US/10/450,763
;  CURRENT FILING DATE:  2003-06-11
;  PRIOR APPLICATION NUMBER: PCT/US01/08631
;  PRIOR FILING DATE: 2001-03-30
;  PRIOR APPLICATION NUMBER: 09/540,217
;  PRIOR FILING DATE: 2000-03-31
;  PRIOR APPLICATION NUMBER: 09/649,167
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 60736
;  SOFTWARE: Custom
; SEQ ID NO 54297
;   LENGTH: 101
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(101)
;   OTHER INFORMATION: Xaa = X or * as defined in Table 2
US-10-450-763-54297

  Query Match            100.0%;  Score 19;  DB 5;  Length 101;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         46 AQGV 49


RESULT 219
US-10-101-464A-699
; Sequence 699, Application US/10101464A
; Publication No. US20030046728A1
; GENERAL INFORMATION:
;  APPLICANT: Strabala, Timothy
;  APPLICANT:  Nieuwenhuizen, Nicolaas
;  APPLICANT:  Higgins, Colleen M.
;  TITLE OF INVENTION: Compositions Isolated from Plant Cells
;  TITLE OF INVENTION:  and Their Use in the Modification of Plant Cell Signaling
;  FILE REFERENCE: 11000.1020c2
;  CURRENT APPLICATION NUMBER: US/10/101,464A
;  CURRENT FILING DATE:  2002-03-18
;  PRIOR APPLICATION NUMBER: 09/704,302
;  PRIOR FILING DATE: 2000-11-01
;  PRIOR APPLICATION NUMBER: 09/228,986
;  PRIOR FILING DATE: 1999-01-12
;  PRIOR APPLICATION NUMBER: 60/162,866
;  PRIOR FILING DATE: 1999-11-01
;  PRIOR APPLICATION NUMBER: PCT/US00/00724
;  PRIOR FILING DATE: 2000-01-11
;  NUMBER OF SEQ ID NOS: 989
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 699
;   LENGTH: 102
;   TYPE: PRT
;   ORGANISM: Pinus radiata
US-10-101-464A-699

  Query Match            100.0%;  Score 19;  DB 4;  Length 102;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         31 AQGV 34


RESULT 220
US-10-080-170-301
; Sequence 301, Application US/10080170
; Publication No. US20030129601A1
```

; GENERAL INFORMATION:
; APPLICANT: COLE, S.T.
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; TITLE OF INVENTION: TREATMENT OF MYCOBACTERIOSES
; FILE REFERENCE: 03495.0218
; CURRENT APPLICATION NUMBER: US/10/080,170
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: 60/270,123
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 301
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-080-170-301

Query Match 100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 66 AQGV 69

RESULT 221
US-10-424-599-159264
; Sequence 159264, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 159264
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(102)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_114836C.1.pep
US-10-424-599-159264

Query Match 100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 222
US-10-080-170-301
; Sequence 301, Application US/10080170
; Publication No. US20040121322A9
; GENERAL INFORMATION:
; APPLICANT: COLE, S.T.
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; TITLE OF INVENTION: TREATMENT OF MYCOBACTERIOSES
; FILE REFERENCE: 03495.0218
; CURRENT APPLICATION NUMBER: US/10/080,170
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: 60/270,123
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 301
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-080-170-301

Query Match 100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 66 AQGV 69

RESULT 223
US-10-468-356-301
; Sequence 301, Application US/10468356
; Publication No. US20040197896A1
; GENERAL INFORMATION:
; APPLICANT: COLE, STEWART
; TITLE OF INVENTION: COMPARATIVE MYCOBACTERIAL GENEOMICS AS A TOOL FOR
; TITLE OF INVENTION: IDENTIFYING TARGETS FOR THE DIAGNOSIS, PROPHYLAXIS OR
; TITLE OF INVENTION: TREATMENT OF MYCOBACTERIOSES
; FILE REFERENCE: 05394.0019
; CURRENT APPLICATION NUMBER: US/10/468,356
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: 10/080,170
; PRIOR FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/270,123
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 655
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 301
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-468-356-301

Query Match 100.0%; Score 19; DB 4; Length 102;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 66 AQGV 69

RESULT 224
US-10-425-115-265628
; Sequence 265628, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 265628
; LENGTH: 102
; TYPE: PRT
; ORGANISM: Zea mays

```
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(102)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_173859C.1.pep
US-10-425-115-265628

  Query Match             100.0%;  Score 19;  DB 4;  Length 102;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         84 AQGV 87


RESULT 225
US-10-864-252-699
; Sequence 699, Application US/10864252
; Publication No. US20050050583A1
; GENERAL INFORMATION:
;  APPLICANT: Strabala, Timothy
;  APPLICANT:  Nieuwenhuizen, Nicolaas
;  APPLICANT:  Higgins, Colleen M.
;  TITLE OF INVENTION: Compositions Isolated from Plant Cells
;  TITLE OF INVENTION:  and Their Use in the Modification of Plant Cell Signaling
;  FILE REFERENCE: 11000.1020c3
;  CURRENT APPLICATION NUMBER: US/10/864,252
;  CURRENT FILING DATE:  2004-06-09
;  PRIOR APPLICATION NUMBER: 10/101,464
;  PRIOR FILING DATE: 2002-03-18
;  PRIOR APPLICATION NUMBER: 09/704,302
;  PRIOR FILING DATE: 2000-11-01
;  PRIOR APPLICATION NUMBER: 09/228,986
;  PRIOR FILING DATE: 1999-01-12
;  PRIOR APPLICATION NUMBER: 60/162,866
;  PRIOR FILING DATE: 1999-11-01
;  PRIOR APPLICATION NUMBER: PCT/US00/00724
;  PRIOR FILING DATE: 2000-01-11
;  NUMBER OF SEQ ID NOS: 989
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 699
;   LENGTH: 102
;   TYPE: PRT
;   ORGANISM: Pinus radiata
US-10-864-252-699

  Query Match             100.0%;  Score 19;  DB 5;  Length 102;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         31 AQGV 34


RESULT 226
US-10-424-599-179799
; Sequence 179799, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 179799
;   LENGTH: 103
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_133374C.1.pep
US-10-424-599-179799

  Query Match             100.0%;  Score 19;  DB 4;  Length 103;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         73 AQGV 76


RESULT 227
US-10-424-599-261546
; Sequence 261546, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 261546
;   LENGTH: 103
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(103)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_78199C.1.pep
US-10-424-599-261546

  Query Match             100.0%;  Score 19;  DB 4;  Length 103;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         38 AQGV 41


RESULT 228
US-10-424-599-198118
; Sequence 198118, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 198118
;   LENGTH: 104
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
```

```
;   LOCATION: (1)..(104)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_20925C.1.pep
US-10-424-599-198118

  Query Match             100.0%;  Score 19;  DB 4;  Length 104;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         87 AQGV 90


RESULT 229
US-10-424-599-244826
; Sequence 244826, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 244826
;   LENGTH: 104
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(104)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_63107C.1.pep
US-10-424-599-244826

  Query Match             100.0%;  Score 19;  DB 4;  Length 104;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db        100 AQGV 103


RESULT 230
US-10-425-115-205212
; Sequence 205212, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 205212
;   LENGTH: 104
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(104)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_118742C.1.pep
US-10-425-115-205212

  Query Match             100.0%;  Score 19;  DB 4;  Length 104;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         84 AQGV 87


RESULT 231
US-10-425-115-273311
; Sequence 273311, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 273311
;   LENGTH: 104
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_180845C.1.pep
US-10-425-115-273311

  Query Match             100.0%;  Score 19;  DB 4;  Length 104;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 232
US-10-424-599-258231
; Sequence 258231, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 258231
;   LENGTH: 105
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_75205C.1.pep
US-10-424-599-258231

  Query Match             100.0%;  Score 19;  DB 4;  Length 105;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db         73 AQGV 76


RESULT 233
US-10-437-963-187330
; Sequence 187330, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 187330
;   LENGTH: 105
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_84043C.1.pep
US-10-437-963-187330

  Query Match             100.0%;  Score 19;  DB 4;  Length 105;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         47 AQGV 50


RESULT 234
US-10-424-599-207947
; Sequence 207947, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 207947
;   LENGTH: 106
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(106)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_29802C.1.pep
US-10-424-599-207947

  Query Match             100.0%;  Score 19;  DB 4;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         78 AQGV 81


RESULT 235
US-10-437-963-124557
; Sequence 124557, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 124557
;   LENGTH: 106
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_27284C.1.pep
US-10-437-963-124557

  Query Match             100.0%;  Score 19;  DB 4;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         14 AQGV 17


RESULT 236
US-10-425-115-197558
; Sequence 197558, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 197558
;   LENGTH: 106
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_111756C.1.pep
US-10-425-115-197558

  Query Match             100.0%;  Score 19;  DB 4;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db        102 AQGV 105


RESULT 237
```

```
US-10-425-115-354333
; Sequence 354333, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 354333
;   LENGTH: 106
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(106)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_86323C.1.pep
US-10-425-115-354333

  Query Match             100.0%;  Score 19;  DB 4;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         45 AQGV 48


RESULT 238
US-10-775-481A-55
; Sequence 55, Application US/10775481A
; Publication No. US20040258687A1
; GENERAL INFORMATION:
;  APPLICANT: Waldman, Scott A.
;  APPLICANT:  Pitari, Giovanni Mario
;  APPLICANT:  Park, Jason
;  APPLICANT:  Schulz, Stephanie
;  APPLICANT:  Wolfe, Henry R.
;  APPLICANT:  Lubbe, Wilhelm
;  TITLE OF INVENTION: The Use Of GCC Ligands
;  FILE REFERENCE: 08321-0168 US1
;  CURRENT APPLICATION NUMBER: US/10/775,481A
;  CURRENT FILING DATE:  2004-02-10
;  PRIOR APPLICATION NUMBER: US 60/446,730
;  PRIOR FILING DATE: 2003-02-10
;  NUMBER OF SEQ ID NOS: 56
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 55
;   LENGTH: 106
;   TYPE: PRT
;   ORGANISM: Rattus norvegicus
US-10-775-481A-55

  Query Match             100.0%;  Score 19;  DB 5;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         19 AQGV 22


RESULT 239
US-09-800-095A-104
; Sequence 104, Application US/09800095A
; Publication No. US20020086988A1
; GENERAL INFORMATION:
;  APPLICANT: Conklin, Darrell C.
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Adler, David A.
;  TITLE OF INVENTION: FULL LENGTH EXPRESS POLYNUCLEOTIDES AND THE POLYPEPTIDES THEY ENC
;  FILE REFERENCE: 00-09
;  CURRENT APPLICATION NUMBER: US/09/800,095A
;  CURRENT FILING DATE:  2001-09-28
;  PRIOR APPLICATION NUMBER: 60/187,221
;  PRIOR FILING DATE: 2000-03-03
;  NUMBER OF SEQ ID NOS: 123
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 104
;   LENGTH: 107
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-800-095A-104

  Query Match             100.0%;  Score 19;  DB 3;  Length 107;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         38 AQGV 41


RESULT 240
US-09-833-245-1848
; Sequence 1848, Application US/09833245
; Publication No. US20040010134A1
; GENERAL INFORMATION:
;  APPLICANT: Human Genome Sciences, Inc.
;  TITLE OF INVENTION: Albumin Fusion Proteins
;  FILE REFERENCE: PF546PCT
;  CURRENT APPLICATION NUMBER: US/09/833,245
;  CURRENT FILING DATE:  2001-04-12
;  PRIOR APPLICATION NUMBER: 60/229, 358
;  PRIOR FILING DATE: 2000-04-12
;  PRIOR APPLICATION NUMBER: 60/256, 931
;  PRIOR FILING DATE: 2000-12-21
;  PRIOR APPLICATION NUMBER: 60/199, 384
;  PRIOR FILING DATE: 2000-04-25
;  NUMBER OF SEQ ID NOS: 2267
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1848
;   LENGTH: 107
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-833-245-1848

  Query Match             100.0%;  Score 19;  DB 3;  Length 107;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         73 AQGV 76


RESULT 241
US-10-424-599-161119
; Sequence 161119, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
```

```
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 161119
;   LENGTH: 107
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(107)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_116508C.1.pep
US-10-424-599-161119

  Query Match             100.0%;  Score 19;  DB 4;  Length 107;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          7 AQGV 10


RESULT 242
US-10-424-599-177891
; Sequence 177891, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 177891
;   LENGTH: 107
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(107)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_131651C.1.pep
US-10-424-599-177891

  Query Match             100.0%;  Score 19;  DB 4;  Length 107;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         90 AQGV 93


RESULT 243
US-10-425-115-291289
; Sequence 291289, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 291289
;   LENGTH: 107
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(107)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_28742C.1.pep
US-10-425-115-291289

  Query Match             100.0%;  Score 19;  DB 4;  Length 107;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         65 AQGV 68


RESULT 244
US-10-425-115-294264
; Sequence 294264, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 294264
;   LENGTH: 108
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_31455C.1.pep
US-10-425-115-294264

  Query Match             100.0%;  Score 19;  DB 4;  Length 108;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         48 AQGV 51


RESULT 245
US-10-437-963-180999
; Sequence 180999, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
```

; SEQ ID NO 180999
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(109)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_78315C.1.pep
US-10-437-963-180999

Query Match 100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 55 AQGV 58

RESULT 246
US-10-425-115-260668
; Sequence 260668, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 260668
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_169344C.1.pep
US-10-425-115-260668

Query Match 100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 58 AQGV 61

RESULT 247
US-10-425-115-280327
; Sequence 280327, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 280327
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(109)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_18760C.1.pep
US-10-425-115-280327

Query Match 100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 44 AQGV 47

RESULT 248
US-10-425-115-361658
; Sequence 361658, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 361658
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_93009C.1.pep
US-10-425-115-361658

Query Match 100.0%; Score 19; DB 4; Length 109;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 38 AQGV 41

RESULT 249
US-10-424-599-164976
; Sequence 164976, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 164976
; LENGTH: 110
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_119991C.1.pep
US-10-424-599-164976

Query Match 100.0%; Score 19; DB 4; Length 110;
Best Local Similarity 100.0%; Pred. No. 3.8e+03;

```
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         26 AQGV 29


RESULT 250
US-10-425-115-352048
; Sequence 352048, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants
;  FILE REFERENCE: 38-21(53222)B
;  CURRENT APPLICATION NUMBER: US/10/425,115
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 352048
;   LENGTH: 110
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: MRT4577_84232C.1.pep
US-10-425-115-352048

  Query Match             100.0%;  Score 19;  DB 4;  Length 110;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         23 AQGV 26


Search completed: February 21, 2006, 09:19:43
Job time : 128 secs
```

GenCore version 5.1.7

OM protein - protein search, using sw model

Run on: February 21, 2006, 08:56:13 ; Search time 33 Seconds
(without alignments)
10.021 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AQGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	100.0	8	2	US-08-884-235-10	Sequence 10, Appl
2	19	100.0	10	2	US-10-122-675-28	Sequence 28, Appl
3	19	100.0	15	2	US-09-220-415-37	Sequence 37, Appl
4	19	100.0	15	2	US-09-675-776-37	Sequence 37, Appl
5	19	100.0	15	2	US-09-676-739-37	Sequence 37, Appl
6	19	100.0	15	2	US-09-675-362-37	Sequence 37, Appl
7	19	100.0	15	2	US-09-677-152-37	Sequence 37, Appl
8	19	100.0	19	2	US-10-394-980-6	Sequence 6, Appli
9	19	100.0	21	2	US-09-936-588-8	Sequence 8, Appli
10	19	100.0	22	1	US-08-482-142-24	Sequence 24, Appl
11	19	100.0	22	1	US-08-478-572-24	Sequence 24, Appl
12	19	100.0	22	2	US-08-484-296-24	Sequence 24, Appl
13	19	100.0	22	4	PCT-US95-04481-15	Sequence 15, Appl
14	19	100.0	23	1	US-08-482-142-40	Sequence 40, Appl
15	19	100.0	23	1	US-08-478-572-40	Sequence 40, Appl
16	19	100.0	23	2	US-08-484-296-40	Sequence 40, Appl
17	19	100.0	23	2	US-08-933-100B-3	Sequence 3, Appli
18	19	100.0	24	1	US-08-141-324-22	Sequence 22, Appl
19	19	100.0	24	1	US-08-541-902-22	Sequence 22, Appl
20	19	100.0	25	1	US-08-482-142-38	Sequence 38, Appl
21	19	100.0	25	1	US-08-478-572-38	Sequence 38, Appl
22	19	100.0	25	2	US-08-484-296-38	Sequence 38, Appl
23	19	100.0	25	2	US-09-596-120-9	Sequence 9, Appli
24	19	100.0	26	1	US-07-879-685B-2	Sequence 2, Appli
25	19	100.0	27	1	US-08-821-119-6	Sequence 6, Appli
26	19	100.0	27	1	US-08-900-660A-6	Sequence 6, Appli
27	19	100.0	29	1	US-08-482-142-39	Sequence 39, Appl
28	19	100.0	29	1	US-08-478-572-39	Sequence 39, Appl
29	19	100.0	29	2	US-08-484-296-39	Sequence 39, Appl
30	19	100.0	34	1	US-07-700-526-7	Sequence 7, Appli
31	19	100.0	34	4	PCT-US92-03132-7	Sequence 7, Appli
32	19	100.0	37	1	US-08-164-151-14	Sequence 14, Appl
33	19	100.0	38	2	US-09-092-315-22	Sequence 22, Appl
34	19	100.0	38	2	US-09-733-524A-22	Sequence 22, Appl
35	19	100.0	38	2	US-10-189-977A-22	Sequence 22, Appl
36	19	100.0	40	2	US-08-096-044C-11	Sequence 11, Appl
37	19	100.0	60	2	US-09-252-991A-27289	Sequence 27289, A
38	19	100.0	62	2	US-09-489-039A-8531	Sequence 8531, Ap
39	19	100.0	64	2	US-09-248-796A-26843	Sequence 26843, A
40	19	100.0	65	2	US-09-489-039A-13242	Sequence 13242, A
41	19	100.0	65	2	US-09-513-999C-6489	Sequence 6489, Ap
42	19	100.0	69	2	US-08-792-013-1	Sequence 1, Appli
43	19	100.0	71	2	US-09-471-276-1548	Sequence 1548, Ap
44	19	100.0	72	1	US-08-225-480-6	Sequence 6, Appli
45	19	100.0	72	2	US-09-118-445-6	Sequence 6, Appli

ALIGNMENTS

RESULT 1
US-08-884-235-10
; Sequence 10, Application US/08884235
; Patent No. 6329573
; GENERAL INFORMATION:
; APPLICANT: Lightfoot, David A.
; APPLICANT: Long, Lynn M.
; APPLICANT: Lightfoot, Maria E. Vidal
; TITLE OF INVENTION: PLANTS CONTAINING THE gdhA GENE AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pillsbury Madison & Sutro, L.L.P.
; STREET: 1100 New York Avenue, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: United States of America
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/884,235
; FILING DATE: 27-JUN-1997
; CLASSIFICATION: 800
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 residues
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: not relevant
; MOLECULE TYPE: protein
US-08-884-235-10

Query Match 100.0%; Score 19; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 4 AQGV 7

RESULT 2
US-10-122-675-28
; Sequence 28, Application US/10122675
; Patent No. 6927031
; GENERAL INFORMATION:

```
;  APPLICANT: Anderson, David
;  APPLICANT:  Li, Weiqun
;  APPLICANT:  Lu, Henry
;  APPLICANT:  Rigel Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Methods for Identifying Polypeptide Factors Interacting
;  TITLE OF INVENTION:  With RNA
;  FILE REFERENCE: 021044-002000US
;  CURRENT APPLICATION NUMBER: US/10/122,675
;  CURRENT FILING DATE:  2002-10-31
;  NUMBER OF SEQ ID NOS: 29
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:inosine
;   OTHER INFORMATION: monophosphate dehydrogenase (IMPDH) peptide
US-10-122-675-28

  Query Match             100.0%;  Score 19;  DB 2;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 97;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 3
US-09-220-415-37
; Sequence 37, Application US/09220415
; Patent No. 6583109
;  GENERAL INFORMATION:
;    APPLICANT:  Gallo, Robert C.
;    APPLICANT:  Bryant, Joseph
;    APPLICANT:  Lunardi-Iskandar, Yanto
;    TITLE OF INVENTION:  Therapeutic Polypeptides from (-hCG and Derivatives
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Intellectual Property/Technology Law
;      STREET:  P.O. Box 14329
;      CITY:  Research Triangle Park
;      STATE:  NC
;      COUNTRY:  USA
;      ZIP:  27709
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  PatentIn
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/220,415
;      FILING DATE:  24-DEC-1998
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US97/11210
;      FILING DATE:  24-JUN-1998
;      APPLICATION NUMBER:  PCT/US97/11209
;      FILING DATE:  24-JUN-1998
;      APPLICATION NUMBER:  PCT/US97/11448
;      FILING DATE:  24-JUN-1998
;      APPLICATION NUMBER:  PCT/US97/11202
;      FILING DATE:  24-JUN-1998
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Steven J. Hultquist
;      REGISTRATION NUMBER:  28,021
;      REFERENCE/DOCKET NUMBER:  4115-116
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-419-9350
;      TELEFAX:  919-419-9354
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-09-220-415-37

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 4
US-09-675-776-37
; Sequence 37, Application US/09675776
; Patent No. 6596688
;  GENERAL INFORMATION:
;       APPLICANT: Gallo, Robert C.
;                  Bryant, Joseph
;                  Lunardi-Iskandar, Yanto
;       TITLE OF INVENTION: METHOD FOR PROMOTING HEMATOPOIESIS
;       NUMBER OF SEQUENCES: 37
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Intellectual Property/Technology Law
;            STREET: P.O. Box 14329
;            CITY: Research Triangle Park
;            STATE: NC
;            COUNTRY: USA
;            ZIP: 27709
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: DOS
;            SOFTWARE: PatentIn
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/675,776
;            FILING DATE: 29-Sep-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/220,415
;            FILING DATE: 24-DEC-1998
;            APPLICATION NUMBER: PCT/US97/11210
;            FILING DATE: 24-JUN-1998
;            APPLICATION NUMBER: PCT/US97/11209
;            FILING DATE: 24-JUN-1998
;            APPLICATION NUMBER: PCT/US97/11448
;            FILING DATE: 24-JUN-1998
;            APPLICATION NUMBER: PCT/US97/11202
;            FILING DATE: 24-JUN-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Marianne Fuierer
;            REGISTRATION NUMBER: 39,983
;            REFERENCE/DOCKET NUMBER: 4115-116 DIV2
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 919-419-9350
;            TELEFAX: 919-419-9354
;  INFORMATION FOR SEQ ID NO: 37:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 15 amino acids
;            TYPE: amino acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: protein
;       SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-675-776-37

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 5
US-09-676-739-37
; Sequence 37, Application US/09676739
; Patent No. 6620416
;   GENERAL INFORMATION:
;        APPLICANT: Gallo, Robert C.
;                   Bryant, Joseph
;                   Lunardi-Iskandar, Yanto
;        TITLE OF INVENTION: METHOD FOR TREATING HIV
;        NUMBER OF SEQUENCES: 37
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Intellectual Property/Technology Law
;             STREET: P.O. Box 14329
;             CITY: Research Triangle Park
;             STATE: NC
;             COUNTRY: USA
;             ZIP: 27709
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: PatentIn
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/676,739
;             FILING DATE: 29-Sep-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/220,415
;             FILING DATE: 24-DEC-1998
;             APPLICATION NUMBER: PCT/US97/11210
;             FILING DATE: 24-JUN-1998
;             APPLICATION NUMBER: PCT/US97/11209
;             FILING DATE: 24-JUN-1998
;             APPLICATION NUMBER: PCT/US97/11448
;             FILING DATE: 24-JUN-1998
;             APPLICATION NUMBER: PCT/US97/11202
;             FILING DATE: 24-JUN-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Marianne Fuierer
;             REGISTRATION NUMBER: 39,983
;             REFERENCE/DOCKET NUMBER: 4115-116 DIV1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 919-419-9350
;             TELEFAX: 919-419-9354
;   INFORMATION FOR SEQ ID NO: 37:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: protein
;        SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-676-739-37

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 6
US-09-675-362-37
; Sequence 37, Application US/09675362
; Patent No. 6699834
;   GENERAL INFORMATION:
;        APPLICANT: Gallo, Robert C.
;                   Bryant, Joseph
;                   Lunardi-Iskandar, Yanto
;        TITLE OF INVENTION: METHOD FOR TREATING CANCER
;        NUMBER OF SEQUENCES: 37
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Intellectual Property/Technology Law
;             STREET: P.O. Box 14329
;             CITY: Research Triangle Park
;             STATE: NC
;             COUNTRY: USA
;             ZIP: 27709
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: PatentIn
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/675,362
;             FILING DATE: 29-Sep-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/220,415
;             FILING DATE: 24-DEC-1998
;             APPLICATION NUMBER: PCT/US97/11210
;             FILING DATE: 24-JUN-1998
;             APPLICATION NUMBER: PCT/US97/11209
;             FILING DATE: 24-JUN-1998
;             APPLICATION NUMBER: PCT/US97/11448
;             FILING DATE: 24-JUN-1998
;             APPLICATION NUMBER: PCT/US97/11202
;             FILING DATE: 24-JUN-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Marianne Fuierer
;             REGISTRATION NUMBER: 39,983
;             REFERENCE/DOCKET NUMBER: 4115-116 DIV3
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 919-419-9350
;             TELEFAX: 919-419-9354
;   INFORMATION FOR SEQ ID NO: 37:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: protein
;        SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-675-362-37

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 7
US-09-677-152-37
; Sequence 37, Application US/09677152
; Patent No. 6805882
;   GENERAL INFORMATION:
;        APPLICANT: Gallo, Robert C.
;                   Bryant, Joseph
;                   Lunardi-Iskandar, Yanto
;        TITLE OF INVENTION: Therapeutic Fractions of Sources of hCG
;        NUMBER OF SEQUENCES: 37
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Intellectual Property/Technology Law
;             STREET: P.O. Box 14329
;             CITY: Research Triangle Park
```

```
;              STATE: NC
;              COUNTRY: USA
;              ZIP: 27709
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Diskette
;              COMPUTER: IBM Compatible
;              OPERATING SYSTEM: DOS
;              SOFTWARE: PatentIn
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/09/677,152
;              FILING DATE: 02-Oct-2000
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: PCT/US97/11210
;              FILING DATE: 24-JUN-1998
;              APPLICATION NUMBER: PCT/US97/11209
;              FILING DATE: 24-JUN-1998
;              APPLICATION NUMBER: PCT/US97/11448
;              FILING DATE: 24-JUN-1998
;              APPLICATION NUMBER: PCT/US97/11202
;              FILING DATE: 24-JUN-1998
;              APPLICATION NUMBER: USSN 09/220,415
;              FILING DATE: <Unknown>
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Steven J. Hultquist
;              REGISTRATION NUMBER: 28,021
;              REFERENCE/DOCKET NUMBER: 4115-116
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: 919-419-9350
;              TELEFAX: 919-419-9354
;    INFORMATION FOR SEQ ID NO: 37:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 15 amino acids
;              TYPE: amino acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         MOLECULE TYPE: protein
;         SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-677-152-37

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 8
US-10-394-980-6
; Sequence 6, Application US/10394980
; Patent No. 6908740
; GENERAL INFORMATION:
;  APPLICANT: Vandekerckhove, Joel
;  APPLICANT:  Gevaert, Kris
;  TITLE OF INVENTION: METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND
;  TITLE OF INVENTION:  QUANTITATIVE PROTEOME ANALYSIS, AND USES THEREFOR
;  FILE REFERENCE: VBV-001
;  CURRENT APPLICATION NUMBER: US/10/394,980
;  CURRENT FILING DATE:  2003-03-21
;  PRIOR APPLICATION NUMBER: PCT/EP02/03368
;  PRIOR FILING DATE: 2002-03-22
;  PRIOR APPLICATION NUMBER: US60/278,171
;  PRIOR FILING DATE: 2001-03-22
;  PRIOR APPLICATION NUMBER: US60/318,749
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US60/323,999
;  PRIOR FILING DATE: 2001-09-20
;  NUMBER OF SEQ ID NOS: 473
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   OTHER INFORMATION: part of AMBP_HUMAN ((P02760) alphae-1-microglobulin)
US-10-394-980-6

  Query Match             100.0%;  Score 19;  DB 2;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 9
US-09-936-588-8
; Sequence 8, Application US/09936588
; Patent No. 6858775
; GENERAL INFORMATION:
;  APPLICANT: XU, Ming-Qun
;  APPLICANT:  EVANS, Thomas C.
;  APPLICANT:  PRADHAN, Sriharsa
;  APPLICANT:  COMB, Donald G.
;  APPLICANT:  PAULUS, Henry
;  APPLICANT:  SUN, Luo
;  APPLICANT:  CHEN, Lixin
;  APPLICANT:  GHOSH, Inca
;  APPLICANT:  NEW ENGLAND BIOLABS, INC.
;  APPLICANT:  BOSTON BIOMEDICAL RESEARCH INSTITUTE
;  TITLE OF INVENTION: METHOD FOR GENERATING SPLIT, NON-TRANSFERABLE GENES
;  TITLE OF INVENTION:  THAT ARE ABLE TO EXPRESS AN ACTIVE PROTEIN PRODUCT
;  FILE REFERENCE: NEB-163-PCT
;  CURRENT APPLICATION NUMBER: US/09/936,588
;  CURRENT FILING DATE:  2001-09-13
;  PRIOR APPLICATION NUMBER: 60/135,677
;  PRIOR FILING DATE: 1999-05-24
;  NUMBER OF SEQ ID NOS: 134
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 21
;   TYPE: PRT
;   ORGANISM: Escherichia coli
US-09-936-588-8

  Query Match             100.0%;  Score 19;  DB 2;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 10
US-08-482-142-24
; Sequence 24, Application US/08482142
; Patent No. 5820862
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
```

```
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,142
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-482-142-24

  Query Match             100.0%;  Score 19;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 11
US-08-478-572-24
; Sequence 24, Application US/08478572
; Patent No. 5968526
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/478,572
;      FILING DATE:  07-June-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-478-572-24

  Query Match             100.0%;  Score 19;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 12
US-08-484-296-24
; Sequence 24, Application US/08484296
; Patent No. 6268491
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,296
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  22 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-484-296-24

  Query Match             100.0%;  Score 19;  DB 2;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 13
PCT-US95-04481-15
; Sequence 15, Application PC/TUS9504481
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Pharmaceutical Peptide Formulations For Treatment of Dust Mit
;    NUMBER OF SEQUENCES:  54
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/04481
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/227,772
;      FILING DATE:  April 14, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Vanstone, Darlene A.
;      REGISTRATION NUMBER:  35,279
;      REFERENCE/DOCKET NUMBER:  017.5 PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  22 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal
PCT-US95-04481-15

  Query Match             100.0%;  Score 19;  DB 4;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 14
US-08-482-142-40
; Sequence 40, Application US/08482142
; Patent No. 5820862
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,142
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  40:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-482-142-40

  Query Match             100.0%;  Score 19;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 15
US-08-478-572-40
; Sequence 40, Application US/08478572
; Patent No. 5968526
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/478,572
;      FILING DATE:  07-June-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  40:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-478-572-40

  Query Match             100.0%;  Score 19;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 16
US-08-484-296-40
; Sequence 40, Application US/08484296
; Patent No. 6268491
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,296
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  40:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-484-296-40

  Query Match             100.0%;  Score 19;  DB 2;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 17
US-08-933-100B-3
; Sequence 3, Application US/08933100B
; Patent No. 6274704
;  GENERAL INFORMATION:
;    APPLICANT:  FUKAI, FUMIO
;    APPLICANT:  KATAYAMA, TAKASHI
;    TITLE OF INVENTION:  BIOLOGICALLY ACTIVE PEPTIDE AND CANCER
;    TITLE OF INVENTION:  METASTASIS INHIBITOR
;    NUMBER OF SEQUENCES:  15
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PILLSBURY, MADISON & SUTRO
;      STREET:  1100 NEW YORK AVENUE, N.W.
;      CITY:  WASHINGTON
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/933,100B
;      FILING DATE:  18-SEP-1997
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PERRY, GLENN
;      REGISTRATION NUMBER:  28458
;      REFERENCE/DOCKET NUMBER:  7898/242094
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-861-3000
;      TELEFAX:  202-822-0944
;      TELEX:  6714627 CUSH
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FEATURE:
;      OTHER INFORMATION:  Sequence of a part (1669 - 1691) of Heparin binding site
; Patent No. 6274704
US-08-933-100B-3

  Query Match             100.0%;  Score 19;  DB 2;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
```

```
              ||||
Db         15 AQGV 18


RESULT 18
US-08-141-324-22
; Sequence 22, Application US/08141324
; Patent No. 5475097
;  GENERAL INFORMATION:
;    APPLICANT:  Travis, James
;    APPLICANT:  Potempa, Jan S.
;    APPLICANT:  Barr, Philip J.
;    APPLICANT:  Pavloff, Nadine
;    APPLICANT:  Pike, Robert N.
;    TITLE OF INVENTION:  Lysine-specific Porphyromonas gingivalis
;    TITLE OF INVENTION:  Protease
;    NUMBER OF SEQUENCES:  28
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Greenlee and Winner, P.C.
;      STREET:  5370 Manhattan Circle, Suite 201
;      CITY:  Boulder
;      STATE:  CO
;      COUNTRY:  US
;      ZIP:  80303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/141,324
;      FILING DATE:  21-OCT-1993
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ferber, Donna M.
;      REGISTRATION NUMBER:  33,878
;      REFERENCE/DOCKET NUMBER:  44-93
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  303-499-8080
;      TELEFAX:  303-499-8089
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
US-08-141-324-22

  Query Match             100.0%;  Score 19;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 19
US-08-541-902-22
; Sequence 22, Application US/08541902
; Patent No. 5707620
;  GENERAL INFORMATION:
;    APPLICANT:  Travis, James
;    APPLICANT:  Potempa, Jan S.
;    APPLICANT:  Barr, Philip J.
;    APPLICANT:  Pavloff, Nadine
;    APPLICANT:  Pike, Robert N.
;    TITLE OF INVENTION:  Lysine-specific Porphyromonas gingivalis
;    TITLE OF INVENTION:  Protease
;    NUMBER OF SEQUENCES:  28
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Greenlee and Winner, P.C.
;      STREET:  5370 Manhattan Circle, Suite 201
;      CITY:  Boulder
;      STATE:  CO
;      COUNTRY:  US
;      ZIP:  80303
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/541,902
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/141,324
;      FILING DATE:  21-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ferber, Donna M.
;      REGISTRATION NUMBER:  33,878
;      REFERENCE/DOCKET NUMBER:  44-93
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  303-499-8080
;      TELEFAX:  303-499-8089
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  24 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
US-08-541-902-22

  Query Match             100.0%;  Score 19;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 20
US-08-482-142-38
; Sequence 38, Application US/08482142
; Patent No. 5820862
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
```

```
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,142
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-482-142-38

  Query Match             100.0%;  Score 19;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 21
US-08-478-572-38
; Sequence 38, Application US/08478572
; Patent No. 5968526
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/478,572
;      FILING DATE:  07-June-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-478-572-38

  Query Match             100.0%;  Score 19;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 22
US-08-484-296-38
; Sequence 38, Application US/08484296
; Patent No. 6268491
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,296
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  25 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-484-296-38
```

```
  Query Match           100.0%;  Score 19;  DB 2;  Length 25;
  Best Local Similarity  100.0%;  Pred. No. 2.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 23
US-09-596-120-9
; Sequence 9, Application US/09596120
; Patent No. 6517838
; GENERAL INFORMATION:
;  APPLICANT: Hook, Magnus A.
;  APPLICANT:  Brown, Eric L.
;  TITLE OF INVENTION: Decorin Binding Proteins Essential Peptides and Methods of Use
;  FILE REFERENCE: 12740.0210.NPUS00  (TAMK:210)
;  CURRENT APPLICATION NUMBER: US/09/596,120
;  CURRENT FILING DATE:  2000-06-16
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 25
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligopeptide
US-09-596-120-9

  Query Match           100.0%;  Score 19;  DB 2;  Length 25;
  Best Local Similarity  100.0%;  Pred. No. 2.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         10 AQGV 13


RESULT 24
US-07-879-685B-2
; Sequence 2, Application US/07879685B
; Patent No. 5296383
;  GENERAL INFORMATION:
;    APPLICANT:  DAIKIN INDUSTRIES, LTD.
;    TITLE OF INVENTION:  A human centromere antigen
;    TITLE OF INVENTION:  polypeptide
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Umeda Center Building, 4-12
;      STREET:  Nakazaki-nishi, 2-chome
;      CITY:  Kita-ku
;      STATE:  Osaka
;      COUNTRY:  Japan
;      ZIP:  530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/879,685B
;      FILING DATE:  19920507
;      CLASSIFICATION:  436
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 3-102517
;      FILING DATE:  08-May-1991
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  26 amino acids
;      TYPE:  AMINO ACID
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  internal fragment
;    ORIGINAL SOURCE:
;      ORGANISM:  human
US-07-879-685B-2

  Query Match           100.0%;  Score 19;  DB 1;  Length 26;
  Best Local Similarity  100.0%;  Pred. No. 2.6e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 25
US-08-821-119-6
; Sequence 6, Application US/08821119
; Patent No. 5821104
;  GENERAL INFORMATION:
;    APPLICANT:  Holm, Kaj Andre
;    APPLICANT:  Rasmussen, Grethe
;    APPLICANT:  Halkier, Torben
;    APPLICANT:  Lehmbeck, Jan
;    TITLE OF INVENTION:  Tripeptidyl Aminopeptidase
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  No. 5821104o No. 5821104disk of No. 5821104th America, Inc.
;      STREET:  405 Lexington Avenue
;      CITY:  New York
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10174
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/821,119
;      FILING DATE:  19-MAR-1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lambiris, Elias J
;      REGISTRATION NUMBER:  33,728
;      REFERENCE/DOCKET NUMBER:  4107.204-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-867-0123
;      TELEFAX:  212-878-9655
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  No. 5821104e
US-08-821-119-6

  Query Match           100.0%;  Score 19;  DB 1;  Length 27;
  Best Local Similarity  100.0%;  Pred. No. 2.7e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 26
US-08-900-660A-6
; Sequence 6, Application US/08900660A
; Patent No. 5876947
;  GENERAL INFORMATION:
;    APPLICANT:  Kudryk, Bohdan J
```

```
;    APPLICANT:  Bini, Alessandra
;    APPLICANT:  Zhang, Jian-Zhong
;    TITLE OF INVENTION:  MONOSPECIFIC ANTIBODY REACTIVE
;    TITLE OF INVENTION:  WITH FIBRINOGEN AND
;    TITLE OF INVENTION:  FIBRINOPEPTIDE B
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann & Baron, LLP
;      STREET:  350 Jericho Turnpike
;      CITY:  Jericho
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  11753
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  MS-DOS
;      SOFTWARE:  WordPerfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/900,660A
;      FILING DATE:  25-JUL-1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Baron, Ronald J
;      REGISTRATION NUMBER:  29281
;      REFERENCE/DOCKET NUMBER:  454-15
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  516 822 3550
;      TELEFAX:  516 822 3582
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  27 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-900-660A-6

  Query Match             100.0%;  Score 19;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         21 AQGV 24


RESULT 27
US-08-482-142-39
; Sequence 39, Application US/08482142
; Patent No. 5820862
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,142
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  39:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-482-142-39

  Query Match             100.0%;  Score 19;  DB 1;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 28
US-08-478-572-39
; Sequence 39, Application US/08478572
; Patent No. 5968526
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/478,572
;      FILING DATE:  07-June-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
```

```
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  39:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-478-572-39

  Query Match           100.0%;  Score 19;  DB 1;  Length 29;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 29
US-08-484-296-39
; Sequence 39, Application US/08484296
; Patent No. 6268491
;  GENERAL INFORMATION:
;    APPLICANT:  Garman, Richard
;    APPLICANT:  Greenstein, Julia
;    APPLICANT:  Kuo, Mei-chang
;    APPLICANT:  Rogers, Bruce
;    APPLICANT:  Franzen, Henry
;    APPLICANT:  Chen, Xian
;    APPLICANT:  Evans, Sean
;    APPLICANT:  Shaked, Ze'ev
;    TITLE OF INVENTION:  T CELL EPITOPES OF THE MAJOR ALLERGENS
;    TITLE OF INVENTION:  FROM DERMATOPHAGOIDES (HOUSE DUST MITE)
;    NUMBER OF SEQUENCES:  207
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  IMMULOGIC PHARMACEUTICAL CORPORATION
;      STREET:  610 LINCOLN STREET
;      CITY:  WALTHAM
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII TEXT
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,296
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/445,307
;      FILING DATE:  07 June 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CRAIG, ANNE I.
;      REGISTRATION NUMBER:  32,976
;      REFERENCE/DOCKET NUMBER:  017.6US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 466-6000
;      TELEFAX:  (617) 466-6040
;  INFORMATION FOR SEQ ID NO:  39:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
US-08-484-296-39

  Query Match           100.0%;  Score 19;  DB 2;  Length 29;
  Best Local Similarity  100.0%;  Pred. No. 2.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 30
US-07-700-526-7
; Sequence 7, Application US/07700526
; Patent No. 5166133
;  GENERAL INFORMATION:
;    APPLICANT:  Houston, L. L.
;    APPLICANT:  Liu, David Y.
;    APPLICANT:  Kaymakcalan, Zehra
;    TITLE OF INVENTION:  Method for Inhibiting Adhesion of White
;    TITLE OF INVENTION:  Blood Cells to Endothelial Cells
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cetus Corporation
;      STREET:  1400 Fifty-Third Street
;      CITY:  Emeryville
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94608
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/700,526
;      FILING DATE:  19910816
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McGarrigle Jr., Philip L.
;      REGISTRATION NUMBER:  31,395
;      REFERENCE/DOCKET NUMBER:  2600.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 420-3217
;      TELEFAX:  (415) 658-5239
;      TELEX:  4992659
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34 amino acids
;      TYPE:  AMINO ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-07-700-526-7

  Query Match           100.0%;  Score 19;  DB 1;  Length 34;
  Best Local Similarity  100.0%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         18 AQGV 21


Search completed: February 21, 2006, 08:57:28
Job time : 34 secs
```

GenCore version 5.1.7

OM protein - protein search, using sw model

Run on: February 21, 2006, 08:56:53 ; Search time 133 Seconds
(without alignments)
13.214 Million cell updates/sec

Title: US-10-821-256-2
Perfect score: 19
Sequence: 1 AQGV 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 6981

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%
Maximum Match 100%
Listing first 500 summaries

Database : A_Geneseq_21:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	19	100.0	4	7	ADC97878	Adc97878 Signallin
2	19	100.0	4	7	ADC97891	Adc97891 Signallin
3	19	100.0	4	7	ADC98118	Adc98118 Signallin
4	19	100.0	4	7	ADC97855	Adc97855 Signallin
5	19	100.0	4	7	ADC98185	Adc98185 Signallin
6	19	100.0	4	7	ADC98145	Adc98145 Signallin
7	19	100.0	4	7	ADC97811	Adc97811 Signallin
8	19	100.0	4	7	ADN01224	Adn01224 Human nuc
9	19	100.0	4	8	ADG86532	Adg86532 NF-kappaB
10	19	100.0	4	8	ADG86590	Adg86590 NF-kappaB
11	19	100.0	4	8	ADH29151	Adh29151 Necrosis
12	19	100.0	4	8	ADG73593	Adg73593 NF-kappaB
13	19	100.0	4	8	ADG86561	Adg86561 NF-kappaB
14	19	100.0	4	8	ADI20991	Adi20991 Human nuc
15	19	100.0	4	8	ADI16437	Adi16437 NF-kappaB
16	19	100.0	4	8	ADK42374	Adk42374 Antibacte
17	19	100.0	4	8	ADM48491	Adm48491 NF-kappaB
18	19	100.0	4	8	ADO15345	Ado15345 Nuclear f
19	19	100.0	4	8	ADT08600	Adt08600 Human cho
20	19	100.0	4	8	ADT08628	Adt08628 Human cho
21	19	100.0	4	8	ADT08656	Adt08656 Human cho
22	19	100.0	4	8	ADT79351	Adt79351 Nuclear f
23	19	100.0	4	8	ADT49387	Adt49387 Human cho
24	19	100.0	4	8	ADU46871	Adu46871 Gene regu
25	19	100.0	4	9	ADY03875	Ady03875 Peptide d
26	19	100.0	4	9	ADY82494	Ady82494 Porcine h
27	19	100.0	4	9	AEA27819	Aea27819 Gene-regu
28	19	100.0	9	6	ABU11098	Abu11098 House dus
29	19	100.0	9	9	ADZ50681	Adz50681 Y. pestis
30	19	100.0	10	4	AAG85717	Aag85717 Saccharom
31	19	100.0	10	8	ADF94302	Adf94302 Human cel
32	19	100.0	12	4	AAB35370	Aab35370 Alpha3bet
33	19	100.0	13	4	ABM00107	Abm00107 T. lanugi
34	19	100.0	14	2	AAR49859	Aar49859 Sequence
35	19	100.0	14	4	AAM98513	Aam98513 Human pep
36	19	100.0	15	2	AAW50068	Aaw50068 Human cho
37	19	100.0	15	2	AAW47508	Aaw47508 Human bet
38	19	100.0	15	2	AAW50103	Aaw50103 Human cho
39	19	100.0	15	5	ABB04474	Abb04474 Human end
40	19	100.0	15	8	ADH52629	Adh52629 Human cho
41	19	100.0	15	8	ADH52592	Adh52592 Human cho
42	19	100.0	15	8	ADK39780	Adk39780 Human cho
43	19	100.0	15	8	ADT90972	Adt90972 Human bet
44	19	100.0	16	2	AAR51746	Aar51746 Der p I d
45	19	100.0	16	8	ADU87133	Adu87133 Peptide d
46	19	100.0	18	5	AAU70963	Aau70963 M. tuberc
47	19	100.0	18	5	AAU70974	Aau70974 M. tuberc
48	19	100.0	18	9	ADV55657	Adv55657 G protein
49	19	100.0	18	9	ADV54661	Adv54661 G protein
50	19	100.0	18	9	ADY64079	Ady64079 Human MCS
51	19	100.0	18	9	ADY64078	Ady64078 Human MCS
52	19	100.0	19	2	AAW92548	Aaw92548 Beta-acti
53	19	100.0	19	2	AAW92549	Aaw92549 Beta-acti
54	19	100.0	19	6	ABP74723	Abp74723 Proteome
55	19	100.0	19	7	ADF14799	Adf14799 SLE/sjogr
56	19	100.0	19	9	ADV55698	Adv55698 G protein
57	19	100.0	19	9	ADV54702	Adv54702 G protein
58	19	100.0	19	9	ADX56536	Adx56536 Cardiovas
59	19	100.0	20	7	ADC99563	Adc99563 Cancer-re
60	19	100.0	20	8	ADK15603	Adk15603 Human G25
61	19	100.0	20	8	ADT36531	Adt36531 RCC-assoc
62	19	100.0	21	4	AAB57305	Aab57305 Antigenic
63	19	100.0	22	2	AAR36398	Aar36398 DPI-16(17
64	19	100.0	22	2	AAR77133	Aar77133 Dermatoph
65	19	100.0	22	2	AAW71926	Aaw71926 Dermatoph
66	19	100.0	22	2	AAY50375	Aay50375 Dermatoph
67	19	100.0	22	4	AAU18978	Aau18978 T-cell ep
68	19	100.0	23	2	AAR36414	Aar36414 DPI-28.2(
69	19	100.0	23	2	AAR51762	Aar51762 Der p I d
70	19	100.0	23	2	AAW37822	Aaw37822 Peptide d
71	19	100.0	23	2	AAW71937	Aaw71937 Dermatoph
72	19	100.0	23	2	AAY50391	Aay50391 Dermatoph
73	19	100.0	23	2	AAY36513	Aay36513 Fragment
74	19	100.0	23	4	AAU18994	Aau18994 T-cell ep
75	19	100.0	23	6	ADA12069	Ada12069 Human nov
76	19	100.0	24	5	ABP46165	Abp46165 Human BLy
77	19	100.0	24	5	ABP46958	Abp46958 Human BLy
78	19	100.0	24	7	ADG96992	Adg96992 scFV VHCD
79	19	100.0	24	7	ADG97785	Adg97785 scFV VHCD
80	19	100.0	25	2	AAR36412	Aar36412 DPI-27.1(
81	19	100.0	25	2	AAR51760	Aar51760 Der p I d
82	19	100.0	25	2	AAW71935	Aaw71935 Dermatoph
83	19	100.0	25	2	AAY50389	Aay50389 Dermatoph
84	19	100.0	25	4	AAM21152	Aam21152 Peptide #
85	19	100.0	25	4	AAU18992	Aau18992 T-cell ep
86	19	100.0	25	4	ABB43470	Abb43470 Peptide #
87	19	100.0	25	4	AAM37363	Aam37363 Peptide #
88	19	100.0	25	4	AAM77220	Aam77220 Human bon
89	19	100.0	25	4	AAM64402	Aam64402 Human bra
90	19	100.0	25	4	ABG58847	Abg58847 Human liv
91	19	100.0	25	7	ADC26857	Adc26857 B. burgdo
92	19	100.0	25	7	ADN59708	Adn59708 Thrombopo
93	19	100.0	25	8	ABO60121	Abo60121 Human gen
94	19	100.0	25	9	ADV54693	Adv54693 G protein
95	19	100.0	25	9	ADV55689	Adv55689 G protein
96	19	100.0	26	2	AAR30640	Aar30640 Epitope o
97	19	100.0	27	2	AAR95624	Aar95624 Tripeptid

98	19	100.0	27	2	AAW97423	Aaw97423	Peptide o
99	19	100.0	27	9	ADX56530	Adx56530	Cardiovas
100	19	100.0	29	2	AAR36413	Aar36413	DPI-28.1(
101	19	100.0	29	2	AAR51761	Aar51761	Der p I d
102	19	100.0	29	2	AAW71936	Aaw71936	Dermatoph
103	19	100.0	29	2	AAY50390	Aay50390	Dermatoph
104	19	100.0	29	4	AAU18993	Aau18993	T-cell ep
105	19	100.0	29	7	ADD35439	Add35439	Streptoco
106	19	100.0	30	2	AAW00643	Aaw00643	Human DEC
107	19	100.0	30	8	ADF45511	Adf45511	Human NUD
108	19	100.0	30	9	ADV85620	Adv85620	Human DEC
109	19	100.0	33	3	AAB27936	Aab27936	Human sec
110	19	100.0	35	9	ADY97195	Ady97195	Herpes si
111	19	100.0	36	9	ADX56537	Adx56537	Cardiovas
112	19	100.0	37	2	AAR25974	Aar25974	Peptide m
113	19	100.0	37	2	AAY21614	Aay21614	Antimicro
114	19	100.0	37	3	AAY92803	Aay92803	Synthetic
115	19	100.0	37	7	ADC73331	Adc73331	Bovine an
116	19	100.0	38	8	ABO59877	Abo59877	Human gen
117	19	100.0	40	9	ADZ97828	Adz97828	Human cor
118	19	100.0	41	6	ABU17305	Abu17305	Protein e
119	19	100.0	41	9	AEB94393	Aeb94393	Human AMD
120	19	100.0	45	4	AAM24224	Aam24224	Human EST
121	19	100.0	45	5	ABB90716	Abb90716	Chlamydia
122	19	100.0	49	2	AAR69856	Aar69856	Fibronect
123	19	100.0	49	4	ABB09222	Abb09222	Mouse put
124	19	100.0	49	8	ADN11831	Adn11831	Fibronect
125	19	100.0	49	8	ABO54048	Abo54048	Human gen
126	19	100.0	51	5	AAE18040	Aae18040	Human ion
127	19	100.0	51	8	ADN48261	Adn48261	Thermococ
128	19	100.0	52	4	AAM86353	Aam86353	Human imm
129	19	100.0	53	3	AAB58486	Aab58486	Lung canc
130	19	100.0	53	5	ABP00538	Abp00538	Human ORF
131	19	100.0	54	5	AAE24593	Aae24593	Fish E93
132	19	100.0	55	4	ABB03527	Abb03527	Human mus
133	19	100.0	55	6	ABU12821	Abu12821	Novel hum
134	19	100.0	55	8	ADJ28847	Adj28847	Human mus
135	19	100.0	56	2	AAR41885	Aar41885	Granulin
136	19	100.0	56	3	AAB50390	Aab50390	Human unc
137	19	100.0	56	4	ABB40247	Abb40247	Peptide #
138	19	100.0	56	4	AAM33926	Aam33926	Peptide #
139	19	100.0	56	4	AAM73737	Aam73737	Human bon
140	19	100.0	56	4	AAM61034	Aam61034	Human bra
141	19	100.0	56	4	ABG55482	Abg55482	Human liv
142	19	100.0	56	5	ABG43619	Abg43619	Human pep
143	19	100.0	56	5	ABP42752	Abp42752	Human ova
144	19	100.0	56	8	ADL27363	Adl27363	Amino aci
145	19	100.0	58	5	ABP07528	Abp07528	Human ORF
146	19	100.0	58	8	ABO59983	Abo59983	Human gen
147	19	100.0	58	9	AEA79702	Aea79702	Cellulomo
148	19	100.0	58	9	AEA48196	Aea48196	Part of t
149	19	100.0	59	3	AAB58882	Aab58882	Breast an
150	19	100.0	59	4	AAU55984	Aau55984	Propionib
151	19	100.0	59	5	ABP00743	Abp00743	Human ORF
152	19	100.0	59	5	ABB04473	Abb04473	Human end
153	19	100.0	59	6	ABM52503	Abm52503	Propionib
154	19	100.0	59	8	ABO54645	Abo54645	Human gen
155	19	100.0	60	4	AAU48065	Aau48065	Propionib
156	19	100.0	60	5	ABP32165	Abp32165	Human ORF
157	19	100.0	60	6	ABM44584	Abm44584	Propionib
158	19	100.0	60	7	ABO78543	Abo78543	Pseudomon
159	19	100.0	61	4	AAU61564	Aau61564	Propionib
160	19	100.0	61	5	ABP04708	Abp04708	Human ORF
161	19	100.0	61	6	ABM58083	Abm58083	Propionib
162	19	100.0	62	4	AAU64327	Aau64327	Propionib
163	19	100.0	62	6	ABM60846	Abm60846	Propionib
164	19	100.0	62	7	ABO62014	Abo62014	Klebsiell
165	19	100.0	62	8	ADY23472	Ady23472	Plant ful
166	19	100.0	63	3	AAG26814	Aag26814	Zea mays
167	19	100.0	63	4	AAM83149	Aam83149	Human imm
168	19	100.0	63	4	ABG26472	Abg26472	Novel hum
169	19	100.0	63	8	ABO58146	Abo58146	Human gen
170	19	100.0	64	5	ABP29155	Abp29155	Streptoco
171	19	100.0	65	3	AAG02408	Aag02408	Human sec
172	19	100.0	65	3	AAG07706	Aag07706	Arabidops
173	19	100.0	65	3	AAG26813	Aag26813	Zea mays
174	19	100.0	65	7	ABO66725	Abo66725	Klebsiell
175	19	100.0	66	3	AAG07705	Aag07705	Arabidops
176	19	100.0	66	4	AAM82556	Aam82556	Human imm
177	19	100.0	66	4	AAU53135	Aau53135	Propionib
178	19	100.0	66	6	ABM49654	Abm49654	Propionib
179	19	100.0	67	4	ABB71058	Abb71058	Drosophil
180	19	100.0	67	8	ADU04369	Adu04369	MHV prote
181	19	100.0	69	3	AAG26016	Aag26016	Zea mays
182	19	100.0	69	4	AAE01158	Aae01158	Novel hum
183	19	100.0	69	5	AAU76429	Aau76429	Novel hum
184	19	100.0	69	6	ADA21106	Ada21106	Human sec
185	19	100.0	69	7	ADA67726	Ada67726	Novel hum
186	19	100.0	71	3	AAY65387	Aay65387	Human 5'
187	19	100.0	71	4	AAB63498	Aab63498	Human gas
188	19	100.0	71	8	ADU72951	Adu72951	Non-signa
189	19	100.0	71	9	ADZ73942	Adz73942	Human inc
190	19	100.0	72	2	AAR58812	Aar58812	E. coli m
191	19	100.0	72	2	AAW71459	Aaw71459	Protein e
192	19	100.0	72	4	AAU07749	Aau07749	House dus
193	19	100.0	72	4	AAM87649	Aam87649	Human imm
194	19	100.0	72	4	AAU43630	Aau43630	Propionib
195	19	100.0	72	6	ABU09526	Abu09526	E. coli m
196	19	100.0	72	6	ABM40149	Abm40149	Propionib
197	19	100.0	72	9	AEA32550	Aea32550	marC prot
198	19	100.0	74	5	ABP04492	Abp04492	Human ORF
199	19	100.0	74	5	ABP32468	Abp32468	Human ORF
200	19	100.0	75	5	ABP64192	Abp64192	Human ORF
201	19	100.0	76	2	AAW72051	Aaw72051	HSV-2 str
202	19	100.0	76	8	ABO56564	Abo56564	Human gen
203	19	100.0	77	8	ADL05542	Adl05542	M. catarr
204	19	100.0	78	4	AAU59277	Aau59277	Propionib
205	19	100.0	78	4	ABG26469	Abg26469	Novel hum
206	19	100.0	78	6	ABM55796	Abm55796	Propionib
207	19	100.0	79	5	ABP01669	Abp01669	Human ORF
208	19	100.0	80	3	AAG19634	Aag19634	Arabidops
209	19	100.0	80	8	ADH39815	Adh39815	FarA amin
210	19	100.0	81	5	ABP10494	Abp10494	Human ORF
211	19	100.0	82	4	AAU52713	Aau52713	Propionib
212	19	100.0	82	6	ABM49232	Abm49232	Propionib
213	19	100.0	83	3	AAG02108	Aag02108	Human sec
214	19	100.0	83	4	AAM87125	Aam87125	Human imm
215	19	100.0	84	3	AAG34308	Aag34308	Arabidops
216	19	100.0	84	4	ABB65061	Abb65061	Drosophil
217	19	100.0	84	4	AAU61282	Aau61282	Propionib
218	19	100.0	84	4	ABG05322	Abg05322	Novel hum
219	19	100.0	84	4	AAG89210	Aag89210	Human sec
220	19	100.0	84	6	ABM57801	Abm57801	Propionib
221	19	100.0	84	6	ABP76020	Abp76020	Human GEN
222	19	100.0	84	6	ABP76176	Abp76176	Human GEN
223	19	100.0	85	3	AAG27024	Aag27024	Zea mays
224	19	100.0	85	3	AAG32676	Aag32676	Zea mays
225	19	100.0	85	3	AAG25324	Aag25324	Zea mays
226	19	100.0	85	4	AAU52346	Aau52346	Propionib
227	19	100.0	85	5	ABP62928	Abp62928	Human pol
228	19	100.0	85	6	ABM48865	Abm48865	Propionib
229	19	100.0	85	8	ADQ75906	Adq75906	Lysine de
230	19	100.0	85	8	ADQ75905	Adq75905	Lysine de
231	19	100.0	85	8	ADY12627	Ady12627	Plant ful
232	19	100.0	85	9	ABM94141	Abm94141	M. xanthu
233	19	100.0	86	4	AAU47746	Aau47746	Propionib
234	19	100.0	86	5	ABB78149	Abb78149	Amino aci
235	19	100.0	86	5	ABP32375	Abp32375	Human ORF
236	19	100.0	86	6	ABM44265	Abm44265	Propionib
237	19	100.0	86	8	ADR87224	Adr87224	Dust mite
238	19	100.0	87	4	AAU62248	Aau62248	Propionib
239	19	100.0	87	6	ABM58767	Abm58767	Propionib
240	19	100.0	88	4	AAU54801	Aau54801	Propionib
241	19	100.0	88	5	ABU60929	Abu60929	Lung spec
242	19	100.0	88	6	ABM51320	Abm51320	Propionib
243	19	100.0	89	2	AAY74147	Aay74147	Human pro

244	19	100.0	89	3	AAY59139	Aay59139 Mouse ser
245	19	100.0	89	8	ADP56448	Adp56448 Human PRO
246	19	100.0	91	4	AAU14672	Aau14672 Novel bon
247	19	100.0	91	4	ABG04651	Abg04651 Novel hum
248	19	100.0	91	5	ABP09720	Abp09720 Human ORF
249	19	100.0	91	5	ABP11499	Abp11499 Human ORF
250	19	100.0	92	6	ABP79711	Abp79711 N. gonorr
251	19	100.0	92	7	ADC01121	Adc01121 Enterohae
252	19	100.0	92	7	ADD49007	Add49007 Fibronect
253	19	100.0	92	9	ADV51055	Adv51055 Human car
254	19	100.0	92	9	ADV51133	Adv51133 Human car
255	19	100.0	92	9	ADW63881	Adw63881 Human fib
256	19	100.0	92	9	ADY37467	Ady37467 Fibronect
257	19	100.0	93	3	AAG07704	Aag07704 Arabidops
258	19	100.0	93	4	AAE01744	Aae01744 Human gen
259	19	100.0	93	4	AAU41229	Aau41229 Propionib
260	19	100.0	93	5	ABP02475	Abp02475 Human ORF
261	19	100.0	93	6	ABM37748	Abm37748 Propionib
262	19	100.0	93	7	ADC42863	Adc42863 REMAP pro
263	19	100.0	93	7	ADF59056	Adf59056 Human pol
264	19	100.0	93	8	ADS98115	Ads98115 Protein f
265	19	100.0	93	8	ADS98807	Ads98807 Protein f
266	19	100.0	94	3	AAG34307	Aag34307 Arabidops
267	19	100.0	95	3	AAG35252	Aag35252 Zea mays
268	19	100.0	95	4	AAM86608	Aam86608 Human imm
269	19	100.0	95	4	AAU49298	Aau49298 Propionib
270	19	100.0	95	6	ABM45817	Abm45817 Propionib
271	19	100.0	96	6	ABM65132	Abm65132 Propionib
272	19	100.0	97	5	ABP07548	Abp07548 Human ORF
273	19	100.0	97	6	ADB07542	Adb07542 Alloiococ
274	19	100.0	98	4	AAB80621	Aab80621 Environme
275	19	100.0	98	9	ABM90893	Abm90893 M. xanthu
276	19	100.0	99	3	AAB42065	Aab42065 Human ORF
277	19	100.0	99	3	AAG34306	Aag34306 Arabidops
278	19	100.0	99	8	ADR96565	Adr96565 Novel S.
279	19	100.0	99	9	AEA60435	Aea60435 Streptoco
280	19	100.0	100	3	AAY58682	Aay58682 Wheat N-a
281	19	100.0	100	5	ABU05405	Abu05405 M. tuberc
282	19	100.0	101	4	AAU57656	Aau57656 Propionib
283	19	100.0	101	4	ABG23938	Abg23938 Novel hum
284	19	100.0	101	4	ABG02006	Abg02006 Novel hum
285	19	100.0	101	5	ABP02607	Abp02607 Human ORF
286	19	100.0	101	5	ABP32523	Abp32523 Human ORF
287	19	100.0	101	6	ABM54175	Abm54175 Propionib
288	19	100.0	102	2	AAW24566	Aaw24566 Serine pr
289	19	100.0	102	3	AAB25380	Aab25380 Pinus rad
290	19	100.0	102	5	ABU05650	Abu05650 M. tuberc
291	19	100.0	102	5	AAU70953	Aau70953 M. tuberc
292	19	100.0	102	5	AAU70949	Aau70949 M. tuberc
293	19	100.0	102	9	AEB26458	Aeb26458 M. tuberc
294	19	100.0	103	5	ABP02145	Abp02145 Human ORF
295	19	100.0	104	4	AAG72373	Aag72373 Human OR-
296	19	100.0	104	4	AAM06840	Aam06840 Human foe
297	19	100.0	105	3	AAB41360	Aab41360 Human ORF
298	19	100.0	105	4	AAU64044	Aau64044 Propionib
299	19	100.0	105	6	ABM60563	Abm60563 Propionib
300	19	100.0	105	8	ADR09942	Adr09942 Human pro
301	19	100.0	106	4	AAU23565	Aau23565 Novel hum
302	19	100.0	106	5	ABP01625	Abp01625 Human ORF
303	19	100.0	106	5	ABP07850	Abp07850 Human ORF
304	19	100.0	106	5	ABP10649	Abp10649 Human ORF
305	19	100.0	106	8	ADR45874	Adr45874 Amino aci
306	19	100.0	107	3	AAG38549	Aag38549 Arabidops
307	19	100.0	107	3	AAG25826	Aag25826 Arabidops
308	19	100.0	107	4	AAU27665	Aau27665 Human pro
309	19	100.0	107	4	AAU43191	Aau43191 Propionib
310	19	100.0	107	4	AAE07078	Aae07078 Human gen
311	19	100.0	107	4	AAU20963	Aau20963 Human nov
312	19	100.0	107	5	ABG65099	Abg65099 Human alb
313	19	100.0	107	6	ABM39710	Abm39710 Propionib
314	19	100.0	107	8	ADL78366	Adl78366 Albumin f
315	19	100.0	108	5	ADK35938	Adk35938 Novel hum
316	19	100.0	109	4	AAU44612	Aau44612 Propionib
317	19	100.0	109	6	ABM41131	Abm41131 Propionib
318	19	100.0	110	8	ADR08805	Adr08805 Human pro
319	19	100.0	112	4	AAM83219	Aam83219 Human imm
320	19	100.0	112	7	ADC32931	Adc32931 Human nov
321	19	100.0	113	4	AAU61907	Aau61907 Propionib
322	19	100.0	113	5	ABU05357	Abu05357 M. tuberc
323	19	100.0	113	6	ABM58426	Abm58426 Propionib
324	19	100.0	114	4	ABG07701	Abg07701 Novel hum
325	19	100.0	114	8	ADQ65348	Adq65348 Novel hum
326	19	100.0	115	4	AAE01694	Aae01694 Human gen
327	19	100.0	115	5	ABG63962	Abg63962 Human alb
328	19	100.0	115	6	ADA57488	Ada57488 Human sec
329	19	100.0	115	6	ADA41366	Ada41366 Human sec
330	19	100.0	115	6	ABR48083	Abr48083 Human sec
331	19	100.0	115	7	ADC74511	Adc74511 Human sec
332	19	100.0	115	8	ADL77227	Adl77227 Albumin f
333	19	100.0	116	2	AAW75888	Aaw75888 Peptide i
334	19	100.0	116	3	AAY78867	Aay78867 Streptomy
335	19	100.0	116	3	AAG26812	Aag26812 Zea mays
336	19	100.0	116	6	ABP77495	Abp77495 N. gonorr
337	19	100.0	116	7	ADM05847	Adm05847 Human pro
338	19	100.0	117	9	ADX40189	Adx40189 HIV Rev p
339	19	100.0	118	3	AAB40639	Aab40639 Human ORF
340	19	100.0	118	3	AAG55453	Aag55453 Arabidops
341	19	100.0	118	3	AAG59261	Aag59261 Arabidops
342	19	100.0	118	7	ADC00756	Adc00756 Enterohae
343	19	100.0	119	9	ABM97506	Abm97506 M. xanthu
344	19	100.0	119	9	AEB42205	Aeb42205 L. pneumo
345	19	100.0	120	3	AAB33216	Aab33216 Pinus rad
346	19	100.0	120	3	AAG26014	Aag26014 Zea mays
347	19	100.0	120	4	AAU48433	Aau48433 Propionib
348	19	100.0	120	5	ABP63947	Abp63947 Human ORF
349	19	100.0	120	6	ABM44952	Abm44952 Propionib
350	19	100.0	121	2	AAY27822	Aay27822 Human sec
351	19	100.0	121	3	AAB40960	Aab40960 Human ORF
352	19	100.0	121	5	ABP06047	Abp06047 Human ORF
353	19	100.0	121	6	ABO14316	Abo14316 Novel hum
354	19	100.0	121	8	ADG78724	Adg78724 Human sec
355	19	100.0	121	8	ADN61014	Adn61014 Human sec
356	19	100.0	121	9	AEB37743	Aeb37743 L. pneumo
357	19	100.0	121	9	AEB41053	Aeb41053 L. pneumo
358	19	100.0	122	4	AAO03181	Aao03181 Human pol
359	19	100.0	122	4	AAU28136	Aau28136 Novel hum
360	19	100.0	122	7	ADJ70355	Adj70355 Human hea
361	19	100.0	122	8	ADX68079	Adx68079 Plant ful
362	19	100.0	123	4	ABB12054	Abb12054 Human sec
363	19	100.0	123	4	AAU46796	Aau46796 Propionib
364	19	100.0	123	6	ABM43315	Abm43315 Propionib
365	19	100.0	124	2	AAY35737	Aay35737 Amino aci
366	19	100.0	124	5	ABP28228	Abp28228 Streptoco
367	19	100.0	124	7	ADF60375	Adf60375 Human con
368	19	100.0	124	8	ADV87901	Adv87901 Streptoco
369	19	100.0	124	8	ADV81351	Adv81351 Streptoco
370	19	100.0	124	8	ADV79154	Adv79154 Streptoco
371	19	100.0	125	3	AAY74516	Aay74516 Neisseria
372	19	100.0	125	3	AAY74518	Aay74518 Neisseria
373	19	100.0	125	3	AAG25886	Aag25886 Zea mays
374	19	100.0	125	3	AAG54828	Aag54828 Arabidops
375	19	100.0	126	5	ADK36711	Adk36711 Novel hum
376	19	100.0	126	6	ABU49557	Abu49557 Protein e
377	19	100.0	127	3	AAG38548	Aag38548 Arabidops
378	19	100.0	127	3	AAG37202	Aag37202 Arabidops
379	19	100.0	127	3	AAG25825	Aag25825 Arabidops
380	19	100.0	127	4	ABG23018	Abg23018 Novel hum
381	19	100.0	127	5	ABG76519	Abg76519 HCV E1 an
382	19	100.0	127	5	AAE17459	Aae17459 Mouse sec
383	19	100.0	128	3	AAB53358	Aab53358 Human col
384	19	100.0	128	8	ADX87918	Adx87918 Plant ful
385	19	100.0	129	3	AAG33896	Aag33896 Arabidops
386	19	100.0	129	6	ABU70484	Abu70484 Human adi
387	19	100.0	130	6	ABU33550	Abu33550 Protein e
388	19	100.0	130	9	AEB41937	Aeb41937 L. pneumo
389	19	100.0	131	3	AAY65360	Aay65360 Human 5'

390	19	100.0	131	3	AAG33895	Aag33895 Arabidops
391	19	100.0	131	8	ADR08724	Adr08724 Human pro
392	19	100.0	131	8	ADU72924	Adu72924 Non-signa
393	19	100.0	131	9	ADZ73915	Adz73915 Human inc
394	19	100.0	132	4	AAB95434	Aab95434 Human pro
395	19	100.0	132	8	ADR01297	Adr01297 Farnesyl
396	19	100.0	133	4	AAM15391	Aam15391 Peptide #
397	19	100.0	133	4	ABB34397	Abb34397 Peptide #
398	19	100.0	133	4	AAM27879	Aam27879 Peptide #
399	19	100.0	133	4	ABB29234	Abb29234 Peptide #
400	19	100.0	133	4	ABB19808	Abb19808 Protein #
401	19	100.0	133	4	AAM67582	Aam67582 Human bon
402	19	100.0	133	4	AAM55187	Aam55187 Human bra
403	19	100.0	133	4	ABG49228	Abg49228 Human liv
404	19	100.0	133	4	AAM03153	Aam03153 Peptide #
405	19	100.0	133	4	AAG92797	Aag92797 C glutami
406	19	100.0	133	5	ABG37173	Abg37173 Human pep
407	19	100.0	133	5	ADK36712	Adk36712 Novel hum
408	19	100.0	133	6	ABU00401	Abu00401 Human nov
409	19	100.0	133	9	ABM92218	Abm92218 M. xanthu
410	19	100.0	134	8	ADU16466	Adu16466 M. tuberc
411	19	100.0	135	2	AAY36512	Aay36512 Fragment
412	19	100.0	135	6	ADA12068	Ada12068 Human nov
413	19	100.0	135	9	AEB38714	Aeb38714 L. pneumo
414	19	100.0	136	5	ABJ10959	Abj10959 Yeast sel
415	19	100.0	136	6	ABU21645	Abu21645 Protein e
416	19	100.0	136	8	ADS32607	Ads32607 Maize per
417	19	100.0	138	5	ABB49093	Abb49093 Listeria
418	19	100.0	138	6	ABU32715	Abu32715 Protein e
419	19	100.0	139	3	AAG41059	Aag41059 Zea mays
420	19	100.0	139	7	ABO64152	Abo64152 Klebsiell
421	19	100.0	140	2	AAY36950	Aay36950 Protein i
422	19	100.0	140	4	ABB11054	Abb11054 Human lam
423	19	100.0	140	4	ABG21912	Abg21912 Novel hum
424	19	100.0	140	5	ABP02193	Abp02193 Human ORF
425	19	100.0	140	5	ABB77702	Abb77702 Amino aci
426	19	100.0	140	7	ADC01512	Adc01512 Enterohae
427	19	100.0	140	8	ADR05621	Adr05621 E coli IH
428	19	100.0	141	4	ABB67857	Abb67857 Drosophil
429	19	100.0	141	5	AAM49445	Aam49445 Lactobaci
430	19	100.0	141	6	ABU25143	Abu25143 Protein e
431	19	100.0	141	7	ADM05254	Adm05254 Human pro
432	19	100.0	141	8	ABO59733	Abo59733 Human gen
433	19	100.0	141	9	AEA79768	Aea79768 Xylanibac
434	19	100.0	141	9	AEA48261	Aea48261 ASP 69B4
435	19	100.0	142	2	AAW28048	Aaw28048 Threonine
436	19	100.0	142	4	AAB87450	Aab87450 Human gen
437	19	100.0	142	8	ADX73317	Adx73317 Plant ful
438	19	100.0	142	9	ABM96670	Abm96670 M. xanthu
439	19	100.0	142	9	AEB39064	Aeb39064 L. pneumo
440	19	100.0	143	2	AAY04782	Aay04782 Mycobacte
441	19	100.0	143	4	AAM25848	Aam25848 Human pro
442	19	100.0	143	6	ABU29973	Abu29973 Protein e
443	19	100.0	144	4	ABG18087	Abg18087 Novel hum
444	19	100.0	144	8	ADX73393	Adx73393 Plant ful
445	19	100.0	144	9	AEA43773	Aea43773 C. necato
446	19	100.0	145	4	AAU40398	Aau40398 Propionib
447	19	100.0	145	6	ABM36917	Abm36917 Propionib
448	19	100.0	145	7	ADF66822	Adf66822 Helicobac
449	19	100.0	145	7	ADF66824	Adf66824 Helicobac
450	19	100.0	145	8	ADX93828	Adx93828 Plant ful
451	19	100.0	146	4	ABG29413	Abg29413 Novel hum
452	19	100.0	146	5	ADG79448	Adg79448 Human sec
453	19	100.0	146	8	ADX73014	Adx73014 Plant ful
454	19	100.0	147	3	AAY86520	Aay86520 Human gen
455	19	100.0	147	4	AAB94605	Aab94605 Human pro
456	19	100.0	147	6	ABO53684	Abo53684 Novel hum
457	19	100.0	147	6	ADA36367	Ada36367 Acinetoba
458	19	100.0	148	3	AAG25824	Aag25824 Arabidops
459	19	100.0	148	3	AAG38547	Aag38547 Arabidops
460	19	100.0	148	3	AAG37201	Aag37201 Arabidops
461	19	100.0	148	4	AAG91759	Aag91759 C glutami
462	19	100.0	148	7	ADB74343	Adb74343 Mycobacte
463	19	100.0	148	8	ADS23636	Ads23636 Bacterial
464	19	100.0	149	4	AAO12923	Aao12923 Human pol
465	19	100.0	150	2	AAY21844	Aay21844 Human sig
466	19	100.0	150	4	AAU54480	Aau54480 Propionib
467	19	100.0	150	6	ABM50999	Abm50999 Propionib
468	19	100.0	150	7	ADH34365	Adh34365 Vibrio ch
469	19	100.0	150	8	ADY23136	Ady23136 Plant ful
470	19	100.0	152	3	AAB57156	Aab57156 Human pro
471	19	100.0	152	4	ABG16639	Abg16639 Novel hum
472	19	100.0	153	2	AAW77754	Aaw77754 Staphyloc
473	19	100.0	153	3	AAY77576	Aay77576 Human cyt
474	19	100.0	153	3	AAB41043	Aab41043 Human ORF
475	19	100.0	153	4	AAM38917	Aam38917 Human pol
476	19	100.0	153	4	ABG27650	Abg27650 Novel hum
477	19	100.0	153	4	AAU31783	Aau31783 Novel hum
478	19	100.0	153	5	ABP09251	Abp09251 Human ORF
479	19	100.0	153	5	AAE17872	Aae17872 Sequence
480	19	100.0	153	5	ABB49178	Abb49178 Listeria
481	19	100.0	153	6	ABU58176	Abu58176 Soybean s
482	19	100.0	153	6	ADA54840	Ada54840 Human pro
483	19	100.0	153	6	ABU08006	Abu08006 Guar meta
484	19	100.0	153	6	ABR47525	Abr47525 Breast ca
485	19	100.0	153	7	ADE61633	Ade61633 Rat Prote
486	19	100.0	153	7	ADG64497	Adg64497 Family A
487	19	100.0	153	8	ADN04998	Adn04998 Antipsori
488	19	100.0	153	8	ADQ67007	Adq67007 Novel hum
489	19	100.0	153	8	ADP55493	Adp55493 Human PRO
490	19	100.0	153	8	ADP25213	Adp25213 PRO polyp
491	19	100.0	153	8	ADT60578	Adt60578 Plant pol
492	19	100.0	154	2	AAW20648	Aaw20648 H. pylori
493	19	100.0	154	2	AAW30642	Aaw30642 A. thalia
494	19	100.0	154	3	AAB44503	Aab44503 Plant vir
495	19	100.0	154	4	AAB93661	Aab93661 Human pro
496	19	100.0	154	6	ABU22969	Abu22969 Protein e
497	19	100.0	154	8	ADR09025	Adr09025 Human pro
498	19	100.0	154	9	AEA79750	Aea79750 Cellulomo
499	19	100.0	154	9	AEA48243	Aea48243 Homologou
500	19	100.0	155	2	AAW95496	Aaw95496 M. leprae

ALIGNMENTS

RESULT 1
ADC97878
ID ADC97878 standard; peptide; 4 AA.
XX
AC ADC97878;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.
XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX

PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Disclosure; Page 44; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 2
ADC97891
ID ADC97891 standard; peptide; 4 AA.
XX
AC ADC97891;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.
XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Example; Page 69; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 3
ADC98118
ID ADC98118 standard; peptide; 4 AA.
XX
AC ADC98118;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.

XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Example; Page 98; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 7;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 4
ADC97855
ID ADC97855 standard; peptide; 4 AA.
XX
AC ADC97855;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.
XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Disclosure; Page 40; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 7;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 5
ADC98185
ID ADC98185 standard; peptide; 4 AA.
XX
AC ADC98185;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;

KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.
XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Example; Page 102; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 7;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 6
ADC98145
ID ADC98145 standard; peptide; 4 AA.
XX
AC ADC98145;
XX
DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.
XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Example; Page 101; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 7;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 7
ADC97811
ID ADC97811 standard; peptide; 4 AA.
XX
AC ADC97811;
XX

DT 01-JAN-2004 (first entry)
XX
DE Signalling molecule gene regulatory peptide.
XX
KW gene expression modulation; signalling molecule;
KW NF-kappaB/Rel protein inhibitor; antiinflammatory; antiarthritic;
KW cerebroprotective; cardiant; antibacterial; immunosuppressive;
KW dermatological; nephrotropic; NF-kappaB/Rel protein modulator;
KW inflammatory disease; arthritis; ischaemia; cerebrovascular disease;
KW ischaemic heart failure; anthrax; angiogenesis; autoimmune disease;
KW systemic lupus erythematosus; ulcerative colitis; Addison's disease;
KW Goodpasture's disease.
XX
OS Synthetic.
XX
PN WO2003029292-A2.
XX
PD 10-APR-2003.
XX
PF 04-OCT-2002; 2002WO-NL000639.
XX
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
XX
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-393380/37.
XX
PT Modulating gene expression in a cell, useful for treating acute or
PT chronic inflammatory diseases (e.g. arthritis), ischemic events or
PT autoimmune diseases, comprises providing the cell with a signaling
PT molecule.
XX
PS Claim 18; Page 125; 217pp; English.
XX
CC The present invention describes a method for modulating gene expression
CC in a cell comprising providing the cell with a signalling molecule
CC comprising a peptide or its functional analogue. Also described: (1)
CC identifying or obtaining a signalling molecule comprising a peptide or
CC its functional derivative or analogue capable of modulating expression of
CC a gene in a cell; (2) a signalling molecule useful in modulating
CC expression of a gene in a cell and identifiable or obtainable by the
CC method of (1); and (3) an inhibitor of nuclear factor (NF)-kappaB/Rel
CC protein activation comprising a signalling molecule of (2). The
CC signalling molecule has antiinflammatory, antiarthritic,
CC cerebroprotective, cardiant, antibacterial, immunosuppressive,
CC dermatological and nephrotropic activities, and can be used as a NF-
CC kappaB/Rel protein modulator. The signalling molecule is useful for the
CC production of a pharmaceutical composition for the modulation of gene
CC expression by inhibiting NF-kappaB/Rel protein activation. The method is
CC useful for modulating gene expression, and for treating acute or chronic
CC inflammatory diseases (e.g. arthritis), ischaemic event including
CC cerebrovascular disease and ischaemic heart failure, anthrax,
CC angiogenesis, or autoimmune diseases (e.g. systemic lupus erythematosus,
CC ulcerative colitis, Addison's disease or Goodpasture's disease). The
CC present sequence represents a peptide used in the exemplification of the
CC present invention.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 8
ADN01224
ID ADN01224 standard; peptide; 4 AA.
XX
AC ADN01224;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human nuclear factor-kappaB modulating peptide NMPF-46.
XX
KW Human; nuclear factor-kappaB; NMPF; inflammatory condition;
KW nitrogen oxide; anthrax; gene transcription factor;
KW tumour necrosis factor alpha; TNF-alpha.
XX
OS Homo sapiens.
XX
PN US2003119720-A1.
XX
PD 26-JUN-2003.
XX
PF 21-DEC-2001; 2001US-00029206.
XX
PR 29-MAR-2001; 2001US-00821380.
XX
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2003-810947/76.
XX
PT Treatment of an inflammatory condition, e.g. anthrax, comprises
PT administering, to a subject, a molecule comprising an oligopeptide
PT peptide or its functional analog.
XX
PS Claim 9; Page 16; 80pp; English.
XX
CC The invention relates to treating an inflammatory condition by
CC administering to a subject a molecule comprising an oligopeptide peptide
CC (termed NMPF) or its functional analogue capable of reducing production
CC of nitrogen oxide by a cell. The peptides are derived from human proteins
CC interacting with nuclear factor-kappaB. The method is for treating an
CC acute inflammatory condition, e.g. anthrax. The inventive molecule
CC reduces production of nitrogen oxide by a cell, and modulates
CC translocation and/or activity of a gene transcription factor in the cell
CC to allow modulation of tumour necrosis factor (TNF)-alpha production by
CC the cell. The present sequence is an oligopeptide of the invention.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 9
ADG86532
ID ADG86532 standard; peptide; 4 AA.
XX
AC ADG86532;
XX
DT 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
KW Ischaemic event; nuclear factor-kappaB; NF-kappaB;
KW gene-regulatory peptide; down-regulation; thrombolytic agent;
KW tissue plasminogen activity; stroke; myocardial infarction;
KW pro-inflammatory cytokine; vasotropic; cerebroprotective; vasotropic;
KW cardiant.
XX

OS Unidentified.
XX
PN US2003220258-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409642.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (BENN/) BENNER R.
PA (KHAN/) KHAN N A.
PA (JACO/) JACOBS B C J.
XX
PI Benner R, Khan NA, Jacobs BCJ;
XX
DR WPI; 2004-097355/10.
XX
PT Modulating ischemic event in subject involves providing the subject with
PT gene-regulatory peptide or its functional analogue.
XX
PS Example; SEQ ID NO 2; 17pp; English.
XX
CC The present invention relates to a method for modulating or treating
CC ischaemic events in a subject. The method involves providing the subject
CC with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide or its
CC functional analogue. The method comprises providing the subject with an
CC NF-kappaB down-regulating peptide or its functional analogue, and a
CC thrombolytic agent having tissue plasminogen activity. The method of the
CC invention is useful for modulating or treating ischaemic events such as
CC stroke or myocardial infarction in a subject. The invention is capable of
CC modulating expression of gene encoding a pro-inflammatory cytokine. The
CC present sequence represents a NF-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 10
ADG86590
ID ADG86590 standard; peptide; 4 AA.
XX
AC ADG86590;
XX
DT 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
KW Iatrogenic event; nuclear factor-kappaB; NF-kappaB;
KW gene-regulatory peptide; down-regulation; cell destruction; cell lysis;
KW tissue; iatrogenic disease; pro-inflammatory cytokine response;
KW antiinflammatory.
XX
OS Unidentified.
XX
PN US2003220261-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409671.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2004-107014/11.
XX
PT Modulating an iatrogenic event in a subject, useful for treating a
PT subject suffering from iatrogenic disease, comprises providing the
PT subject with a gene-regulatory peptide or its functional analogue.
XX
PS Example; SEQ ID NO 2; 16pp; English.
XX
CC The present invention relates to a method for modulating or treating an
CC iatrogenic event in a subject. The method involves providing the subject
CC with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide or its
CC functional analogue. The method comprises providing the subject with an
CC NF-kappaB down-regulating peptide or its functional analogue. The
CC iatrogenic event involves destruction or lysis of a cell or tissue of the
CC subject or of a pathogen hosted by the subject. Modulating an iatrogenic
CC event is useful for treating subjects suffering from iatrogenic disease.
CC The gene-regulatory peptide, e.g. nuclear factor-kappa B down-regulating
CC peptide, is useful for producing a pharmaceutical composition for the
CC treatment of an additional pro-inflammatory cytokine response occurring
CC after an iatrogenic event in a subject. The present sequence represents a
CC NF-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 11
ADH29151
ID ADH29151 standard; peptide; 4 AA.
XX
AC ADH29151;
XX
DT 11-MAR-2004 (first entry)
XX
DE Necrosis factor kappa B (NFkB) down regulating peptide #2.
XX
KW immunosuppressant; gene therapy; NF-kappaB antagonist;
KW Rel protein-antagonist; transplant; gene-regulatory;
KW hypertonic pharmaceutical composition; NF-kappaB down-regulating peptide;
KW chronic rejection; necrosis factor kappa B down-regulating peptide;
KW immune repsonse.
XX
OS Synthetic.
XX
PN US2003219425-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409027.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
PA (YZER/) YZERMANS J N M.
XX
PI Khan NA, Benner R, Yzermans JNM;
XX
DR WPI; 2004-089275/09.
XX
PT Modulation of transplant survival in recipient of transplant comprises
PT providing transplant with gene-regulatory peptide or functional analog.
XX
PS Example; SEQ ID NO 2; 18pp; English.

XX
CC The invention describes a method of modulating transplant survival in a
CC recipient of the transplant comprising providing the transplant with a
CC gene-regulatory peptide or its functional analogue. Also described is a
CC hypertonic pharmaceutical composition comprising NF-kappaB down-
CC regulating peptide or its functional analogue. The invention prevents and
CC treats rejection, particularly chronic rejection, of a transplant by a
CC recipient of the transplant. This is the amino acid sequence of a
CC necrosis factor kappa B (NFkB) down-regulating peptide used to modify the
CC immune repsonse and treat transplant rejection.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 12
ADG73593
ID ADG73593 standard; peptide; 4 AA.
XX
AC ADG73593;
XX
DT 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
KW Immunosuppressive state; nuclear factor-kappaB; NF-kappaB;
KW gene-regulatory peptide; disseminated intravascular coagulation; trauma;
KW counter anti-inflammatory response syndrome; upregulation;
KW anti-inflammatory response; interleukin-10; IL-10;
KW pro-inflammatory response; tumour necrosis factor-alpha; TNF-alpha;
KW nitric oxide; interleukin-5; IL-5; interleukin-1beta; IL-1beta;
KW anticoagulation.
XX
OS Unidentified.
XX
PN US2003220257-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409032.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (BENN/) BENNER R.
PA (KHAN/) KHAN N A.
XX
PI Benner R, Khan NA;
XX
DR WPI; 2004-069536/07.
XX
PT Modulating or treating immunosuppressive state in subject involves
PT providing the subject with a gene-regulatory peptide or its functional
PT analogue.
XX
PS Example; SEQ ID NO 2; 14pp; English.
XX
CC The present invention relates to a method for modulating or treating
CC immunosuppressive states in a subject. The method involves providing the
CC subject with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide
CC or its functional analogue. Also disclosed is a pharmaceutical
CC composition comprising an NF-kappaB up-regulating peptide or its
CC functional analogue, and an agent directed against disseminated
CC intravascular coagulation. The method of the invention is useful for
CC modulating or treating immunosuppressive state in a subject that has
CC experienced trauma or is at risk of suffering a counter anti-inflammatory
CC response syndrome. The invention allows the upregulation of anti-
CC inflammatory responses such as interleukin-10 (IL-10), and the
CC downregulation of pro-inflammatory responses such as those mediated by
CC tumour necrosis factor-alpha (TNF-alpha), nitric oxide, IL-5, and IL-
CC 1beta. The present sequence represents a NF-kappaB gene-regulatory
CC peptide.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 13
ADG86561
ID ADG86561 standard; peptide; 4 AA.
XX
AC ADG86561;
XX
DT 11-MAR-2004 (first entry)
XX
DE NF-kappaB gene-regulatory peptide #2.
XX
KW Nuclear factor-kappaB; NF-kappaB; gene-regulatory peptide;
KW conjunctivitis; dry eye; immunosuppression; down-regulation;
KW inflammatory pathway; NF-kappaB/Rel family; ophthalmological;
KW immunosuppressive.
XX
OS Unidentified.
XX
PN US2003220260-A1.
XX
PD 27-NOV-2003.
XX
PF 08-APR-2003; 2003US-00409659.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2004-097357/10.
XX
PT Pharmaceutical composition for topical application used to treat
PT conjunctivitis and to modulate immunosuppression, comprises gene-
PT regulatory peptide or its functional analogue.
XX
PS Example; SEQ ID NO 2; 20pp; English.
XX
CC The present invention relates to a method for modulating or treating a
CC variety of diseases in a subject. The method involves providing the
CC subject with a nuclear factor-kappaB (NF-kappaB) gene-regulatory peptide
CC or its functional analogue. The method of the invention is useful for
CC modulating NF-kappaB. The method may be used to treated conjunctivitis
CC for the treatment of dry eyes. It is also used to modulate
CC immunosuppression. The invention is capable of down-regulating
CC inflammatory pathways. It is also capable of modulating the transcription
CC of genes that are under the control of NF-kappaB/Rel family of factors.
CC The present sequence represents a NF-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4

```
                ||||
Db          1 AQGV 4


RESULT 14
ADI20991
ID   ADI20991 standard; peptide; 4 AA.
XX
AC   ADI20991;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human nuclear factor kappa B (NFkappaB) gene regulatory peptide #2.
XX
KW   Human; nuclear factor kappa B; NFkappaB; gene regulatory peptide; hCG;
KW   human chorionic gonadotrophin; inflammatory cytokine;
KW   neurological disorder; schizophrenia; manic depression; bipolar disorder;
KW   multiple sclerosis; post-partum psychosis; autism;
KW   chronic fatigue syndrome; fibromyalgia; Alzheimer's disease;
KW   mood disorder; stress; transcription factor; Rel protein;
KW   cell-mediated immunity; IL-10; tumour necrosis factor; nitric oxide;
KW   IL-5; IL-6; IL-1beta.
XX
OS   Homo sapiens.
XX
PN   US2003220259-A1.
XX
PD   27-NOV-2003.
XX
PF   08-APR-2003; 2003US-00409654.
XX
PR   21-DEC-2001; 2001US-00028075.
XX
PA   (BENN/) BENNER R.
PA   (KHAN/) KHAN N A.
PA   (WENS/) WENSVOORT G.
XX
PI   Benner R,  Khan NA,  Wensvoort G;
XX
DR   WPI; 2004-097356/10.
XX
PT   Modulating neurological disorder in a subject involves providing the
PT   subject with a gene-regulatory peptide or its functional analogue.
XX
PS   Example; Page 5; 11pp; English.
XX
CC   The invention relates to modulating a neurological disorder in a subject
CC   involves providing the subject with a gene-regulatory peptide or its
CC   functional analogue (e.g. those derived from human chorionic
CC   gonadotrophin, produced during pregnancy and thought to regulate pro-
CC   inflammatory cytokine production via regulation of NF-kappaB (nuclear
CC   factor kappa B)). The gene regulatory peptide or its functional analogue
CC   down-regulates translocation and/or activity, of a gene transcription
CC   factor (comprises NF-kappaB/Rel protein). The invention is used for
CC   modulating a neurological disorder (such as in a subject that presents
CC   clinical signs of autism), e.g. schizophrenia, manic depression and other
CC   bipolar disorders, multiple sclerosis, postpartum psychosis, autism,
CC   chronic fatigue syndrome, fibromyalgia, Alzheimer's, mood disorders, and
CC   certain form of stress. The invention reduces the frequency and limits
CC   the lasting effects of psychological manifestations of neuroimmune
CC   disease. It counters the involvement of cell-mediated immunity in the
CC   etiology of neurologic disease. It allows up-regulating anti-inflammatory
CC   responses such as IL-10, and downregulating pro-inflammatory responses
CC   such as mediated by tumour necrosis factor (TNF)-alpha, nitric oxide, IL-
CC   5, IL-6 and IL-1beta. The present sequence is a gene regulating peptide
CC   of the invention.
XX
SQ   Sequence 4 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
                ||||
Db          1 AQGV 4


RESULT 15
ADI16437
ID   ADI16437 standard; peptide; 4 AA.
XX
AC   ADI16437;
XX
DT   22-APR-2004  (first entry)
XX
DE   NF-kappaB down-regulating peptide, SEQ ID No 2.
XX
KW   burn injury; gene-regulatory; NF-kappaB down-regulating peptide;
KW   disseminated intravascular coagulation; bacteriostatic; silver;
KW   hypotonic; burn.
XX
OS   Unidentified.
XX
PN   US2003224995-A1.
XX
PD   04-DEC-2003.
XX
PF   08-APR-2003; 2003US-00409694.
XX
PR   21-DEC-2001; 2001US-00028075.
XX
PA   (KHAN/) KHAN N A.
PA   (WENS/) WENSVOORT G.
PA   (BENN/) BENNER R.
XX
PI   Khan NA,  Wensvoort G,  Benner R;
XX
DR   WPI; 2004-033998/03.
XX
PT   Modulating burn injury in subject, comprises providing gene-regulatory
PT   peptide or its analog to subject.
XX
PS   Example; SEQ ID NO 2; 17pp; English.
XX
CC   The invention relates to a novel method for modulating burn injury in a
CC   subject. The method involves providing a gene-regulatory peptide or its
CC   analogue to the subject. The invention further relates to: a
CC   pharmaceutical composition comprising an NF-kappaB down-regulating
CC   peptide or its functional analogue, and an agent directed against
CC   disseminated intravascular coagulation, or a bacteriostatic compound
CC   comprising silver; a hypotonic pharmaceutical composition comprising an
CC   NF-kappaB down-regulating peptide or its functional analogue; and a
CC   method for treating a subject suffering from a burn, involving providing
CC   the subject with a sufficient amount of a gene-regulatory peptide to down
CC   -regulate translocation and/or activity of NF-kappaB/Rel protein and
CC   further providing an agent having activated protein C activity and
CC   directed against disseminated intravascular coagulation. This sequence
CC   represents an NF-kappaB down-regulating peptide to be used in a
CC   pharmaceutical composition of the invention.
XX
SQ   Sequence 4 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
                ||||
Db          1 AQGV 4


RESULT 16
ADK42374
ID   ADK42374 standard; peptide; 4 AA.
XX
```

```
AC   ADK42374;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antibacterial peptide from pHBP #135.
XX
KW   Pig; heparin binding protein; HBP; neutrophil elastase; antibacterial;
KW   cytokine IL-6; monocyte; bacterial infection; sepsis; septic shock;
KW   disseminated intravascular coagulation; meningococcal meningitis;
KW   pneumococcal pneumonia; inflammatory response; cell apoptosis;
KW   suppressed immune system; cancer; autoimmune diseases; trauma.
XX
OS   Sus scrofa.
XX
PN   WO2004016653-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-DK000542.
XX
PR   15-AUG-2002; 2002DK-00001212.
PR   19-AUG-2002; 2002US-0404155P.
PR   27-JUN-2003; 2003DK-00000987.
XX
PA   (LEUK-) LEUKETOCH AS.
XX
PI   Djurup R,  Flodgaard HJ,  Norris K;
XX
DR   WPI; 2004-257185/24.
XX
PT   New peptides of heparin-binding protein and/or human neutrophil elastase
PT   for manufacturing a medicament for the treatment of e.g. bacterial
PT   infections, disseminated intravascular coagulation, cancer or autoimmune
PT   diseases.
XX
PS   Claim 52; SEQ ID NO 356; 211pp; English.
XX
CC   The invention relates to an antibacterial peptide conforming to the
CC   generic peptide sequence appearing as ADK42632, the motif being derived
CC   from analysis of the protein sequences of human heparin binding protein,
CC   hHBP, pig pHBP and human neutrophil elastase (hNLE). Also included are a
CC   process for producing the new peptide (comprising providing an expression
CC   vector containing a DNA sequence encoding one or more of the above-
CC   mentioned amino acid sequences, transforming host cells with the vector,
CC   culturing the transformed host cells and purifying the expressed peptide)
CC   and a pharmaceutical composition comprising the new peptide. The peptide
CC   is capable of inhibiting or stimulating the secretion of cytokine IL-6
CC   from monocytes. The peptides are useful in manufacturing a medicament for
CC   the treatment of Gram-negative or Gram-positive bacterial infection, such
CC   as sepsis, severe sepsis, septic shock, disseminated intravascular
CC   coagulation, meningococcal meningitis or pneumococcal pneumonia. These
CC   may also be used in manufacturing a medicament for the stimulation or
CC   inhibition of inflammatory response, for the prevention of cell
CC   apoptosis, or for the treatment of individuals having suppressed immune
CC   system, cancer, autoimmune diseases and/or trauma. The present sequence
CC   represents an antibacterial peptide of the invention derived from pig
CC   HBP.
XX
SQ   Sequence 4 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 17
ADM48491
ID   ADM48491 standard; peptide; 4 AA.
XX
AC   ADM48491;
XX
DT   03-JUN-2004  (first entry)
XX
DE   NF-kappaB down-regulating peptide #2.
XX
KW   Multiple sclerosis; MS; gene-regulatory peptide; NF-kappaB.
XX
OS   Unidentified.
XX
PN   US2003215434-A1.
XX
PD   20-NOV-2003.
XX
PF   08-APR-2003; 2003US-00409630.
XX
PR   21-DEC-2001; 2001US-00028075.
XX
PA   (KHAN/) KHAN N A.
PA   (BENN/) BENNER R.
XX
PI   Khan NA,  Benner R;
XX
DR   WPI; 2004-080670/08.
XX
PT   Modulation of relapsing/remitting disease in subject suffering from
PT   multiple sclerosis, by providing the subject with gene-regulatory peptide
PT   or its functional analogues.
XX
PS   Example; Page 4; 11pp; English.
XX
CC   The invention relates to a method for modulating relapsing/remitting
CC   disease in subject suffering from multiple sclerosis (MS), by providing
CC   the subject with gene-regulatory peptide or its functional analogues. The
CC   gene-regulatory peptide or its functional analogue has NF-kappaB down-
CC   regulating activity in LPS (sic) stimulated RAW264.7 cells. The method is
CC   useful for modulating relapsing/remitting disease in subject suffering
CC   from multiple sclerosis. The present sequence is a NF-kappaB down-
CC   regulating peptide. This sequence is used to illustrate the method of the
CC   invention.
XX
SQ   Sequence 4 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 18
ADO15345
ID   ADO15345 standard; peptide; 4 AA.
XX
AC   ADO15345;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Nuclear factor-kappaB down-regulating peptide #2.
XX
KW   Inflammatory condition; counter-inflammatory condition;
KW   gene-regulatory peptide; pro-inflammatory cytokine;
KW   tumour necrosis factor-alpha; interferon-gamma; interleukin-1beta;
KW   interleukin-6; counter-inflammatory cytokine; interleukin-4;
KW   interleukin-10; HLA-DR expression; circulating monocyte;
KW   arachidonic acid metabolite; plasma prostaglandin.
XX
OS   Unidentified.
XX
PN   US2004013661-A1.
XX
```

PD 22-JAN-2004.
XX
PF 08-APR-2003; 2003US-00409657.
XX
PR 21-DEC-2001; 2001US-00028075.
XX
PA (WENS/) WENSVOORT G.
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
XX
PI Wensvoort G, Khan NA, Benner R;
XX
DR WPI; 2004-108189/11.
XX
PT Treating subject suffering from inflammatory and/or counter-inflammatory
PT condition, by determining disease stage using diagnostic process,
PT providing gene-regulatory peptide to subject depending on disease stage.
XX
PS Example; Page 6; 14pp; English.
XX
CC The invention relates to treating a subject suffering from inflammatory
CC and/or counter-inflammatory condition, involves determining subject's
CC inflammatory disease stage using diagnostic process, and providing
CC subject with gene-regulatory peptide or its functional analogue depending
CC on the outcome of determination of disease stage. The diagnostic process
CC includes determining the level of a pro-inflammatory cytokine in a sample
CC taken from a patient (where the pro-inflammatory cytokine is chosen from
CC tumour necrosis factor-alpha, interferon-gamma, interleukin-1beta,
CC interleukin-6, and its combination), determining the level of a counter-
CC inflammatory cytokine (e.g., interleukin-4 or interleukin-10),
CC determining HLA-DR expression on circulating monocytes, determining
CC arachidonic acid metabolite levels and determining plasma prostaglandin
CC levels (a ratio between prostaglandins 1 and 2) in the subject. The gene-
CC regulatory peptide or its functional analogue down-regulates (for an
CC inflammatory condition) or up-regulates (for a counter-inflammatory
CC condition) translocation activity, or translocation and activity of pro-
CC inflammatory cytokine gene expression mediated by a gene transcription
CC factor (NF-kappaB/Rel protein). The method is useful for treating subject
CC suffering from inflammatory and/or counter-inflammatory condition. The
CC present sequence is a NF-kappaB/Rel down-regulating peptide.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 19
ADT08600
ID ADT08600 standard; peptide; 4 AA.
XX
AC ADT08600;
XX
DT 30-DEC-2004 (first entry)
XX
DE Human chorionic gonadotropin related peptide #2.
XX
KW Antiinflammatory; Nuclear factor kappa B; NF-kappaB; human;
KW chorionic gonadotropin; hCG.
XX
OS Homo sapiens.
XX
PN EP1466611-A1.
XX
PD 13-OCT-2004.
XX
PF 08-APR-2003; 2003EP-00076022.
XX
PR 08-APR-2003; 2003EP-00076022.
XX
PA (BIOT-) BIOTEMPT BV.
XX
DR WPI; 2004-749906/74.
XX
PT Modulating an iatrogenic event comprises providing the subject with a
PT gene-regulatory peptide or its functional analogue, particularly an
PT inhibitor of NF-kappaB/Rel translocation or activity.
XX
PS Example; Page 9; 16pp; English.
XX
CC The present invention relates to a method for modulating an iatrogenic
CC event (i.e. an adverse event that results from medical treatment) in a
CC subject. The method comprises providing the subject with a gene-
CC regulatory peptide or its functional analogue, where the peptide or
CC analogue inhibits the translocation and/or activity of a gene
CC transcription factor such as Nuclear Factor (NF)-kappaB/ ReI protein or
CC AP-1 protein. The iatrogenic event comprises destruction or lysis of a
CC cell or tissue of the subject or of a pathogen hosted by the subject. The
CC lysis is due to treatment of the subject with a pharmaceutical
CC composition selected from antigens, vaccines, antibodies, anticoagulants,
CC antibiotics, antitoxins, antibacterial agents, antiparasitic agents,
CC antiprotozootic agents, antifungal agents, antiviral agents, cytolytic
CC agents, cytostatic agents and thrombolytic agents. The lysis may be due
CC to treatment of the subject with a virus comprising a lytic phage. The
CC present sequence is one such gene-regulatory peptide used in the method
CC of the invention which is derived from human chorionic gonadotropin
CC (hCG). This peptide is a NF-kappaB down regulating peptide.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 20
ADT08628
ID ADT08628 standard; peptide; 4 AA.
XX
AC ADT08628;
XX
DT 30-DEC-2004 (first entry)
XX
DE Human chorionic gonadotropin related peptide #2.
XX
KW Antiinflammatory; Antibacterial; Immunosuppressive; Immunostimulant;
KW Immunomodulator; inflammatory disorder; Nuclear Factor kappaB; NF-kappaB;
KW human; chorionic gonadotropin; hCG.
XX
OS Homo sapiens.
XX
PN EP1466612-A1.
XX
PD 13-OCT-2004.
XX
PF 08-APR-2003; 2003EP-00076023.
XX
PR 08-APR-2003; 2003EP-00076023.
XX
PA (BIOT-) BIOTEMPT BV.
XX
DR WPI; 2004-711295/70.
XX
PT Treating a subject suffering from an inflammatory or counter-inflammatory
PT condition comprises subjecting the subject to a diagnostic process and
PT administering an appropriate gene-regulatory peptide based on the
PT results.

XX
PS Example; Page 10; 20pp; English.
XX
CC The present invention relates to a method for treating a subject
CC suspected to suffer from an inflammatory and/or a counter-inflammatory
CC condition. The method comprises subjecting the subject to a diagnostic
CC process aimed at determining inflammatory disease stage and providing the
CC subject with a gene-regulatory peptide or its functional analogue
CC depending on the results of the diagnostic process. The diagnostic
CC process includes determining the level of a pro-inflammatory cytokine,
CC which is preferably selected from tumor necrosis factor-alpha, interferon
CC -gamma, interleukin-1-beta and interleukin-6. The diagnostic process
CC includes determining the level of a counter-inflammatory cytokine
CC selected from interleukin-4 and interleukin-10. The diagnostic process
CC preferably includes determining HLA-DR expression on circulating
CC monocytes of the subject. The diagnostic process preferably includes
CC determining arachidonic acid metabolite levels. The process preferably
CC includes determining plasma prostaglandin levels, specifically
CC determining a ration between prostaglandins 1 and 2 (PGE1 and PGE2). The
CC method comprises providing the subject with a gene-regulatory peptide or
CC its functional analogue based on the determination of disease stage as an
CC essentially inflammatory condition, where the gene-regulatory peptide
CC down-regulates translocation and/or activity of pro-inflammatory cytokine
CC gene expression mediated by a gene transcription factor. The
CC transcription factor preferably comprises an Nuclear Factor (NF)-
CC kappaB/ReI protein and the translocation and/or activity of the protein
CC is inhibited. The peptide is preferably selected from peptides having NF-
CC kappaB down-regulating activity in lipopolysaccharide (LPS) stimulated or
CC unstimulated RAW264.7 cells. Inflammatory conditions that may be treated
CC include systemic inflammatory response syndrome (SIRS) and sepsis.
CC Counter-inflammatory conditions that may be treated include
CC immunosuppression associated with major trauma. The present sequence is
CC one such gene-regulatory peptide used in the method of the invention
CC which is derived from human chorionic gonadotropin (hCG). This peptide is
CC a NF-kappaB down regulating peptide.
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 21
ADT08656
ID ADT08656 standard; peptide; 4 AA.
XX
AC ADT08656;
XX
DT 30-DEC-2004 (first entry)
XX
DE Human chorionic gonadotropin related peptide #2.
XX
KW Antiinflammatory; Antidiabetic; Neuroprotective; Immunosuppressive;
KW Dermatological; Antirheumatic; Antiarthritic; Antiallergic;
KW Antiasthmatic; Antiparasitic; Virucide; Antibacterial;
KW Nuclear Factor kappaB; NF-kappaB; inflammatory disorder; human;
KW chorionic gonadotropin; hCG.
XX
OS Homo sapiens.
XX
PN EP1466613-A1.
XX
PD 13-OCT-2004.
XX
PF 08-APR-2003; 2003EP-00076030.
XX
PR 08-APR-2003; 2003EP-00076030.
XX
PA (BIOT-) BIOTEMPT BV.
XX
DR WPI; 2004-711296/70.
XX
PT Pharmaceutical composition useful for treating e.g. diabetes, multiple
PT sclerosis comprises gene-regulatory peptide.
XX
PS Example; Page 6; 29pp; English.
XX
CC The present invention relates to novel pharmaceutical compositions
CC comprising a gene-regulatory peptide, its functional analog and diluent.
CC The gene-regulatory peptide modulates (preferably inhibits) translocation
CC and gene transcription factor e.g. Nuclear Factor (NF)-kappaB/ ReI
CC protein; regulates expression of gene encoding an inflammatory mediator
CC containing cytokine selected from TNF-alpha, TGF-beta, interferon gamma,
CC IL-1beta, IL-4, IL-5, IL-6, IL-10, IL-12, IL-23 and IL-40. The
CC compositions are useful for treating disease such as inflammatory disease
CC such as chronic inflammation e.g. diabetes, multiple sclerosis, chronic
CC transplant rejection; acute inflammation e.g. septic or anaphylactic
CC shock, acute or hyper acute transplant rejection; autoimmune disease e.g.
CC systemic lupus erythematosus or rheumatoid arthritis; allergy e.g. asthma
CC or parasitic disease; overly strong immune response directed against an
CC infectious agent e.g. virus or bacterium, systemically. The present
CC sequence is one such gene-regulatory peptide used in the method of the
CC invention which is derived from human chorionic gonadotropin (hCG).
XX
SQ Sequence 4 AA;

```
  Query Match             100.0%;  Score 19;  DB 8;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 2e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 22
ADT79351
ID ADT79351 standard; peptide; 4 AA.
XX
AC ADT79351;
XX
DT 30-DEC-2004 (first entry)
XX
DE Nuclear factor (NF)-kappaB up-regulating peptide #1.
XX
KW Gene-regulatory peptide; chronic inflammatory disease; diabetes;
KW multiple sclerosis; acute inflammation; septic shock; anaphylactic shock;
KW transplant rejection; autoimmune disease; systemic lupus erythematosus;
KW rheumatoid arthritis; allergic reaction; asthma; parasitic disease;
KW immune response; antiinflammatory; antidiabetic; neuroprotective;
KW immunosuppressive; antibacterial; antiallergic; dermatological;
KW antiarthritic; antirheumatic; antiasthmatic; antiparasitic;
KW nuclear factor-kappaB; NF-kappaB.
XX
OS Synthetic.
XX
PN US2004202645-A1.
XX
PD 14-OCT-2004.
XX
PF 08-APR-2003; 2003US-00409668.
XX
PR 08-APR-2003; 2003US-00409668.
XX
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2004-727977/71.
XX

PT Composition, useful to treat e.g. acute/chronic inflammation, autoimmune
PT disease and an allergic reaction, comprises a gene-regulatory peptide or
PT its functional analogue together with a diluent.
XX
PS Disclosure; SEQ ID NO 2; 28pp; English.
XX
CC The invention relates to a pharmaceutical composition comprising a gene-
CC regulatory peptide or its functional analogue together with a diluent.
CC The pharmaceutical composition is useful to systemically treat chronic
CC inflammatory disease (diabetes, multiple sclerosis or chronic transplant
CC rejection); acute inflammation (septic or anaphylactic shock or acute and
CC hyper acute transplant rejection); autoimmune disease (systemic lupus
CC erythematosus or rheumatoid arthritis); allergic reaction (asthma or
CC parasitic disease); and/or overly strong immune response directed against
CC an infectious agent (bacteria or virus) infecting the subject. The
CC present sequence is a nuclear factor (NF)-kappaB gene-regulatory peptide.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 23
ADT49387
ID ADT49387 standard; peptide; 4 AA.
XX
AC ADT49387;
XX
DT 13-JAN-2005 (first entry)
XX
DE Human chorionic gonadotropin derived peptide, NMPF-46.
XX
KW Immunomodulator; human chorionic gonadotropin; hCG; sepsis; shock;
KW septic shock; gene regulation; bone disease; osteoporosis; inflammation;
KW tissue damage; multiple organ failure; diabetes; insulitis; glucosuria;
KW immune-mediated disorder; wasting syndrome; NMPF-46.
XX
OS Homo sapiens.
XX
PN US2004208885-A1.
XX
PD 21-OCT-2004.
XX
PF 07-JAN-2004; 2004US-00753510.
XX
PR 03-MAR-2001; 2001WO-NL000259.
PR 21-DEC-2001; 2001US-00028075.
PR 30-SEP-2002; 2002US-00262522.
PR 10-APR-2003; 2002WO-NL000639.
XX
PA (KHAN/) KHAN N A.
PA (BENN/) BENNER R.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2004-747166/73.
XX
PT Composition useful for treating e.g. a bone disease such as osteoporosis,
PT or sepsis, comprises a purified or isolated peptide that modulates
PT production of nitric oxide by a cell.
XX
PS Claim 11; SEQ ID NO 2; 50pp; English.
XX
CC The present invention relates to compounds exhibiting immunomodulatory
CC activity as determined by measuring the compounds ability to modulate
CC production of NO by a cell. In particular, the compounds include
CC oligopeptides derived from human chorionic gonadotropin (hCG), and with
CC the antigenic binding activity of hCG. The peptides comprise a small
CC amino acid segment of a larger sequence, defined in the specification, or
CC a derivative of the segment having one or more conservative
CC substitutions, and exhibiting an immunoregulatory activity. The
CC oligopeptides are useful in the treatment of sepsis, shock, septic shock,
CC tissue damage, multiple organ failure, diabetes, glucosuria, insulitis,
CC immune-mediated disorder, wasting syndrome and have gene regulation
CC activities. The invention provides a method for the treatment of bone
CC disease such as osteoporosis, useful in post menopausal women that no
CC longer have a natural source of hCG and its breakdown products.
CC Immunomodulatory effects of the oligopeptides has been observed in T-cell
CC assays showing the inhibition of pathological Th1 immune responses,
CC suppression of inflammation cytokines (MIF), increase in antiinflammatory
CC cytokines (IL-10, TGF-beta) and immunomodulatory effects on antigen-
CC presenting cells, monocytes and macrophages. The present sequence is an
CC amino acid portion of a longer sequence derived from hCG, and is named as
CC NMPF-46 in the specification.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 24
ADU46871
ID ADU46871 standard; peptide; 4 AA.
XX
AC ADU46871;
XX
DT 27-JAN-2005 (first entry)
XX
DE Gene regulatory peptide for treatment of immune-related disorder.
XX
KW Gene regulation; human chorionic gonadotropin; antiinflammatory;
KW antidiabetic; neuroprotective; immunosuppressive; dermatological;
KW antirheumatic; antiarthritic; antiallergic; antiasthmatic; antiparasitic;
KW gynecological; nuclear factor kappa B.
XX
OS Synthetic.
XX
PN WO2004093897-A1.
XX
PD 04-NOV-2004.
XX
PF 08-APR-2004; 2004WO-EP003747.
XX
PR 08-APR-2003; 2003EP-00076021.
PR 08-APR-2003; 2003EP-00076022.
PR 08-APR-2003; 2003EP-00076023.
PR 08-APR-2003; 2003EP-00076024.
PR 08-APR-2003; 2003EP-00076025.
PR 08-APR-2003; 2003EP-00076026.
PR 08-APR-2003; 2003EP-00076027.
PR 08-APR-2003; 2003EP-00076028.
PR 08-APR-2003; 2003EP-00076029.
PR 08-APR-2003; 2003EP-00076030.
PR 08-APR-2003; 2003US-00409671.
PR 30-APR-2003; 2003CN-00131227.
XX
PA (BIOT-) BIOTEMPT BV.
XX
PI Khan NA, Benner R, Wensvoort G;
XX
DR WPI; 2004-784832/77.
XX
PT A pharmaceutical composition for mucosal or oral treatment of immune-
PT mediated disorders (e.g. allergy, transplant disorders or inflammatory

PT diseases) comprises an amount of a gene-regulatory peptide and a
PT pharmaceutical diluent.
XX
PS Example; SEQ ID NO 2; 95pp; English.
XX
CC The present sequence is that of a nuclear factor kappa B (NFkB)
CC regulating peptide that is an example of gene regulatory peptides of the
CC invention. The invention provides the treatment of a disease by mucosal,
CC preferably oral, administration of a pharmaceutical composition
CC comprising a gene regulatory peptide obtained or derived from human
CC chorionic gonadotropin (hCG) in order to generate systemic modulation of
CC the expression of a gene. Such peptides are present naturally in pregnant
CC women and are derived from proteolytic breakdown of placental
CC gonadotropins such as hCG produced during pregnancy. However, synthetic
CC variants and modifications of these peptides having equivalent activity
CC can be synthesised and tested for activity using e.g. NOD mice.
CC Pharmaceutical compositions comprising gene regulatory peptides of the
CC invention can be used to treat an inflammatory disease such as: a disease
CC comprising chronic inflammation, such as diabetes, multiple sclerosis or
CC chronic transplant rejection; acute inflammation such as septic or
CC anaphylactic shock or acute or hyper-acute transplant rejection; an
CC autoimmune disease such as systemic lupus erythematosus or rheumatoid
CC arthritis; an allergy such as asthma or parasitic disease; or an overly
CC strong immune response directed against an infectious agent (all
CC claimed). The gene regulatory peptides modulate the translocation and/or
CC activity of a gene transcription factor, especially they inhibit NFkB/Rel
CC protein or regulate expression of an inflammatory mediator such as a
CC cytokine. The present peptide is a NFkB down-regulating peptide, and was
CC shown to modulate the translocation of NFkB into the nucleus of RAW264.7
CC macrophages. It can be produced by solid-phase synthesis. The peptide is
CC preferred for oral administration, and is preferred for use in the
CC treatment of a neurological disorder, a relapsing/remitting disease such
CC as multiple sclerosis, diabetes, or a menopausal, post-menopausal or
CC osteoporosis condition, and can be added to transplant preservation fluid
CC or transplant perfusion fluid. It is the most preferred peptide for oral
CC treatment of reperfusion injury.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 25
ADY03875
ID ADY03875 standard; peptide; 4 AA.
XX
AC ADY03875;
XX
DT 05-MAY-2005 (first entry)
XX
DE Peptide database creation method peptide #2.
XX
KW peptide library; peptide mapping; gonadotropin; tumor necrosis factor;
KW interleukin; interferon.
XX
OS Synthetic.
XX
PN US2005037430-A1.
XX
PD 17-FEB-2005.
XX
PF 08-APR-2004; 2004US-00821240.
XX
PR 29-MAR-2000; 2000EP-00201139.
PR 03-MAR-2001; 2001WO-NL000259.
PR 04-OCT-2001; 2001EP-00203748.
PR 21-DEC-2001; 2001US-00028075.
PR 30-SEP-2002; 2002US-00262522.
PR 10-APR-2003; 2002WO-NL000639.
PR 07-JAN-2004; 2004US-00753510.
XX
PA (BIOT-) BIOTEMPT BV.
XX
PI Khan NA, Benner R;
XX
DR WPI; 2005-172262/18.
XX
PT Creating a peptide database, involves screening peptides to determine
PT activity of peptide, analyzing physical, chemical, or biological property
PT of peptides, recording properties of all peptides in peptide database.
XX
PS Disclosure; SEQ ID NO 2; 95pp; English.
XX
CC The invention relates to a method of creating (M1) a peptide database, by
CC providing a first source of peptides, screening a peptide to determine
CC the activity of the peptide, analyzing the results, characterizing a
CC physical, chemical, or biological property of the peptides, recording in
CC a peptide database the characteristics of all peptides, recording in the
CC peptide database results of analysis of the peptides, thus generating a
CC database or part of a database of peptides. (M1) is useful for creating a
CC peptide database. The peptides are related to gonadotropin, especially
CC human chorionic gonadotropin. Analyzing the peptides comprises analyzing
CC an anti-shock effect, analyzing TNF-alpha, analyzing effect of peptide on
CC angiogenesis, analyzing a condition associated with a dysfunctional LDL
CC receptor or analyzing the effect of the peptide on at least one
CC inflammatory mediator chosen from IL-1-alpha, IL-1-beta, IL-6, TNF-alpha,
CC LIF, IFN-gamma, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18 and IL-8.
CC The peptides are related to beta-catenin, C-reactive protein, matrix
CC metalloproteinase-2 or Bruton's tyrosine kinase. (M1) is useful for
CC assaying several peptides by ex vivo, in vivo, and animal assays, thus
CC allowing for rational design of molecular mixtures that better alleviate
CC the symptoms of certain diseases. This sequence corresponds to a peptide
CC of the invention.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 26
ADY82494
ID ADY82494 standard; peptide; 4 AA.
XX
AC ADY82494;
XX
DT 16-JUN-2005 (first entry)
XX
DE Porcine heparin binding protein (hHBP) antigenic peptide, SEQ ID 356.
XX
KW Antibacterial; Antiinflammatory; inflammation; Cytostatic; Vulnerary;
KW Anticoagulant; Heparin binding agent antagonist; bacterial infection;
KW infection; cancer; cytostatic; neoplasm; trauma; injury;
KW autoimmune disease; immunosuppressive; immune disorder;
KW bacterial meningitis; meningitis; neuroprotective; neurological disease;
KW heparin binding protein; HBP; monoclonal antibody; antibody production;
KW antigen; disseminated intravascular coagulation; hematological disease.
XX
OS Sus sp.
XX
PN WO2005028512-A1.
XX
PD 31-MAR-2005.
XX
PF 17-SEP-2004; 2004WO-DK000634.

XX
PR 19-SEP-2003; 2003DK-00001369.
XX
PA (LEUK-) LEUKOTECH AS.
XX
PI Djurup R, Flodgaard HJ, Norris K;
XX
DR WPI; 2005-254117/26.
XX
PT New pro-inflammatory monoclonal antibody produced by clone F19A5B1 or
PT F19A5B4, for stimulating or inhibiting an inflammatory response, or for
PT treating sepsis, septic shock, or disseminated intravascular coagulation.
XX
PS Disclosure; SEQ ID NO 356; 193pp; English.
XX
CC The invention relates to a pro-inflammatory monoclonal antibody produced
CC by clone F19A5B1 (ECACC Ass. No. 03090301) and an anti-inflammatory
CC monoclonal antibody, F19A5B4 (ECACC Ass. No. 03090302). Also described is
CC a pharmaceutical composition for modulating at least one inflammatory
CC response associated with human heparin binding protein (hHBP). The
CC composition comprises an antibody against hHBP, or a fragment of the
CC antibody, or an antibody against a homolog of hHBP, or a fragment of the
CC antibody, where the antibody is capable of binding to an epitope within
CC hHBP. The HBP homolog is porcine heparin binding protein (pHBP) and/or
CC human neutrophil elastase (hNEL). The antibody is a pro-inflammatory
CC antibody capable of stimulating at least one inflammatory response in the
CC absence of bacterial products in the blood, or capable of stimulating at
CC least one inflammatory response in synergistic action with bacterial
CC products present in the blood. It is also capable of stimulating the
CC synthesis and/or release of cytokine IL-6. The antibody is also an anti-
CC inflammatory antibody capable of inhibiting at least one inflammatory
CC response in the absence or presence of bacterial products in the blood.
CC The pharmaceutical composition is useful for the stimulation and/or
CC inhibition of inflammatory response to bacterial infection, where the
CC infection is a Gram-negative or a Gram-positive bacterial infection. The
CC infection is by Pneumococcus pneumoniae. It is also associated with
CC sepsis, severe sepsis, septic shock, and/or disseminated intravascular
CC coagulation and meningitis, preferably meningococcal meningitis. The
CC antibody F19A5B1 is also useful for the manufacture of a medicament for
CC treatment of individuals having suppressed immune system, cancer,
CC autoimmune diseases, and/or trauma. It is also useful for the manufacture
CC of a medicament for treatment of individuals to suppress a sustained
CC inflammatory response. The present sequence represents a porcine heparin
CC binding protein (pHBP) peptide fragment used to produce the monoclonal
CC antibodies of the invention.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 27
AEA27819
ID AEA27819 standard; peptide; 4 AA.
XX
AC AEA27819;
XX
DT 28-JUL-2005 (first entry)
XX
DE Gene-regulatory peptide used for treatment of SARS infection.
XX
KW Severe acute respiratory syndrome; SARS coronavirus infection;
KW respiratory disease; respiratory-gen.; virucide.
XX
OS Homo sapiens.
XX
PN WO2005046569-A2.
XX
PD 26-MAY-2005.
XX
PF 08-APR-2004; 2004WO-US010872.
XX
PR 08-APR-2003; 2003EP-00076021.
PR 08-APR-2003; 2003EP-00076022.
PR 08-APR-2003; 2003EP-00076023.
PR 08-APR-2003; 2003EP-00076024.
PR 08-APR-2003; 2003EP-00076025.
PR 08-APR-2003; 2003EP-00076026.
PR 08-APR-2003; 2003EP-00076027.
PR 08-APR-2003; 2003EP-00076028.
PR 08-APR-2003; 2003EP-00076029.
PR 08-APR-2003; 2003EP-00076030.
PR 08-APR-2003; 2003US-00409671.
PR 30-APR-2003; 2003CN-00131227.
XX
PA (BIOT-) BIOTEMPT BV.
XX
PI Khan NA, Benner R, Wensvoort G, Galpin JE;
XX
DR WPI; 2005-386191/39.
XX
PT Use of gene-regulatory peptide for producing a pharmaceutical composition
PT for the treatment of severe acute respiratory syndrome.
XX
PS Claim 10; SEQ ID NO 2; 68pp; English.
XX
CC The present sequence is that of a gene-regulatory peptide of the
CC invention that can be used in the production of a pharmaceutical
CC composition for the treatment of a subject suffering from, or believed to
CC be suffering from, severe acute respiratory syndrome (SARS) caused by the
CC SARS coronavirus infection. The subject may be suffering from a late
CC phase and possibly lethal course of SARS characterized by elevated
CC lactate dehydrogenase levels, elevated creatine kinase levels,
CC neutrophilia, thrombocytopenia, elevated prothrombin time, migratory
CC pneumonia and/or hypoxia. Peptides of the invention may be obtained from
CC the urine of a pregnant woman, especially a woman in the first trimester
CC of pregnancy, or from a gonadotropin preparation comprising human
CC chorionic gonadotropin (hCG), or (in the present case) by chemical
CC synthesis. A preferred composition includes the present peptide and 2
CC others: AEA27818 and AEA27822. The peptide is a nuclear factor kappa B
CC inducing kinase down-regulating peptide.
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 19; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 28
ABU11098
ID ABU11098 standard; peptide; 9 AA.
XX
AC ABU11098;
XX
DT 05-FEB-2003 (first entry)
XX
DE House dust mite Der p1 antigen peptide #21.
XX
KW House dust mite; Der p1 antigen; human CD8 cell epitope; allergy;
KW immune response; atopic patient; CD8+ T-cell epitope; antiallergic.
XX
OS Dermatophagoides pteronyssinus.
XX
PN WO200281512-A1.
XX

PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-GB001534.
XX
PR 06-APR-2001; 2001GB-00008752.
XX
PA (ISIS-) ISIS INNOVATION LTD.
XX
PI Ogg G, Seneviratne S;
XX
DR WPI; 2003-058499/05.
XX
PT New peptide fragments of the Der p1 antigen of the house dust mite
PT Dermatophagoides pteronyssinus contain a human CD8+ T cell epitope and
PT are useful to treat and prevent allergy to the major house dust mite
PT allergen.
XX
PS Disclosure; Page 31; 47pp; English.
XX
CC The present invention relates to house dust mite (Dermatophagoides
CC pteronyssinus) Der p1 antigen peptides containing human CD8 cell
CC epitopes. The peptides of the invention are useful in the treatment of
CC human or animal patients, particularly to raise an immune response to the
CC Der p1 antigen. They are useful in the treatment and prevention of
CC allergies to the major house dust mite antigen, and to monitor disease
CC activity in atopic patients. ABU11078-ABU11146 represent house dust mite
CC Der p1 antigen peptides containing CD8+ T-cell epitopes
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 19; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 4 AQGV 7

RESULT 29
ADZ50681
ID ADZ50681 standard; peptide; 9 AA.
XX
AC ADZ50681;
XX
DT 14-JUL-2005 (first entry)
XX
DE Y. pestis cytotoxic T-cell epitope SEQ ID 749.
XX
KW Yersinia pestis infection; antibacterial; infection; epitope; T-cell;
KW vaccine; biological warfare.
XX
OS Yersinia pestis.
XX
PN WO2005037855-A2.
XX
PD 28-APR-2005.
XX
PF 15-OCT-2004; 2004WO-US033883.
XX
PR 17-OCT-2003; 2003US-0511653P.
XX
PA (PECO-) PECOS LABS INC.
XX
PI Lund O, Lundegaard C, Nielsen M, Worning P, Deans RJ, Buus S;
PI Brunak S;
XX
DR WPI; 2005-315677/32.
XX
PT New cytotoxic Yersinia pestis T-cell epitope comprising 10 amino acids,
PT useful as a vaccine or diagnostic tool and for inducing immune response
PT in a subject.
XX
PS Claim 1; SEQ ID NO 749; 235pp; English.
XX
CC The invention relates to a cytotoxic Yersinia pestis T-cell epitope,
CC selected from any of the 1000 sequences of 9 amino acids appearing as
CC ADZ49933-ADZ50932. Also included are predicting peptides that are
CC epitopes or can be used as diagnostic tools (comprising predicting which
CC peptides bind to a HMC molecule (not defined) with high affinity using a
CC neural network with at least one of the following features: some or all
CC of the inputs to the neural networks are generated using a hidden Markov
CC model; or some or all of the inputs are encoded by an amino acid
CC substitution matrix, different from an identity matrix)and a vaccine or
CC diagnostic tool using a limited number such as at least 1, 2, 3, 4, 5, 8,
CC 16, 32, 64, 128, 256, 512 of the peptides of ADZ49933-ADZ50932. In
CC predicting peptides, the prediction of the neural network is combined
CC with prediction or measurement of one of the following: proteasomal
CC cleavage sites; MHC binding; presence of sequence or related sequence(s)
CC in patent databases; TAP binding; gene or protein expression level;
CC function of the protein; localization of the protein; and similarity to
CC self proteins. The epitope is useful as a vaccine or diagnostic tool, and
CC for inducing immune response in a subject (said immunity to yersinia
CC pestis infection, the causative agent of plague). The present sequence is
CC a cytotoxic Yersinia pestis T-cell epitope of the invention.
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 19; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 2e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 4 AQGV 7

RESULT 30
AAG85717
ID AAG85717 standard; peptide; 10 AA.
XX
AC AAG85717;
XX
DT 11-SEP-2001 (first entry)
XX
DE Saccharomyces cerevisiae peptide, SEQ ID NO: 666.
XX
KW Saccharomyces cerevisiae; complementary peptide; peptide identification;
KW drug discovery; drug design.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200142276-A1.
XX
PD 14-JUN-2001.
XX
PF 13-DEC-2000; 2000WO-GB004773.
XX
PR 13-DEC-1999; 99GB-00029471.
XX
PA (PROT-) PROTEOM LTD.
XX
PI Roberts GW, Heal JR;
XX
DR WPI; 2001-367863/38.
XX
PT Identifying complementary peptides by analysis of protein and nucleotide
PT sequence databases, useful in drug design.
XX
PS Example 3; Page 121; 488pp; English.
XX
CC The invention relates to the identification of complementary peptides by
CC analysis of protein and nucleotide sequence databases from higher
CC eukaryotic genomes, excluding human and plants. The specific
CC complementary peptides interact with their relevant target proteins
CC encoded in the eukaryote genome. The peptides may be used as reagents and

```
CC   drugs for drug discovery and as lead ligands for drug design and
CC   development. The present sequence is a complementary peptide from
CC   Saccharomyces cerevisiae
XX
SQ   Sequence 10 AA;

  Query Match           100.0%;  Score 19;  DB 4;  Length 10;
  Best Local Similarity  100.0%;  Pred. No. 3.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 31
ADF94302
ID   ADF94302 standard; peptide; 10 AA.
XX
AC   ADF94302;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human cell protein fragment #27.
XX
KW   affinity-labelled RNA; drug discovery; HCV infection; biotin labelled;
KW   human.
XX
OS   Homo sapiens.
XX
PN   US2003194712-A1.
XX
PD   16-OCT-2003.
XX
PF   12-APR-2002; 2002US-00122675.
XX
PR   12-APR-2002; 2002US-00122675.
XX
PA   (RIGE-) RIGEL PHARM INC.
XX
PI   Lu H,  Li W,  Anderson D;
XX
DR   WPI; 2004-010212/01.
XX
PT   Screening for polypeptides that bind to an RNA, useful for treating
PT   hepatitis C virus infection, comprises incubating an affinity-labeled RNA
PT   with a cellular extract, isolating the RNA and identifying polypeptides
PT   bound to the RNA.
XX
PS   Example 2; Page 11; 14pp; English.
XX
CC   The invention relates to a method of screening for polypeptides that bind
CC   to an RNA comprising incubating an affinity-labelled RNA with a
CC   cytoplasmic extract, where the RNA is linked to an affinity-labelled
CC   oligonucleotide, isolating the affinity-labelled RNA, and identifying
CC   polypeptides bound to the affinity-labelled RNA. The method is useful in
CC   identifying polypeptide factors interacting with RNA. The polypeptide may
CC   be used for drug discovery and in preventing or treating diseases, e.g.
CC   HCV infection. The present sequence represents the amino acid sequence of
CC   a cell protein fragment extracted by a biotinylated hepatitis C virus
CC   IRES.
XX
SQ   Sequence 10 AA;

  Query Match           100.0%;  Score 19;  DB 8;  Length 10;
  Best Local Similarity  100.0%;  Pred. No. 3.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 32
AAB35370
ID   AAB35370 standard; peptide; 12 AA.
XX
AC   AAB35370;
XX
DT   08-MAY-2001  (first entry)
XX
DE   Alpha3beta1 integrin binding peptide #35.
XX
KW   Alpha3beta1 integrin; angiogenesis; cell proliferation; cancer;
KW   diabetic retinopathy; restenosis; atherosclerosis; rheumatoid arthritis;
KW   macular degeneration; psoriasis; cell adhesion; cell motility.
XX
OS   Synthetic.
XX
PN   WO200105812-A2.
XX
PD   25-JAN-2001.
XX
PF   12-JUL-2000; 2000WO-US018986.
XX
PR   15-JUL-1999;   99US-0144549P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Roberts DD,  Krutzsch HC;
XX
DR   WPI; 2001-182656/18.
XX
PT   New peptides that bind to or are recognized by alpha3-beta1 integrins,
PT   useful for inhibiting cell adhesion to extracellular matrix, cell
PT   motility and proliferation and for treating rheumatoid arthritis and
PT   cancer.
XX
PS   Claim 4; Page 34; 84pp; English.
XX
CC   The present invention provides a number of peptides which bind to
CC   alpha3beta1 integrins. They are useful in the modulation of cell adhesion
CC   and motility, and in the treatment of cancer, diabetic retinopathy,
CC   rheumatoid arthritis, macular degeneration, atherosclerosis, psoriasis
CC   and restenosis. The present sequence is an example of one of the peptides
CC   of the invention
XX
SQ   Sequence 12 AA;

  Query Match           100.0%;  Score 19;  DB 4;  Length 12;
  Best Local Similarity  100.0%;  Pred. No. 4.7e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 33
ABM00107
ID   ABM00107 standard; peptide; 13 AA.
XX
AC   ABM00107;
XX
DT   02-APR-2003  (first entry)
XX
DE   T. lanuginosus lipase antibody binding peptide sequence 24.
XX
KW   Allergen; protein coordinate data; vaccine; antiallergic; immunogenicity;
KW   detergent; personal care composition; cosmetic.
XX
OS   Unidentified.
XX
PN   WO200183559-A2.
XX
PD   08-NOV-2001.
```

XX
PF 30-APR-2001; 2001WO-DK000293.
XX
PR 28-APR-2000; 2000DK-00000707.
PR 10-MAY-2000; 2000US-0203345P.
PR 28-FEB-2001; 2001DK-00000327.
PR 21-MAR-2001; 2001US-0277817P.
XX
PA (NOVO) NOVOZYMES AS.
XX
PI Roggen EL, Ernst S, Svendsen A, Friis EP, Von Der Osten C;
XX
DR WPI; 2001-626552/72.
XX
PT Selecting protein variants having modified immunogenicity, used to
PT produce vaccines, detergents and personal care compositions, involves
PT localizing epitope sequences on the three-dimensional structure of a
PT protein.
XX
PS Example 1; Page 146; 513pp; English.
XX
CC The invention relates to selecting a protein variant having modified
CC immunogenicity, compared to a parent protein, comprising using the
CC antibody binding sequence to localise epitope sequences on the three
CC dimensional structure of the parent protein and defining an epitope area
CC including amino acids within 5 Angstrom of the epitope amino acids. The
CC method is useful for identifying structural epitopes on the 3-dimensional
CC surface of commercial and environmental allergens. Compositions
CC containing the protein variants are used as vaccines, detergents and
CC personal care compositions, e.g. shampoo, balsam, hair conditioners, hair
CC waving compositions, hair dyeing compositions, hair tonic, hair liquid,
CC hair cream, hair rinse, hair spray, chewing gum, skin cream, sunscreen,
CC shaving foam, cream soap, skin milk or foundation. The present sequence
CC is that of an antibody binding peptide sequence related to the invention
XX
SQ Sequence 13 AA;

Query Match 100.0%; Score 19; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 34
AAR49859
ID AAR49859 standard; peptide; 14 AA.
XX
AC AAR49859;
XX
DT 25-MAR-2003 (revised)
DT 12-SEP-1994 (first entry)
XX
DE Sequence of tryptic digest peptide of bovine glial growth factor III (GGF
DE III).
XX
KW Glial growth factor; GGF III; mitogen; Schwann cell.
XX
OS Bos taurus.
XX
PN WO9404560-A1.
XX
PD 03-MAR-1994.
XX
PF 13-AUG-1993; 93WO-GB001721.
XX
PR 14-AUG-1992; 92GB-00017316.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
XX
PI Goodearl ADJ, Stroobant P, Waterfield MD;
XX
DR WPI; 1994-083104/10.
XX
PT New polypeptide factor and peptide(s) from bovine pituitary - having
PT mitogenic activity in stimulating division of Schwann cells, used for
PT therapy, prophylaxis, diagnosis of neuro-degenerative disease, glial cell
PT tumours, etc.
XX
PS Claim 32; Page 31; 44pp; English.
XX
CC A novel polypeptide was purified from bovine pituitaries. It has
CC mitogenic activity stimulating the division of Schwann cells, and
CC exhibits a mol. wt. of 43-35kD when carrying native glycosylation. It was
CC digested with trypsin and lysylendopeptidase to obtain novel peptides
CC AAR49858-R49866 and AAR49867-R49871 respectively. When peptides AAR49862-
CC R49866 were sequenced to completion it was found that none of these
CC sequences is apparently related to GGF-I or GGF-II peptide sequences. A
CC polypeptide contg. any of the sequences in AAR49858- AAR49871 is claimed,
CC as is DNA encoding each of the peptides. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 14 AA;

Query Match 100.0%; Score 19; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 4 AQGV 7

RESULT 35
AAM98513
ID AAM98513 standard; peptide; 14 AA.
XX
AC AAM98513;
XX
DT 24-JAN-2002 (first entry)
XX
DE Human peptide #1788 encoded by a SNP oligonucleotide.
XX
KW Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;
KW neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;
KW amyloid protein; angiopoietin; apoptosis related protein; cadherin;
KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KW complement related protein; cytochrome; kinesin; cytokine; interferon;
KW interleukin; G-protein coupled receptor; thioesterase; inflammation;
KW multifactorial disease; autoimmune disease; infection;
KW nervous system disease.
XX
OS Homo sapiens.
XX
PN WO200147944-A2.
XX
PD 05-JUL-2001.
XX
PF 28-DEC-2000; 2000WO-US035498.
XX
PR 28-DEC-1999; 99US-0173419P.
PR 27-DEC-2000; 2000US-00173419.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach M;
XX
DR WPI; 2001-465210/50.
XX
PT Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,
PT oncogenes and histones, useful for diagnosing and treating, e.g. cancer,
PT autoimmune diseases and infections.
XX
PS Disclosure; Page 4060; 4143pp; English.

```
XX
CC   The present invention relates to oligonucleotides (see AAL26793-AAL34659)
CC   encoding polymorphic variants of proteins related to amylases, amyloid
CC   proteins, angiopoietin, apoptosis related proteins, cadherin, cyclin,
CC   polymerase, oncogenes, histones, kinases, colony stimulating factors,
CC   complement related proteins, cytochromes, kinesins, cytokines,
CC   interferons, interleukins, G-protein coupled receptors and thioesterases.
CC   The present sequence is a peptide encoded by one such oligonucleotide.
CC   The oligonucleotides and the peptides encoded by them may be used in the
CC   prevention, diagnosis and treatment of diseases associated with
CC   inappropriate expression of the proteins listed above. Disorders that may
CC   be prevented, diagnosed and/or treated include multifactorial diseases
CC   with a genetic component, such as autoimmune diseases (e.g. rheumatoid
CC   arthritis, multiple sclerosis, diabetes, systemic lupus erythromatosus
CC   and Grave's disease), inflammation, cancer (e.g. cancers of the bladder,
CC   brain, breast, colon and kidney, leukaemia), diseases of the nervous
CC   system and an infection of pathogenic organisms
XX
SQ   Sequence 14 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 5.5e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 36
AAW50068
ID   AAW50068 standard; peptide; 15 AA.
XX
AC   AAW50068;
XX
DT   26-JUN-1998  (first entry)
XX
DE   Human chorionic gonadotrophin beta-chain scrambled fragment.
XX
KW   Beta-chain; human; chorionic gonadotrophin; beta-hCG; inhibition;
KW   human immunodeficiency virus; HIV; infection; replication;
KW   Kaposi's sarcoma; haematopoiesis.
XX
OS   Synthetic.
XX
PN   WO9749373-A2.
XX
PD   31-DEC-1997.
XX
PF   24-JUN-1997;   97WO-US011202.
XX
PR   24-JUN-1996;   96US-00669681.
PR   09-SEP-1996;   96US-00709948.
XX
PA   (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI   Gallo RC,  Bryant J,  Lunardi-Iskandar Y;
XX
DR   WPI; 1998-076887/07.
XX
PT   Human chorionic gonadotropin peptide derivatives - are active in
PT   inhibiting, e.g. HIV infection or replication, Kaposi's Sarcoma or have
PT   pro-haematopoietic activity.
XX
PS   Example; Page 112; 174pp; English.
XX
CC   The present sequence is a peptide derivative of the beta-chain of human
CC   chorionic gonadotrophin (beta-hCG). The peptide is active in inhibiting,
CC   e.g. HIV infection or replication or Kaposi's sarcoma, or has pro-
CC   haematopoietic activity
XX
SQ   Sequence 15 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 37
AAW47508
ID   AAW47508 standard; protein; 15 AA.
XX
AC   AAW47508;
XX
DT   23-SEP-1998  (first entry)
XX
DE   Human beta-hCG scrambled protein fragment #2.
XX
KW   Beta-human chorionic gonadotropin; beta-hCG; hematopoiesic cell; HIV;
KW   treatment; proliferation; human immunodeficiency virus; disulphide;
KW   idiopathic thrombocytopaenia purpura; anaemia; neutropaenia; tumour;
KW   chemotherapy; radiation; autoimmune disease; genetic disorder.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO9749418-A1.
XX
PD   31-DEC-1997.
XX
PF   24-JUN-1997;   97WO-US011209.
XX
PR   24-JUN-1996;   96US-00669654.
PR   09-SEP-1996;   96US-00709924.
XX
PA   (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI   Gallo RC,  Bryant J,  Lunardi-Iskandar Y;
XX
DR   WPI; 1998-076906/07.
XX
PT   Treating or preventing disease by increasing production of haematopoietic
PT   cells - using human chorionic gonadotropin or its fragments or
PT   derivatives, in vivo or in vitro, e.g. in cases of HIV infection, anaemia
PT   etc.
XX
PS   Disclosure; Page 101; 162pp; English.
XX
CC   AAW47474-W47508 represent fragments of the beta subunit of human
CC   chorionic gonadotropin which is used in a method for the treatment or
CC   prevention of disease, by increasing production of at least one type of
CC   haematopoietic cell. A method is also described in which non-terminally
CC   differentiated haematopoietic cells are treated in vitro to increase
CC   proliferation then returned to the patient. The method is specified for
CC   treating human immunodeficiency virus (HIV) infection, idiopathic
CC   thrombocytopaenia purpura, anaemia or neutropaenia, or subjects who have
CC   undergone chemotherapy or radiation treatment. More generally it can be
CC   used to treat a wide range of conditions involving haematopoietic
CC   failure, (non-) haematopoietic tumours, autoimmune disease and genetic
CC   disorders (using a transformed haematopoietic cell). The in vitro method
CC   can also be used to expand haematopoietic cells for subsequent
CC   therapeutic use
XX
SQ   Sequence 15 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6
```

RESULT 38
AAW50103
ID AAW50103 standard; peptide; 15 AA.
XX
AC AAW50103;
XX
DT 26-JUN-1998 (first entry)
XX
DE Human chorionic gonadotrophin beta-chain scrambled fragment.
XX
KW Beta-chain; human; chorionic gonadotrophin; beta-hCG; treatment;
KW prevention; wasting syndrome; viral infection; cancer;
KW chronic cardiovascular disease; chemotherapy; radiation therapy.
XX
OS Homo sapiens.
XX
PN WO9749721-A1.
XX
PD 31-DEC-1997.
XX
PF 24-JUN-1997; 97WO-US011448.
XX
PR 24-JUN-1996; 96US-00669675.
PR 09-SEP-1996; 96US-00709933.
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI; 1998-077106/07.
XX
PT Treating or preventing wasting syndrome - by administration of human
PT chorionic gonadotropin, beta-hCG, peptides or derivatives of these.
XX
PS Example; Page 80; 126pp; English.
XX
CC The present sequence is a peptide derivative of the beta-chain of human
CC chorionic gonadotrophin (beta-hCG). The peptide can be used to treat or
CC prevent a wasting syndrome associated with viral infection, e.g. human
CC immunodeficiency syndrome virus infection, cancer, chronic cardiovascular
CC disease, chemotherapy or radiation therapy
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 39
ABB04474
ID ABB04474 standard; peptide; 15 AA.
XX
AC ABB04474;
XX
DT 15-MAR-2002 (first entry)
XX
DE Human endoprotease 6 N-terminal peptide.
XX
KW Human; endoprotease 6; cancer; haemopathy; HIV infection; gene therapy.
XX
OS Homo sapiens.
XX
PN CN1315558-A.
XX
PD 03-OCT-2001.
XX
PF 24-MAR-2000; 2000CN-00115125.
XX
PR 24-MAR-2000; 2000CN-00115125.
XX
PA (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI Mao Y, Xie Y;
XX
DR WPI; 2002-056348/08.
XX
PT New human endoprotease 6 and encoding polynucleotide, useful for treating
PT cancer, hemopathy and human immunodeficiency virus.
XX
PS Example 5; Page 18(Disclosure); 32pp; Chinese.
XX
CC The present invention provides the protein and coding sequences of human
CC endoprotease 6. The sequences can be used in the treatment of cancer,
CC haemopathy and HIV infection. The present sequence is the N-terminus of
CC the protein of the invention
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 5; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 40
ADH52629
ID ADH52629 standard; peptide; 15 AA.
XX
AC ADH52629;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human chorionic gonadotrophin beta-chain (beta-hCG) scrambled A2 peptide.
XX
KW beta-chain; human chorionic gonadotrophin; beta-hCG; cytostatic;
KW anti-HIV; HIV-viral load; HIV infection; cancer; scrambled A2.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US6583109-B1.
XX
PD 24-JUN-2003.
XX
PF 24-DEC-1998; 98US-00220415.
XX
PR 24-JUN-1997; 97WO-US011202.
PR 24-JUN-1997; 97WO-US011209.
PR 24-JUN-1997; 97WO-US011210.
PR 24-JUN-1997; 97WO-US011448.
XX
PA (GALL/) GALLO R C.
PA (BRYA/) BRYANT J.
PA (LUNA/) LUNARDI-ISKANDAR Y.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI; 2004-118040/12.
XX
PT New isolated beta hCG protein or peptide, useful for preventing
PT progression of HIV injection.
XX
PS Example; SEQ ID NO 37; 118pp; English.
XX
CC The invention relates to a novel isolated protein or peptide comprising a
CC fragment of the beta-chain of human chorionic gonadotrophin (beta-hCG)

CC having at least one conservative substitution relative to the beta-hCG
CC sequence and exhibiting a therapeutic effect such as reducing HIV viral
CC load. The peptide of the invention demonstrates cytostatic and anti-HIV
CC activities and may be useful for reducing HIV-viral load, preventing the
CC progression of HIV infection, reducing cancer cells and preventing the
CC progression of cancer. The current sequence is that of the human beta-hCG
CC peptide of the invention.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 41
ADH52592
ID ADH52592 standard; peptide; 15 AA.
XX
AC ADH52592;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human chorionic gonadotrophin beta-chain (beta-hCG) scrambled A2 peptide.
XX
KW haemopoiesis; haemopoietic cell; beta chain;
KW human chorionic gonadotropin; beta-hCG; antianaemic; cytostatic;
KW haemostatic; anti-HIV; immunosuppressive; anabolic; anaemia; blood;
KW neoplastic; chemotherapy; radiation; bone marrow transplant; tumour;
KW HIV infection; autoimmune disorder; wasting syndrome; human;
KW scrambled A2.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US6596688-B1.
XX
PD 22-JUL-2003.
XX
PF 29-SEP-2000; 2000US-00675776.
XX
PR 24-JUN-1997; 97WO-US011202.
PR 24-JUN-1997; 97WO-US011209.
PR 24-JUN-1997; 97WO-US011210.
PR 24-JUN-1997; 97WO-US011448.
PR 24-DEC-1998; 98US-00220415.
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI; 2004-068173/07.
XX
PT Promoting hematopoiesis comprises contacting hematopoietic cells with an
PT amount of the beta chain of human chorionic gonadotropin.
XX
PS Example; SEQ ID NO 37; 118pp; English.
XX
CC The invention relates to a novel method for promoting haemopoiesis
CC comprising contacting haemopoietic cells with an amount of an isolated
CC beta chain of human chorionic gonadotropin (beta-hCG) protein or peptide.
CC The method of the invention has antianaemic, cytostatic, haemostatic,
CC anti-HIV, immunosuppressive and anabolic applications and may be useful
CC for treating, preventing or delaying the onset of a disease or disorder
CC associated with one or more haemopoietic cell deficiencies such as
CC anaemia, a disease resulting from a failure or dysfunction of normal
CC blood cell production and/or maturation or a neoplastic disease of a
CC haemopoietic organ. The protein or peptide may be used to promote
CC haemopoiesis following chemotherapy, exposure to radiation, bone marrow
CC transplant or a treatment comprising infusion of genetically modified
CC haemopoietic stem cells, as well as to effect a bone marrow rescue
CC procedure following otherwise lethal chemotherapy or irradiation of a
CC malignant tumour. Furthermore, the protein may be used to prevent or
CC treat HIV infection, autoimmune disorders or wasting syndrome. The
CC current sequence is that of the human chorionic gonadotrophin beta-chain
CC (beta-hCG) scrambled A2 peptide of the invention.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 42
ADK39780
ID ADK39780 standard; peptide; 15 AA.
XX
AC ADK39780;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human chorionic gonadotropin beta chain-derived peptide #35.
XX
KW human; Cytostatic; Anti-HIV; Virucide; Immunosuppressive; Gene-Therapy;
KW cancer; beta-human chorionic gonadotropin; hCG; hyperplasia; metaplasia;
KW dysplasia; hyperproliferative malignant stem cell disorder; leukaemia;
KW sarcoma; carcinoma; human immunodeficiency virus; HIV;
KW autoimmune disorder; wasting syndrome.
XX
OS Homo sapiens.
XX
PN US6699834-B1.
XX
PD 02-MAR-2004.
XX
PF 29-SEP-2000; 2000US-00675362.
XX
PR 24-JUN-1997; 97WO-US011202.
PR 24-JUN-1997; 97WO-US011209.
PR 24-JUN-1997; 97WO-US011210.
PR 24-JUN-1997; 97WO-US011448.
PR 24-DEC-1998; 98US-00220415.
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI; 2004-200901/19.
XX
PT Treating and inhibiting the growth of cancer, HIV infections and wasting
PT syndrome in a subject by administering a protein or peptide having at
PT least one segment of the beta-human chorionic gonadotropin.
XX
PS Disclosure; SEQ ID NO 37; 118pp; English.
XX
CC The invention relates to a method of treating and inhibiting the growth
CC of cancer in a subject, comprising administering a protein or peptide
CC comprising at least one segment consisting of 5-50 amino acid segment of
CC the sequence of beta-human chorionic gonadotropin (hCG), where the
CC protein or peptide exhibits an anti-cancer effect. The protein or peptide
CC is administered in conjunction with another cancer therapy, and is
CC administered to treat a pre-malignant condition, wherein the pre-
CC malignant condition comprises non-neoplastic cell growth selected from
CC the group consisting of hyperplasia, metaplasia and dysplasia. The
CC methods and compositions of the present invention are useful for treating
CC and/or preventing cancer, wherein the cancer is a gestational
CC trophoblastic tumour, a testicular germ cell tumour, a bladder cancer, a

CC pancreatic cancer, a cervical cancer, lung cancer, liver cancer, ovarian
CC cancer, colon or stomach cancer, a virally induced cancer, neuroblastoma,
CC breast cancer, prostate cancer or renal cancer, or is a
CC hyperproliferative malignant stem cell disorder, or is a leukaemia
CC selected from the group consisting of acute lymphocytic leukaemia, acute
CC myelocytic leukaemia, myeloblastic, promyelocytic, myelomonocytic,
CC monocytic, erythroleukaemia, chronic myelocytic (granulocytic) leukaemia,
CC and chronic lymphocytic leukaemia, or is selected from the group
CC consisting of sarcomas and carcinomas, fibrosarcoma, myxosarcoma,
CC liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,
CC endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,
CC synovioma, mesothelioma, Ewing's tumour, leiomyosarcoma,
CC rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,
CC ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell
CC carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland
CC carcinoma, papillary carcinoma, papillary adenocarcinomas,
CC cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal
CC cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma,
CC embryonal carcinoma, Wilms' tumour, cervical cancer, uterine cancer,
CC testicular tumour, lung carcinoma, small cell lung carcinoma, bladder
CC carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
CC craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic
CC neuroma, oligodendroglioma, meningioma, melanoma and retinoblastoma,
CC and/or Kaposi's sarcoma. They can also be used in preventing and/or
CC treating human immunodeficiency virus (HIV) infection, autoimmune
CC disorders and wasting syndrome. The present sequence represents the amino
CC acid sequence of a peptide derived from beta-human chorionic gonadotropin
CC (hCG), used in the method of the invention.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 43
ADT90972
ID ADT90972 standard; peptide; 15 AA.
XX
AC ADT90972;
XX
DT 30-DEC-2004 (first entry)
XX
DE Human beta-hCG (human chorionic gonadotropin) scrambled peptide #2.
XX
KW Human chorionic gonadotropin; hCG; AIDS;
KW acquired immune deficiency syndrome; ARC; AIDS-related complex;
KW haematopoiesis; normal blood cell production disfunction;
KW aplastic anaemia; pancytopaenia; thrombocytopaenia;
KW Blackfan-Diamond syndrome; haematopoietic disorder;
KW acute lymphocytic leukaemia; chronic lymphocytic leukaemia;
KW Waldenstrom's macroglobulinaemia; Hodgkin's lymphoma;
KW non-Hodgkin's lymphoma; immunosuppression; malignant tumour;
KW solid tumour; cancer; retinoblastoma; glioblastoma; rhabdomyosarcoma;
KW Ewing's sarcoma; Kaposi's sarcoma; KS; autoimmune disorder;
KW rheumatoid arthritis; chronic hepatitis; multiple sclerosis;
KW systemic lupus erythematosus; SLE; genetic disorder; Fanconi's syndrome;
KW Bloom's syndrome; Chwachmann-Diamond syndrome; Lesch-Nyhan syndrome;
KW severe combined immunodeficiency disease; SCID; Gaucher's disease;
KW Kostmann's syndrome; osteoporosis; myelosclerosis;
KW Chediak-Higachi syndrome; mucopolysaccharidoses; mucolipidoses;
KW infectious disease; bacterial infection; brucellosis; listeriosis;
KW leprosy; tuberculosis; parasitic infection; malaria; leishmaniasis;
KW fungal infection; gene therapy; anti-HIV; antimicrobial; cytostatic;
KW antianaemic; human; mutant; mutein.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US6805882-B1.
XX
PD 19-OCT-2004.
XX
PF 02-OCT-2000; 2000US-00677152.
XX
PR 24-JUN-1997; 97WO-US011202.
PR 24-JUN-1997; 97WO-US011209.
PR 24-JUN-1997; 97WO-US011210.
PR 24-JUN-1997; 97WO-US011448.
PR 24-DEC-1998; 98US-00220415.
XX
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI Gallo RC, Bryant J, Lunardi-Iskandar Y;
XX
DR WPI; 2004-735330/72.
XX
PT Therapeutic composition, useful to treat e.g. HIV infection and cancer,
PT comprises at least one fraction separated from a urine sample comprising
PT at least one fraction of naturally occurring human chorionic
PT gonadotropin.
XX
PS Example; SEQ ID NO 37; 117pp; English.
XX
CC The present invention relates to fractions of sources and/or preparations
CC of human chorionic gonadotropin (hCG) such as fractions of human early
CC pregnancy urine, which fractions have anti-HIV (human immunodeficiency
CC virus) activity. The invention is useful to treat and prevent the
CC progression of HIV infection to AIDS (acquired immune deficiency
CC syndrome) and ARC (AIDS-related complex). The invention is also useful
CC for treating diseases by promoting haematopoiesis. The diseases or
CC disorders treated by increasing the production of haematopoietic cells
CC includes diseases resulting from a failure or disfunction of normal blood
CC cell production and maturation such as aplastic anaemia, pancytopaenia,
CC thrombocytopaenia, Blackfan-Diamond syndrome etc., haematopoietic
CC disorders such as acute and chronic lymphocytic (lymphoblastic)
CC leukaemia, Waldenstrom's macroglobulinaemia, Hodgkin's lymphoma, non-
CC Hodgkin's lymphoma etc., immunosuppression in patients with malignant and
CC solid tumours such as cancer, retinoblastoma, glioblastoma,
CC rhabdomyosarcoma, Ewing's sarcoma, Kaposi's sarcoma (KS) etc., autoimmune
CC disorders such as rheumatoid arthritis, chronic hepatitis, multiple
CC sclerosis, systemic lupus erythematosus (SLE), etc., genetic (congenital)
CC disorders such as Fanconi's syndrome, Bloom's syndrome, Chwachmann-
CC Diamond syndrome, Lesch-Nyhan syndrome, severe combined immunodeficiency
CC disease (SCID), Gaucher's disease, Kostmann's syndrome etc., diseases
CC such as osteoporosis, myelosclerosis, Chediak-Higachi syndrome,
CC mucopolysaccharidoses, mucolipidoses etc. and other infectious diseases
CC including bacterial infections such as brucellosis, listeriosis, leprosy,
CC tuberculosis etc., parasitic infections such as malaria, leishmaniasis
CC etc. and fungal infections. The invention is also useful in gene therapy.
CC The present sequence is human beta-hCG (human chorionic gonadotropin)
CC scrambled peptide. This beta-hCG peptide is also termed as scrambled A2.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 19; DB 8; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 44
AAR51746
ID AAR51746 standard; protein; 16 AA.
XX
AC AAR51746;
XX
DT 01-FEB-1995 (first entry)

XX
DE Der p I derived peptide, DP I-16(170-191).
XX
KW Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
KW homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
KW epitopes; fusion peptides; antigenic fragments; substitution; deletion;
KW addition; chemical synthesis; chemical cleavage; recombinant techniques;
KW allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
KW IgE-mediated responses; anergise; lymphokine secretion profile; modify;
KW T cell subpopulations; unresponsive; immune response; tolerise.
XX
OS Dermatophagoides pteronyssinus.
XX
PN ZA9302677-A.
XX
PD 26-JAN-1994.
XX
PF 16-APR-1993; 93ZA-00002677.
XX
PR 16-APR-1993; 93ZA-00002677.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL;
XX
DR WPI; 1994-126807/15.
XX
PT Isolated and/or modified peptides comprising T-cell epitopes - of major
PT protein allergens of genus Dermatophagoides, used to treat or diagnose
PT sensitivity to house dust mites.
XX
PS Disclosure; Fig 3; 154pp; English.
XX
CC The sequences given in AAR51731-841 represent T-cell epitopes derived
CC from the group I and II protein allergens from the house dust mite D.
CC farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
CC respectively.The Der f II proteinsCC shows high homology having an
CC identity of 88%, with an identity of 81% between the two group I proteins
CC (see also AAR51727-30). Fusion peptides may be produced which comprise at
CC least two or these antigenic fragments. Each region of these fusion
CC petides may be derived from the same, or different, mite allergens. The
CC antigenic fragments may be altered by substitution, deletion or addition
CC to enhance their antigenicity. These peptides may be produced by chemical
CC synthesis, chemical cleavage of the protien allergen or by recombinant
CC techniques. These peptides, or the fusion peptides, when administered to
CC a house dust mite sensitive individual, are capable of modifying the
CC allergic response of the individual to the allergen. The peptides do not
CC bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
CC full length protein allergen. This reduces the major complications of
CC standard immunotherapy, which are IgE-mediated responses such as
CC anaphylaxis. Exposure of mite allergic patients to these peptides may
CC tolerise or anergise appropriate T cell subpopulations such that they
CC become unresponsive to mite allergens and do not participate in mounting
CC an immune response upon exposure. Administration of the peptides may also
CC modify the lymphokine secretion profile as compared with exposure to the
CC naturally occuring mite protein allergen
XX
SQ Sequence 16 AA;

Query Match 100.0%; Score 19; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 11 AQGV 14

RESULT 45
ADU87133
ID ADU87133 standard; peptide; 16 AA.
XX
AC ADU87133;
XX
DT 10-FEB-2005 (first entry)
XX
DE Peptide display system related CDR 3 #165.
XX
KW antiinflammatory; antibacterial; virucide; cytostatic; antipsoriatic;
KW antidiabetic; vasotropic; vaccine; protein purification; protein folding;
KW diagnosis; inflammation; immune disorder; allergic hypersensitivity;
KW infection; autoimmune disease; asthma; psoriasis;
KW insulin dependent diabetes; multiple sclerosis; rheumatoid arthritis;
KW systemic lupus erythematosus; myasthenia gravis; hematological disease;
KW neoplasm; complentarity determining region 3; CDR3.
XX
OS Homo sapiens.
XX
PN WO2004101790-A1.
XX
PD 25-NOV-2004.
XX
PF 14-MAY-2004; 2004WO-GB002102.
XX
PR 14-MAY-2003; 2003US-0470340P.
PR 17-MAR-2004; 2004US-0554021P.
XX
PA (DOMA-) DOMANTIS LTD.
XX
PI Jespers LS, Jones PC, Famm KHJ, Winter GP;
XX
DR WPI; 2004-821888/81.
XX
PT Recovering a polypeptide that unfolds reversibly from a repertoire of
PT polypeptides for treating e.g., cancer, by unfolding a portion of the
PT displayed polypeptides and refolding a portion of the unfolded
PT polypeptides.
XX
PS Disclosure; Fig 4; 222pp; English.
XX
CC The invention describes a method of recovering a polypeptide that unfolds
CC reversibly from a repertoire of polypeptides that unfolds reversibly and
CC has a common selectable characteristic that distinguishes folded
CC polypeptides from unfolded or misfolded polypeptides. The method
CC comprises: providing a polypeptide display system comprising the
CC repertoire of displayed polypeptides; unfolding at least a portion of the
CC displayed polypeptides; refolding at least a portion of the unfolded
CC polypeptides; and recovering at least one polypeptide that unfolds
CC reversibly and has the selectable characteristic from the refolded
CC portion. The method is useful in recovering a polypeptide that unfolds
CC reversibly from a repertoire of polypeptides that unfolds reversibly. The
CC library or repertoire is useful for selecting a polypeptide comprising an
CC antibody variable domain that unfolds reversibly or a polypeptide that
CC refolds reversibly and comprising an antibody format. The polypeptide is
CC useful in the manufacture of a medicament for diagnosing, treating or
CC preventing a disease or medical condition mediated by a cytokine,
CC cytokine receptor, enzyme, enzyme co-factor or DNA binding protein, such
CC as an inflammatory state, allergic hypersensitivity, cancer, bacterial or
CC viral infection or an autoimmune disorder, e.g., asthma, psoriasis, Type
CC I diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus
CC erythematosus, Crohn's disease, myasthenia gravis, leukemia or solid
CC tumor. This is the amino acid sequence of complementarity determining
CC region (CDR) used in a polypeptide display system for selection of
CC reversibly folding peptides.
XX
SQ Sequence 16 AA;

Query Match 100.0%; Score 19; DB 8; Length 16;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 46
AAU70963
ID AAU70963 standard; peptide; 18 AA.
XX
AC AAU70963;
XX
DT 25-FEB-2002 (first entry)
XX
DE M. tuberculosis Rv0285 protein immunogenic peptide P6.
XX
KW Tuberculosis; Tuberculostatic; antibacterial; vaccine; Rv0284; Rv0285;
KW Rv0455c; Rv0569; Rv1195; Rv1386; Rv3477; Rv3878; Rv3879; MT3106.1;
KW ORF13A; Rv0284ct; Mycobacterium bovis; Mycobacterium africanum;
KW BCG vaccine; immunogenic peptide.
XX
OS Mycobacterium tuberculosis.
XX
PN WO200179274-A2.
XX
PD 25-OCT-2001.
XX
PF 19-APR-2001; 2001WO-DK000276.
XX
PR 19-APR-2000; 2000DK-00000666.
PR 21-FEB-2001; 2001DK-00000283.
XX
PA (STAT-) STATENS SERUM INST.
XX
PI Agger EM, Andersen P, Okkels LMM, Weldingh K;
XX
DR WPI; 2002-061970/08.
XX
PT New Mycobacterium tuberculosis antigens, useful for diagnosing
PT tuberculosis, and as a vaccine for treating or preventing infections
PT caused by species of tuberculosis complex.
XX
PS Example 3; Page 39; 111pp; English.
XX
CC The invention relates to a substantially pure polypeptide comprising an
CC amino acid sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569,
CC Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1 (also disclosed are
CC ORF13A and Rv0284ct), or their immunogenic portion, nucleic acids
CC encoding them and an amino acid sequence analogue having at least 70%
CC sequence identity to the polypeptide and is immunogenic. The protein is
CC useful in preparing a pharmaceutical composition for diagnosing
CC tuberculosis and in preparing a vaccine against tuberculosis caused by
CC virulent mycobacteria. The vaccine or immunogenic/ pharmaceutical
CC composition can be used prophylactically in a subject not infected with a
CC virulent mycobacterium, or therapeutically in a subject already infected
CC with a virulent mycobacterium. The protein is useful for preventing,
CC treating and detecting infections caused by species of tuberculosis
CC complex (M. tuberculosis, M. bovis, M. africanum). The nucleic acids may
CC be used for effecting in vivo expression of the antigen, and in
CC diagnostic assays for detecting the presence of pathogenic organisms in a
CC sample. The vaccine is an improvement of the living BCG vaccine presently
CC available, where one or more copies of the DNA sequence encoding one or
CC more polypeptide has been incorporated into the genome of the
CC microorganism to allow the microorganism to express and secrete the
CC polypeptide. Incorporation of more than one copy of a nucleotide sequence
CC enhances the immune response. The present sequence represents an
CC immunogenic peptide derived from an M. tuberculosis protein of the
CC invention
XX
SQ Sequence 18 AA;

```
  Query Match             100.0%;  Score 19;  DB 5;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9
```

RESULT 47
AAU70974
ID AAU70974 standard; peptide; 18 AA.
XX
AC AAU70974;
XX
DT 25-FEB-2002 (first entry)
XX
DE M. tuberculosis Rv1386 protein immunogenic peptide P7.
XX
KW Tuberculosis; Tuberculostatic; antibacterial; vaccine; Rv0284; Rv0285;
KW Rv0455c; Rv0569; Rv1195; Rv1386; Rv3477; Rv3878; Rv3879; MT3106.1;
KW ORF13A; Rv0284ct; Mycobacterium bovis; Mycobacterium africanum;
KW BCG vaccine; immunogenic peptide.
XX
OS Mycobacterium tuberculosis.
XX
PN WO200179274-A2.
XX
PD 25-OCT-2001.
XX
PF 19-APR-2001; 2001WO-DK000276.
XX
PR 19-APR-2000; 2000DK-00000666.
PR 21-FEB-2001; 2001DK-00000283.
XX
PA (STAT-) STATENS SERUM INST.
XX
PI Agger EM, Andersen P, Okkels LMM, Weldingh K;
XX
DR WPI; 2002-061970/08.
XX
PT New Mycobacterium tuberculosis antigens, useful for diagnosing
PT tuberculosis, and as a vaccine for treating or preventing infections
PT caused by species of tuberculosis complex.
XX
PS Example 3; Page 40; 111pp; English.
XX
CC The invention relates to a substantially pure polypeptide comprising an
CC amino acid sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569,
CC Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1 (also disclosed are
CC ORF13A and Rv0284ct), or their immunogenic portion, nucleic acids
CC encoding them and an amino acid sequence analogue having at least 70%
CC sequence identity to the polypeptide and is immunogenic. The protein is
CC useful in preparing a pharmaceutical composition for diagnosing
CC tuberculosis and in preparing a vaccine against tuberculosis caused by
CC virulent mycobacteria. The vaccine or immunogenic/ pharmaceutical
CC composition can be used prophylactically in a subject not infected with a
CC virulent mycobacterium, or therapeutically in a subject already infected
CC with a virulent mycobacterium. The protein is useful for preventing,
CC treating and detecting infections caused by species of tuberculosis
CC complex (M. tuberculosis, M. bovis, M. africanum). The nucleic acids may
CC be used for effecting in vivo expression of the antigen, and in
CC diagnostic assays for detecting the presence of pathogenic organisms in a
CC sample. The vaccine is an improvement of the living BCG vaccine presently
CC available, where one or more copies of the DNA sequence encoding one or
CC more polypeptide has been incorporated into the genome of the
CC microorganism to allow the microorganism to express and secrete the
CC polypeptide. Incorporation of more than one copy of a nucleotide sequence
CC enhances the immune response. The present sequence represents an
CC immunogenic peptide derived from an M. tuberculosis protein of the
CC invention
XX
SQ Sequence 18 AA;

```
  Query Match             100.0%;  Score 19;  DB 5;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9
```

```
RESULT 48
ADV55657
ID   ADV55657 standard; peptide; 18 AA.
XX
AC   ADV55657;
XX
DT   10-MAR-2005  (first entry)
XX
DE   G protein coupled receptor peptide SEQ ID NO 3155.
XX
KW   diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW   food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
OS   Unidentified.
XX
PN   WO2004111636-A2.
XX
PD   23-DEC-2004.
XX
PF   17-JUN-2004; 2004WO-EP051158.
XX
PR   17-JUN-2003; 2003EP-00101775.
PR   17-JUN-2003; 2003US-0479061P.
XX
PA   (VIBV-) VIB VZW.
PA   (UYGE-) UNIV GENT.
XX
PI   Kas K,  Vandekerckhove J,  Krols L;
XX
DR   WPI; 2005-057893/06.
XX
PT   Identifying a peptide combo which corresponds with a family of proteins,
PT   useful for diagnosing a variety of diseases, drug development or in
PT   agriculture, comprises generating peptides by applying a digest on the
PT   family of protein.
XX
PS   Example; SEQ ID NO 3155; 265pp; English.
XX
CC   The invention relates to a method of identifying a peptide combo which
CC   corresponds with a family of proteins where each of the members of the
CC   peptide combo is derived from a unique protein from the family. The
CC   peptide combo is useful for quantifying specific known splice variants of
CC   one or more particular proteins in a sample, for diagnosing complex
CC   genetic diseases such as cancer, obesity, diabetes, asthma and
CC   inflammation, neuropsychiatric disorders such as depression, for
CC   quantifying one to several hundreds of protein disease markers
CC   simultaneously leading to a more accurate diagnostic sub-classification,
CC   for determining the extent of protein modification in a particular sample
CC   of proteins, for tissue-typing analysis, for prenatal testing to detect
CC   the presence of a congenital disease or for quantitating protein levels
CC   diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC   or neurological diseases, as biomarkers preclinical drug development,
CC   development of improved animal models, biomarkers related with
CC   toxicology, clinical drug development, guidance marketed drugs,
CC   prognostic or diagnostic disease markers, drug target validation and
CC   selection, monitoring protein splicing, drug lead profiling, pathway
CC   analysis, answering basic disease biology questions, and in the fields of
CC   food and feed, cosmetics, agriculture and animal breeding. The present
CC   sequence represents a peptide from a G-protein coupled receptor peptide
CC   combo.
XX
SQ   Sequence 18 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8
```

```
RESULT 49
ADV54661
ID   ADV54661 standard; peptide; 18 AA.
XX
AC   ADV54661;
XX
DT   10-MAR-2005  (first entry)
XX
DE   G protein coupled receptor peptide SEQ ID NO 2158.
XX
KW   diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW   food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
OS   Unidentified.
XX
PN   WO2004111636-A2.
XX
PD   23-DEC-2004.
XX
PF   17-JUN-2004; 2004WO-EP051158.
XX
PR   17-JUN-2003; 2003EP-00101775.
PR   17-JUN-2003; 2003US-0479061P.
XX
PA   (VIBV-) VIB VZW.
PA   (UYGE-) UNIV GENT.
XX
PI   Kas K,  Vandekerckhove J,  Krols L;
XX
DR   WPI; 2005-057893/06.
XX
PT   Identifying a peptide combo which corresponds with a family of proteins,
PT   useful for diagnosing a variety of diseases, drug development or in
PT   agriculture, comprises generating peptides by applying a digest on the
PT   family of protein.
XX
PS   Example; SEQ ID NO 2158; 265pp; English.
XX
CC   The invention relates to a method of identifying a peptide combo which
CC   corresponds with a family of proteins where each of the members of the
CC   peptide combo is derived from a unique protein from the family. The
CC   peptide combo is useful for quantifying specific known splice variants of
CC   one or more particular proteins in a sample, for diagnosing complex
CC   genetic diseases such as cancer, obesity, diabetes, asthma and
CC   inflammation, neuropsychiatric disorders such as depression, for
CC   quantifying one to several hundreds of protein disease markers
CC   simultaneously leading to a more accurate diagnostic sub-classification,
CC   for determining the extent of protein modification in a particular sample
CC   of proteins, for tissue-typing analysis, for prenatal testing to detect
CC   the presence of a congenital disease or for quantitating protein levels
CC   diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC   or neurological diseases, as biomarkers preclinical drug development,
CC   development of improved animal models, biomarkers related with
CC   toxicology, clinical drug development, guidance marketed drugs,
CC   prognostic or diagnostic disease markers, drug target validation and
CC   selection, monitoring protein splicing, drug lead profiling, pathway
CC   analysis, answering basic disease biology questions, and in the fields of
CC   food and feed, cosmetics, agriculture and animal breeding. The present
CC   sequence represents a peptide from a G-protein coupled receptor peptide
CC   combo.
XX
SQ   Sequence 18 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8
```

```
RESULT 50
ADY64079
ID   ADY64079 standard; peptide; 18 AA.
XX
AC   ADY64079;
XX
DT   02-JUN-2005  (first entry)
XX
DE   Human MCSP epitope peptide #239.
XX
KW   melanoma-associated chondroitin sulfate proteoglycan; cytotoxin;
KW   melanoma; cytostatic; neoplasm; cancer; diagnosis; antibody therapy.
XX
OS   Homo sapiens.
XX
PN   US2005063967-A1.
XX
PD   24-MAR-2005.
XX
PF   24-SEP-2004; 2004US-00949846.
XX
PR   21-JAN-2003; 2003US-00348231.
PR   19-DEC-2003; 2003US-00743451.
PR   20-JAN-2004; 2004US-00762129.
PR   26-MAR-2004; 2004US-00810744.
XX
PA   (ARIU-) ARIUS RES INC.
XX
PI   Young DSF,  Hahn SE,  Findlay HP,  Ferry AL;
XX
DR   WPI; 2005-241247/25.
XX
PT   Mediating cytotoxicity of human tumor cell expressing melanoma-associated
PT   chondroitin sulfate proteoglycan (MCSP) on the cell surface comprises
PT   contacting with an isolated MCSP binding monoclonal antibody or its
PT   antigen binding fragment.
XX
PS   Example 4; Page 15; 47pp; English.
XX
CC   The invention relates to a novel method for mediating cytotoxicity of a
CC   human tumor cell using cancerous disease modifying antibodies (CDMAB),
CC   especially cells expressing a melanoma-associated chondroitin sulfate
CC   proteoglycan (MCSP) antigenic moiety on the cell surface. The method
CC   involves contacting the cell with an isolated monoclonal antibody
CC   (deposited with the ATCC as PTA-5643) or its antigen binding fragment
CC   that binds to the expressed MCSP antigenic moiety, where cell
CC   cytotoxicity occurs as a result of the binding. A CDMAB used in a method
CC   of the invention has cytostatic activity. The method is useful for
CC   mediating cytotoxicity of a human tumor cell and especially useful for
CC   treating a patient suffering from a cancerous disease. The sequences
CC   shown in (ADY63841-ADY64097) represent peptide fragments of MCSP, used to
CC   create an overlapping peptide array in order to carry out antibody
CC   epitope mapping experiments.
XX
SQ   Sequence 18 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 51
ADY64078
ID   ADY64078 standard; peptide; 18 AA.
XX
AC   ADY64078;
XX
DT   02-JUN-2005  (first entry)
XX
DE   Human MCSP epitope peptide #238.
XX
KW   melanoma-associated chondroitin sulfate proteoglycan; cytotoxin;
KW   melanoma; cytostatic; neoplasm; cancer; diagnosis; antibody therapy.
XX
OS   Homo sapiens.
XX
PN   US2005063967-A1.
XX
PD   24-MAR-2005.
XX
PF   24-SEP-2004; 2004US-00949846.
XX
PR   21-JAN-2003; 2003US-00348231.
PR   19-DEC-2003; 2003US-00743451.
PR   20-JAN-2004; 2004US-00762129.
PR   26-MAR-2004; 2004US-00810744.
XX
PA   (ARIU-) ARIUS RES INC.
XX
PI   Young DSF,  Hahn SE,  Findlay HP,  Ferry AL;
XX
DR   WPI; 2005-241247/25.
XX
PT   Mediating cytotoxicity of human tumor cell expressing melanoma-associated
PT   chondroitin sulfate proteoglycan (MCSP) on the cell surface comprises
PT   contacting with an isolated MCSP binding monoclonal antibody or its
PT   antigen binding fragment.
XX
PS   Example 4; Page 15; 47pp; English.
XX
CC   The invention relates to a novel method for mediating cytotoxicity of a
CC   human tumor cell using cancerous disease modifying antibodies (CDMAB),
CC   especially cells expressing a melanoma-associated chondroitin sulfate
CC   proteoglycan (MCSP) antigenic moiety on the cell surface. The method
CC   involves contacting the cell with an isolated monoclonal antibody
CC   (deposited with the ATCC as PTA-5643) or its antigen binding fragment
CC   that binds to the expressed MCSP antigenic moiety, where cell
CC   cytotoxicity occurs as a result of the binding. A CDMAB used in a method
CC   of the invention has cytostatic activity. The method is useful for
CC   mediating cytotoxicity of a human tumor cell and especially useful for
CC   treating a patient suffering from a cancerous disease. The sequences
CC   shown in (ADY63841-ADY64097) represent peptide fragments of MCSP, used to
CC   create an overlapping peptide array in order to carry out antibody
CC   epitope mapping experiments.
XX
SQ   Sequence 18 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 7.2e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         15 AQGV 18


RESULT 52
AAW92548
ID   AAW92548 standard; peptide; 19 AA.
XX
AC   AAW92548;
XX
DT   26-APR-1999  (first entry)
XX
DE   Beta-actin array biotinylated peptide substrate #6.
XX
KW   Peptide substrate; CCT; eukaryotic type II chaperonin complex; cyclin;
KW   binding agent; substrate-binding site; SBS; substrate folding; actin;
KW   tubulin; treatment; cancer; anticancer drug; viral infection; screening;
KW   reduced toxicity.
XX
OS   Synthetic.
```

```
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Ser modified by biotin"
XX
PN   WO9853322-A1.
XX
PD   26-NOV-1998.
XX
PF   22-MAY-1998;   98WO-GB001485.
XX
PR   23-MAY-1997;   97GB-00010762.
XX
PA   (CANC-) INST CANCER RES ROYAL CANCER HOSPITAL.
XX
PI   Willison K,  Hynes G,  Liou AK;
XX
DR   WPI; 1999-070162/06.
XX
PT   Identifying specific binding agents for substrate binding site in CCT
PT   chaperonin complex - also new peptide binding agents and their mimetics,
PT   and peptides containing a specific CCT binding site, used for treating
PT   cancer.
XX
PS   Disclosure; Fig 11; 97pp; English.
XX
CC   This invention describes a method which uses the CCT (eukaryotic type II
CC   chaperonin) complex or part of it, for identifying a binding agent that
CC   can occupy a substrate-binding site (SBS) on the CCT complex. By binding
CC   to the CCT complex, the binding agents block an SBS so that biological
CC   activity of the CCT complex is affected, particularly its ability to fold
CC   substrates such as actin, tubulin and cyclin. The binding agents are
CC   useful for treatment of cancer, particularly when used in combination
CC   with an anticancer drug, or viral infections. Nucleic acid fragments are
CC   used to screen for agents, e.g. binding agents that modulate interaction
CC   between the CCT complex and a protein that is to be folded. The binding
CC   agents may target cells that are actively synthesising tubulin etc.
CC   (unlike known microtubule-stabilising agents that affect all cells), so
CC   should have reduced toxicity for normal cells. AAW92543-W92549 are
CC   peptide substrates used in the method of the invention
XX
SQ   Sequence 19 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 7.6e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          9 AQGV 12


RESULT 53
AAW92549
ID   AAW92549 standard; peptide; 19 AA.
XX
AC   AAW92549;
XX
DT   26-APR-1999  (first entry)
XX
DE   Beta-actin array biotinylated peptide substrate #7.
XX
KW   Peptide substrate; CCT; eukaryotic type II chaperonin complex; cyclin;
KW   binding agent; substrate-binding site; SBS; substrate folding; actin;
KW   tubulin; treatment; cancer; anticancer drug; viral infection; screening;
KW   reduced toxicity.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Ser modified by biotin"
XX
PN   WO9853322-A1.
XX
PD   26-NOV-1998.
XX
PF   22-MAY-1998;   98WO-GB001485.
XX
PR   23-MAY-1997;   97GB-00010762.
XX
PA   (CANC-) INST CANCER RES ROYAL CANCER HOSPITAL.
XX
PI   Willison K,  Hynes G,  Liou AK;
XX
DR   WPI; 1999-070162/06.
XX
PT   Identifying specific binding agents for substrate binding site in CCT
PT   chaperonin complex - also new peptide binding agents and their mimetics,
PT   and peptides containing a specific CCT binding site, used for treating
PT   cancer.
XX
PS   Disclosure; Fig 11; 97pp; English.
XX
CC   This invention describes a method which uses the CCT (eukaryotic type II
CC   chaperonin) complex or part of it, for identifying a binding agent that
CC   can occupy a substrate-binding site (SBS) on the CCT complex. By binding
CC   to the CCT complex, the binding agents block an SBS so that biological
CC   activity of the CCT complex is affected, particularly its ability to fold
CC   substrates such as actin, tubulin and cyclin. The binding agents are
CC   useful for treatment of cancer, particularly when used in combination
CC   with an anticancer drug, or viral infections. Nucleic acid fragments are
CC   used to screen for agents, e.g. binding agents that modulate interaction
CC   between the CCT complex and a protein that is to be folded. The binding
CC   agents may target cells that are actively synthesising tubulin etc.
CC   (unlike known microtubule-stabilising agents that affect all cells), so
CC   should have reduced toxicity for normal cells. AAW92543-W92549 are
CC   peptide substrates used in the method of the invention
XX
SQ   Sequence 19 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 7.6e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          9 AQGV 12


RESULT 54
ABP74723
ID   ABP74723 standard; peptide; 19 AA.
XX
AC   ABP74723;
XX
DT   03-FEB-2003  (first entry)
XX
DE   Proteome analysis related peptide #8.
XX
KW   Proteome analysis; isolation; determination; diagnostic assay; detection;
KW   protein marker; identification; metastatic; invasive cancer;
KW   differential expression; signalling pathway; chromatography.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200277016-A2.
XX
PD   03-OCT-2002.
XX
PF   22-MAR-2002; 2002WO-EP003368.
XX
PR   22-MAR-2001; 2001US-0278171P.
PR   12-SEP-2001; 2001US-0318749P.
PR   20-SEP-2001; 2001US-0323999P.
```

XX
PA (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI Vandekerckhove J, Gevaert K;
XX
DR WPI; 2003-067379/06.
XX
PT Method for isolation of peptides from complex mixture of peptides
PT involves specific chemical and/or enzymatic alteration of at least one
PT type of peptide.
XX
PS Example 19; Page 138; 193pp; English.
XX
CC The present invention describes a method (M1) for the isolation of a
CC subset of peptides from a protein peptide mixture (P1). M1 involves: (a)
CC separating the protein peptide mixture into fractions of peptides via
CC chromatography; (b) chemically, or enzymatically, or chemically and
CC enzymatically, altering at least one amino acid of at least one of the
CC peptides in each fraction, thereby generating a subset of altered
CC peptides; and (c) isolating the altered (flagged) peptides out of each
CC fraction via chromatography, where the chromatography of steps (a) and
CC (c) is performed with the same type of chromatography. M1 can be used for
CC the isolation and determination of peptides from protein peptide
CC mixtures. M1 can also be used in diagnostic assays for detection of the
CC presence, the absence or a variation in expression level of at least one
CC protein marker or a specific set of proteins indicative of a disease
CC state. M1 can be used for identifying target proteins present in
CC metastatic and invasive cancers, in differential expression of proteins
CC in transgenic mice, identification of proteins that are upregulated or
CC down regulated in disease tissues, in identification of intracellular
CC changes in cells with physiological changes such as metabolic shift, in
CC the identification of biomarkers in cancers and in the identification of
CC signalling pathways. The method is gel-free methodology for qualitative
CC and quantitative proteome analysis without the need for multidimensional
CC chromatography and without the use of affinity tags. ABP74714 to ABP75190
CC represent peptide sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 19; DB 6; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 55
ADF14799
ID ADF14799 standard; peptide; 19 AA.
XX
AC ADF14799;
XX
DT 12-FEB-2004 (first entry)
XX
DE SLE/sjogren syndrome autoantigen-derived peptide - SEQ ID 294.
XX
KW plant; deamidation; tissue transglutaminase; tTG; celiac disease; CD;
KW gluten intolerance; autoimmune; rheumatoid arthritis; multiple sclerosis;
KW systemic lupus erythematosus; sjogren syndrome; diabetes;
KW immunosuppressive; antirheumatic; antiarthritic; antidiabetic;
KW dermatological; antiinflammatory.
XX
OS Unidentified.
XX
PN EP1332760-A1.
XX
PD 06-AUG-2003.
XX
PF 04-FEB-2002; 2002EP-00075456.
XX
PR 04-FEB-2002; 2002EP-00075456.
XX
PA (ZIEK-) ACAD ZIEKENHUIS LEIDEN.
XX
DR WPI; 2003-647889/62.
XX
PT New gluten peptides or epitopes prone to deamidation by tissue
PT transglutaminase, useful for treating celiac disease or an autoimmune
PT disease, rheumatoid arthritis, multiple sclerosis, systemic lupus
PT erythematosus, or diabetes.
XX
PS Claim 3; SEQ ID NO 294; 143pp; English.
XX
CC The invention relates to a novel peptide or epitope which is prone to
CC deamidation by tissue transglutaminase (tTG) and is a causative factor of
CC celiac disease (CD, gluten intolerance) or an autoimmune disease such as
CC rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus,
CC sjogren syndrome or diabetes. The peptide of the invention demonstrates
CC immunosuppressive, antirheumatic, antiarthritic, antidiabetic,
CC dermatological and antiinflammatory activities whilst pharmaceutical
CC compositions comprising the peptides or epitopes may be useful for the
CC treatment of a celiac disease or an autoimmune disease such as rheumatoid
CC arthritis, multiple sclerosis, systemic lupus erythematosus, sjogren
CC syndrome or diabetes. Gluten-derived peptides may be useful in the
CC preparation of therapeutic agents capable of eliminating a subset of
CC cells, particularly gluten-sensitive or auto-antigen sensitive T cells.
CC The current sequence is that of the systemic lupus erythematosus
CC (SLE)/sjogren syndrome autoantigen-derived peptide of the invention.
XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 19; DB 7; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 9 AQGV 12

RESULT 56
ADV55698
ID ADV55698 standard; peptide; 19 AA.
XX
AC ADV55698;
XX
DT 10-MAR-2005 (first entry)
XX
DE G protein coupled receptor peptide SEQ ID NO 3197.
XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
OS Unidentified.
XX
PN WO2004111636-A2.
XX
PD 23-DEC-2004.
XX
PF 17-JUN-2004; 2004WO-EP051158.
XX
PR 17-JUN-2003; 2003EP-00101775.
PR 17-JUN-2003; 2003US-0479061P.
XX
PA (VIBV-) VIB VZW.
PA (UYGE-) UNIV GENT.
XX
PI Kas K, Vandekerckhove J, Krols L;
XX
DR WPI; 2005-057893/06.
XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in

PT agriculture, comprises generating peptides by applying a digest on the
PT family of protein.
XX
PS Example; SEQ ID NO 3197; 265pp; English.
XX
CC The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 19; DB 9; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 57
ADV54702
ID ADV54702 standard; peptide; 19 AA.
XX
AC ADV54702;
XX
DT 10-MAR-2005 (first entry)
XX
DE G protein coupled receptor peptide SEQ ID NO 2199.
XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
OS Unidentified.
XX
PN WO2004111636-A2.
XX
PD 23-DEC-2004.
XX
PF 17-JUN-2004; 2004WO-EP051158.
XX
PR 17-JUN-2003; 2003EP-00101775.
PR 17-JUN-2003; 2003US-0479061P.
XX
PA (VIBV-) VIB VZW.
PA (UYGE-) UNIV GENT.
XX
PI Kas K, Vandekerckhove J, Krols L;
XX
DR WPI; 2005-057893/06.
XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in
PT agriculture, comprises generating peptides by applying a digest on the
PT family of protein.
XX
PS Example; SEQ ID NO 2199; 265pp; English.
XX
CC The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 19; DB 9; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 58
ADX56536
ID ADX56536 standard; peptide; 19 AA.
XX
AC ADX56536;
XX
DT 05-MAY-2005 (first entry)
XX
DE Cardiovascular disorder plasma protein tryptic fragment SEQ ID NO 353.
XX
KW coronary artery disease; primary biliary cirrhosis,; gallstones;
KW celiac disease; irritable bowel syndrome; diabetes; scleroderma; nausea;
KW emesis; constipation; diarrhea; cardiovascular disease; immune disorder;
KW endocrine disease; gastrointestinal disease; metabolic disorder;
KW dermatological disease; musculoskeletal disease; Cardiant; Vasotropic;
KW Hepatotropic; Litholytic; Immunosuppressive; Gastrointestinal-Gen.;
KW Antiinflammatory; Antidiabetic; Dermatological; Antiemetic; Laxative;
KW Antidiarrheic; diagnosis.
XX
OS Homo sapiens.
XX
PN WO2005015206-A2.
XX
PD 17-FEB-2005.
XX
PF 06-AUG-2004; 2004WO-EP008860.
XX
PR 08-AUG-2003; 2003US-0493599P.
PR 08-AUG-2003; 2003US-0493836P.
PR 08-AUG-2003; 2003US-0493867P.
PR 08-AUG-2003; 2003US-0493985P.
XX
PA (XENO-) XENOVA LTD.
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.

XX
PI Argoud-Puy G, Bederr N, Bougueleret L, Cusin I, Mahe E;
PI Niknejad A, Reffas S, Rose K, Saudrais C, Scherer A, Papoian R;
XX
DR WPI; 2005-195824/20.
XX
PT Screening and/or diagnosing cardiovascular disorder in subject involves
PT detecting and/or quantifying level of polypeptide in biological sample
PT from subject and comparing with control sample.
XX
PS Claim 1; SEQ ID NO 353; 349pp; English.
XX
CC The invention relates to a method of screening and/or diagnosing a
CC cardiovascular disorder (CD) in a subject which comprises detecting
CC and/or quantifying the level of a polypeptide in a biological sample from
CC the subject and comparing the level to that of control sample. The method
CC is useful for screening, diagnosing and treating coronary artery disease,
CC biliary cirrhosis, gallstones, celiac disease, irritable bowel syndrome,
CC diabetes, scleroderma, nausea, vomiting, constipation and diarrhea. The
CC method is rapid and efficient. The present sequence represents a
CC cardiovascular disorder plasma protein tryptic fragment.
XX
SQ Sequence 19 AA;

Query Match 100.0%; Score 19; DB 9; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 59
ADC99563
ID ADC99563 standard; peptide; 20 AA.
XX
AC ADC99563;
XX
DT 01-JAN-2004 (first entry)
XX
DE Cancer-related VEGF-R1/FLT1-binder peptide - SEQ ID 401.
XX
KW cytostatic; cancer; gene therapy; DGI-2; DGI-5; DGI-7; DGI-9; Hras;
KW leptin; VEGF; vascular endothelial growth factor receptor; VEGF-R1;
KW VEGF-R2; VEGF-R3; FLT1; FMS-related tyrosine kinase 1; FLK1; KDR;
KW kinase insert domain protein receptor; EGFR; epidermal growth factor;
KW FGFR1; fibroblast growth factor; Tie-1.
XX
OS Unidentified.
XX
PN WO2003035839-A2.
XX
PD 01-MAY-2003.
XX
PF 24-OCT-2002; 2002WO-US034021.
XX
PR 24-OCT-2001; 2001US-0345471P.
XX
PA (DGIB-) DGI BIOTECHNOLOGIES INC.
XX
PI Pillutla RC, Brissette R, Spruyt M, Dedova O, Blume A;
PI Prendergast J, Goldstein N;
XX
DR WPI; 2003-457332/43.
XX
PT Selecting target and target binder pairs for preparing a composition for
PT treating cancer by mixing in a reaction vessel phage expressing
PT biological targets and phage expressing target binders.
XX
PS Claim 26; SEQ ID NO 401; 172pp; English.
XX
CC The invention relates to a novel method of selecting target and target
CC binder pairs comprising mixing in a reaction vessel phage expressing
CC biological targets and phage expressing target binders, each having
CC distinguishable selection markers and selecting target and target binder
CC pairs based on the selection markers. The molecules of the invention
CC demonstrate cytostatic activity whilst the method may be useful for
CC selecting target and target binder pairs for preparing a composition for
CC treating cancer. Furthermore, the method may be utilised during gene
CC therapy procedures. The current sequence is that of the cancer-related
CC VEGF-R1/FLT1 (vascular endothelial growth factor-receptor 1/FMS-related
CC tyrosine kinase 1)-binder peptide of the invention.
XX
SQ Sequence 20 AA;

Query Match 100.0%; Score 19; DB 7; Length 20;
Best Local Similarity 100.0%; Pred. No. 8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 60
ADK15603
ID ADK15603 standard; peptide; 20 AA.
XX
AC ADK15603;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human G250 tumour antigen derived peptide #13.
XX
KW Human; G250 tumour antigen; immunogenic peptide; CD4+; CD8+;
KW T-cell immune response; renal cell carcinoma; RCC; cancer; kidney;
KW prostate; head; neck; gastrointestinal tract; colon; stomach; bladder;
KW cytostatic; immunostimulant.
XX
OS Homo sapiens.
XX
PN US2004053391-A1.
XX
PD 18-MAR-2004.
XX
PF 11-SEP-2002; 2002US-00241814.
XX
PR 11-SEP-2002; 2002US-00241814.
XX
PA (UYNI-) UNIV NIJMEGEN.
XX
PI Vissers JLM, De Vries IJM, Oosterwijk E, Figdor CG, Adema GJ;
XX
DR WPI; 2004-247730/23.
XX
PT New renal cell carcinoma-antigen G250-derived peptide, useful as vaccine
PT for treating or preventing cancer, e.g. renal cell carcinoma, cancer of
PT the kidney, prostate, head, neck, bladder or gastrointestinal tract, e.g.
PT colon or stomach.
XX
PS Example; SEQ ID NO 13; 17pp; English.
XX
CC The present invention relates to human G250 tumour antigen derived
CC immunogenic peptides capable of eliciting CD4+ and CD8+ T-cell immune
CC responses. The immunogenic peptides can elicit an immune response against
CC cells that express the G250 antigen, such as those found in renal cell
CC carcinoma (RCC). The immunogenic peptides and/or the nucleotide sequences
CC that encode them are useful for the manufacture of a composition for
CC treating or preventing cancer, e.g. renal cell carcinoma or a cancer of
CC the kidney, prostate, head, neck, gastrointestinal tract or any of its
CC part, e.g. colon or stomach or bladder. The peptides are also useful for
CC the preparation of a composition for treating or preventing a tumour that
CC expresses the G250 antigen. The immunogenic peptides are also useful in
CC eliciting an immune response in a human or animal against a tumour. The
CC present sequence represents a human G250 tumour antigen derived peptide.

```
XX
SQ   Sequence 20 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 61
ADT36531
ID   ADT36531 standard; peptide; 20 AA.
XX
AC   ADT36531;
XX
DT   02-DEC-2004  (first entry)
XX
DE   RCC-associated antigen G250-derived peptide (residues 337-356), SEQ:13.
XX
KW   Human; renal cell carcinoma-associated antigen G250;
KW   RCC-associated antigen G250; tumour-associated antigen MN/CA IX; cancer;
KW   kidney; prostate; head; neck; gastrointestinal tract;
KW   renal cell carcinoma; colon; stomach; bladder; CD4+ T cell response;
KW   CD8+ T cell response; cytostatic; vaccine; gene therapy; immunotherapy;
KW   HLA class II binding; MHC class II binding; human leukocyte antigen;
KW   major histocompatibility complex.
XX
OS   Homo sapiens.
XX
PN   AU2002300986-A1.
XX
PD   01-APR-2004.
XX
PF   12-SEP-2002; 2002AU-00300986.
XX
PR   12-SEP-2002; 2002AU-00300986.
XX
PA   (UYNI-) UNIV NIJMEGEN.
XX
PI   Adema GJ,  Figdor CG,  Oosterwijk E,  De Vries IJM,  Vissers JLM;
XX
DR   WPI; 2004-662544/65.
XX
PT   New renal cell carcinoma-antigen G250-derived peptide other than human
PT   G250 protein, useful for preventing or treating cancer such as renal cell
PT   carcinoma or cancer of kidney, prostate, colon, stomach or bladder.
XX
PS   Example; SEQ ID NO 13; 40pp; English.
XX
CC   The invention relates to a peptide derived from human renal cell
CC   carcinoma (RCC)-associated antigen G250 comprising the sequence shown in
CC   ADT36533 or a sequence having at most 3 amino acid replacements with
CC   respect to it. The peptide of the invention is not the human G250 protein
CC   (ADT36534, also known as tumour-associated antigen MN/CA IX), and
CC   preferably comprises the sequence shown in ADT36530 or a sequence with 1-
CC   4 amino acid substitutions compared to ADT36530. The invention also
CC   relates to compositions comprising a peptide of the invention or an
CC   antigen presenting cell loaded with a peptide of the invention; a gene
CC   therapy agent comprising a nucleotide sequence encoding a peptide of the
CC   invention; and the use of the gene therapy agent for treating cancer. The
CC   peptides, compositions and gene therapy agents are useful in the
CC   treatment and prevention of cancers such as those of the kidney,
CC   prostate, bladder, head, neck, gastrointestinal tract (or part thereof).
CC   They are especially useful for treating or preventing renal cell
CC   carcinoma, colon cancer, stomach cancer, bladder cancer or a cancer which
CC   expresses the G250 protein or a sequence at least 95% identical to it.
CC   Because the peptides of the invention are able to elicit CD4+ and CD8+ T-
CC   cell responses against cells expressing the G250 antigen, they can be
CC   used in immunotherapy for the treatment of cancers. The peptides may also
CC   be used as vaccines for the prevention of cancer, and in immunological,
CC   diagnostic and/or analytical applications. Sequences ADT36519-ADT36532
CC   represent RCC-associated antigen G250-derived peptides predicted to bind
CC   to HLA (human leukocyte antigen) class II molecules which were tested for
CC   their ability to induce a CD4+ (helper) T cell response in the example of
CC   the invention. The position given on page 23 for this peptide in the full
CC   -length G250 protein differs by one amino acid to its position in
CC   ADT36534.
XX
SQ   Sequence 20 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4


RESULT 62
AAB57305
ID   AAB57305 standard; peptide; 21 AA.
XX
AC   AAB57305;
XX
DT   09-MAR-2001  (first entry)
XX
DE   Antigenic peptide from acetolactate synthase N-terminal.
XX
KW   Protein expression; genetic engineering; horizontal transfer.
XX
OS   Escherichia coli.
XX
PN   WO200071701-A1.
XX
PD   30-NOV-2000.
XX
PF   23-MAY-2000; 2000WO-US014122.
XX
PR   24-MAY-1999;   99US-0135677P.
XX
PA   (NEWE ) NEW ENGLAND BIOLABS INC.
PA   (BOST-) BOSTON BIOMEDICAL RES INST.
XX
PI   Xu M,  Evans TC,  Pradhan S,  Comb DG,  Paulus H,  Sun L,  Chen L;
PI   Ghosh I;
XX
DR   WPI; 2001-032033/04.
XX
PT   Reconstituting a target protein in a predetermined location in an
PT   organism useful for creating transgenic crops comprises splitting DNA
PT   coding for the target protein into fragments and separating and
PT   expressing the fragments in the organism.
XX
PS   Example 1; Page 54; 177pp; English.
XX
CC   The present invention relates to reconstituting a target protein in a
CC   predetermined location within an organism, involving splitting DNA coding
CC   for the target protein into at least two fragments, separating and
CC   expressing the DNA fragments within the organism and reconstituting the
CC   target protein. This may be used for genetic engineering of crops. This
CC   type of transgene allows efficient protein expression but does not
CC   require a gene coupling approach and has a significantly lower chance of
CC   spread by horizontal gene transfer than current methods
XX
SQ   Sequence 21 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 8.4e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
```

```
Db         11 AQGV 14


RESULT 63
AAR36398
ID   AAR36398 standard; peptide; 22 AA.
XX
AC   AAR36398;
XX
DT   25-MAR-2003  (revised)
DT   12-AUG-1993  (first entry)
XX
DE   DPI-16(170-191) a Dermatophagoides protein allergen.
XX
KW   T cell epitope; house dust mite; allergy; soluble; Der pI.
XX
OS   Synthetic.
XX
PN   WO9308279-A1.
XX
PD   29-APR-1993.
XX
PF   15-OCT-1992;   92WO-US008637.
XX
PR   16-OCT-1991;   91US-00777859.
PR   08-MAY-1992;   92US-00881396.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Kuo MC,  Rogers BL;
XX
DR   WPI; 1993-152472/18.
XX
PT   Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
PT   and treatment of sensitivity to house dust mite.
XX
PS   Claim 10; Fig 3; 176pp; English.
XX
CC   The peptide is one of a series of overlapping peptides synthsised by
CC   standard techniques to cover the whole Dermatophagoides pteronyssinus Der
CC   pI sequence. The T cell epitopes of the protein were mapped by detection
CC   of the peptide's ability to stimulate T cell activity. The peptides may
CC   be used for diagnosis and treatment of sensitivity to house dust mite
CC   allergens. When administered to house dust mite sensitive individuals,
CC   the peptides are capable of modifying the allergic response to the
CC   allergens. The peptides may be modified for e.g. increasing solubility,
CC   enhancing therapeutic or preventive efficacy or stability. See also
CC   AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 22 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 8.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 64
AAR77133
ID   AAR77133 standard; peptide; 22 AA.
XX
AC   AAR77133;
XX
DT   25-MAR-2003  (revised)
DT   31-MAY-1996  (first entry)
XX
DE   Dermatophagoides pteronyssinus group I peptide DPI-16 (170-191).
XX
KW   House dust mite; DerpI; DerfI; DerpII; DerfII; allergen; allergy;
KW   overlapping peptide; screening.
XX
OS   Dermatophagoides pteronyssinus.
XX
PN   WO9528424-A1.
XX
PD   26-OCT-1995.
XX
PF   12-APR-1995;   95WO-US004481.
XX
PR   14-APR-1994;   94US-00227772.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Chen X,  Evans S,  Shaked Z,  Franzen HM,  Kuo M;
XX
DR   WPI; 1995-373765/48.
XX
PT   Compsns. contg. house mite allergen-derived peptide(s), some of which are
PT   new - are used to treat allergy, and are stable, soluble and able to
PT   induce T cell non-responsiveness.
XX
PS   Disclosure; Fig 2; 61pp; English.
XX
CC   Claimed therapeutic compositions contain at least one of the peptides DPI
CC   -21.2 and DFI-22.2 and also at least one of the new peptides DPI-23.31,
CC   DPI-26.6, DPII-20.9, DPII-22.14 and DPII-25.15. The compositions are
CC   useful for treating sensitivity to house dust mite allergens. The
CC   peptides were identified by screening overlapping peptides derived from
CC   D.pteronyssinus and D.farinae group I and II allergens for T-cell
CC   reactivity in sensitised individuals. The present sequence is that of
CC   overlapping peptide DPI-16 (170-191). (Updated on 25-MAR-2003 to correct
CC   PR field.)
XX
SQ   Sequence 22 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 8.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 65
AAW71926
ID   AAW71926 standard; peptide; 22 AA.
XX
AC   AAW71926;
XX
DT   27-AUG-2003  (revised)
DT   25-MAR-2003  (revised)
DT   16-DEC-1998  (first entry)
XX
DE   Dermatophagoides Der p I protein peptide DPI-16.
XX
KW   genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
KW   Der p II; Der f I; Der f II; house dust mite allergy.
XX
OS   Dermatophagoides.
XX
PN   US5820862-A.
XX
PD   13-OCT-1998.
XX
PF   07-JUN-1995;   95US-00482142.
XX
PR   14-APR-1993;   93WO-US003471.
PR   14-APR-1994;   94US-00227772.
PR   19-MAY-1995;   95US-00445307.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
```

```
XX
PI   Franzen HM,  Kuo M,  Evans S,  Garman RD,  Greenstein JL,  Chen X;
PI   Shaked Z,  Rogers BL;
XX
DR   WPI; 1998-567590/48.
XX
PT   Dermatophagoides allergen peptides - useful for treating house dust mite
PT   allergy.
XX
PS   Disclosure; Col 89-91; 155pp; English.
XX
CC   The present invention describes peptides for treating sensitivity to
CC   house dust mite allergens from the genus Dermatophagoides. Peptides
CC   within the scope of the invention comprise at least one T cell epitope,
CC   or preferably at least two T cell epitopes of a protein allergen selected
CC   from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC   also describes modified peptides having similar or enhanced therapeutic
CC   properties as the corresponding, naturally occurring allergen, but having
CC   reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330
CC   represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC   correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 22 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 8.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 66
AAY50375
ID   AAY50375 standard; peptide; 22 AA.
XX
AC   AAY50375;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Dermatophagoides sp major protein allergen DP I-16.
XX
KW   Allergen; house dust mite; detection; sensitivity; T cell epitope;
KW   screening; allergic disorder; asthma; rhinitis; ectopic dermatitis;
KW   Der f I; Der p I; Der p II; Der f II.
XX
OS   Dermatophagoides sp.
XX
PN   US5968526-A.
XX
PD   19-OCT-1999.
XX
PF   07-JUN-1995;   95US-00478572.
XX
PR   14-APR-1994;   94US-00227772.
PR   12-APR-1995;   95WO-US004481.
PR   19-MAY-1995;   95US-00445307.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Rogers BL,  Franzen HM,  Shaked Z;
PI   Chen X,  Evans S,  Kuo M;
XX
DR   WPI; 1999-590385/50.
XX
PT   Screening individuals for allergic reactions to T cell epitopes of major
PT   allergens from house dust mites.
XX
PS   Claim 1o; Col 91-92; 158pp; English.
XX
CC   This invention describes a novel method (I) for detecting whether an
CC   individual is sensitive to Dermatophagoides (house dust mites). The
CC   method involves detecting sensitivity to house dust mites in patients,
CC   comprising combining a blood sample from the individual with 1 or more
CC   isolated T cell epitopes of the protein allergens I and II ((DP I) and
CC   (DP II)) from Dermatophagoides (house dust mites). 32 T cell epitopes
CC   with varying, defined amino acids sequences (given in the specification)
CC   may be used in (I). The sample and allergens are combined under
CC   conditions appropriate for the binding of blood components with the
CC   polypeptides. The extent of binding is then indicative of the sensitivity
CC   of the patient to house dust mites. (I) may be used to screen individuals
CC   for sensitivity to Dermatophagoides (house dust mites). The house dust
CC   mite is a major cause of a variety of allergic disorders such as asthma,
CC   rhinitis and ectopic dermatitis. AAY50360-Y50542 and AAY50546-Y50555
CC   represent house dust mite allergen peptide fragments derived from Der p
CC   I, Der f II, Der f I and Der f II
XX
SQ   Sequence 22 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 8.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 67
AAU18978
ID   AAU18978 standard; peptide; 22 AA.
XX
AC   AAU18978;
XX
DT   04-DEC-2001  (first entry)
XX
DE   T-cell epitope containing peptide DPI-16.
XX
KW   House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KW   Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KW   T-cell epitope.
XX
OS   Dermatophagoides pteronyssinus.
XX
PN   US6268491-B1.
XX
PD   31-JUL-2001.
XX
PF   07-JUN-1995;   95US-00484296.
XX
PR   16-OCT-1991;   91US-00777859.
PR   08-MAY-1992;   92US-00881396.
PR   14-APR-1993;   93WO-US003471.
PR   14-APR-1994;   94US-00227772.
PR   19-MAY-1995;   95US-00445307.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Kuo M,  Rogers BL,  Franzen HM,  Chen X;
PI   Evans S,  Shaked Z;
XX
DR   WPI; 2001-549074/61.
XX
PT   Peptides comprising T cell groups of the major allergens from
PT   Dermatophagoides (house dust mites), useful for treating house dust mite
PT   allergy in humans, and for diagnosing sensitivity to house dust mite
PT   protein allergens.
XX
PS   Example 3; Fig 3; 158pp; English.
XX
CC   The invention relates to an isolated peptide of the major protein
CC   allergens of the genus Dermatophagoides, which comprises at least one T
CC   cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC   or DF II. The isolated peptide comprises at least two regions, each
CC   region comprising at least one T cell group of a protein allergen of the
```

```
CC   genus Dermatophagoides. The regions are derived from the same or
CC   different protein allergens of the genus Dermatophagoides. The peptides
CC   are useful for treating house dust mite allergy in humans. The peptides
CC   are also useful for detecting or diagnosing sensitivity to house dust
CC   mite protein allergens. The present peptides have similar or enhanced
CC   therapeutic properties as the naturally-occurring allergen, but have
CC   reduced side effects, and increased solubility and stability. The present
CC   sequence represents an allergenic T-cell epitope containing peptide
CC   derived from the Dermatophagoides allergenic proteins
XX
SQ   Sequence 22 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 8.9e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 68
AAR36414
ID   AAR36414 standard; peptide; 23 AA.
XX
AC   AAR36414;
XX
DT   25-MAR-2003  (revised)
DT   12-AUG-1993  (first entry)
XX
DE   DPI-28.2(173-195) a Dermatophagoides protein allergen.
XX
KW   T cell epitope; house dust mite; allergy; soluble; Der pI.
XX
OS   Synthetic.
XX
PN   WO9308279-A1.
XX
PD   29-APR-1993.
XX
PF   15-OCT-1992;   92WO-US008637.
XX
PR   16-OCT-1991;   91US-00777859.
PR   08-MAY-1992;   92US-00881396.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Kuo MC,  Rogers BL;
XX
DR   WPI; 1993-152472/18.
XX
PT   Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
PT   and treatment of sensitivity to house dust mite.
XX
PS   Claim 10; Fig 3; 176pp; English.
XX
CC   The peptide is one of a series of overlapping peptides synthsised by
CC   standard techniques to cover the whole Dermatophagoides pteronyssinus Der
CC   pI sequence. The T cell epitopes of the protein were mapped by detection
CC   of the peptide's ability to stimulate T cell activity. The peptides may
CC   be used for diagnosis and treatment of sensitivity to house dust mite
CC   allergens. When administered to house dust mite sensitive individuals,
CC   the peptides are capable of modifying the allergic response to the
CC   allergens. The peptides may be modified for e.g. increasing solubility,
CC   enhancing therapeutic or preventive efficacy or stability. See also
CC   AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 23 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 9.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 69
AAR51762
ID   AAR51762 standard; protein; 23 AA.
XX
AC   AAR51762;
XX
DT   01-FEB-1995  (first entry)
XX
DE   Der p I derived peptide, DP I-28.2(173-195).
XX
KW   Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
KW   homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
KW   epitopes; fusion peptides; antigenic fragments; substitution; deletion;
KW   addition; chemical synthesis; chemical cleavage; recombinant techniques;
KW   allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
KW   IgE-mediated responses; anergise; lymphokine secretion profile; modify;
KW   T cell subpopulations; unresponsive; immune response; tolerise.
XX
OS   Dermatophagoides pteronyssinus.
XX
PN   ZA9302677-A.
XX
PD   26-JAN-1994.
XX
PF   16-APR-1993;   93ZA-00002677.
XX
PR   16-APR-1993;   93ZA-00002677.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Kuo M,  Rogers BL;
XX
DR   WPI; 1994-126807/15.
XX
PT   Isolated and/or modified peptides comprising T-cell epitopes - of major
PT   protein allergens of genus Dermatophagoides, used to treat or diagnose
PT   sensitivity to house dust mites.
XX
PS   Claim 28; Page 67; 154pp; English.
XX
CC   The sequences given in AAR51731-841 represent T-cell epitopes derived
CC   from the group I and II protein allergens from the house dust mite D.
CC   farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
CC   respectively.The Der f II proteinsCC shows high homology having an
CC   identity of 88%, with an identity of 81% between the two group I proteins
CC   (see also AAR51727-30). Fusion peptides may be produced which comprise at
CC   least two or these antigenic fragments. Each region of these fusion
CC   petides may be derived from the same, or different, mite allergens. The
CC   antigenic fragments may be altered by substitution, deletion or addition
CC   to enhance their antigenicity. These peptides may be produced by chemical
CC   synthesis, chemical cleavage of the protien allergen or by recombinant
CC   techniques. These peptides, or the fusion peptides, when administered to
CC   a house dust mite sensitive individual, are capable of modifying the
CC   allergic response of the individual to the allergen. The peptides do not
CC   bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
CC   full length protein allergen. This reduces the major complications of
CC   standard immunotherapy, which are IgE-mediated responses such as
CC   anaphylaxis. Exposure of mite allergic patients to these peptides may
CC   tolerise or anergise appropriate T cell subpopulations such that they
CC   become unresponsive to mite allergens and do not participate in mounting
CC   an immune response upon exposure. Administration of the peptides may also
CC   modify the lymphokine secretion profile as compared with exposure to the
CC   naturally occuring mite protein allergen
XX
SQ   Sequence 23 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 23;
```

```
  Best Local Similarity   100.0%;  Pred. No. 9.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 70
AAW37822
ID   AAW37822 standard; peptide; 23 AA.
XX
AC   AAW37822;
XX
DT   14-AUG-1998  (first entry)
XX
DE   Peptide derived from the heparin binding site of plasma fibrinonectin.
XX
KW   Cell adhesion activity; heparin binding site; human;
KW   plasma fibrinonectin; inhibition; cancer metastasis.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP837074-A2.
XX
PD   22-APR-1998.
XX
PF   18-SEP-1997;   97EP-00116293.
XX
PR   19-SEP-1996;   96JP-00248247.
XX
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Fukai F,  Katayama T;
XX
DR   WPI; 1998-219072/20.
XX
PT   Peptide(s) that inhibit cell adhesion - comprising fragments of heparin-
PT   binding site of fibronectin.
XX
PS   Example 1; Page 9; 21pp; English.
XX
CC   Synthetic peptides AAW37820-24 and AAW56673-80 have cell adhesion
CC   inhibition activity. All the peptides were modified with maleimide-
CC   activated Keyhole Limpet Haemocyanine in order to improve their
CC   solubility. The peptides are derived from a part of the heparin binding
CC   site of human plasma fibrinonectin, the present sequence being derived
CC   from residues 1669 to 1691. Peptide AAW56680 has the strongest cell
CC   adhesion inhibition activity. The peptides are used for inhibiting cancer
CC   metastasis
XX
SQ   Sequence 23 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 9.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         15 AQGV 18


RESULT 71
AAW71937
ID   AAW71937 standard; peptide; 23 AA.
XX
AC   AAW71937;
XX
DT   27-AUG-2003  (revised)
DT   25-MAR-2003  (revised)
DT   16-DEC-1998  (first entry)
XX
DE   Dermatophagoides Der p I protein peptide DPI-28.2.
XX
KW   genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
KW   Der p II; Der f I; Der f II; house dust mite allergy.
XX
OS   Dermatophagoides.
XX
PN   US5820862-A.
XX
PD   13-OCT-1998.
XX
PF   07-JUN-1995;   95US-00482142.
XX
PR   14-APR-1993;   93WO-US003471.
PR   14-APR-1994;   94US-00227772.
PR   19-MAY-1995;   95US-00445307.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Franzen HM,  Kuo M,  Evans S,  Garman RD,  Greenstein JL,  Chen X;
PI   Shaked Z,  Rogers BL;
XX
DR   WPI; 1998-567590/48.
XX
PT   Dermatophagoides allergen peptides - useful for treating house dust mite
PT   allergy.
XX
PS   Disclosure; Col 97-99; 155pp; English.
XX
CC   The present invention describes peptides for treating sensitivity to
CC   house dust mite allergens from the genus Dermatophagoides. Peptides
CC   within the scope of the invention comprise at least one T cell epitope,
CC   or preferably at least two T cell epitopes of a protein allergen selected
CC   from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC   also describes modified peptides having similar or enhanced therapeutic
CC   properties as the corresponding, naturally occurring allergen, but having
CC   reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330
CC   represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC   correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 23 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 9.3e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 72
AAY50391
ID   AAY50391 standard; peptide; 23 AA.
XX
AC   AAY50391;
XX
DT   25-JAN-2000  (first entry)
XX
DE   Dermatophagoides sp major protein allergen DP I-28.2.
XX
KW   Allergen; house dust mite; detection; sensitivity; T cell epitope;
KW   screening; allergic disorder; asthma; rhinitis; ectopic dermatitis;
KW   Der f I; Der p I; Der p II; Der f II.
XX
OS   Dermatophagoides sp.
XX
PN   US5968526-A.
XX
PD   19-OCT-1999.
XX
PF   07-JUN-1995;   95US-00478572.
XX
```

PR 14-APR-1994; 94US-00227772.
PR 12-APR-1995; 95WO-US004481.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
PI Chen X, Evans S, Kuo M;
XX
DR WPI; 1999-590385/50.
XX
PT Screening individuals for allergic reactions to T cell epitopes of major
PT allergens from house dust mites.
XX
PS Claim 1e'; Column 99-100; 158pp; English.
XX
CC This invention describes a novel method (I) for detecting whether an
CC individual is sensitive to Dermatophagoides (house dust mites). The
CC method involves detecting sensitivity to house dust mites in patients,
CC comprising combining a blood sample from the individual with 1 or more
CC isolated T cell epitopes of the protein allergens I and II ((DP I) and
CC (DP II)) from Dermatophagoides (house dust mites). 32 T cell epitopes
CC with varying, defined amino acids sequences (given in the specification)
CC may be used in (I). The sample and allergens are combined under
CC conditions appropriate for the binding of blood components with the
CC polypeptides. The extent of binding is then indicative of the sensitivity
CC of the patient to house dust mites. (I) may be used to screen individuals
CC for sensitivity to Dermatophagoides (house dust mites). The house dust
CC mite is a major cause of a variety of allergic disorders such as asthma,
CC rhinitis and ectopic dermatitis. AAY50360-Y50542 and AAY50546-Y50555
CC represent house dust mite allergen peptide fragments derived from Der p
CC I, Der f II, Der f I and Der f II
XX
SQ Sequence 23 AA;

Query Match 100.0%; Score 19; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 73
AAY36513
ID AAY36513 standard; protein; 23 AA.
XX
AC AAY36513;
XX
DT 17-SEP-1999 (first entry)
XX
DE Fragment of human secreted protein encoded by gene 32.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW foetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS.
XX
OS Homo sapiens.
XX
PN WO9931117-A1.
XX
PD 24-JUN-1999.
XX
PF 17-DEC-1998; 98WO-US027059.
XX
PR 18-DEC-1997; 97US-0068006P.
PR 18-DEC-1997; 97US-0068007P.
PR 18-DEC-1997; 97US-0068008P.
PR 18-DEC-1997; 97US-0068053P.
PR 18-DEC-1997; 97US-0068054P.
PR 18-DEC-1997; 97US-0068057P.
PR 18-DEC-1997; 97US-0068064P.
PR 18-DEC-1997; 97US-0070923P.
PR 19-DEC-1997; 97US-0068169P.
PR 19-DEC-1997; 97US-0068365P.
PR 19-DEC-1997; 97US-0068367P.
PR 19-DEC-1997; 97US-0068368P.
PR 19-DEC-1997; 97US-0068369P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Moore PA, Ruben SM, Carter KC, Shi Y, Rosen CA, Soppet DR;
PI Kyaw H, Wei Y, Florence K, Duan RD, Florence C, Greene JM, Feng P;
PI Ferrie AM, Yu G, Janat F, Ni J;
XX
DR WPI; 1999-418749/35.
XX
PT New isolated human genes encoding secreted polypeptides.
XX
PS Disclosure; Page 470; 537pp; English.
XX
CC AAX97916 to AAX98029 represent 110 isolated human secreted protein genes.
CC AAY36224 to AAY36727 represent the secreted proteins encoded by the 110
CC human genes. The genes and their corresponding secreted polypeptides are
CC useful for preventing, treating or ameliorating medical conditions, e.g.
CC by protein or gene therapy. Also pathological conditions can be diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new genes. Specific uses are
CC described for each of the 110 genes, based on which tissues they are most
CC highly expressed in, and include developing products for the diagnosis or
CC treatment of cancer, tumours, developmental abnormalities and foetal
CC deficiencies, blood disorders, diseases of the immune system, autoimmune
CC diseases, inflammation, allergies, Alzheimer's and cognitive disorders,
CC schizophrenia, arthritis, asthma, psoriasis, sepsis, skin disorders,
CC atherosclerosis, diabetes, cardiovascular disorders, kidney disorders,
CC digestive/endocrine disorders, infections and AIDS. The polypeptides are
CC also useful for identifying their binding partners. The sequences given
CC in AAX97907 to AAX97915 and AAY36223 are used in the exemplification of
CC the present invention
XX
SQ Sequence 23 AA;

Query Match 100.0%; Score 19; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 74
AAU18994
ID AAU18994 standard; peptide; 23 AA.
XX
AC AAU18994;
XX
DT 04-DEC-2001 (first entry)
XX
DE T-cell epitope containing peptide DPI-28.2.
XX
KW House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KW Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KW T-cell epitope.
XX
OS Dermatophagoides pteronyssinus.
XX
PN US6268491-B1.
XX
PD 31-JUL-2001.
XX
PF 07-JUN-1995; 95US-00484296.

XX
PR 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;
XX
DR WPI; 2001-549074/61.
XX
PT Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.
XX
PS Claim 1; Fig 3; 158pp; English.
XX
CC The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC or DF II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the
CC genus Dermatophagoides. The regions are derived from the same or
CC different protein allergens of the genus Dermatophagoides. The peptides
CC are useful for treating house dust mite allergy in humans. The peptides
CC are also useful for detecting or diagnosing sensitivity to house dust
CC mite protein allergens. The present peptides have similar or enhanced
CC therapeutic properties as the naturally-occurring allergen, but have
CC reduced side effects, and increased solubility and stability. The present
CC sequence represents an allergenic T-cell epitope containing peptide
CC derived from the Dermatophagoides allergenic proteins
XX
SQ Sequence 23 AA;

Query Match 100.0%; Score 19; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 75
ADA12069
ID ADA12069 standard; protein; 23 AA.
XX
AC ADA12069;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human novel secreted protein associated polypeptide #339.
XX
KW cancer; inflammation; immune disorder; neurological disorder;
KW blood clotting disorder; food additive; food preservative;
KW storage capability; fat content; nutritional component; human;
KW secreted protein.
XX
OS Homo sapiens.
XX
PN US2003055236-A1.
XX
PD 20-MAR-2003.
XX
PF 14-MAR-2002; 2002US-00097065.
XX
PR 18-DEC-1997; 97US-0068006P.
PR 18-DEC-1997; 97US-0068007P.
PR 18-DEC-1997; 97US-0068008P.
PR 18-DEC-1997; 97US-0068053P.
PR 18-DEC-1997; 97US-0068054P.
PR 18-DEC-1997; 97US-0068057P.
PR 18-DEC-1997; 97US-0068064P.
PR 18-DEC-1997; 97US-0070923P.
PR 19-DEC-1997; 97US-0068169P.
PR 19-DEC-1997; 97US-0068365P.
PR 19-DEC-1997; 97US-0068367P.
PR 19-DEC-1997; 97US-0068368P.
PR 19-DEC-1997; 97US-0068369P.
PR 17-DEC-1998; 98WO-US027059.
PR 17-JUN-1999; 99US-00334595.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Moore PA, Ruben SM, Carter KC, Shi Y, Rosen CA, Soppet DR;
PI Kyaw H, Wei Y, Florence KA, Duan DR, Florence C, Greene JM, Feng P;
PI Ferrie AM, Yu G, Janat F, Ni J;
XX
DR WPI; 2003-567105/53.
XX
PT New secreted HKABT24 nucleic acid molecules and polypeptides, useful for
PT preventing, treating, or ameliorating a medical condition, such as
PT cancer, inflammation, immune disorders, neurological and blood clotting
PT disorders.
XX
PS Disclosure; Page 58; 118pp; English.
XX
CC The invention relates to an isolated HKABT24 nucleic acid molecule. The
CC polypeptides, nucleic acids and antibodies are useful for diagnosing a
CC pathological condition or a susceptibility to a pathological condition,
CC for preventing, treating, or ameliorating a medical condition, such as
CC cancer, inflammation and other immune disorders, neurological and blood
CC clotting disorders. The nucleic acids are also useful for chromosome
CC identification, radiation hybrid mapping or long-range restriction
CC mapping. The polypeptides and antibodies are useful for providing
CC immunological probes for differential identification of the tissues
CC immunohistochemistry assays. The polypeptide, polynucleotide, agonist or
CC antagonist may also be used as a food additive or preservative to
CC increase or decrease storage capabilities, fat content or other
CC nutritional components. The present sequence represents the amino acid
CC sequence of a novel human secreted protein associated polypeptide. Note:
CC The sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format directly from USPTO
CC at seqdata.uspto.gov.uk/sequence.html?DocID=20030055236.
XX
SQ Sequence 23 AA;

Query Match 100.0%; Score 19; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 76
ABP46165
ID ABP46165 standard; peptide; 24 AA.
XX
AC ABP46165;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human BLyS binding scFv VH CDR3 SEQ ID 2176.
XX
KW BLys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW tumour necrosis factor; B cell proliferation; B cell differentiation;
KW immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW common variable immunodeficiency; acquired immunodeficiency syndrome.

```
XX
OS   Homo sapiens.
XX
PN   WO200202641-A1.
XX
PD   10-JAN-2002.
XX
PF   15-JUN-2001; 2001WO-US019110.
XX
PR   16-JUN-2000; 2000US-0212210P.
PR   17-OCT-2000; 2000US-0240816P.
PR   16-MAR-2001; 2001US-0276248P.
PR   21-MAR-2001; 2001US-0277379P.
PR   25-MAY-2001; 2001US-0293499P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
PA   (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI   Ruben SM,  Barash SC,  Choi GH,  Vaughan T,  Hilbert D;
XX
DR   WPI; 2002-114799/15.
XX
PT   Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT   diagnosis and treatment of cancers and immune disorders.
XX
PS   Claim 2; Page 2945; 3148pp; English.
XX
CC   This invention describes novel antibodies that immunospecifically bind to
CC   B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
CC   tumour necrosis factor (TNF) super family and induces B cell
CC   proliferation and differentiation. The antibodies of the invention have
CC   cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC   antirheumatic and antiAIDS activity and can be used in vaccines to
CC   inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC   and so may be used to detect and quantitate the presence of BLyS in
CC   biological samples and may be used in this way to diagnose disease
CC   associated with aberrant expression of BLyS. They may also be
CC   administered to treat diseases associated with aberrant BLyS expression
CC   and activity such as cancer, immune, and autoimmune disorders and
CC   diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC   immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC   acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC   the antibodies and fragments of the antibodies described in the method of
CC   the invention
XX
SQ   Sequence 24 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 77
ABP46958
ID   ABP46958 standard; peptide; 24 AA.
XX
AC   ABP46958;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human BLyS binding scFv VH CDR3 SEQ ID 2969.
XX
KW   BLys; B lymphocyte stimulator; TNF superfamily; human; cytostatic;
KW   tumour necrosis factor; B cell proliferation; B cell differentiation;
KW   immunosuppressive; immunostimulant; immunomodulatory; antirheumatic;
KW   antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency;
KW   systemic lupus erythematosus; rheumatoid arthritis; CVID; AIDS;
KW   common variable immunodeficiency; acquired immunodeficiency syndrome.
XX
OS   Homo sapiens.
XX
PN   WO200202641-A1.
XX
PD   10-JAN-2002.
XX
PF   15-JUN-2001; 2001WO-US019110.
XX
PR   16-JUN-2000; 2000US-0212210P.
PR   17-OCT-2000; 2000US-0240816P.
PR   16-MAR-2001; 2001US-0276248P.
PR   21-MAR-2001; 2001US-0277379P.
PR   25-MAY-2001; 2001US-0293499P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
PA   (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
PI   Ruben SM,  Barash SC,  Choi GH,  Vaughan T,  Hilbert D;
XX
DR   WPI; 2002-114799/15.
XX
PT   Antibodies against B Lymphocyte Stimulating polypeptides, useful for the
PT   diagnosis and treatment of cancers and immune disorders.
XX
PS   Claim 2; Page 3088-3089; 3148pp; English.
XX
CC   This invention describes novel antibodies that immunospecifically bind to
CC   B Lymphocyte Stimulator (BLyS) polypeptides. BLyS is a member of the
CC   tumour necrosis factor (TNF) super family and induces B cell
CC   proliferation and differentiation. The antibodies of the invention have
CC   cytostatic, immunosuppressive, immunostimulant, immunomodulatory,
CC   antirheumatic and antiAIDS activity and can be used in vaccines to
CC   inhibit the expression and activity of BLyS. The antibodies bind to BLyS
CC   and so may be used to detect and quantitate the presence of BLyS in
CC   biological samples and may be used in this way to diagnose disease
CC   associated with aberrant expression of BLyS. They may also be
CC   administered to treat diseases associated with aberrant BLyS expression
CC   and activity such as cancer, immune, and autoimmune disorders and
CC   diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis,
CC   immunodeficiency (e.g. common variable immunodeficiency (CVID) and
CC   acquired immunodeficiency syndrome (AIDS)). ABP43990-ABP47228 represent
CC   the antibodies and fragments of the antibodies described in the method of
CC   the invention
XX
SQ   Sequence 24 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 9.7e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 78
ADG96992
ID   ADG96992 standard; peptide; 24 AA.
XX
AC   ADG96992;
XX
DT   11-MAR-2004  (first entry)
XX
DE   scFV VHCDR3 peptide that immunospecifically binds BLyS SeqID 2176.
XX
KW   antibody; B lymphocyte stimulator; BLyS; tumour necrosis factor;
KW   B cell proliferation; differentiation; scFv; myasthenia gravis;
KW   multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW   carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW   antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
OS   Unidentified.
XX
```

PN WO2003055979-A2.
XX
PD 10-JUL-2003.
XX
PF 14-NOV-2002; 2002WO-US036496.
XX
PR 16-NOV-2001; 2001US-0331469P.
PR 19-DEC-2001; 2001US-0340817P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
DR WPI; 2003-505530/47.
XX
PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT (BLys), useful for detecting and treating diseases or disorders e.g.
PT rheumatoid arthritis, asthma and leukemia.
XX
PS Example 1; SEQ ID NO 2176; 394pp; English.
XX
CC This invention relates to novel antibodies that immunospecifically bind
CC to B lymphocyte stimulator (BLyS). The BLyS gene has been mapped to
CC chromosome 13q34 and encodes a protein that is a member of the tumour
CC necrosis factor superfamily and induces both in vivo and in vitro B cell
CC proliferation and differentiation. Specifically, it refers to single
CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey BLyS. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of BLyS or its receptor. As
CC such, these compositions are useful for identifying immune disorders
CC including myasthenia gravis and multiple sclerosis, inflammatory
CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC as AIDS and proliferative disorders including leukaemia, carcinoma and
CC lymphoma. Accordingly, they can be described as exhibiting various
CC activities such as antirheumatic, antiarthritic, neuroprotective,
CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
CC peptide sequence is a single chain antibody variable heavy CDR3 peptide
CC that immunospecifically binds BLyS of the invention.
XX
SQ Sequence 24 AA;

Query Match 100.0%; Score 19; DB 7; Length 24;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 79
ADG97785
ID ADG97785 standard; peptide; 24 AA.
XX
AC ADG97785;
XX
DT 11-MAR-2004 (first entry)
XX
DE scFV VHCDR3 peptide that immunospecifically binds BLyS SeqID 2969.
XX
KW antibody; B lymphocyte stimulator; BLyS; tumour necrosis factor;
KW B cell proliferation; differentiation; scFv; myasthenia gravis;
KW multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia;
KW carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective;
KW antiinflammatory; antiasthmatic; antiallergic; cytostatic.
XX
OS Unidentified.
XX
PN WO2003055979-A2.
XX
PD 10-JUL-2003.
XX
PF 14-NOV-2002; 2002WO-US036496.
XX
PR 16-NOV-2001; 2001US-0331469P.
PR 19-DEC-2001; 2001US-0340817P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
XX
DR WPI; 2003-505530/47.
XX
PT Novel antibody that immunospecifically binds to a B lymphocyte stimulator
PT (BLys), useful for detecting and treating diseases or disorders e.g.
PT rheumatoid arthritis, asthma and leukemia.
XX
PS Example 1; SEQ ID NO 2969; 394pp; English.
XX
CC This invention relates to novel antibodies that immunospecifically bind
CC to B lymphocyte stimulator (BLyS). The BLyS gene has been mapped to
CC chromosome 13q34 and encodes a protein that is a member of the tumour
CC necrosis factor superfamily and induces both in vivo and in vitro B cell
CC proliferation and differentiation. Specifically, it refers to single
CC chain antibody molecules (scFvs) derived, preferably, from the variable
CC heavy CDR3 region that immunospecifically bind to a polypeptide, or
CC fragment thereof, of either human, murine, rat or monkey BLyS. The
CC present invention refers to the use of such antibodies in various methods
CC for the detection, diagnosis and prognosis of diseases related to the
CC aberrant expression or inappropriate function of BLyS or its receptor. As
CC such, these compositions are useful for identifying immune disorders
CC including myasthenia gravis and multiple sclerosis, inflammatory
CC disorders e.g. asthma and rheumatoid arthritis, infectious diseases such
CC as AIDS and proliferative disorders including leukaemia, carcinoma and
CC lymphoma. Accordingly, they can be described as exhibiting various
CC activities such as antirheumatic, antiarthritic, neuroprotective,
CC antiinflammatory, antiasthmatic, antiallergic and cytostatic. This
CC peptide sequence is a single chain antibody variable heavy CDR3 peptide
CC that immunospecifically binds BLyS of the invention.
XX
SQ Sequence 24 AA;

Query Match 100.0%; Score 19; DB 7; Length 24;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 80
AAR36412
ID AAR36412 standard; peptide; 25 AA.
XX
AC AAR36412;
XX
DT 25-MAR-2003 (revised)
DT 12-AUG-1993 (first entry)
XX
DE DPI-27.1(161-185) a Dermatophagoides protein allergen.
XX
KW T cell epitope; house dust mite; allergy; soluble; Der pI.
XX
OS Synthetic.
XX
PN WO9308279-A1.
XX
PD 29-APR-1993.
XX
PF 15-OCT-1992; 92WO-US008637.
XX
PR 16-OCT-1991; 91US-00777859.

PR 08-MAY-1992; 92US-00881396.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo MC, Rogers BL;
XX
DR WPI; 1993-152472/18.
XX
PT Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
PT and treatment of sensitivity to house dust mite.
XX
PS Claim 10; Fig 3; 176pp; English.
XX
CC The peptide is one of a series of overlapping peptides synthsised by
CC standard techniques to cover the whole Dermatophagoides pteronyssinus Der
CC pI sequence. The T cell epitopes of the protein were mapped by detection
CC of the peptide's ability to stimulate T cell activity. The peptides may
CC be used for diagnosis and treatment of sensitivity to house dust mite
CC allergens. When administered to house dust mite sensitive individuals,
CC the peptides are capable of modifying the allergic response to the
CC allergens. The peptides may be modified for e.g. increasing solubility,
CC enhancing therapeutic or preventive efficacy or stability. See also
CC AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 20 AQGV 23

RESULT 81
AAR51760
ID AAR51760 standard; protein; 25 AA.
XX
AC AAR51760;
XX
DT 01-FEB-1995 (first entry)
XX
DE Der p I derived peptide, DP I-27.1(161-185).
XX
KW Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
KW homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
KW epitopes; fusion peptides; antigenic fragments; substitution; deletion;
KW addition; chemical synthesis; chemical cleavage; recombinant techniques;
KW allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
KW IgE-mediated responses; anergise; lymphokine secretion profile; modify;
KW T cell subpopulations; unresponsive; immune response; tolerise.
XX
OS Dermatophagoides pteronyssinus.
XX
PN ZA9302677-A.
XX
PD 26-JAN-1994.
XX
PF 16-APR-1993; 93ZA-00002677.
XX
PR 16-APR-1993; 93ZA-00002677.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL;
XX
DR WPI; 1994-126807/15.
XX
PT Isolated and/or modified peptides comprising T-cell epitopes - of major
PT protein allergens of genus Dermatophagoides, used to treat or diagnose
PT sensitivity to house dust mites.
XX
PS Claim 28; Page 66; 154pp; English.
XX
CC The sequences given in AAR51731-841 represent T-cell epitopes derived
CC from the group I and II protein allergens from the house dust mite D.
CC farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
CC respectively.The Der f II proteinsCC shows high homology having an
CC identity of 88%, with an identity of 81% between the two group I proteins
CC (see also AAR51727-30). Fusion peptides may be produced which comprise at
CC least two or these antigenic fragments. Each region of these fusion
CC petides may be derived from the same, or different, mite allergens. The
CC antigenic fragments may be altered by substitution, deletion or addition
CC to enhance their antigenicity. These peptides may be produced by chemical
CC synthesis, chemical cleavage of the protien allergen or by recombinant
CC techniques. These peptides, or the fusion peptides, when administered to
CC a house dust mite sensitive individual, are capable of modifying the
CC allergic response of the individual to the allergen. The peptides do not
CC bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
CC full length protein allergen. This reduces the major complications of
CC standard immunotherapy, which are IgE-mediated responses such as
CC anaphylaxis. Exposure of mite allergic patients to these peptides may
CC tolerise or anergise appropriate T cell subpopulations such that they
CC become unresponsive to mite allergens and do not participate in mounting
CC an immune response upon exposure. Administration of the peptides may also
CC modify the lymphokine secretion profile as compared with exposure to the
CC naturally occuring mite protein allergen
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 20 AQGV 23

RESULT 82
AAW71935
ID AAW71935 standard; peptide; 25 AA.
XX
AC AAW71935;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 16-DEC-1998 (first entry)
XX
DE Dermatophagoides Der p I protein peptide DPI-27.1.
XX
KW genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
KW Der p II; Der f I; Der f II; house dust mite allergy.
XX
OS Dermatophagoides.
XX
PN US5820862-A.
XX
PD 13-OCT-1998.
XX
PF 07-JUN-1995; 95US-00482142.
XX
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Franzen HM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;
PI Shaked Z, Rogers BL;
XX
DR WPI; 1998-567590/48.
XX
PT Dermatophagoides allergen peptides - useful for treating house dust mite

PT allergy.
XX
PS Disclosure; Col 97-98; 155pp; English.
XX
CC The present invention describes peptides for treating sensitivity to
CC house dust mite allergens from the genus Dermatophagoides. Peptides
CC within the scope of the invention comprise at least one T cell epitope,
CC or preferably at least two T cell epitopes of a protein allergen selected
CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC also describes modified peptides having similar or enhanced therapeutic
CC properties as the corresponding, naturally occurring allergen, but having
CC reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330
CC represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 20 AQGV 23

RESULT 83
AAY50389
ID AAY50389 standard; peptide; 25 AA.
XX
AC AAY50389;
XX
DT 25-JAN-2000 (first entry)
XX
DE Dermatophagoides sp major protein allergen DP I-27.1.
XX
KW Allergen; house dust mite; detection; sensitivity; T cell epitope;
KW screening; allergic disorder; asthma; rhinitis; ectopic dermatitis;
KW Der f I; Der p I; Der p II; Der f II.
XX
OS Dermatophagoides sp.
XX
PN US5968526-A.
XX
PD 19-OCT-1999.
XX
PF 07-JUN-1995; 95US-00478572.
XX
PR 14-APR-1994; 94US-00227772.
PR 12-APR-1995; 95WO-US004481.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
PI Chen X, Evans S, Kuo M;
XX
DR WPI; 1999-590385/50.
XX
PT Screening individuals for allergic reactions to T cell epitopes of major
PT allergens from house dust mites.
XX
PS Claim 1c'; Column 99-100; 158pp; English.
XX
CC This invention describes a novel method (I) for detecting whether an
CC individual is sensitive to Dermatophagoides (house dust mites). The
CC method involves detecting sensitivity to house dust mites in patients,
CC comprising combining a blood sample from the individual with 1 or more
CC isolated T cell epitopes of the protein allergens I and II ((DP I) and
CC (DP II)) from Dermatophagoides (house dust mites). 32 T cell epitopes
CC with varying, defined amino acids sequences (given in the specification)
CC may be used in (I). The sample and allergens are combined under
CC conditions appropriate for the binding of blood components with the
CC polypeptides. The extent of binding is then indicative of the sensitivity
CC of the patient to house dust mites. (I) may be used to screen individuals
CC for sensitivity to Dermatophagoides (house dust mites). The house dust
CC mite is a major cause of a variety of allergic disorders such as asthma,
CC rhinitis and ectopic dermatitis. AAY50360-Y50542 and AAY50546-Y50555
CC represent house dust mite allergen peptide fragments derived from Der p
CC I, Der f II, Der f I and Der f II
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 20 AQGV 23

RESULT 84
AAM21152
ID AAM21152 standard; protein; 25 AA.
XX
AC AAM21152;
XX
DT 12-OCT-2001 (first entry)
XX
DE Peptide #7586 encoded by probe for measuring cervical gene expression.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000670.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.
XX
PS Claim 27; SEQ ID NO 25978; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 4; Length 25;

```
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         16 AQGV 19


RESULT 85
AAU18992
ID   AAU18992 standard; peptide; 25 AA.
XX
AC   AAU18992;
XX
DT   04-DEC-2001  (first entry)
XX
DE   T-cell epitope containing peptide DPI-27.1.
XX
KW   House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KW   Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KW   T-cell epitope.
XX
OS   Dermatophagoides pteronyssinus.
XX
PN   US6268491-B1.
XX
PD   31-JUL-2001.
XX
PF   07-JUN-1995;   95US-00484296.
XX
PR   16-OCT-1991;   91US-00777859.
PR   08-MAY-1992;   92US-00881396.
PR   14-APR-1993;   93WO-US003471.
PR   14-APR-1994;   94US-00227772.
PR   19-MAY-1995;   95US-00445307.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Kuo M,  Rogers BL,  Franzen HM,  Chen X;
PI   Evans S,  Shaked Z;
XX
DR   WPI; 2001-549074/61.
XX
PT   Peptides comprising T cell groups of the major allergens from
PT   Dermatophagoides (house dust mites), useful for treating house dust mite
PT   allergy in humans, and for diagnosing sensitivity to house dust mite
PT   protein allergens.
XX
PS   Claim 1; Fig 3; 158pp; English.
XX
CC   The invention relates to an isolated peptide of the major protein
CC   allergens of the genus Dermatophagoides, which comprises at least one T
CC   cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC   or DF II. The isolated peptide comprises at least two regions, each
CC   region comprising at least one T cell group of a protein allergen of the
CC   genus Dermatophagoides. The regions are derived from the same or
CC   different protein allergens of the genus Dermatophagoides. The peptides
CC   are useful for treating house dust mite allergy in humans. The peptides
CC   are also useful for detecting or diagnosing sensitivity to house dust
CC   mite protein allergens. The present peptides have similar or enhanced
CC   therapeutic properties as the naturally-occurring allergen, but have
CC   reduced side effects, and increased solubility and stability. The present
CC   sequence represents an allergenic T-cell epitope containing peptide
CC   derived from the Dermatophagoides allergenic proteins
XX
SQ   Sequence 25 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 86
ABB43470
ID   ABB43470 standard; peptide; 25 AA.
XX
AC   ABB43470;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #10976 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 36105; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 25 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         16 AQGV 19


RESULT 87
AAM37363
ID   AAM37363 standard; protein; 25 AA.
XX
AC   AAM37363;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #11400 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
```

KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 37632; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 16 AQGV 19

RESULT 88
AAM77220
ID AAM77220 standard; protein; 25 AA.
XX
AC AAM77220;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 37526.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 37526; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 16 AQGV 19

RESULT 89
AAM64402
ID AAM64402 standard; protein; 25 AA.
XX
AC AAM64402;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 36507.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 36507; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid

```
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 25 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         16 AQGV 19


RESULT 90
ABG58847
ID   ABG58847 standard; peptide; 25 AA.
XX
AC   ABG58847;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 37495.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 37495; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 25 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         16 AQGV 19


RESULT 91
ADC26857
ID   ADC26857 standard; peptide; 25 AA.
XX
AC   ADC26857;
XX
DT   18-DEC-2003  (first entry)
XX
DE   B. burgdorferi decorin binding protein A (DbpA) synthetic peptide P8.
XX
KW   Decorin binding protein A; DbpA; immune response; bacterial infection;
KW   decorin adhesion; colonisation; spirochete; adhesion; collagen fibre;
KW   decorin; dermatan sulphate proteoglycan; DbpB; lipoprotein; vaccine;
KW   delayed type hypersensitivity; DTH; Lyme disease; LD;
KW   multisystemic disorder; Lyme arthritis; antibacterial.
XX
OS   Borrelia burgdorferi.
XX
PN   US6517838-B1.
XX
PD   11-FEB-2003.
XX
PF   16-JUN-2000; 2000US-00596120.
XX
PR   16-JUN-2000; 2000US-00596120.
XX
PA   (TEXA ) UNIV TEXAS A & M SYSTEM.
XX
PI   Hoeok MA,  Brown EL;
XX
DR   WPI; 2003-634321/60.
XX
PT   Generating immune response against Borrelia bacteria, for treating Lyme
PT   disease, by administering decorin binding protein A-derived peptide or a
PT   combination of decorin binding protein A-derived peptides to mammal.
XX
PS   Example 1; Fig 1; 33pp; English.
XX
CC   The invention discloses a method for generating an immune response
CC   against Borrelia bacteria infection which involves administering a
CC   decorin binding protein A (DbpA)-derived peptide or a combination of two
CC   or more DbpA-derived peptides, where the peptides span critical binding
CC   regions required for DbpA/decorin adhesion. Colonisation of the
CC   spirochetes occurs by adhesion of B. burgdorferi to collagen fibres,
CC   particularly to decorin, a dermatan sulphate proteoglycan. DbpA and B are
CC   expressed at the surface of the spirochetes as lipoproteins and act as
CC   adhesins, binding to the decorin. Also disclosed are antisera and
CC   antibodies generated against the decorin binding proteins, vaccines
CC   comprising decorin binding peptides, antisera and antibodies raised
CC   against the decorin binding proteins, diagnostic kits comprising the
CC   decorin binding peptides, or antibodies or antisera raised against them,
CC   pharmaceutical compositions comprising the decorin binding peptides, or
CC   antibodies or antisera raised against them, inhibiting decorin binding
CC   protein from binding decorin in a blood sample by contacting the blood
CC   sample with DbpA-derived peptide fragment, identifying a candidate
CC   substance that alters the binding of DbpA-derived protein fragment or
CC   related peptide to decorin, a modulator of DbpA-derived protein or
CC   peptide fragment binding to decorin, modulating DbpA-derived protein or
CC   peptide fragment binding to decorin, identifying a candidate DbpA-derived
CC   peptide fragment with improved decorin binding and use of decorin binding
CC   peptides, or antibodies or antisera raised against them for the
CC   treatment, prevention and diagnosis of Borrelia burgdorferi infections
```

CC and for coating medical devices or polymeric biomaterials in vitro and in
CC vivo. The peptides are administered by topical, oral, anal, vaginal,
CC intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or
CC intradermal route. The method is useful (e.g. as a vaccine) for
CC generating an immune response against Borrelia bacteria or preventing
CC Borrelia infection in a mammal and as a delayed type hypersensitivity
CC (DTH) response inducer. Preferably, the method is useful for treating
CC Lyme disease (LD), which can lead to multisystemic disorders that may
CC affect the joints (Lyme arthritis), skin, heart and central nervous
CC sytem. The sequence presented is a peptide which was synthesised as part
CC of a series of peptides spanning the full length of the B. burgdorferi
CC DbpA protein.
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 7; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 10 AQGV 13

RESULT 92
ADN59708
ID ADN59708 standard; peptide; 25 AA.
XX
AC ADN59708;
XX
DT 01-JUL-2004 (first entry)
XX
DE Thrombopoietin mimetic peptide TMP12, seq id 57.
XX
KW Haemostatic; antianaemic; immunosuppressive; platelet;
KW transmembrane signaling; mpl receptor; thrombopoietin mimetic peptide;
KW TMP; c-mpl receptor; platelet precursor; megakaryocyte;
KW thrombocytopaenia; aplastic anaemia; autoimmune thrombocytopaenia;
KW autoimmune haemolytic anaemia; Hughe's syndrome;
KW lupoid thrombocytopaenia.
XX
OS Homo sapiens.
XX
PN WO2003031589-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032552.
XX
PR 11-OCT-2001; 2001US-0328666P.
PR 10-OCT-2002; 2002US-00269806.
XX
PA (AMGE-) AMGEN INC.
XX
PI Min H, Sitney KC, Hartley C;
XX
DR WPI; 2003-403101/38.
DR N-PSDB; ADN59707.
XX
PT Novel thrombopoietin mimetic peptides which bind to mpl receptor, and
PT which stimulate the production of platelets and/or the production of
PT platelet precursors, useful for treating thrombocytopenia.
XX
PS Disclosure; SEQ ID NO 57; 126pp; English.
XX
CC The invention relates to a thrombopoietin mimetic peptide (TMP) (I) that
CC binds to the c-mpl (mpl) receptor, and which stimulates the production of
CC platelets and/or the production of platelet precursors, is new. Further
CC disclosed is a composition of matter (II) that binds to an mpl receptor,
CC and a pharmaceutical composition comprising (II) and a carrier. The
CC pharmaceutical composition of the invention is useful for treating
CC thrombocytopaenia in an animal, and for increasing megakaryocytes or
CC platelets in a patient. The TMP of the invention is useful for treating
CC conditions involving a megakaryocyte and/or platelet deficiency, e.g.
CC disease conditions involving thrombocytopaenia such as aplastic anaemia,
CC autoimmune thrombocytopaenia, drug induced immune thrombocytopaenia,
CC autoimmune haemolytic anaemia, Hughe's syndrome and lupoid
CC thrombocytopaenia. The TMP of the invention is also useful for
CC maintaining the viability or storage life of platelets and/or
CC megakaryocytes and its derived cells. The compounds demonstrate an
CC improved ability to bind to and/or trigger transmembrane signal through,
CC i.e. activating, the mpl receptor the compounds have superior
CC thromobopoietic activity, i.e. the ability to stimulate, in vivo and in
CC vitro, the production of platelets and/or megakaryocytopoietic activity,
CC i.e. the ability to stimulate, in vivo and in vitro, the production of
CC platelet precursors. Further, certain of the compounds also exhibit
CC superior therapeutic properties, such as improved plasma half-life,
CC biological activity and in vivo circulation time. The current sequence
CC represents a TMP fragment.
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 19; DB 7; Length 25;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 1 AQGV 4

RESULT 93
ABO60121
ID ABO60121 standard; protein; 25 AA.
XX
AC ABO60121;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #6355.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 33755; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-

CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 25 AA;

```
  Query Match             100.0%;  Score 19;  DB 8;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          1 AQGV 4
```

RESULT 94
ADV54693
ID ADV54693 standard; peptide; 25 AA.
XX
AC ADV54693;
XX
DT 10-MAR-2005 (first entry)
XX
DE G protein coupled receptor peptide SEQ ID NO 2190.
XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
OS Unidentified.
XX
PN WO2004111636-A2.
XX
PD 23-DEC-2004.
XX
PF 17-JUN-2004; 2004WO-EP051158.
XX
PR 17-JUN-2003; 2003EP-00101775.
PR 17-JUN-2003; 2003US-0479061P.
XX
PA (VIBV-) VIB VZW.
PA (UYGE-) UNIV GENT.
XX
PI Kas K, Vandekerckhove J, Krols L;
XX
DR WPI; 2005-057893/06.
XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in
PT agriculture, comprises generating peptides by applying a digest on the
PT family of protein.
XX
PS Example; SEQ ID NO 2190; 265pp; English.
XX
CC The invention relates to a method of identifying a peptide combo which
CC corresponds with a family of proteins where each of the members of the
CC peptide combo is derived from a unique protein from the family. The
CC peptide combo is useful for quantifying specific known splice variants of
CC one or more particular proteins in a sample, for diagnosing complex
CC genetic diseases such as cancer, obesity, diabetes, asthma and
CC inflammation, neuropsychiatric disorders such as depression, for
CC quantifying one to several hundreds of protein disease markers
CC simultaneously leading to a more accurate diagnostic sub-classification,
CC for determining the extent of protein modification in a particular sample
CC of proteins, for tissue-typing analysis, for prenatal testing to detect
CC the presence of a congenital disease or for quantitating protein levels
CC diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC or neurological diseases, as biomarkers preclinical drug development,
CC development of improved animal models, biomarkers related with
CC toxicology, clinical drug development, guidance marketed drugs,
CC prognostic or diagnostic disease markers, drug target validation and
CC selection, monitoring protein splicing, drug lead profiling, pathway
CC analysis, answering basic disease biology questions, and in the fields of
CC food and feed, cosmetics, agriculture and animal breeding. The present
CC sequence represents a peptide from a G-protein coupled receptor peptide
CC combo.
XX
SQ Sequence 25 AA;

```
  Query Match             100.0%;  Score 19;  DB 9;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8
```

RESULT 95
ADV55689
ID ADV55689 standard; peptide; 25 AA.
XX
AC ADV55689;
XX
DT 10-MAR-2005 (first entry)
XX
DE G protein coupled receptor peptide SEQ ID NO 3188.
XX
KW diagnosis; cancer; obesity; diabetes; asthma; inflammation; depression;
KW food; feedstuff; cosmetics; agriculture; animal breeding; GPCR.
XX
OS Unidentified.
XX
PN WO2004111636-A2.
XX
PD 23-DEC-2004.
XX
PF 17-JUN-2004; 2004WO-EP051158.
XX
PR 17-JUN-2003; 2003EP-00101775.
PR 17-JUN-2003; 2003US-0479061P.
XX
PA (VIBV-) VIB VZW.
PA (UYGE-) UNIV GENT.
XX
PI Kas K, Vandekerckhove J, Krols L;
XX
DR WPI; 2005-057893/06.
XX
PT Identifying a peptide combo which corresponds with a family of proteins,
PT useful for diagnosing a variety of diseases, drug development or in
PT agriculture, comprises generating peptides by applying a digest on the

```
PT   family of protein.
XX
PS   Example; SEQ ID NO 3188; 265pp; English.
XX
CC   The invention relates to a method of identifying a peptide combo which
CC   corresponds with a family of proteins where each of the members of the
CC   peptide combo is derived from a unique protein from the family. The
CC   peptide combo is useful for quantifying specific known splice variants of
CC   one or more particular proteins in a sample, for diagnosing complex
CC   genetic diseases such as cancer, obesity, diabetes, asthma and
CC   inflammation, neuropsychiatric disorders such as depression, for
CC   quantifying one to several hundreds of protein disease markers
CC   simultaneously leading to a more accurate diagnostic sub-classification,
CC   for determining the extent of protein modification in a particular sample
CC   of proteins, for tissue-typing analysis, for prenatal testing to detect
CC   the presence of a congenital disease or for quantitating protein levels
CC   diagnostic of a chromosomal abnormality, for diagnosing immune diseases
CC   or neurological diseases, as biomarkers preclinical drug development,
CC   development of improved animal models, biomarkers related with
CC   toxicology, clinical drug development, guidance marketed drugs,
CC   prognostic or diagnostic disease markers, drug target validation and
CC   selection, monitoring protein splicing, drug lead profiling, pathway
CC   analysis, answering basic disease biology questions, and in the fields of
CC   food and feed, cosmetics, agriculture and animal breeding. The present
CC   sequence represents a peptide from a G-protein coupled receptor peptide
CC   combo.
XX
SQ   Sequence 25 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8


RESULT 96
AAR30640
ID   AAR30640 standard; peptide; 26 AA.
XX
AC   AAR30640;
XX
DT   06-MAY-1993  (first entry)
XX
DE   Epitope of human CENP-B.
XX
KW   Centromere protein; antibodies; polypeptide.
XX
OS   Homo sapiens.
XX
PN   JP04334398-A.
XX
PD   20-NOV-1992.
XX
PF   08-MAY-1991;   91JP-00102517.
XX
PR   08-MAY-1991;   91JP-00102517.
XX
PA   (DAIK ) DAIKIN KOGYO KK.
XX
DR   WPI; 1993-005542/01.
XX
PT   Human centromere antigen polypeptide - for detection of human antibodies
PT   and identification of disease.
XX
PS   Claim 1; Page 2; 15pp; Japanese.
XX
CC   The polypeptide constitutes an epitope of the human centromere protein B
CC   (CENP-B) and can be produced by standard recombinant DNA techniques. The
CC   polypeptide can be used to detect anti-human centromere antibodies. The
CC   type of diseases of a patient having the antibody can be exactly
CC   classified using the polypeptide. See also AAR30639-41
XX
SQ   Sequence 26 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 26;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 97
AAR95624
ID   AAR95624 standard; peptide; 27 AA.
XX
AC   AAR95624;
XX
DT   18-DEC-1996  (first entry)
XX
DE   Tripeptidyl aminopeptidase fragment #3.
XX
KW   Tripeptidyl aminopeptidase; tripeptide cleavage; enzyme deactivation;
KW   enzyme; increased stability; microbially produced human enzyme; TPAP;
KW   aspergillus.
XX
OS   Aspergillus niger.
XX
PN   WO9614404-A1.
XX
PD   17-MAY-1996.
XX
PF   08-NOV-1995;   95WO-DK000446.
XX
PR   08-NOV-1994;   94DK-00001288.
PR   22-DEC-1994;   94DK-00001470.
XX
PA   (NOVO ) NOVO-NORDISK AS.
XX
PI   Holm KA,  Rasmussen G,  Halkier T,  Lehmbeck J;
XX
DR   WPI; 1996-251755/25.
XX
PT   New isolated fungal tri:peptidyl amino:peptidase enzymes - and related
PT   DNA, used for cleavage of proteins or for developing prods. which can
PT   provide protein prods. with increased stability.
XX
PS   Claim 2; Page 43; 58pp; English.
XX
CC   AAR95622-R95627 represent partial sequences of the Aspergillus niger
CC   tripeptidyl aminopeptidase (TPAP). TPAP is capable of non-specifically
CC   cleaving tripeptides from the unsubstituted N-terminus of protein
CC   products. The enzyme can also be used for the cleavage of proteins, such
CC   as for the deactivation of enzymes after they have exerted a desired
CC   effect. By altering this sequence a host cell with reduced (or
CC   eliminated) TPAP production can be produced. This alteration comprises
CC   random (or site-directed) mutagenesis of part of the essential DNA
CC   sequence (such as the promoter sequence) encoding TPAP (see AAT27801-
CC   T27803 for partial sequences). Alternatively inhibition may occur through
CC   hybridisation of a complementary sequence to reduce (or eliminate)
CC   translation of the protein. Products free from TPAP can be produced by
CC   fermentation of a TPAP-producing cell to a combined pH and temperature
CC   treatment to reduce the TPAP activity. The product of interest can then
CC   be isolated from the broth. This method can therefore be used to produce
CC   products with reduced TPAP activity, such as enzyme preparations with
CC   increased stability. This is particularly useful in the stability of
CC   microbially produced products, such as human enzymes
XX
SQ   Sequence 27 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+03;
```

```
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 98
AAW97423
ID   AAW97423 standard; peptide; 27 AA.
XX
AC   AAW97423;
XX
DT   20-MAY-1999  (first entry)
XX
DE   Peptide of the specification.
XX
KW   Epitope; fibrinogen; fibrinopeptide B; monospecific antibody;
KW   thrombotic status; thrombogenesis; atherogenesis.
XX
OS   Unidentified.
XX
PN   WO9905176-A1.
XX
PD   04-FEB-1999.
XX
PF   22-JUL-1998;   98WO-US015059.
XX
PR   25-JUL-1997;   97US-00900660.
XX
PA   (NYBL-) NEW YORK BLOOD CENT INC.
XX
PI   Kudryk BJ,  Redman CM,  Zhang J;
XX
DR   WPI; 1999-142856/12.
XX
PT   New fibrinogen-specific antibodies - can bind fibrinopeptide B, used for
PT   detection, purification and diagnosing thrombogenesis or atherogenesis.
XX
PS   Disclosure; Page 60; 64pp; English.
XX
CC   The specification describes an epitope derived from fibrinogen or a
CC   fibrinopeptide, and a monospecific antibody that binds specifically with
CC   that epitope. The antibodies can be used for detecting and measuring
CC   enzyme-mediated digestion of fibrinogen. They can be used for the precise
CC   and accurate detection of fibrinopeptide B and des-Arg FPB resulting in
CC   an objective measure of the thrombotic status of the patient. They can be
CC   used for diagnosing the presence or probability of thrombogenesis or
CC   atherogenesis in a subject. They can also be used for purifying
CC   fibrinogen or fibrinopeptide. The present sequence appears in the
CC   specification
XX
SQ   Sequence 27 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         21 AQGV 24


RESULT 99
ADX56530
ID   ADX56530 standard; peptide; 27 AA.
XX
AC   ADX56530;
XX
DT   05-MAY-2005  (first entry)
XX
DE   Cardiovascular disorder plasma protein tryptic fragment SEQ ID NO 347.
XX
KW   coronary artery disease; primary biliary cirrhosis,; gallstones;
KW   celiac disease; irritable bowel syndrome; diabetes; scleroderma; nausea;
KW   emesis; constipation; diarrhea; cardiovascular disease; immune disorder;
KW   endocrine disease; gastrointestinal disease; metabolic disorder;
KW   dermatological disease; musculoskeletal disease; Cardiant; Vasotropic;
KW   Hepatotropic; Litholytic; Immunosuppressive; Gastrointestinal-Gen.;
KW   Antiinflammatory; Antidiabetic; Dermatological; Antiemetic; Laxative;
KW   Antidiarrheic; diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2005015206-A2.
XX
PD   17-FEB-2005.
XX
PF   06-AUG-2004; 2004WO-EP008860.
XX
PR   08-AUG-2003; 2003US-0493599P.
PR   08-AUG-2003; 2003US-0493836P.
PR   08-AUG-2003; 2003US-0493867P.
PR   08-AUG-2003; 2003US-0493985P.
XX
PA   (XENO-) XENOVA LTD.
PA   (NOVS ) NOVARTIS AG.
PA   (NOVS ) NOVARTIS PHARMA GMBH.
XX
PI   Argoud-Puy G,  Bederr N,  Bougueleret L,  Cusin I,  Mahe E;
PI   Niknejad A,  Reffas S,  Rose K,  Saudrais C,  Scherer A,  Papoian R;
XX
DR   WPI; 2005-195824/20.
XX
PT   Screening and/or diagnosing cardiovascular disorder in subject involves
PT   detecting and/or quantifying level of polypeptide in biological sample
PT   from subject and comparing with control sample.
XX
PS   Claim 1; SEQ ID NO 347; 349pp; English.
XX
CC   The invention relates to a method of screening and/or diagnosing a
CC   cardiovascular disorder (CD) in a subject which comprises detecting
CC   and/or quantifying the level of a polypeptide in a biological sample from
CC   the subject and comparing the level to that of control sample. The method
CC   is useful for screening, diagnosing and treating coronary artery disease,
CC   biliary cirrhosis, gallstones, celiac disease, irritable bowel syndrome,
CC   diabetes, scleroderma, nausea, vomiting, constipation and diarrhea. The
CC   method is rapid and efficient. The present sequence represents a
CC   cardiovascular disorder plasma protein tryptic fragment.
XX
SQ   Sequence 27 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 100
AAR36413
ID   AAR36413 standard; peptide; 29 AA.
XX
AC   AAR36413;
XX
DT   25-MAR-2003  (revised)
DT   12-AUG-1993  (first entry)
XX
DE   DPI-28.1(173-201) a Dermatophagoides protein allergen.
XX
KW   T cell epitope; house dust mite; allergy; soluble; Der pI.
XX
OS   Synthetic.
XX
```

PN WO9308279-A1.
XX
PD 29-APR-1993.
XX
PF 15-OCT-1992; 92WO-US008637.
XX
PR 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo MC, Rogers BL;
XX
DR WPI; 1993-152472/18.
XX
PT Isolated peptide(s) of dermatophagoides protein allergens - for diagnosis
PT and treatment of sensitivity to house dust mite.
XX
PS Claim 10; Fig 3; 176pp; English.
XX
CC The peptide is one of a series of overlapping peptides synthsised by
CC standard techniques to cover the whole Dermatophagoides pteronyssinus Der
CC pI sequence. The T cell epitopes of the protein were mapped by detection
CC of the peptide's ability to stimulate T cell activity. The peptides may
CC be used for diagnosis and treatment of sensitivity to house dust mite
CC allergens. When administered to house dust mite sensitive individuals,
CC the peptides are capable of modifying the allergic response to the
CC allergens. The peptides may be modified for e.g. increasing solubility,
CC enhancing therapeutic or preventive efficacy or stability. See also
CC AAR34686-700 and AAR36398-490. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 29 AA;

Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 101
AAR51761
ID AAR51761 standard; protein; 29 AA.
XX
AC AAR51761;
XX
DT 01-FEB-1995 (first entry)
XX
DE Der p I derived peptide, DP I-28.1(173-201).
XX
KW Group I; protein allergen; house dust mite; D. pteronyssinus; Der p I;
KW homology; D. farinae; Der f I; group II; Der p II; Der f II; T-cell;
KW epitopes; fusion peptides; antigenic fragments; substitution; deletion;
KW addition; chemical synthesis; chemical cleavage; recombinant techniques;
KW allergic response; immunoglobulin E; IgE; immunotherapy; anaphylaxis;
KW IgE-mediated responses; anergise; lymphokine secretion profile; modify;
KW T cell subpopulations; unresponsive; immune response; tolerise.
XX
OS Dermatophagoides pteronyssinus.
XX
PN ZA9302677-A.
XX
PD 26-JAN-1994.
XX
PF 16-APR-1993; 93ZA-00002677.
XX
PR 16-APR-1993; 93ZA-00002677.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL;
XX
DR WPI; 1994-126807/15.
XX
PT Isolated and/or modified peptides comprising T-cell epitopes - of major
PT protein allergens of genus Dermatophagoides, used to treat or diagnose
PT sensitivity to house dust mites.
XX
PS Claim 10; Page 66; 154pp; English.
XX
CC The sequences given in AAR51731-841 represent T-cell epitopes derived
CC from the group I and II protein allergens from the house dust mite D.
CC farinae and D. pteronyssinus, Der f I, Der f II, Der p I and Der p II
CC respectively.The Der f II proteinsCC shows high homology having an
CC identity of 88%, with an identity of 81% between the two group I proteins
CC (see also AAR51727-30). Fusion peptides may be produced which comprise at
CC least two or these antigenic fragments. Each region of these fusion
CC petides may be derived from the same, or different, mite allergens. The
CC antigenic fragments may be altered by substitution, deletion or addition
CC to enhance their antigenicity. These peptides may be produced by chemical
CC synthesis, chemical cleavage of the protien allergen or by recombinant
CC techniques. These peptides, or the fusion peptides, when administered to
CC a house dust mite sensitive individual, are capable of modifying the
CC allergic response of the individual to the allergen. The peptides do not
CC bind to immunoglobulin E (IgE), or bind IgE to a lesser extent than the
CC full length protein allergen. This reduces the major complications of
CC standard immunotherapy, which are IgE-mediated responses such as
CC anaphylaxis. Exposure of mite allergic patients to these peptides may
CC tolerise or anergise appropriate T cell subpopulations such that they
CC become unresponsive to mite allergens and do not participate in mounting
CC an immune response upon exposure. Administration of the peptides may also
CC modify the lymphokine secretion profile as compared with exposure to the
CC naturally occuring mite protein allergen
XX
SQ Sequence 29 AA;

Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 102
AAW71936
ID AAW71936 standard; peptide; 29 AA.
XX
AC AAW71936;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 16-DEC-1998 (first entry)
XX
DE Dermatophagoides Der p I protein peptide DPI-28.1.
XX
KW genus Dermatophagoides; major protein allergen; T cell epitope; Der p I;
KW Der p II; Der f I; Der f II; house dust mite allergy.
XX
OS Dermatophagoides.
XX
PN US5820862-A.
XX
PD 13-OCT-1998.
XX
PF 07-JUN-1995; 95US-00482142.
XX
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.

XX
PI Franzen HM, Kuo M, Evans S, Garman RD, Greenstein JL, Chen X;
PI Shaked Z, Rogers BL;
XX
DR WPI; 1998-567590/48.
XX
PT Dermatophagoides allergen peptides - useful for treating house dust mite
PT allergy.
XX
PS Disclosure; Col 97-98; 155pp; English.
XX
CC The present invention describes peptides for treating sensitivity to
CC house dust mite allergens from the genus Dermatophagoides. Peptides
CC within the scope of the invention comprise at least one T cell epitope,
CC or preferably at least two T cell epitopes of a protein allergen selected
CC from the allergens Der p I, Der p II, Der f I, or Der f II. The invention
CC also describes modified peptides having similar or enhanced therapeutic
CC properties as the corresponding, naturally occurring allergen, but having
CC reduced side effects. AAW71912 to AAW72000, and AAW72257 to AAW72330
CC represent peptides from the present invention. (Updated on 25-MAR-2003 to
CC correct PR field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ Sequence 29 AA;

Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 103
AAY50390
ID AAY50390 standard; peptide; 29 AA.
XX
AC AAY50390;
XX
DT 25-JAN-2000 (first entry)
XX
DE Dermatophagoides sp major protein allergen DP I-28.1.
XX
KW Allergen; house dust mite; detection; sensitivity; T cell epitope;
KW screening; allergic disorder; asthma; rhinitis; ectopic dermatitis;
KW Der f I; Der p I; Der p II; Der f II.
XX
OS Dermatophagoides sp.
XX
PN US5968526-A.
XX
PD 19-OCT-1999.
XX
PF 07-JUN-1995; 95US-00478572.
XX
PR 14-APR-1994; 94US-00227772.
PR 12-APR-1995; 95WO-US004481.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Rogers BL, Franzen HM, Shaked Z;
PI Chen X, Evans S, Kuo M;
XX
DR WPI; 1999-590385/50.
XX
PT Screening individuals for allergic reactions to T cell epitopes of major
PT allergens from house dust mites.
XX
PS Claim 1d'; Column 99-100; 158pp; English.
XX
CC This invention describes a novel method (I) for detecting whether an
CC individual is sensitive to Dermatophagoides (house dust mites). The
CC method involves detecting sensitivity to house dust mites in patients,
CC comprising combining a blood sample from the individual with 1 or more
CC isolated T cell epitopes of the protein allergens I and II ((DP I) and
CC (DP II)) from Dermatophagoides (house dust mites). 32 T cell epitopes
CC with varying, defined amino acids sequences (given in the specification)
CC may be used in (I). The sample and allergens are combined under
CC conditions appropriate for the binding of blood components with the
CC polypeptides. The extent of binding is then indicative of the sensitivity
CC of the patient to house dust mites. (I) may be used to screen individuals
CC for sensitivity to Dermatophagoides (house dust mites). The house dust
CC mite is a major cause of a variety of allergic disorders such as asthma,
CC rhinitis and ectopic dermatitis. AAY50360-Y50542 and AAY50546-Y50555
CC represent house dust mite allergen peptide fragments derived from Der p
CC I, Der f II, Der f I and Der f II
XX
SQ Sequence 29 AA;

Query Match 100.0%; Score 19; DB 2; Length 29;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 104
AAU18993
ID AAU18993 standard; peptide; 29 AA.
XX
AC AAU18993;
XX
DT 04-DEC-2001 (first entry)
XX
DE T-cell epitope containing peptide DPI-28.1.
XX
KW House dust mite; allergenic peptide; Der p I; Der p II; Der f I;
KW Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KW T-cell epitope.
XX
OS Dermatophagoides pteronyssinus.
XX
PN US6268491-B1.
XX
PD 31-JUL-2001.
XX
PF 07-JUN-1995; 95US-00484296.
XX
PR 16-OCT-1991; 91US-00777859.
PR 08-MAY-1992; 92US-00881396.
PR 14-APR-1993; 93WO-US003471.
PR 14-APR-1994; 94US-00227772.
PR 19-MAY-1995; 95US-00445307.
XX
PA (IMMU-) IMMULOGIC PHARM CORP.
XX
PI Garman RD, Greenstein JL, Kuo M, Rogers BL, Franzen HM, Chen X;
PI Evans S, Shaked Z;
XX
DR WPI; 2001-549074/61.
XX
PT Peptides comprising T cell groups of the major allergens from
PT Dermatophagoides (house dust mites), useful for treating house dust mite
PT allergy in humans, and for diagnosing sensitivity to house dust mite
PT protein allergens.
XX
PS Claim 2; Fig 3; 158pp; English.
XX
CC The invention relates to an isolated peptide of the major protein
CC allergens of the genus Dermatophagoides, which comprises at least one T
CC cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC or DF II. The isolated peptide comprises at least two regions, each
CC region comprising at least one T cell group of a protein allergen of the

```
CC   genus Dermatophagoides. The regions are derived from the same or
CC   different protein allergens of the genus Dermatophagoides. The peptides
CC   are useful for treating house dust mite allergy in humans. The peptides
CC   are also useful for detecting or diagnosing sensitivity to house dust
CC   mite protein allergens. The present peptides have similar or enhanced
CC   therapeutic properties as the naturally-occurring allergen, but have
CC   reduced side effects, and increased solubility and stability. The present
CC   sequence represents an allergenic T-cell epitope containing peptide
CC   derived from the Dermatophagoides allergenic proteins
XX
SQ   Sequence 29 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 105
ADD35439
ID   ADD35439 standard; peptide; 29 AA.
XX
AC   ADD35439;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Streptococcus pneumoniae aroA peptide #2.
XX
KW   crystallised recombinant protein; metabolism; Staphylococcus aureus;
KW   Streptococcus pneumoniae; Helicobacter pylori; Escherichia coli;
KW   Pseudomonas aeruginosa; vaccine.
XX
OS   Streptococcus pneumoniae.
XX
PN   WO2003044185-A2.
XX
PD   30-MAY-2003.
XX
PF   21-NOV-2002; 2002WO-CA001768.
XX
PR   21-NOV-2001; 2001US-0332160P.
PR   27-NOV-2001; 2001US-0333661P.
PR   27-NOV-2001; 2001US-0333665P.
PR   18-DEC-2001; 2001US-0341770P.
PR   19-DEC-2001; 2001US-0341954P.
PR   19-DEC-2001; 2001US-0342003P.
PR   20-DEC-2001; 2001US-0342542P.
PR   21-DEC-2001; 2001US-0344252P.
PR   28-DEC-2001; 2001US-0343570P.
PR   28-DEC-2001; 2001US-0343606P.
PR   28-DEC-2001; 2001US-0343679P.
XX
PA   (AFFI-) AFFINIUM PHARM INC.
XX
PI   Edwards A,  Dharamsi A,  Vedadi M,  Alam MZ,  Awrey D,  Beattie B;
PI   Canadien V,  Domagala M,  Houston S,  Mansoury K,  Necakov S,  Nethery K;
PI   Ng I,  Pinder B,  Sheldrick B,  Vallee F,  Wrezel O;
XX
DR   WPI; 2003-513596/48.
XX
PT   New crystallized recombinant polypeptides from Staphylococcus aureus,
PT   Streptococcus pneumoniae, Helicobacter pylori or Pseudomonas aeruginosa
PT   involved in general metabolism, useful as drug targets for pathogenic
PT   bacteria.
XX
PS   Disclosure; SEQ ID NO 38; 277pp; English.
XX
CC   The invention comprises a crystallised recombinant protein that is
CC   involved in general metabolism, the recombinant protein may be from
CC   Staphylococcus aureus, Streptococcus pneumoniae, Helicobacter pylori,
CC   Escherichia coli or Pseudomonas aeruginosa. The crystallised recombinant
CC   protein of the invention is useful in the prevention (vaccine) or
CC   treatment of a disease or disorder caused by S. pneumoniae, H. pylori, E.
CC   coli or P. aeruginosa. The present amino acid sequence was used in the
CC   exemplification of the invention.
XX
SQ   Sequence 29 AA;

  Query Match             100.0%;  Score 19;  DB 7;  Length 29;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         21 AQGV 24


RESULT 106
AAW00643
ID   AAW00643 standard; peptide; 30 AA.
XX
AC   AAW00643;
XX
DT   19-NOV-1996  (first entry)
XX
DE   Human DEC-205 C-terminal peptide (aa1714-1743).
XX
KW   Dentritic and epithelial cell 205 kDa; DEC-205; receptor; C-type lectin;
KW   antigen presentation; immune stimulation; vaccine; immune suppression.
XX
OS   Homo sapiens.
XX
PN   WO9623882-A1.
XX
PD   08-AUG-1996.
XX
PF   31-JAN-1996;   96WO-US001383.
XX
PR   31-JAN-1995;   95US-00381528.
XX
PA   (UYRQ ) UNIV ROCKEFELLER.
XX
PI   Steinman RM,  Nussenzweig MC,  Swiggard WJ,  Jiang W;
XX
DR   WPI; 1996-371431/37.
XX
PT   Ligands for integral membrane protein DEC - useful in compsns. to target
PT   molecules to partic. areas of the body, e.g. for immune modulation, and
PT   to induce immune suppression.
XX
PS   Claim 8; Page 118; 152pp; English.
XX
CC   A peptide sequence (AAW00643) comprises the C-terminal portion (amino
CC   acids 1714-1743) of human DEC-205 (see also AAW00644), an integral
CC   membrane protein expressed by dendritic cells. DEC-205 is useful for
CC   screening for ligands useful in compsns. to target molecules to partic.
CC   areas of the body, e.g. for immune stimulation (i.e., vaccination) or
CC   immune suppression
XX
SQ   Sequence 30 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 30;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         15 AQGV 18


RESULT 107
ADF45511
ID   ADF45511 standard; peptide; 30 AA.
```

XX
AC ADF45511;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human NUDE1 exon 9b related amino acid sequence.
XX
KW DISC1 partner; DISC1; ATF4; KIAA1167; KIAA0380; AKAP450; NUDE1;
KW neuroleptic; gene therapy; schizophrenia; psychotic disorder;
KW mood disorder; human.
XX
OS Homo sapiens.
XX
PN WO2003102587-A1.
XX
PD 11-DEC-2003.
XX
PF 02-JUN-2003; 2003WO-GB002396.
XX
PR 01-JUN-2002; 2002GB-00012856.
XX
PA (UYED-) UNIV EDINBURGH.
XX
PI Millar K, Porteous DJ, Muir WJ, Blackwood D;
XX
DR WPI; 2004-053510/05.
XX
PT Screening for a candidate agent, useful in treating, ameliorating or
PT preventing schizophrenia, psychotic or mood disorder, comprises forming a
PT mixture comprising the candidate agent, a DISC1 partner polypeptide and
PT DISC1 polypeptide.
XX
PS Disclosure; Page 6; 88pp; English.
XX
CC The present invention describes a method of screening for a candidate
CC agent (I) which modulates an interaction between a DISC1 partner
CC polypeptide and DISC1 polypeptide, which comprises forming a mixture
CC comprising the candidate agent, a DISC1 partner polypeptide selected from
CC ATF4, KIAA1167, KIAA0380, AKAP450 or NUDE1 or their splice variants,
CC mutant, fragments or orthologues and DISC1 polypeptide. (I) has
CC neuroleptic activity, and can be used in gene therapy. The method is
CC useful for screening a candidate agent, which modulates an interaction
CC between a DISC1 partner polypeptide and DISC1 polypeptide. Mutant forms
CC of ATF4, KIAA1167, KIAA0380, AKAP450 or NUDE1 are useful for identify
CC agents which substantially restore a wild-type functional activity of a
CC native or mutated DISC1 polypeptide or a mutated form of ATF4, KIAA1167,
CC KIAA0380, AKAP450 or NUDE1. A polynucleotide sequence encoding ATF4,
CC KIAA1167, KIAA0380, AKAP450 or NUDE1 or its fragment, derivative, mutant
CC or orthologue or sequences complementary to the polynucleotide sequences
CC is useful in determining a loss of expression of any one of the DISC1
CC partner. The polynucleotide and polypeptides are useful in the
CC manufacture of a medicament for the treatment of schizophrenia, other
CC psychotic disorders and mood disorders. The present sequence is used in
CC the exemplification of the present invention.
XX
SQ Sequence 30 AA;

Query Match 100.0%; Score 19; DB 8; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 22 AQGV 25

RESULT 108
ADV85620
ID ADV85620 standard; peptide; 30 AA.
XX
AC ADV85620;
XX
DT 10-MAR-2005 (first entry)
XX
DE Human DEC-205 C-terminal sequence, SEQ ID 1.
XX
KW Cytostatic; Virucide; Antibacterial; Antiparasitic; Vaccine;
KW endocytic receptor; dendritic cell; infection; cancer; DEC-205.
XX
OS Homo sapiens.
XX
PN US2004258688-A1.
XX
PD 23-DEC-2004.
XX
PF 12-MAR-2004; 2004US-00800023.
XX
PR 31-JAN-1995; 95US-00381528.
PR 31-JAN-1996; 96WO-US001383.
PR 05-JUN-2000; 2000US-00586704.
PR 09-AUG-2001; 2001US-00925284.
XX
PA (HAWI/) HAWIGER D.
PA (NUSS/) NUSSENZWEIG M.
PA (STEI/) STEINMAN R M.
PA (BONI/) BONIFAZ L.
XX
PI Hawiger D, Nussenzweig M, Steinman RM, Bonifaz L;
XX
DR WPI; 2005-078933/09.
XX
PT Promoting antigen presentation comprises targeting antigen to dendritic
PT cells using an anti-DEC-205 antibody.
XX
PS Disclosure; SEQ ID NO 1; 116pp; English.
XX
CC The present invention relates to a method (M1) for promoting highly
CC efficient antigen presentation in a mammal, by targeting a preselected
CC antigen to an endocytic receptor on an antigen-presenting cell, e.g. a
CC dendritic cell. An example of a dendritic cell is the cell endocytic
CC receptor DEC-205. The method comprises exposing dendritic cells from the
CC mammal to either: a conjugate comprising a preselected antigen covalently
CC bound to an antibody to DEC-205; or a recombinant anti-DEC-205 antibody
CC genetically engineered to contain at least one preselected antigen on at
CC least one preselected site on the antibody molecule; and promoting
CC maturation of the dendritic cells. The sequence encoding an anti-DEC-205
CC antibody (fragment) is preferably selected from ADV85632 and ADV85633,
CC which encode the heavy or light chain variable region of an anti-DEC-205
CC antibody. The antigen is targeted to antigen presenting cells through the
CC inclusion of the anti-DEC-205 antibody, making antigen presentation
CC highly efficient. The immunity induced is robust and long lasting, even
CC from a single dose at low concentration. The method of the invention is
CC useful for immunizing a mammal to prevent or treat a disease such as a
CC viral, bacterial or other infection or cancer. The immunization
CC preferably results in induction of long term T cell, B cell or mucosal
CC immunity. The present sequence is a C-terminal fragment of the human DEC-
CC 205 protein, corresponding to residues 1714-1743 of the sequence given in
CC ADV85625.
XX
SQ Sequence 30 AA;

Query Match 100.0%; Score 19; DB 9; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 15 AQGV 18

RESULT 109
AAB27936
ID AAB27936 standard; peptide; 33 AA.
XX
AC AAB27936;
XX

DT 02-FEB-2001 (first entry)
XX
DE Human secreted protein SEQ ID NO: 90.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX
PN WO200055171-A1.
XX
PD 21-SEP-2000.
XX
PF 09-MAR-2000; 2000WO-US006043.
XX
PR 12-MAR-1999; 99US-0124146P.
PR 23-NOV-1999; 99US-0167061P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Komatsoulis G;
XX
DR WPI; 2000-638174/61.
DR N-PSDB; AAC59078.
XX
PT Isolated nucleic acid molecule encoding a human secreted protein is used
PT in preventing, treating or ameliorating a medical condition.
XX
PS Claim 11; Page 376; 438pp; English.
XX
CC Sequences AAB27907-B27956 represent the amino acid sequences of 50 human
CC secreted proteins encoded by the genes AAC59049-C59098. The genes and
CC proteins are useful for preventing, ameliorating or treating medical
CC conditions, e.g. by protein or gene therapy. The genes are isolated from
CC a range of human tissues disclosed in the specification. The nucleic
CC acids, proteins, antibodies and (ant)agonists are useful in the
CC diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer, and other cancers of the adrenal gland, bone, bone
CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital; (b)
CC immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections
XX
SQ Sequence 33 AA;

Query Match 100.0%; Score 19; DB 3; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 25 AQGV 28

RESULT 110
ADY97195
ID ADY97195 standard; peptide; 35 AA.
XX
AC ADY97195;
XX
DT 16-JUN-2005 (first entry)
XX
DE Herpes simplex virus type 2 (HSV-2) HLA-binding epitope peptide RS1-3.
XX
KW antigen; anti-HSV; virucide; HSV-1 infection; HSV-2 infection;
KW immunotherapy; vaccine.
XX
OS Human herpesvirus 2.
XX
PN WO2005028496-A2.
XX
PD 31-MAR-2005.
XX
PF 13-SEP-2004; 2004WO-US029908.
XX
PR 12-SEP-2003; 2003US-0503148P.
XX
PA (ANTI-) ANTIGENICS INC.
XX
PI Truneh A, Levey DL, Mo X, Leclair KP, Kashi RS, Liu C;
XX
DR WPI; 2005-262770/27.
XX
PT New composition comprising different antigenic peptides, each comprising
PT one or more HLA-binding epitopes of a different herpesvirus peptide,
PT useful for treating or preventing infection, e.g. herpes simplex virus 1
PT or 2 infection.
XX
PS Disclosure; SEQ ID NO 53; 114pp; English.
XX
CC The invention relates to a novel composition comprising different
CC antigenic peptides, whereby each peptide comprises one or more HLA-
CC binding epitopes of a different herpesvirus peptide selected from among
CC herpesvirus peptides differing in amino acid sequence, the amino acid
CC sequence of each herpesvirus peptide selected from SEQ ID Nos. 1-49,
CC given in the specification. The Herpesviruses include the Herpes simplex
CC viruses which, in turn, include two closely-related variants designated
CC types 1 (HSV-1) and 2 (HSV-2). HSV-1 and HSV-2 are associated in some
CC individuals with frequent and/or painful recurrences that manifest
CC themselves as cold sores and genital herpes, respectively. Although
CC continuous administration of antiviral drugs, such as acyclovir,
CC ameliorates the severity of HSV infection and reduces the frequency and
CC duration of associated episodes, such treatment does not tackle the
CC establishment of latency or indeed the state of the latent virus. There
CC currently exists no effective vaccine for the prevention or treatment of
CC HSV-1 or HSV-2. The composition of the invention demonstrates anti-HSV
CC and virucide activities and may be useful for treating or preventing
CC infection, preferably a recurrent infection by HSV-1 or HSV-2, possibly
CC via immunotherapy. The current sequence is that of a HSV-2 HLA-binding
CC epitope peptide of the invention.
XX
SQ Sequence 35 AA;

Query Match 100.0%; Score 19; DB 9; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 10 AQGV 13

RESULT 111
ADX56537
ID ADX56537 standard; peptide; 36 AA.
XX
AC ADX56537;
XX
DT 05-MAY-2005 (first entry)
XX
DE Cardiovascular disorder plasma protein tryptic fragment SEQ ID NO 354.
XX
KW coronary artery disease; primary biliary cirrhosis,; gallstones;
KW celiac disease; irritable bowel syndrome; diabetes; scleroderma; nausea;
KW emesis; constipation; diarrhea; cardiovascular disease; immune disorder;
KW endocrine disease; gastrointestinal disease; metabolic disorder;
KW dermatological disease; musculoskeletal disease; Cardiant; Vasotropic;
KW Hepatotropic; Litholytic; Immunosuppressive; Gastrointestinal-Gen.;
KW Antiinflammatory; Antidiabetic; Dermatological; Antiemetic; Laxative;

KW Antidiarrheic; diagnosis.
XX
OS Homo sapiens.
XX
PN WO2005015206-A2.
XX
PD 17-FEB-2005.
XX
PF 06-AUG-2004; 2004WO-EP008860.
XX
PR 08-AUG-2003; 2003US-0493599P.
PR 08-AUG-2003; 2003US-0493836P.
PR 08-AUG-2003; 2003US-0493867P.
PR 08-AUG-2003; 2003US-0493985P.
XX
PA (XENO-) XENOVA LTD.
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.
XX
PI Argoud-Puy G, Bederr N, Bougueleret L, Cusin I, Mahe E;
PI Niknejad A, Reffas S, Rose K, Saudrais C, Scherer A, Papoian R;
XX
DR WPI; 2005-195824/20.
XX
PT Screening and/or diagnosing cardiovascular disorder in subject involves
PT detecting and/or quantifying level of polypeptide in biological sample
PT from subject and comparing with control sample.
XX
PS Claim 1; SEQ ID NO 354; 349pp; English.
XX
CC The invention relates to a method of screening and/or diagnosing a
CC cardiovascular disorder (CD) in a subject which comprises detecting
CC and/or quantifying the level of a polypeptide in a biological sample from
CC the subject and comparing the level to that of control sample. The method
CC is useful for screening, diagnosing and treating coronary artery disease,
CC biliary cirrhosis, gallstones, celiac disease, irritable bowel syndrome,
CC diabetes, scleroderma, nausea, vomiting, constipation and diarrhea. The
CC method is rapid and efficient. The present sequence represents a
CC cardiovascular disorder plasma protein tryptic fragment.
XX
SQ Sequence 36 AA;

Query Match 100.0%; Score 19; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 3 AQGV 6

RESULT 112
AAR25974
ID AAR25974 standard; protein; 37 AA.
XX
AC AAR25974;
XX
DT 25-MAR-2003 (revised)
DT 21-JAN-1993 (first entry)
XX
DE Peptide monomer 12.
XX
KW Reverse peptide; microbial pathogen; phytotoxicity; head-to-tail;
KW proteolytic degradation; dimer; peptide bond; bridging group; omega loop.
XX
OS Synthetic.
XX
PN EP497366-A2.
XX
PD 05-AUG-1992.
XX
PF 31-JAN-1992; 92EP-00101616.
XX
PR 01-FEB-1991; 91US-00649784.
XX
PA (DONG) IST DONEGANI SPA GUIDO.
PA (ENIE) ENICHEM SPA.
XX
PI Mapelli C, Dugas De Robertis C, Stahl GF, Bascomb NF;
PI Swerdloff MD, Williams JI, Everett NP;
XX
DR WPI; 1992-260816/32.
XX
PT Reverse antimicrobial peptide(s) and oligopeptide(s) - useful for
PT protecting plants from pathogens and for determining phytotoxicity.
XX
PS Disclosure; Fig 1; 79pp; English.
XX
CC The sequences given in AAR25963-83 are a collection of natural and
CC reverse peptides which are active against at least one microbial pathogen
CC and, preferably, at least one plant pathogen. It has been found that
CC acceptable activity and acceptable levels of protection against at least
CC one microbial pathogen and at least one microbial plant pathogen may be
CC obtained by reversing the sequence of amino acids contained within
CC naturally occuring antimicrobial peptides while maintaining the
CC directionality of the peptide bonds. These peptides possess relatively
CC low phytotoxicity and/or low susceptibility to proteolytic degradation.
CC The oligopeptides may be used as dimers composed of two peptide units
CC with or without an intervening bridge. The simplest structure taken by
CC these dimers is the "head-to-tail" configuration. This comprises at least
CC one first peptide monomer and at least one second peptide monomer. Each
CC peptide monomer has an N- and C-terminus, both of which are capable of
CC forming peptide bonds. In the head-to-tail configuration the C-terminal
CC amino acid of the first monomer peptide is directly bound to the N-
CC terminus of the second monomer peptide, by a peptide bond, without an
CC intervening bridging group. In other peptide dimers bridging groups may
CC be used and may be as few as one amino acid but may be as large as 100
CC amino acids in length and form omega loops or other secondary structures.
CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to
CC correct PA field.)
XX
SQ Sequence 37 AA;

Query Match 100.0%; Score 19; DB 2; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 113
AAY21614
ID AAY21614 standard; peptide; 37 AA.
XX
AC AAY21614;
XX
DT 20-MAR-2003 (revised)
DT 11-AUG-1999 (first entry)
XX
DE Antimicrobial oligopeptide.
XX
KW Antimicrobial; oligopeptide; cecropin P1; microbial pathogen; magainin;
KW plant pathogen; food additive; preservative; cosmetic; pharmaceutical.
XX
OS Synthetic.
XX
PN EP919566-A2.
XX
PD 02-JUN-1999.
XX
PF 31-JAN-1992; 98EP-00121780.
XX
PR 01-FEB-1991; 91US-00649784.
PR 31-JAN-1992; 92EP-00101616.

XX
PA (ENIE) ENICHEM SPA.
XX
PI Mapelli C, Dugas De Robertis C, Stahl GF, Bascomb NF;
PI Swerdloff MD, Williams JI, Everett NP;
XX
DR WPI; 1999-304793/26.
XX
PT New oligopeptides containing at least two antimicrobial peptides, useful
PT for protecting plants against microbial pathogens.
XX
PS Claim 26; Fig 1; 67pp; English.
XX
CC The invention relates to antimicrobial peptides including reverse
CC antimicrobial peptides, antimicrobial oligopeptides and other
CC antimicrobial compositions such as cecropin P1. The antimicrobial
CC oligopeptides are active against at least one microbial pathogen, and
CC comprise at least one of a first and one of a second peptide monomer,
CC interconnected directly through a peptide bond via the N and C terminals,
CC or indirectly through a disulfide bond or via bridges. At least one of
CC the first and second monomers confers activity. Oligopeptides connected
CC by bridges do not have the structure of Magainin Pre-pro protein. The
CC antimicrobial peptides are used for providing protection to plants
CC against plant pathogens, thus enhancing crop yields. The peptides are
CC also useful for treatment of human or animal disease, as an additive to
CC foods for preservation, or as a preservative in cosmetics and
CC pharmaceuticals. Unlike prior art antimicrobial peptides Magainins 1 and
CC 2, the new antimicrobial peptides don't have undesirable properties, are
CC not subject to extensive proteolytic degradation, are not phytotoxic to
CC the cell, and have a broader range of activity. The present sequence
CC represents an antimicrobial oligopeptide. (Updated on 20-MAR-2003 to
CC correct PF field.) (Updated on 20-MAR-2003 to correct PR field.)
XX
SQ Sequence 37 AA;

Query Match 100.0%; Score 19; DB 2; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 114
AAY92803
ID AAY92803 standard; peptide; 37 AA.
XX
AC AAY92803;
XX
DT 29-AUG-2000 (first entry)
XX
DE Synthetic antimicrobial peptide, reverse cecropin A amide (Rev2).
XX
KW Magainin; antimicrobial; transgenic plant; protease degradation; Rev4;
KW indolicidin; protein production; reverse peptide.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 37
FT /note= "amidated"
XX
PN WO200026344-A1.
XX
PD 11-MAY-2000.
XX
PF 29-OCT-1999; 99WO-US025561.
XX
PR 30-OCT-1998; 98US-0106373P.
PR 02-NOV-1998; 98US-0106537P.
XX
PA (INTE-) INTERLINK BIOTECHNOLOGIES LLC.
PA (KENT) UNIV KENTUCKY RES FOUND.
XX
PI Everett NP, Li Q, Lawrence C, Davies MH;
XX
DR WPI; 2000-365597/31.
XX
PT Polypeptides for reducing proteolytic degradation of proteins
PT administered to, or produced by a plant comprise indolicin or its
PT functional equivalents.
XX
PS Example 7; Page 34; 50pp; English.
XX
CC Indolicidin is a potent antimicrobial tridecapeptide, originally purified
CC from cytoplasmic granules of bovine neutrophils. Reverse peptide, Rev4 of
CC indolicidin (see AAY92794) was found to have increased stability against
CC plant protease degradation. The ranking of peptide stabilities against
CC proteases present in plant extracellular fluid was shown to be Rev4
CC (AAY92796) > Rev6 (AAY92801) > Rev3 (AAY92802) > Rev2 > Rev8 (AAY92804).
CC Expression of antimicrobial peptides in transgenic plants suffers a major
CC limitation in that the foreign peptides are susceptible to rapid
CC degradation by proteases. The invention concerns reducing the extent of
CC protease degradation of a protein applied to, or produced by a plant by
CC administering indolicidin, Rev4 or a functional equivalent to the plant.
CC Transgenic plants expressing indolicidin and Rev4 are useful for
CC production of the antimicrobial peptides. Compositions containing
CC indolicidin and Rev4 are also useful for production of agronomically
CC important proteins in plants
XX
SQ Sequence 37 AA;

Query Match 100.0%; Score 19; DB 3; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 115
ADC73331
ID ADC73331 standard; peptide; 37 AA.
XX
AC ADC73331;
XX
DT 01-JAN-2004 (first entry)
XX
DE Bovine antibacterial peptide Indolicidin, reverse peptide Rev2.
XX
KW Antibacterial peptide; antibacterial; protease resistance; Rev4;
KW Indolicidin; plant disease; Rev2.
XX
OS Synthetic.
XX
PN US2003131383-A1.
XX
PD 10-JUL-2003.
XX
PF 23-SEP-2002; 2002US-00252773.
XX
PR 30-OCT-1998; 98US-0106373P.
PR 02-NOV-1998; 98US-0106573P.
PR 29-OCT-1999; 99US-00431546.
XX
PA (INTE-) INTERLINK BIOTECHNOLOGIES LLC.
XX
PI Everett NP, Li Q, Lawrence C, Davies HM;
XX
DR WPI; 2003-829607/77.
XX
PT New Rev4 peptide having enhanced stability to protease degradation,
PT useful for controlling plant diseases and protecting other peptides from
PT degradation by proteases of plant, fungal, viral, bacterial, insect or

PT other origin.
XX
PS Example 7; SEQ ID NO 11; 21pp; English.
XX
CC The invention relates to a peptide comprising an amino acid sequence,
CC designated as Rev4 (ADC73324), or its functional equivalent. Rev4 is a
CC reverse peptide analogue of bovine Indolicidin. Also included is a
CC composition for use in protecting a peptide, polypeptide or protein from
CC protease degradation comprising Rev4 or its functional equivalent and a
CC carrier. The peptides and compositions of the present invention are
CC useful for the control of plant diseases and protecting other peptides
CC from degradation by proteases of plant, fungal, viral, bacterial, insect
CC or other origin. The present sequence is an Indolicidin reverse peptide
CC Rev2.
XX
SQ Sequence 37 AA;

Query Match 100.0%; Score 19; DB 7; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 116
ABO59877
ID ABO59877 standard; protein; 38 AA.
XX
AC ABO59877;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #6111.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 33511; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 38 AA;

Query Match 100.0%; Score 19; DB 8; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 24 AQGV 27

RESULT 117
ADZ97828
ID ADZ97828 standard; protein; 40 AA.
XX
AC ADZ97828;
XX
DT 14-JUL-2005 (first entry)
XX
DE Human coronavirus 229E protease (amino acid residues 121-160).
XX
KW severe acute respiratory syndrome; SARS coronavirus infection;
KW respiratory disease; protease; infection; virucide; respiratory-gen. .
XX
OS Human coronavirus 229E.
XX
PN WO2005041904-A2.
XX
PD 12-MAY-2005.
XX
PF 01-NOV-2004; 2004WO-US038391.
XX
PR 31-OCT-2003; 2003US-0516008P.
XX
PA (FULC-) FULCRUM PHARM INC.
XX
PI Freire E, Ottenbrite R, Xiao Y, Velazquez-Campoy A, Leavitt S;
PI Bacha U, Barrila J;
XX
DR WPI; 2005-356029/36.
XX
PT New boron-containing compounds are coronavirus protease inhibitors useful
PT to treat infection caused by coronavirus (severe acute respiratory
PT syndrome-associated coronavirus).
XX
PS Disclosure; SEQ ID NO 18; 418pp; English.

```
XX
CC   The invention relates to boron-containing compounds that are inhibitors
CC   of severe acute respiratory syndrome (SARS) coronavirus protease. The
CC   boron-containing compounds, e.g. boric acid or boronic acids of formulae
CC   (1-4), are fully defined in the specification. Also described are: a
CC   method for inhibiting coronavirus protease comprising contacting the
CC   coronavirus protease with a boron-containing compound, and a method for
CC   detecting coronavirus in a test sample comprising contacting the sample
CC   with a boron-containing compound. The SARS coronavirus protease has one
CC   or more serine or threonine residues at or near its active site.
CC   Administration of a boron-containing compound of the invention is by
CC   oral, rectal, sub-lingual, mucosal, nasal, ophthalmic, subcutaneous,
CC   intramuscular, intravenous, transdermal, spinal, intrathecal, intra-
CC   articular, intra-arterial, sub-arachinoid, bronchial, lymphatic, or
CC   intrauterille methods. The invention specifically discloses 403 boron-
CC   containing compounds. The boron-containing compounds are useful for
CC   treating infection caused by SARS coronavirus. This sequence represents a
CC   region (amino acid residues 121-160) of a coronavirus protease that shows
CC   homology with the same region of other coronavirus proteases.
XX
SQ   Sequence 40 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          3 AQGV 6


RESULT 118
ABU17305
ID   ABU17305 standard; protein; 41 AA.
XX
AC   ABU17305;
XX
DT   19-JUN-2003  (first entry)
XX
DE   Protein encoded by Prokaryotic essential gene #2832.
XX
KW   Antisense; prokaryotic essential gene; cell proliferation; drug design.
XX
OS   Acinetobacter baumannii.
XX
PN   WO200277183-A2.
XX
PD   03-OCT-2002.
XX
PF   21-MAR-2002; 2002WO-US009107.
XX
PR   21-MAR-2001; 2001US-00815242.
PR   06-SEP-2001; 2001US-00948993.
PR   25-OCT-2001; 2001US-0342923P.
PR   08-FEB-2002; 2002US-00072851.
PR   06-MAR-2002; 2002US-0362699P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Wang L,  Zamudio C,  Malone C,  Haselbeck R,  Ohlsen KL,  Zyskind JW;
PI   Wall D,  Trawick JD,  Carr GJ,  Yamamoto R,  Forsyth RA,  Xu HH;
XX
DR   WPI; 2003-029926/02.
DR   N-PSDB; ACA21175.
XX
PT   New antisense nucleic acids, useful for identifying proteins or screening
PT   for homologous nucleic acids required for cellular proliferation to
PT   isolate candidate molecules for rational drug discovery programs.
XX
PS   Claim 25; SEQ ID NO 45229; 1766pp; English.
XX
CC   The invention relates to an isolated nucleic acid comprising any one of
CC   the 6213 antisense sequences given in the specification where expression
CC   of the nucleic acid inhibits proliferation of a cell. Also included are:
CC   (1) a vector comprising a promoter operably linked to the nucleic acid
CC   encoding a polypeptide whose expression is inhibited by the antisense
CC   nucleic acid; (2) a host cell containing the vector; (3) an isolated
CC   polypeptide or its fragment whose expression is inhibited by the
CC   antisense nucleic acid; (4) an antibody capable of specifically binding
CC   the polypeptide;(5) producing the polypeptide; (6) inhibiting cellular
CC   proliferation or the activity of a gene in an operon required for
CC   proliferation; (7) identifying a compound that influences the activity of
CC   the gene product or that has an activity against a biological pathway
CC   required for proliferation, or that inhibits cellular proliferation; (8)
CC   identifying a gene required for cellular proliferation or the biological
CC   pathway in which a proliferation-required gene or its gene product lies
CC   or a gene on which the test compound that inhibits proliferation of an
CC   organism acts; (9) manufacturing an antibiotic; (10) profiling a
CC   compound's activity; (11) a culture comprising strains in which the gene
CC   product is overexpressed or underexpressed; (12) determining the extent
CC   to which each of the strains is present in a culture or collection of
CC   strains; or (13) identifying the target of a compound that inhibits the
CC   proliferation of an organism. The antisense nucleic acids are useful for
CC   identifying proteins or screening for homologous nucleic acids required
CC   for cellular proliferation to isolate candidate molecules for rational
CC   drug discovery programs, or for screening homologous nucleic acids
CC   required for proliferation in cells other than S. aureus, S. typhimurium,
CC   K. pneumoniae or P. aeruginosa. The present sequence is encoded by one of
CC   the target prokaryotic essential genes. Note: The sequence data for this
CC   patent did not form part of the printed specification, but was obtained
CC   in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 41 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 41;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 119
AEB94393
ID   AEB94393 standard; protein; 41 AA.
XX
AC   AEB94393;
XX
DT   20-OCT-2005  (first entry)
XX
DE   Human AMDP-3 protein, SEQ ID NO: 115.
XX
KW   AMDP-related gene modulator; phagocytosis-related gene modulator;
KW   age related macular degeneration; ophthalmological; ocular disease;
KW   phagocytosis; therapeutic; animal disease model; screening; AMDP-3.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Encoded by ACC"
XX
PN   US2005176662-A1.
XX
PD   11-AUG-2005.
XX
PF   09-FEB-2004; 2004US-00773446.
XX
PR   09-FEB-2004; 2004US-00773446.
XX
PA   (UYMI-) UNIV MIAMI.
XX
PI   Inana G,  Mclaren M;
XX
```

DR WPI; 2005-541777/55.
DR N-PSDB; AEB94295.
XX
PT Method for delaying/reversing a retinal or choroidal degenerative disease
PT or condition in a subject comprises contacting a retinal or choroidal
PT cell with an agent that modulates the expression/activity of a
PT phagocytosis-related gene.
XX
PS Disclosure; SEQ ID NO 115; 142pp; English.
XX
CC The present invention relates to multiple genes related to age-related
CC macular degeneration (AMD) and/or phagocytosis by retinal pigment
CC epithelial (RPE) cells of the eye. The methods and compositions of the
CC invention includes detecting and treating AMD and other retinal
CC degenerative conditions based on these phagocytosis-related and/or AMD-
CC related genes. The invention is useful for delaying/reversing/treating a
CC retinal or choroidal degenerative disease or condition such as age-
CC related macular degeneration (AMD) in a subject who is suffering from AMD
CC or at risk of developing AMD. The invention also provides animal models
CC useful for testing therapeutic compounds and treatment protocols for AMD
CC and gene arrays including polymorphic variants of phagocytosis-related
CC and/or AMD-related genes, useful in genetic screening of nucleic acid
CC samples from subjects to obtains profiles of polymorphic variant
CC sequences in a plurality of genes associated with AMD. The present
CC sequence is human AMDP-3 (also designated as AMD-related phagogene; AMDP
CC gene) protein.
XX
SQ Sequence 41 AA;

Query Match 100.0%; Score 19; DB 9; Length 41;
Best Local Similarity 100.0%; Pred. No. 1.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 12 AQGV 15

RESULT 120
AAM24224
ID AAM24224 standard; protein; 45 AA.
XX
AC AAM24224;
XX
DT 12-OCT-2001 (first entry)
XX
DE Human EST encoded protein SEQ ID NO: 1749.
XX
KW Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW diagnostics; forensic test; gene mapping; genetic disorder; biodiversity;
KW gene therapy; nutrition.
XX
OS Homo sapiens.
XX
PN WO200154477-A2.
XX
PD 02-AUG-2001.
XX
PF 25-JAN-2001; 2001WO-US002687.
XX
PR 25-JAN-2000; 2000US-00491404.
PR 17-JUL-2000; 2000US-00617746.
PR 03-AUG-2000; 2000US-00631451.
PR 15-SEP-2000; 2000US-00663870.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
PI Cao Y, Drmanac RA, Zhang J, Werhman T;
XX
DR WPI; 2001-476164/51.
DR N-PSDB; AAH98883.
XX
PT Isolated polypeptide for treatment of diseases, diagnostics, raising
PT antibodies and research use.
XX
PS Claim 20; Page 1154; 1275pp; English.
XX
CC The present invention provides the protein and coding sequences of novel
CC proteins from a variety of organisms, including human, dog, cat, horse,
CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC from the organism of interest. They can be used in diagnostics,
CC forensics, gene mapping, identification of mutations, to assess
CC biodiversity and for nutritional purposes. The present sequence is a
CC protein of the invention
XX
SQ Sequence 45 AA;

Query Match 100.0%; Score 19; DB 4; Length 45;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 40 AQGV 43

RESULT 121
ABB90716
ID ABB90716 standard; peptide; 45 AA.
XX
AC ABB90716;
XX
DT 29-AUG-2003 (revised)
DT 29-JUL-2002 (first entry)
XX
DE Chlamydia pneumoniae cp7107 protein homology region.
XX
KW Chlamydial infection; antigen; immunogen; vaccine; diagnosis;
KW human respiratory disease; cardiovascular disease; atherosclerosis;
KW coronary artery disease; carotid artery stenosis; myocardial infarction;
KW cerebrovascular disease; aortic aneurysm; claudication; stroke;
KW strain CWL029.
XX
OS Chlamydophila pneumoniae.
XX
PN WO200202606-A2.
XX
PD 10-JAN-2002.
XX
PF 03-JUL-2001; 2001WO-IB001445.
XX
PR 03-JUL-2000; 2000GB-00016363.
PR 11-JUL-2000; 2000GB-00017047.
PR 21-JUL-2000; 2000GB-00017983.
PR 07-AUG-2000; 2000GB-00019368.
PR 18-AUG-2000; 2000GB-00020440.
PR 14-SEP-2000; 2000GB-00022583.
PR 10-NOV-2000; 2000GB-00027549.
PR 22-DEC-2000; 2000GB-00031706.
XX
PA (CHIR-) CHIRON SPA.
XX
PI Ratti G, Grandi G;
XX
DR WPI; 2002-154726/20.
XX
PT Novel Chlamydia pneumoniae protein useful in the manufacture of a
PT medicament for treatment or prevention of infection due to Chlamydia,
PT preferably Chlamydia pneumoniae, and for diagnostic purposes.
XX
PS Disclosure; Fig 191; 364pp; English.
XX
CC Sequences ABB90526-ABB90715 represent novel proteins from Chlamydia

```
CC   pneumoniae (strain CWL029), and ABL91184-ABL91373 represent DNA encoding
CC   them. The proteins are predicted to be immunogenic and may therefore be
CC   useful in vaccine production and for diagnostic purposes. Chlamydia
CC   pneumoniae is a common cause of respiratory disease in humans, and is
CC   also involved in the development of cardiovascular diseases such as
CC   atherosclerosis, coronary artery disease, carotid artery stenosis,
CC   myocardial infarction, cerebrovascular disease, aortic aneurysm,
CC   claudication and stroke. The proteins and nucleic acids of the invention
CC   may be used in vaccines and pharmaceutical compositions for the
CC   prevention or treatment of chlamydial infections, particularly Chlamydia
CC   pneumoniae infections. The proteins may also be used in the detection of
CC   Chlamydia pneumoniae, and the nucleic acids may be used in PCR, branched
CC   DNA probe assay or blotting techniques for determining Chlamydia
CC   pneumoniae gene expression. Sequences ABB90716-ABB90720 represent regions
CC   of Chlamydia pneumoniae proteins of the invention which share some
CC   sequence homology. (Updated on 29-AUG-2003 to standardise OS field)
XX
SQ   Sequence 45 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 45;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         37 AQGV 40


RESULT 122
AAR69856
ID   AAR69856 standard; peptide; 49 AA.
XX
AC   AAR69856;
XX
DT   25-MAR-2003  (revised)
DT   18-MAR-1995  (first entry)
XX
DE   Fibronectin peptide.
XX
KW   Rheumatoid arthritis; diagnosis; therapy; fibronectin; streptokinase.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .49
FT                   /note= "amino acids 1741-1790 of fibronectin"
FT   Misc-difference 27. .32
FT                   /note= "SEQ ID No.1"
XX
PN   WO9417411-A1.
XX
PD   04-AUG-1994.
XX
PF   27-JAN-1994;   94WO-US001077.
XX
PR   27-JAN-1993;   93US-00009471.
XX
PA   (UYDU-) UNIV DUKE.
PA   (TRIN-) TRINITY LAB INC.
XX
PI   Pizzo SV,  Gonzalez-Gronow M,  Clinton BA;
XX
DR   WPI; 1994-264260/32.
XX
PT   Diagnosis and treatment of rheumatoid arthritis - using a predictive
PT   factor peptide corresp. to a region common to fibronectin and
PT   streptokinase.
XX
PS   Disclosure; Page 55; 83pp; English.
XX
CC   The peptide corresponds to amino acids 1741-1790 of fibronectin, and
CC   regions of sequence similarity with AAR57728 (streptokinase peptide) are
CC   shown in Fig.1. A common peptide region is highlighted, and this peptide
CC   is used in the diagnosis of the onset/presence of rheumatoid arthritis,
CC   for monitoring the progress of therapy, or for therapy. (Updated on 25-
CC   MAR-2003 to correct PN field.)
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         32 AQGV 35


RESULT 123
ABB09222
ID   ABB09222 standard; peptide; 49 AA.
XX
AC   ABB09222;
XX
DT   08-JUL-2002  (first entry)
XX
DE   Mouse putative transmembrane anchor sequence SEQ ID NO:16.
XX
KW   GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
KW   glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
KW   glial cell line derived neurotrophic factor; osteopathic; tumour;
KW   neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
KW   medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
KW   neuronal disorder; aberrant axonal sprouting.
XX
OS   Mus musculus.
XX
PN   WO200162795-A1.
XX
PD   30-AUG-2001.
XX
PF   14-NOV-2000; 2000WO-FI000994.
XX
PR   21-FEB-2000; 2000FI-00000394.
XX
PA   (LICE-) LICENTIA LTD.
XX
PI   Airaksinen M,  Saarma M,  Poteriaev D,  Lindahl M,  Timmusk T;
PI   Rossi J;
XX
DR   WPI; 2001-596722/67.
XX
PT   New nucleic acid sequence for manufacturing polypeptides for treating
PT   endocrine cancers comprises a cDNA encoding a splicing isoform of
PT   mammalian growth factor receptor (GFR)alpha4.
XX
PS   Disclosure; Page 127; 143pp; English.
XX
CC   The present invention describes an isolated and purified cDNA sequence
CC   encoding a splicing isoform of a mammalian growth factor receptor
CC   (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
CC   osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
CC   a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
CC   neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
CC   polynucleotide sequence can be used for recording GFRalpha4 mediated
CC   signalling in neurons or endocrine cells such as thyroid calcitonin-
CC   producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
CC   cells from the pituitary intermediate lobe. GFRalpha4 protein and
CC   polynucleotide sequences can be are used for manufacturing polypeptides
CC   useful for diagnosing and/or treating tumours in parathyroid gland cells,
CC   adrenal chromaffin cells, cells of pituitary intermediate lobe,
CC   neoplasia, endocrine tumours, medullary thyroid carcinoma and
CC   pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
CC   preventing neuronal death or aberrant axonal sprouting. The present
CC   sequence represents the mouse putative transmembrane anchor sequence,
CC   which can be used in the identification and isolation of nucleotide
```

```
CC   sequences encoding GFRalpha4 proteins in the present invention
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         21 AQGV 24


RESULT 124
ADN11831
ID   ADN11831 standard; peptide; 49 AA.
XX
AC   ADN11831;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Fibronectin fragment.
XX
KW   mannose-6-phosphate/insulin-like growth factor-2 receptor; CD222;
KW   fibrinolysis; cell adhesion; cell migration;
KW   transforming growth factor beta; TGFb; activation; apoptosis;
KW   arteriosclerosis; restenosis; autoimmunity; inflammation; cancer;
KW   streptokinase; plasminogen activation; vasotropic; cytostatic;
KW   immunosuppressive; antiinflammatory.
XX
OS   Unidentified.
XX
PN   WO2004013177-A1.
XX
PD   12-FEB-2004.
XX
PF   05-AUG-2003; 2003WO-AT000224.
XX
PR   06-AUG-2002; 2002AT-00001193.
XX
PA   (STOC/) STOCKINGER H.
XX
PI   Stockinger H,  Binder B,  Leksa V,  Godar S,  Breuss J;
XX
DR   WPI; 2004-157103/15.
XX
PT   Use of mannose-6-phosphate/insulin-like growth factor-2 receptor (CD222)
PT   as regulator of urokinase plasminogen activator functions, useful for
PT   treating arteriosclerosis, restenosis, autoimmunity, inflammation and
PT   cancer.
XX
PS   Disclosure; Fig 4; 35pp; German.
XX
CC   This invention describes a novel mannose-6-phosphate/insulin-like growth
CC   factor-2 receptor (CD222) and its fragments or derivatives, as regulator
CC   of fibrinolysis, cell adhesion or migration, transforming growth factor
CC   beta (TGFb) activation and apoptosis, specifically arteriosclerosis,
CC   restenosis, autoimmunity, inflammation and cancer. The N-terminal region
CC   of CD222 (which is similar to streptokinase) is the active component, and
CC   can be used in the form of a peptide or other derivative. CD222 regulates
CC   plasminogen activation, cell adhesion and migration, TGFb activation and
CC   apoptosis mediated through the urokinase-type plasminogen activator (uPA)
CC   receptor (CD87). The products of the invention have antiarteriosclerotic,
CC   vasotropic, cytostatic, immunosuppressive and antiinflammatory activity.
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 125
ABO54048
ID   ABO54048 standard; protein; 49 AA.
XX
AC   ABO54048;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human genome derived single exon protein #282.
XX
KW   Human; gene expression; single exon probe; microarray;
KW   alternative splicing event; genomic alteration.
XX
OS   Homo sapiens.
XX
PN   US2003194704-A1.
XX
PD   16-OCT-2003.
XX
PF   03-APR-2002; 2002US-00029386.
XX
PR   03-APR-2002; 2002US-00029386.
XX
PA   (PENN/) PENN S G.
PA   (RANK/) RANK D R.
PA   (HANZ/) HANZEL D K.
XX
PI   Penn SG,  Rank DR,  Hanzel DK;
XX
DR   WPI; 2004-119264/12.
XX
PT   New human genome-derived single exon nucleic acid probes useful for human
PT   gene expression analysis, for identifying or characterizing alternative
PT   splicing events, for assessing genomic alterations or as tools for
PT   surveying tissues.
XX
PS   Claim 45; SEQ ID NO 27682; 80pp; English.
XX
CC   The invention relates to a nucleic acid probe for measuring human gene
CC   expression, comprising any of the 27,400 fully defined nucleotide
CC   sequences in the specification, or their complements or fragments, and
CC   encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC   fully defined in the specification. The probe is a single exon probe that
CC   hybridises under high stringency conditions to a nucleic acid molecule
CC   expressed in human cells or tissues. Also included are a spatially-
CC   addressable set of single exon nucleic acid probes for measuring human
CC   gene expression (comprising a plurality of single exon nucleic acid
CC   probes cited above, where each of the plurality of probes is separately
CC   and addressably isolatable or amplifiable from the plurality), a single
CC   exon microarray for measuring human gene expression, a method of
CC   measuring human gene expression, a vector comprising the single exon
CC   probe cited above, an ORF-encoded peptide comprising at least 8
CC   contiguous amino acids of any of the above- mentioned amino acid
CC   sequences (optionally with conservative amino acid substitutions), an
CC   isolated antibody that binds specifically to a peptide cited above,
CC   methods of selling and/or licensing single exon probes or microarrays to
CC   a customer desiring to measure gene expression, a method of providing
CC   human gene expression data by subscription, and a computer-readable
CC   storage medium which contains a database having a plurality of records
CC   (each record including data on the expression of a single exon probe
CC   cited above. The probe, methods and apparatus are useful in gene
CC   expression analysis. The probes may be used as tools for surveying
CC   tissues to detect the presence of expressed messages that contain their
CC   specific exon, or in constructing genome-derived single exon microarrays.
CC   In addition, the probes are used in identifying and characterising
CC   alternative splicing events, in detecting and characterising gross
CC   alterations in the genomic locus that includes their exon, in assessing
CC   smaller genomic alterations, in priming the synthesis of nucleic acids,
CC   or in expressing the ORF-encoded peptide. The present sequence is a human
CC   single exon probe protein of the invention. Note: The sequence data for
```

```
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from USPTO at
CC   seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ   Sequence 49 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 49;
  Best Local Similarity   100.0%;  Pred. No. 2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47


RESULT 126
AAE18040
ID   AAE18040 standard; protein; 51 AA.
XX
AC   AAE18040;
XX
DT   07-MAY-2002  (first entry)
XX
DE   Human ion channel, ion-172.
XX
KW   Human; ion channel; neurological disorder; psychiatric disorder;
KW   schizophrenia; attention deficit hyperactivity disorder; depression;
KW   proliferation disease; migraine; ischaemia; neurodegenerative disease;
KW   macular degeneration; Alzheimer's disease; congestive heart failure;
KW   glaucoma; Parkinson's disease; cardiovascular disease; arrhythmia;
KW   high blood pressure; restenosis; metabolic disease; neuroprotective;
KW   obesity; hormonal disorder; polycystic ovarian syndrome; gene therapy;
KW   alopecia; anxiety; stroke; neuroleptic; nootropic; cancer; diabetes.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 28. .29
FT                   /note= "Encoded by AGCTGAAGC of the inverse complementary
FT                   strand of SEQ.ID.NO.16 (AAD28740)"
XX
PN   WO200192303-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016967.
XX
PR   26-MAY-2000; 2000US-0207119P.
PR   26-MAY-2000; 2000US-0207152P.
PR   26-MAY-2000; 2000US-0207257P.
XX
PA   (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI   Benjamin CW,  Roberds SL,  Karnovsky AM,  Ruble CL,  Gotow LF;
XX
DR   WPI; 2002-147617/19.
DR   N-PSDB; AAD28740.
XX
PT   New human ion channel polypeptides and nucleic acids, useful for treating
PT   or diagnosing neurological, psychiatric or neurodegenerative diseases,
PT   e.g. depression, anxiety, stroke, ischemia, or Alzheimer's or Parkinson's
PT   disease.
XX
PS   Claim 31; Page 78; 126pp; English.
XX
CC   The invention relates to ion channel polypeptides designated as ion-x
CC   (where x is 157-175) and their corresponding nucleic acids. The ion-x
CC   sequences and their modulators are useful for the treatment of human
CC   diseases and conditions such as neurological or psychiatric disorders.
CC   These compounds are useful for treating schizophrenia, attention deficit
CC   hyperactivity disorder, depression, anxiety, stroke, migraine, ischaemia
CC   or neurodegenerative disease (e.g. macular degeneration, Alzheimer's
CC   disease, glaucoma, or Parkinson's disease). The compounds that modulate
CC   ion channels can be used for treating of cardiovascular diseases (e.g.
CC   congestive heart failure, arrhythmia, high blood pressure or restenosis),
CC   metabolic diseases and disorders (e.g. diabetes or obesity), hormonal
CC   disorders (e.g. polycystic ovarian syndrome or alopecia) and
CC   proliferation diseases and cancers. The ion channels are also useful as
CC   targets for discovering ligands or drugs to treat many diverse disorders
CC   and defects. The ion-x sequences and their modulators may also be used in
CC   diagnostic assays for such diseases or conditions. Ion-x nucleic acids
CC   are used in gene therapy. The present amino acid sequence is human ion
CC   channel designated as ion-172
XX
SQ   Sequence 51 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 51;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 127
ADN48261
ID   ADN48261 standard; protein; 51 AA.
XX
AC   ADN48261;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Thermococcus kodakaraensis KOD1 protein sequence SeqID2139.
XX
KW   gene disruption; gene targeting; marker gene; transformation;
KW   homologous recombination; hyperthermostable archaebacterium; KOD1;
KW   gene structure; gene function; enzyme activity; medicine;
KW   forensic science; food; drug inspection; molecular biology; immunology.
XX
OS   Thermococcus kodakaraensis.
XX
PN   WO2004022736-A1.
XX
PD   18-MAR-2004.
XX
PF   29-AUG-2003; 2003WO-IB003597.
XX
PR   30-AUG-2002; 2002JP-00319011.
XX
PA   (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI   Imanaka T,  Atomi H;
XX
DR   WPI; 2004-257583/24.
XX
PT   Method for disrupting targeted gene in genome of organism particularly
PT   thermostable bacterium and with genome chips for analysis, applicable in
PT   studying gene structure and functions.
XX
PS   Claim 9; SEQ ID NO 2139; 598pp; Japanese.
XX
CC   This invention relates to a novel method for targeting disruption of an
CC   arbitrary gene in a genome of an organism which comprises providing the
CC   whole sequential data of the genome of such organism, selecting at least
CC   1 arbitrary region in the sequence, providing a vector that contains a
CC   sequence homologous with the selected region and a marker gene,
CC   transformation, and homologous recombination. The genome is preferably
CC   the genome of a hyperthermostable archaebacterium, particularly
CC   Thermococcus kodakaraensis KOD1. The method is for targeting the
CC   disruption of a gene in the genome of an organism, which is applicable in
CC   studying gene structure and functions as well as enzyme activities of
CC   encoded proteins and useful in medicine, forensic science, food or drug
CC   inspection, molecular biology and immunology. With this method, the
CC   disruption of a gene at an arbitrary position in a genome can be achieved
CC   efficiently and reliably. The present sequence is that of a protein
```

```
CC   encoded by the genome of Thermococcus kodakaraensis which was derived
CC   using the method of the invention. Note: The sequence data for this
CC   patent did not form part of the printed specification, but was obtained
CC   in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 51 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 51;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          2 AQGV 5


RESULT 128
AAM86353
ID   AAM86353 standard; protein; 52 AA.
XX
AC   AAM86353;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:13946.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001354.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231968P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
PR   20-OCT-2000; 2000US-0241787P.
PR   20-OCT-2000; 2000US-0241808P.
PR   20-OCT-2000; 2000US-0241809P.
PR   20-OCT-2000; 2000US-0241826P.
PR   01-NOV-2000; 2000US-0244617P.
PR   08-NOV-2000; 2000US-0246474P.
PR   08-NOV-2000; 2000US-0246475P.
PR   08-NOV-2000; 2000US-0246476P.
PR   08-NOV-2000; 2000US-0246477P.
PR   08-NOV-2000; 2000US-0246478P.
PR   08-NOV-2000; 2000US-0246523P.
PR   08-NOV-2000; 2000US-0246524P.
PR   08-NOV-2000; 2000US-0246525P.
PR   08-NOV-2000; 2000US-0246526P.
PR   08-NOV-2000; 2000US-0246527P.
PR   08-NOV-2000; 2000US-0246528P.
PR   08-NOV-2000; 2000US-0246532P.
PR   08-NOV-2000; 2000US-0246609P.
PR   08-NOV-2000; 2000US-0246610P.
PR   08-NOV-2000; 2000US-0246611P.
PR   08-NOV-2000; 2000US-0246613P.
PR   17-NOV-2000; 2000US-0249207P.
PR   17-NOV-2000; 2000US-0249208P.
PR   17-NOV-2000; 2000US-0249209P.
PR   17-NOV-2000; 2000US-0249210P.
```

```
PR   17-NOV-2000; 2000US-0249211P.
PR   17-NOV-2000; 2000US-0249212P.
PR   17-NOV-2000; 2000US-0249213P.
PR   17-NOV-2000; 2000US-0249214P.
PR   17-NOV-2000; 2000US-0249215P.
PR   17-NOV-2000; 2000US-0249216P.
PR   17-NOV-2000; 2000US-0249217P.
PR   17-NOV-2000; 2000US-0249218P.
PR   17-NOV-2000; 2000US-0249244P.
PR   17-NOV-2000; 2000US-0249245P.
PR   17-NOV-2000; 2000US-0249264P.
PR   17-NOV-2000; 2000US-0249265P.
PR   17-NOV-2000; 2000US-0249297P.
PR   17-NOV-2000; 2000US-0249299P.
PR   17-NOV-2000; 2000US-0249300P.
PR   01-DEC-2000; 2000US-0250160P.
PR   01-DEC-2000; 2000US-0250391P.
PR   05-DEC-2000; 2000US-0251030P.
PR   05-DEC-2000; 2000US-0251988P.
PR   05-DEC-2000; 2000US-0256719P.
PR   06-DEC-2000; 2000US-0251479P.
PR   08-DEC-2000; 2000US-0251856P.
PR   08-DEC-2000; 2000US-0251868P.
PR   08-DEC-2000; 2000US-0251869P.
PR   08-DEC-2000; 2000US-0251989P.
PR   08-DEC-2000; 2000US-0251990P.
PR   11-DEC-2000; 2000US-0254097P.
PR   05-JAN-2001; 2001US-0259678P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   N-PSDB; AAK59134.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
PS   Claim 11; SEQ ID NO 13946; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting the
CC   nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention
XX
SQ   Sequence 52 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 52;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         27 AQGV 30


RESULT 129
AAB58486
ID   AAB58486 standard; protein; 53 AA.
XX
AC   AAB58486;
XX
DT   14-MAR-2001  (first entry)
XX
DE   Lung cancer associated polypeptide sequence SEQ ID 824.
XX
KW   Human; lung cancer associated protein; neuroprotective; cytostatic;
KW   cardioactive; immunomodulatory; muscular active; vulnerary;
KW   gastrointestinal; nephrotropic; antiinfective; gynecological;
KW   antibacterial; diagnosis; neural disorder; immune disorder; reproductive;
KW   proliferative disorder; wound healing; infectious disease.
XX
OS   Homo sapiens.
XX
PN   WO200055180-A2.
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US005918.
XX
PR   12-MAR-1999;   99US-0124270P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
PA   (ROSE/) ROSEN C A.
XX
PI   Ruben SM;
XX
DR   WPI; 2000-587514/55.
DR   N-PSDB; AAF18362.
XX
PT   Lung cancer associated gene sequences, referred to as lung cancer
PT   antigens, useful for treatment, prevention, and diagnosis of disorders
PT   such as lung cancer.
XX
PS   Claim 11; Page 1366; 1425pp; English.
XX
CC   Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer
CC   associated proteins represented in AAB58106 - AAB58548. Lung cancer
CC   associated proteins and polynucleotide sequences, their agonists, and
CC   antagonists may have neuroprotective; cytostatic; cardioactive;
CC   immunomodulatory; muscular active general; vulnerary; gastrointestinal
CC   general; nephrotropic; antiinfective; gynecological; or antibacterial
CC   activity. The invention also includes antibodies specific for the protein
CC   or polynucleotide sequences. The lung cancer associated polynucleotide
CC   sequences may be used for detection of lung cancer, chromosome
CC   identification, as chromosome markers, and for numerous other diagnostic
CC   or research purposes. The proteins may be used to treat disorders such as
CC   neural, immune, muscular, reproductive, gastrointestinal, pulmonary,
CC   cardiovascular, renal, and proliferative disorders. The proteins may also
CC   be used in the treatment of wounds and infectious diseases.
CC   Polynucleotide sequences AAF18425 - AAF18433 and peptide AAB58549 are
CC   used in the course of the invention for the identification and
CC   characterisation of the polynucleotide and protein sequences
XX
SQ   Sequence 53 AA;

  Query Match             100.0%;  Score 19;  DB 3;  Length 53;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 130
ABP00538
ID   ABP00538 standard; protein; 53 AA.
XX
AC   ABP00538;
XX
DT   24-JUN-2002  (first entry)
```

```
XX
DE   Human ORFX protein sequence SEQ ID NO:1058.
XX
KW   Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW   hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW   degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW   cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW   hypertension; hypothyroidism; cholesterol ester storage disease;
KW   immune deficiency; immune disorder; infectious disease;
KW   autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW   myasthenia gravis.
XX
OS   Homo sapiens.
XX
PN   WO200192523-A2.
XX
PD   06-DEC-2001.
XX
PF   29-MAY-2001; 2001WO-US010836.
XX
PR   30-MAY-2000; 2000US-0206132P.
PR   29-AUG-2000; 2000US-0228716P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Leach MD;
XX
DR   WPI; 2002-106308/14.
DR   N-PSDB; ABN16290.
XX
PT   Novel human polypeptides and polynucleotides useful for diagnosing,
PT   preventing and treating cardiovascular disease, neurodegenerative,
PT   hyperproliferative disorders and autoimmune disorders.
XX
PS   Disclosure; SEQ ID NO 1058; 1037pp; English.
XX
CC   The present invention describes substantially purified human proteins
CC   (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC   in the specification). ABN15762 to ABN27252 encode the human ORFX
CC   proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC   treating or preventing a pathology associated with an ORFX-associated
CC   disorder in humans, and in the manufacture of a medicament for treating a
CC   syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC   sequences can be used in gene therapy. ORFX sequences can be used in the
CC   treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC   psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC   osteoarthritis, neurodegenerative disorders, disorders related to organ
CC   transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC   lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC   storage disease, various immune deficiencies and disorders, infectious
CC   diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC   arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC   disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC   useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC   bone degenerative disorders, or periodontal disease, and for gut
CC   protection or regeneration and treatment of lung or liver fibrosis,
CC   reperfusion injury in various tissues and conditions resulting from
CC   systemic cytokine damage. N.B. The sequence data for this patent did not
CC   form part of the printed specification, but was obtained in electronic
CC   format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 53 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 53;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11

RESULT 131
AAE24593
ID   AAE24593 standard; protein; 54 AA.
XX
AC   AAE24593;
XX
DT   04-OCT-2002  (first entry)
XX
DE   Fish E93 programmed cell death modulating protein conserved domain.
XX
KW   Fish; cancer; programmed cell death modulating protein; adenocarcinoma;
KW   cellular apoptosis; leukaemia; acquired immunodeficiency syndrome; AIDS;
KW   neurodegenerative disease; Alzheimer's disease; retinitis pigmentosa;
KW   Parkinson's disease; myelodysplastic syndrome; cerebellar degeneration;
KW   aplastic anaemia; ischaemic injury; myocardial infarction; stroke;
KW   reperfusion injury; toxin-induced disease; genetic immunodeficiency;
KW   vaccine; gene therapy; lymphoma; cytostatic; melanoma; neuroprotective;
KW   myeloma; nootropic; vasotropic; immunostimulant; cerebroprotective;
KW   cardiant; E93 protein.
XX
OS   Tetraodon nigroviridis.
XX
PN   WO200234882-A2.
XX
PD   02-MAY-2002.
XX
PF   29-OCT-2001; 2001WO-US048053.
XX
PR   27-OCT-2000; 2000US-0243865P.
XX
PA   (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
PI   Baehrecke EH;
XX
DR   WPI; 2002-479717/51.
XX
PT   Novel programmed cell death modulating proteins, useful for treating or
PT   preventing disorders associated with abnormal cell proliferation and
PT   apoptosis such as cancer, stroke, Parkinson's disease, myocardial
PT   infarction.
XX
PS   Claim 1; Fig 1; 88pp; English.
XX
CC   The present invention relates to novel programmed cell death modulating
CC   proteins and polynucleotides encoding such proteins. Sequences of the
CC   invention are useful to screen potential cellular apoptosis inhibiting
CC   compounds to determine their use as therapeutic agents for treatment of
CC   diseases associated with increased programmed cell death. They are also
CC   useful for treating or preventing disorders associated with decrease in
CC   apoptosis. Programmed cell death modulating sequences are useful for
CC   treating or preventing cancer e.g. adenocarcinoma, leukaemia, lymphoma,
CC   melanoma, myeloma. Inhibition of the activity of the sequences of the
CC   invention are useful for treating disorders associated with increase in
CC   cell death or apoptosis such as acquired immunodeficiency syndrome
CC   (AIDS), neurodegenerative diseases (e.g., Alzheimer's disease, retinitis
CC   pigmentosa, Parkinson's disease and cerebellar degeneration), ischaemic
CC   injuries (e.g., myocardial infarction, stroke, reperfusion injury),
CC   myelodysplastic syndromes (e.g., aplastic anaemia), toxin-induced
CC   diseases and other infectious or genetic immunodeficiencies. Sequences of
CC   the invention are used as vaccines and in gene therapy. The present
CC   sequence is fish E93 programmed cell death modulating protein conserved
CC   domain
XX
SQ   Sequence 54 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 54;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         36 AQGV 39
```

```
RESULT 132
ABB03527
ID   ABB03527 standard; protein; 55 AA.
XX
AC   ABB03527;
XX
DT   08-JAN-2002  (first entry)
XX
DE   Human musculoskeletal system related polypeptide SEQ ID NO 1474.
XX
KW   Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW   antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW   vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW   cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; human; secreted protein;
KW   musculoskeletal system.
XX
OS   Homo sapiens.
XX
PN   WO200155367-A1.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001338.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231968P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
PR   20-OCT-2000; 2000US-0241787P.
PR   20-OCT-2000; 2000US-0241808P.
PR   20-OCT-2000; 2000US-0241809P.
PR   20-OCT-2000; 2000US-0241826P.
PR   01-NOV-2000; 2000US-0244617P.
PR   08-NOV-2000; 2000US-0246474P.
PR   08-NOV-2000; 2000US-0246475P.
PR   08-NOV-2000; 2000US-0246476P.
PR   08-NOV-2000; 2000US-0246477P.
PR   08-NOV-2000; 2000US-0246478P.
PR   08-NOV-2000; 2000US-0246523P.
PR   08-NOV-2000; 2000US-0246524P.
PR   08-NOV-2000; 2000US-0246525P.
PR   08-NOV-2000; 2000US-0246526P.
PR   08-NOV-2000; 2000US-0246527P.
PR   08-NOV-2000; 2000US-0246528P.
PR   08-NOV-2000; 2000US-0246532P.
PR   08-NOV-2000; 2000US-0246609P.
PR   08-NOV-2000; 2000US-0246610P.
PR   08-NOV-2000; 2000US-0246611P.
PR   08-NOV-2000; 2000US-0246613P.
PR   17-NOV-2000; 2000US-0249207P.
PR   17-NOV-2000; 2000US-0249208P.
PR   17-NOV-2000; 2000US-0249209P.
PR   17-NOV-2000; 2000US-0249210P.
PR   17-NOV-2000; 2000US-0249211P.
PR   17-NOV-2000; 2000US-0249212P.
PR   17-NOV-2000; 2000US-0249213P.
PR   17-NOV-2000; 2000US-0249214P.
PR   17-NOV-2000; 2000US-0249215P.
PR   17-NOV-2000; 2000US-0249216P.
PR   17-NOV-2000; 2000US-0249217P.
PR   17-NOV-2000; 2000US-0249218P.
PR   17-NOV-2000; 2000US-0249244P.
PR   17-NOV-2000; 2000US-0249245P.
PR   17-NOV-2000; 2000US-0249264P.
PR   17-NOV-2000; 2000US-0249265P.
PR   17-NOV-2000; 2000US-0249297P.
```

```
PR   17-NOV-2000; 2000US-0249299P.
PR   17-NOV-2000; 2000US-0249300P.
PR   01-DEC-2000; 2000US-0250160P.
PR   01-DEC-2000; 2000US-0250391P.
PR   05-DEC-2000; 2000US-0251030P.
PR   05-DEC-2000; 2000US-0251988P.
PR   05-DEC-2000; 2000US-0256719P.
PR   06-DEC-2000; 2000US-0251479P.
PR   08-DEC-2000; 2000US-0251856P.
PR   08-DEC-2000; 2000US-0251868P.
PR   08-DEC-2000; 2000US-0251869P.
PR   08-DEC-2000; 2000US-0251989P.
PR   08-DEC-2000; 2000US-0251990P.
PR   11-DEC-2000; 2000US-0254097P.
PR   05-JAN-2001; 2001US-0259678P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-451937/48.
DR   N-PSDB; AAL35109.
XX
PT   Isolated polypeptide for treating, preventing and/ or prognosing
PT   disorders related to the musculoskeletal system including musculoskeletal
PT   cancers and also for testing and detection e.g. diagnosis.
XX
PS   Claim 11; SEQ ID NO 1474; 781pp + Sequence Listing; English.
XX
CC   The invention relates to novel genes (AAL34669-AAL37666) and proteins
CC   (ABB03087-ABB04109) associated with the musculoskeletal system useful for
CC   preventing, treating or ameliorating medical conditions e.g. by protein
CC   or gene therapy. The genes are isolated from a range of human tissues
CC   disclosed in the specification. The nucleic acids, proteins, antibodies
CC   and (ant)agonists are useful in the diagnosis, treatment and prevention
CC   of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the
CC   adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC   lung, or urogenital; (b) immune disorders e.g. Addison's disease,
CC   allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC   diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC   arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC   myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC   cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC   bacterial, fungal and parasitic infections. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 55 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 55;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 133
ABU12821
ID   ABU12821 standard; protein; 55 AA.
XX
AC   ABU12821;
XX
DT   26-FEB-2003  (first entry)
XX
DE   Novel human musculoskeletal system antigen #441.
XX
KW   Musculoskeletal system antigen; cancer; metastasis; re-vascularisation;
KW   thrombosis; arteriosclerosis; mineral content; cardiovascular condition;
KW   wound; injury; burn; angiogenesis; ulcer; post-operative tissue repair;
KW   limb regeneration; neuronal growth; neurodegenerative disorder;
KW   Alzheimer's disease; Parkinson's disease; AIDS-related complex;
KW   chondrocyte growth; bone regeneration; periodontal regeneration;
KW   tissue transport; bone graft; skin aging; keratinocyte growth; hair loss;
KW   melanocyte growth; cell proliferation; cell growth; organ transplant;
KW   cell differentiation; body height; weight; hair colour; eye colour; skin;
KW   percentage of adipose tissue; pigmentation; cosmetic surgery; metabolism;
KW   biorhythm; caricadic rhythm; depression; tendency for violence; pain;
KW   reproductive capability; hormone level; endocrine level; appetite;
KW   libido; memory; stress; storage capability; fat content; lipid content;
KW   protein content; carbohydrate content; vitamin content; cofactor content;
KW   nutritional component.
XX
OS   Homo sapiens.
XX
PN   US2002147140-A1.
XX
PD   10-OCT-2002.
XX
PF   17-JAN-2001; 2001US-00764877.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   28-JUN-2000; 2000US-0214886P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   22-AUG-2000; 2000US-0226868P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   08-SEP-2000; 2000US-0231413P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   27-SEP-2000; 2000US-0235834P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241809P.
PR   01-NOV-2000; 2000US-0244617P.
PR   17-NOV-2000; 2000US-0249299P.
PR   08-DEC-2000; 2000US-0251856P.
PR   08-DEC-2000; 2000US-0251868P.
PR   08-DEC-2000; 2000US-0251869P.
XX
PA   (ROSE/) ROSEN C A.
PA   (RUBE/) RUBEN S M.
```

PA (BARA/) BARASH S C.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2003-128199/12.
DR N-PSDB; ABX58097.
XX
PT Isolated nucleic acid molecules encoding musculoskeletal system
PT associated polypeptides, useful for detecting disorders, e.g. cancer.
XX
PS Claim 11; SEQ ID NO 1474; 321pp; English.
XX
CC The invention describes an isolated nucleic acid molecule comprising a
CC sequence encoding musculoskeletal system associated polypeptides useful
CC for detecting disorders, e.g., cancer or cancer metastases, in animals or
CC humans. The nucleic acid: stimulates re-vascularisation of ischaemic
CC tissues associated with conditions such as thrombosis, arteriosclerosis,
CC and other cardiovascular conditions; treats wounds due to injuries,
CC burns, post-operative tissue repair, and ulcers; stimulates angiogenesis
CC and limb regeneration; stimulates neuronal growth; can treat and prevent
CC neuronal damage occurring in certain disorders or neurodegenerative
CC conditions, such as, Alzheimer's disease, Parkinson's disease, and AIDS-
CC related complex; stimulates chondrocyte growth, thus they can be used to
CC enhance bone and periodontal regeneration and aid in tissue transports or
CC bone grafts; prevents skin aging due to sunburn by stimulating
CC keratinocyte growth; prevents hair loss, since FGF family members
CC activate hair-forming cells and promotes melanocyte growth; stimulates
CC growth and differentiation of hematopoietic cells and bone marrow cells
CC when used in combination with other cytokines; maintains organs before
CC transplantation or for supporting cell culture of primary tissues;
CC induces tissue of mesodermal origin to differentiate in early embryos;
CC increases or decreases the differentiation or proliferation of embryonic
CC stem cells, besides, haematopoietic lineage; modulates mammalian
CC characteristics, such as, body height, weight, hair colour, eye colour,
CC skin, percentage of adipose tissue, pigmentation, size, and shape (e.g.,
CC cosmetic surgery); modulates mammalian metabolism; changes mammal's metal
CC state or physical state by influencing biorhythms, caricadic rhythms,
CC depression, tendency for violence, tolerance for pain, reproductive
CC capabilities, hormonal or endocrine levels, appetite, libido, memory, or
CC stress; increases or decreases storage capabilities, fat content, lipid,
CC protein, carbohydrate, vitamins, minerals, cofactors or other nutritional
CC components. This is the amino acid sequence of a novel human
CC musculoskeletal system antigen. Note: The sequence data for this patent
CC did not form part of the printed specification, but was obtained in
CC electronic format directly from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID=20020147140
XX
SQ Sequence 55 AA;

Query Match 100.0%; Score 19; DB 6; Length 55;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              ||||
Db         17 AQGV 20
```

RESULT 134
ADJ28847
ID ADJ28847 standard; protein; 55 AA.
XX
AC ADJ28847;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human musculoskeletal system-associated protein - SEQ ID 1474.
XX
KW musculoskeletal system; cytostatic; osteopathic; cancer; osteoporosis;
KW gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX

PN US2004009488-A1.
XX
PD 15-JAN-2004.
XX
PF 13-SEP-2002; 2002US-00242515.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.

PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
PR 17-JAN-2001; 2001US-00764877.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2004-090458/09.
DR N-PSDB; ADJ27824.
XX
PT New nucleic acid molecule, useful for preparing a medicament for
PT preventing, treating or ameliorating a medical condition e.g., cancer of
PT musculoskeletal tissues or osteoporosis.
XX
PS Claim 11; SEQ ID NO 1474; 289pp; English.
XX
CC The invention relates to a novel isolated musculoskeletal system-
CC associated nucleic acid molecule. The nucleic acid of the invention
CC demonstrates cytostatic and osteopathic activities and may be useful for
CC preparing a medicament for preventing, treating or ameliorating a medical
CC condition such as cancer of the musculoskeletal tissues or osteoporosis,
CC possibly via gene therapy or vaccine production. The current sequence is
CC that of the human musculoskeletal system-associated polypeptide of the
CC invention. The current sequence is not shown within the specification per
CC se but is available on the USPTO web-site
CC http:seqdata.uspto.gov/sequence.html?DocID=20040009488.
XX
SQ Sequence 55 AA;

Query Match 100.0%; Score 19; DB 8; Length 55;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 135
AAR41885
ID AAR41885 standard; peptide; 56 AA.
XX
AC AAR41885;
XX
DT 25-MAR-2003 (revised)
DT 22-APR-1994 (first entry)
XX
DE Granulin E.
XX
KW Granulin; keratinocytes; wound healing; inhibition; peptide;
KW granulocytes; leucocytes.
XX
OS Homo sapiens.
XX
PN WO9315195-A1.
XX
PD 05-AUG-1993.
XX
PF 28-FEB-1992; 92WO-CA000089.
XX
PR 03-FEB-1992; 92US-00829233.
XX
PA (SOLO/) SOLOMON S.
XX
PI Solomon S;
XX
DR WPI; 1993-320328/40.
XX
PT New cystine rich granulin peptide(s) from leucocyte(s) - are keratinocyte
PT inhibitors useful topically for wound healing.
XX
PS Claim 8; Page 33; 53pp; English.
XX
CC The granulin inhibits keratinocytes and is useful in formulations for
CC promoting the healing of wounds. This peptide was designated granulin E.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 56 AA;

```
  Query Match             100.0%;  Score 19;  DB 2;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 136
AAB50390
ID   AAB50390 standard; protein; 56 AA.
XX
AC   AAB50390;
XX
DT   12-MAR-2001  (first entry)
XX
DE   Human uncoupling protein #13.
XX
KW   Human; uncoupling protein; immunosuppressive; antiarthritic;
KW   antirheumatic; antiproliferative; cardiant; vasotropic;
KW   cerebroprotective; neuroprotective, antibacterial; opthalmological;
KW   gastrointestinal; nephrotropic; gynaecological; vulnerary; thrombolytic;
KW   gene therapy; cancer; wound; infectious disease; thrombosis; arthritis;
KW   infertility.
XX
OS   Homo sapiens.
XX
PN   WO200061614-A2.
XX
PD   19-OCT-2000.
XX
PF   06-APR-2000; 2000WO-US009534.
XX
PR   09-APR-1999;   99US-0128701P.
PR   08-JUL-1999;   99US-0142821P.
PR   18-AUG-1999;   99US-0149448P.
PR   12-NOV-1999;   99US-0164751P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Komatsoulis G,  Rosen CA,  Soppet DR;
XX
DR   WPI; 2000-656322/63.
DR   N-PSDB; AAC90464.
XX
PT   Uncoupling proteins and nucleic acid sequences encoding them, useful for
PT   detecting, preventing and treating proliferative, neurological, immune
PT   system, cardiovascular and gastrointestinal disorders.
XX
PS   Claim 11; Page 330; 343pp; English.
XX
CC   The present sequence is a human uncoupling protein. The nucleotide
CC   sequences encoding the uncoupling proteins may be used for the detection
CC   of various disorders such as cancer, for chromosome identification, as
CC   chromosome markers and for numerous other diagnostic or research
CC   purposes. The uncoupling protein encoded by the nucleotide sequences may
CC   be used to treat disorders such as neural, immune, muscular,
CC   reproductive, gastrointestinal, pulmonary, cardiovascular, renal and
CC   proliferative disorders, wounds, infectious diseases, thrombosis,
CC   arthritis, and infertility
XX
SQ   Sequence 56 AA;

  Query Match             100.0%;  Score 19;  DB 3;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         39 AQGV 42


RESULT 137
ABB40247
ID   ABB40247 standard; peptide; 56 AA.
XX
AC   ABB40247;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #7753 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 32882; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 56 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 138
AAM33926
ID   AAM33926 standard; protein; 56 AA.
XX
AC   AAM33926;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #7963 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
```

OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 34195; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 56 AA;

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 139
AAM73737
ID AAM73737 standard; protein; 56 AA.
XX
AC AAM73737;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 34043.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 34043; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 56 AA;

Query Match 100.0%; Score 19; DB 4; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 140
AAM61034
ID AAM61034 standard; protein; 56 AA.
XX
AC AAM61034;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 33139.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 33139; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,

```
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 56 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 141
ABG55482
ID   ABG55482 standard; peptide; 56 AA.
XX
AC   ABG55482;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 34130.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 34130; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 56 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          6 AQGV 9


RESULT 142
ABG43619
ID   ABG43619 standard; peptide; 56 AA.
XX
AC   ABG43619;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 33284.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US000665.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples.
XX
PS   Claim 27; SEQ ID NO 33284; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
```

CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of
CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 56 AA;

Query Match 100.0%; Score 19; DB 5; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 143
ABP42752
ID ABP42752 standard; protein; 56 AA.
XX
AC ABP42752;
XX
DT 22-AUG-2002 (first entry)
XX
DE Human ovarian antigen HOVEN86, SEQ ID NO:3884.
XX
KW Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW inflammatory condition; immune disorder; blood disorder;
KW cardiovascular disorder; respiratory disorder; neurological disorder;
KW gastrointestinal disorder; urinary system disorder; drug screening;
KW gene therapy; chromosome mapping; forensic analysis;
KW antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW antiinflammatory; gynaecological; reproductive.
XX
OS Homo sapiens.
XX
PN WO200200677-A1.
XX
PD 03-JAN-2002.
XX
PF 07-JUN-2001; 2001WO-US018569.
XX
PR 07-JUN-2000; 2000US-0209467P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Birse CE, Rosen CA;
XX
DR WPI; 2002-147878/19.
DR N-PSDB; ABQ55829.
XX
PT Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian
PT cancer), immune disorders, cardiovascular disorders and neurological
PT diseases.
XX
PS Claim 11; SEQ ID NO 3884; 2922pp; English.
XX
CC The invention relates to 2175 novel human ovarian antigens (ABP41054-
CC ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
CC encompasses polypeptides 90% identical and polynucleotides 95% identical
CC to the sequences of the invention. The invention additionally relates to
CC recombinant vectors and host cells comprising human ovarian antigen
CC polynucleotides, antibodies against human ovarian antigens, and the use
CC of ovarian antigen polynucleotides and polypeptides in diagnosing,
CC treating, prognosing or preventing various ovary and/or breast-related
CC disorders. Such conditions include ovarian cancer and breast cancer, and
CC metastatic tumours of ovarian or breast origin, reproductive system
CC disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
CC vaginitis), immune disorders (e.g., congenital and acquired
CC immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
CC blood-related disorders (e.g., anaemia), cardiovascular disorders,
CC respiratory disorders, neurological disorders, gastrointestinal disorders
CC and urinary system disorders. Ovarian antigen polypeptides and
CC polynucleotides may also be used in screening for compounds which
CC modulate ovarian antigen expression or activity. The polynucleotides may
CC further be used for gene therapy, chromosome mapping, in the
CC identification of individuals and in forensic analysis, and the
CC polypeptides may be used as food additives or to prepare antibodies
CC useful in disease diagnosis, drug targeting and phenotyping. The present
CC sequence represents a human ovarian antigen of the invention. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 56 AA;

Query Match 100.0%; Score 19; DB 5; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 28 AQGV 31

RESULT 144
ADL27363
ID ADL27363 standard; peptide; 56 AA.
XX
AC ADL27363;
XX
DT 03-JUN-2004 (first entry)
XX
DE Amino acid sequence of the DEC-205 transmembrane cytoplasmic domain.
XX
KW allergen; endoplasmic reticulum; LAMP-1;
KW Lysosome-Associated Membrane Protein 1; tissue plasminogen activator;
KW LAMP-II; Lysosome-Associated Membrane Protein 2; DEC-205; P-selectin;
KW tyrosinase; GLUT4; glucose transporter; endotubin; Nef protein; lysosome;
KW Blo t5; Blo 11; Der p1; Der p2; Der p3; Der f1; Der f2; Der f3;
KW T helper cell epitope; allergic reaction; asthma; rhinitis.
XX
OS Homo sapiens.
XX
PN WO2004019978-A1.
XX
PD 11-MAR-2004.
XX
PF 29-AUG-2003; 2003WO-SG000205.
XX
PR 29-AUG-2002; 2002US-0406659P.
XX

PA (UYSI-) UNIV SINGAPORE NAT.
XX
PI Chua KY, Liew LN;
XX
DR WPI; 2004-239125/22.
XX
PT New recombinant nucleic acid comprising a gene encoding a first signal
PT peptide operably linked to a gene encoding an allergen, useful for the
PT manufacture of a medicament for treating or preventing an allergic
PT reaction, e.g., asthma.
XX
PS Disclosure; Page 67; 79pp; English.
XX
CC The specification describes a recombinant nucleic acid comprising a gene
CC encoding a first signal peptide operably linked to a gene encoding an
CC allergen, where the first signal peptide mediates the translocation of
CC the allergen into the endoplasmic reticulum. The first signal peptide is
CC the N-terminal signal peptide of LAMP-1 (Lysosome-Associated Membrane
CC Protein 1), human tissue plasminogen activator, LAMP-II (Lysosome-
CC Associated Membrane Protein 2), DEC-205, P-selectin, tyrosinase, GLUT4
CC (glucose transporter), endotubin or Nef protein or its equivalent. The
CC nucleic acid further comprises an operably linked gene encoding a second
CC signal peptide where the second signal peptide targets the allergen to an
CC endosome or lysosome. The second signal peptide is the C-terminal
CC lysosome or endosome targeting sequence of LAMP-1, human tissue
CC plasminogen activator, LAMP-11, DEC-205, P-selectin, tyrosinase, GLUT4,
CC endotubin or Nef protein or its equivalent. The nucleic acid encodes the
CC allergen Blo t5, Blo 11, Der pl or Der p2, Der p3, Der f1, Der f2, Der
CC f3, a T helper cell epitope or its antigenic fragment containing one or
CC more T helper cell epitope or its functional equivalent. The recombinant
CC nucleic acid is useful for the manufacture of a medicament for treating
CC or preventing an allergic reaction, e.g. asthma or rhinitis. The present
CC sequence represents a peptide, which is used to construct nucleic acids
CC of the invention.
XX
SQ Sequence 56 AA;

Query Match 100.0%; Score 19; DB 8; Length 56;
Best Local Similarity 100.0%; Pred. No. 2.3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 41 AQGV 44

RESULT 145
ABP07528
ID ABP07528 standard; protein; 58 AA.
XX
AC ABP07528;
XX
DT 24-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:15038.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN23280.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 15038; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 58 AA;

Query Match 100.0%; Score 19; DB 5; Length 58;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 35 AQGV 38

RESULT 146
ABO59983
ID ABO59983 standard; protein; 58 AA.
XX
AC ABO59983;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #6217.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX

PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 33617; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 58 AA;

Query Match 100.0%; Score 19; DB 8; Length 58;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 31 AQGV 34

RESULT 147
AEA79702
ID AEA79702 standard; protein; 58 AA.
XX
AC AEA79702;
XX
DT 11-AUG-2005 (first entry)
XX
DE Cellulomonas sp. isolate 69B4 serine protease fragment SEQ ID NO 12.
XX
KW serine protease; cellulomonadin; feedstuff; textile; leather;
KW protein engineering; enzyme engineering.
XX
OS Cellulomonas sp.
XX
PN WO2005052146-A2.
XX
PD 09-JUN-2005.
XX
PF 19-NOV-2004; 2004WO-US039066.
XX
PR 19-NOV-2003; 2003US-0523609P.
XX
PA (GEMV) GENENCOR INT INC.
PA (PROC) PROCTER & GAMBLE CO.
XX
PI Jones BE, Kolkman M, Leeflang C, Oh H, Poulose AJ, Sadlowski ES;
PI Shaw A, Van Der Kleij WA, Van Marrewijk L;
XX
DR WPI; 2005-425197/43.
DR N-PSDB; AEA79703.
XX
PT New serine protease obtained from a member of the Micrococcineae, useful
PT in preparing cleaning, animal feed or textile or leather processing
PT compositions.
XX
PS Example 4; SEQ ID NO 12; 356pp; English.
XX
CC This invention describes a novel serine protease (cellulomonadin)
CC obtained from a member of the Micrococcineae e.g. Cellulomonas 69B4,
CC Oerskovia, Cellulosimicrobium, Xylanibacterium or Promicromonospora,
CC useful in preparing cleaning compositions, animal feed compositions or
CC textile or leather processing compositions. The invention also describes
CC novel stable variant serine protease having at least one improved
CC property as compared to wild-type protease e.g. altered substrate
CC specificity, altered pI, improved activity and better performance in at
CC least one property consisting of keratin hydrolysis, thermostability,
CC casein activity, LAS stability or cleaning, as compared to wild-type
CC Cellulomonas 69B4 protease. The invention also describes 1) a novel
CC composition comprising an isolated serine protease having immunological
CC cross-reactivity; 2) polynucleotides encoding the variant serine
CC proteases; 3) an expression vector comprising a polynucleotide sequence
CC encoding the protease variant; 4) a host cell comprising or transformed
CC with the expression vector; 5) a method of producing an enzyme having
CC protease activity; 6) a probe for detecting a nucleic acid sequence
CC encoding an enzyme having proteolytic activity and obtained from a member
CC of the Micrococcineae; 7) a liquid cleaning composition comprising at
CC least one serine protease obtained from a member of the Micrococcineae or
CC a proteolytic acid stable enzyme combined with additional enzymes or
CC enzyme derivatives consisting of proteases, amylases, lipases,
CC mannanases, pectinases, cutinases, oxidoreductases, hemicellulases or
CC cellulases or stabilizing agent e.g. borax, glycerol or competitive
CC inhibitors; 8) a method of cleaning using the composition and 9) the
CC manufacture of an animal feed comprising the serine protease. This
CC sequence represents a fragment of the Cellulomonas sp. isolate 69B4
CC serine protease. The polynucleotide encoding this fragment is used to
CC design primers AEA79700 and AEA79701.
XX
SQ Sequence 58 AA;

Query Match 100.0%; Score 19; DB 9; Length 58;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 47 AQGV 50

RESULT 148
AEA48196
ID AEA48196 standard; protein; 58 AA.

XX
AC AEA48196;
XX
DT 11-AUG-2005 (first entry)
XX
DE Part of the serine protease derived from Cellulomonas, SEQ ID NO: 12.
XX
KW serine protease; hydrolysis; animal feed; detergent; textile; leather;
KW enzyme.
XX
OS Cellulomonas.
XX
PN WO2005052161-A2.
XX
PD 09-JUN-2005.
XX
PF 19-NOV-2004; 2004WO-US039006.
XX
PR 19-NOV-2003; 2003US-0523609P.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Jones BE, Kolkman M, Leeflang C, Poulose AJ, Shaw A;
PI Van Der Kleij WA, Van Marrewijk L;
XX
DR WPI; 2005-425198/43.
XX
PT New serine protease (isolated from a member of the Micrococcineae) useful
PT in e.g. cleaning composition and animal feed composition.
XX
PS Example 4; SEQ ID NO 12; 333pp; English.
XX
CC The present invention relates to new isolated variant serine protease as
CC given in SEQ ID NO:8 (I), obtained from a member of the Micrococcineae.
CC Also claimed are compositions comprising an isolated serine protease
CC having immunological cross-reactivity with the serine proteases obtained
CC from a member of the Micrococcineae and particularly the protease
CC obtained from Cellomonas 69B4. The variant has improved stability as
CC compared to wild-type Cellulomonas 69B4 protease. The protease is
CC obtained from Cellulomonas, Oerskovia, Cellulosimicrobium,
CC Xylanibacterium or Promicromonospora (preferably Cellulomonas 69B4). The
CC variant serine protease comprises at least one substitution corresponding
CC to the amino acid positions in SEQ ID No. 8, and where the variant
CC protease has better performance in at least one property of keratin
CC hydrolysis, thermostability, casein activity, LAS stability or cleaning,
CC as compared to wild-type Cellulomonas 69B4 protease. The invention deals
CC with serine proteases, genetic material encoding the proteases,
CC proteolytic proteins obtained from Micrococcineae spp, variant proteins
CC developed from them, vectors comprising the DNA encoding the protease,
CC host cells transformed with the vector DNA and enzymes produced by the
CC host cells. (I) is useful in cleaning compositions and animal feed
CC compositions, and is useful in laundry and dish detergents. It is useful
CC in textile and leather processing compositions. The isolated
CC polynucleotide of (I) provides the capability of isolating further
CC polynucleotides, which encode proteins having serine protease activity.
CC The enzyme compositions have comparable or improved wash performance, as
CC compared to presently used subtilisin proteases. The present sequence is
CC part of the serine protease derived from Cellulomonas, SEQ ID NO: 12.
XX
SQ Sequence 58 AA;

```
  Query Match             100.0%;  Score 19;  DB 9;  Length 58;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         47 AQGV 50
```

RESULT 149
AAB58882
ID AAB58882 standard; protein; 59 AA.

XX
AC AAB58882;
XX
DT 27-MAR-2001 (first entry)
XX
DE Breast and ovarian cancer associated antigen protein sequence SEQ ID 590.
XX
KW Human; breast cancer; ovarian cancer; cytostatic; immunosuppressive;
KW nootropic; neurpprotective; antiviral; antiallergic; hepatotropic;
KW antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant;
KW antibacterial; antifungal; antiparasitic; cardiant; immune disorder;
KW Addison's disease; allergy; autoimmune haemolytic anaemia;
KW autoimmune thyroiditis; diabetes mellitus; Crohn's disease;
KW multiple sclerosis; rheumatoid arthritis; ulcerative colitis;
KW cardiovascular disorder; wound healing; neurological disease.
XX
OS Homo sapiens.
XX
PN WO200055173-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US005881.
XX
PR 12-MAR-1999; 99US-0124270P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2000-611515/58.
DR N-PSDB; AAF21785.
XX
PT New human breast and ovarian cancer associated gene sequences and the
PT polypeptides encoded by these genes, useful in the prevention, treatment
PT and diagnosis of cancer, immune disorders, cardiovascular disorders and
PT neurological diseases.
XX
PS Claim 11; Page 1027; 1299pp; English.
XX
CC Sequences AAF21614 - AAF22031 represent DNA sequences encoding human
CC proteins AAB58711 - AAB59128. The DNA and protein sequences are
CC associated with breast and ovarian cancer. Included in the invention are
CC sequences AAF22032 - AAF22040 and AAB59129 which are used in the
CC isolation and characterisation of the DNA and protein sequences of the
CC invention. The breast and ovarian cancer associated DNA, protein, agonist
CC or antagonist sequences exhibit cytostatic; immunosuppressive; nootropic;
CC neuroprotective; antiviral; antiallergic; hepatotropic; antidiabetic;
CC antiinflammatory; antiulcer; vulnerary; anticonvulsant; antibacterial;
CC antifungal; antiparasitic and cardiant activity. The polynucleotide and
CC protein sequences are used in the diagnosis of cancer, particularly
CC breast and ovarian cancer. The nucleic acid sequences, proteins, agonists
CC and agonists may also be used in the diagnosis, prevention and treatment
CC of immune disorders e.g. Addison's disease, allergies, autoimmune
CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis;
CC cardiovascular disorders such as myocardial ischaemias; wound healing;
CC neurological diseases such as cerebral anoxia and epilepsy; and
CC infectious diseases
XX
SQ Sequence 59 AA;

```
  Query Match             100.0%;  Score 19;  DB 3;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16
```

RESULT 150
AAU55984

ID AAU55984 standard; protein; 59 AA.
XX
AC AAU55984;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #16880.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59573.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 17179; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 59 AA;

Query Match 100.0%; Score 19; DB 4; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 44 AQGV 47

RESULT 151
ABP00743

ID ABP00743 standard; protein; 59 AA.
XX
AC ABP00743;
XX
DT 24-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:1468.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN16495.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 1468; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 59 AA;

Query Match 100.0%; Score 19; DB 5; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4

```
                ||||
Db          5 AQGV 8


RESULT 152
ABB04473
ID   ABB04473 standard; protein; 59 AA.
XX
AC   ABB04473;
XX
DT   15-MAR-2002  (first entry)
XX
DE   Human endoprotease 6.
XX
KW   Human; endoprotease 6; cancer; haemopathy; HIV infection; gene therapy.
XX
OS   Homo sapiens.
XX
PN   CN1315558-A.
XX
PD   03-OCT-2001.
XX
PF   24-MAR-2000; 2000CN-00115125.
XX
PR   24-MAR-2000; 2000CN-00115125.
XX
PA   (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-056348/08.
DR   N-PSDB; ABA05803.
XX
PT   New human endoprotease 6 and encoding polynucleotide, useful for treating
PT   cancer, hemopathy and human immunodeficiency virus.
XX
PS   Claim 1; Page 26(Disclosure); 32pp; Chinese.
XX
CC   The present invention provides the protein and coding sequences of human
CC   endoprotease 6. The sequences can be used in the treatment of cancer,
CC   haemopathy and HIV infection. The present sequence is the protein of the
CC   invention
XX
SQ   Sequence 59 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
                ||||
Db          6 AQGV 9


RESULT 153
ABM52503
ID   ABM52503 standard; protein; 59 AA.
XX
AC   ABM52503;
XX
DT   20-OCT-2003  (first entry)
XX
DE   Propionibacterium acnes predicted ORF-encoded polypeptide #17179.
XX
KW   Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW   immunostimulant; immune response; vaccine.
XX
OS   Propionibacterium acnes.
XX
PN   WO2003033515-A1.
XX
PD   24-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032727.
XX
PR   15-OCT-2001; 2001US-00978825.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Mitcham JL,  Skeiky YAW,  Persing DH,  Bhatia A,  Maisonneuve JL;
PI   Zhang Y,  Wang S,  Jen S,  Lodes MJ,  Benson DR,  Jones R,  Carter D;
PI   Barth B,  Vallieve-Douglass J;
XX
DR   WPI; 2003-381789/36.
DR   N-PSDB; ACF64502.
XX
PT   New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT   polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT   or for stimulating an immune response specific for a P. acnes protein.
XX
PS   Example 1; SEQ ID NO 17179; 1481pp; English.
XX
CC   The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC   encoding a Propionibacterium acnes protein. The invention also relates to
CC   polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC   immunogenic fragments of P. acnes polypeptides. The invention
CC   additionally encompasses expression vectors and host cells comprising a
CC   polynucleotide of the invention; antibodies against polypeptides of the
CC   invention; fusion proteins comprising a polypeptide of the invention; a
CC   method for stimulating an immune response specific for a P. acnes
CC   polypeptide and an isolated T cell population comprising T cells prepared
CC   via this method; a vaccine composition (comprising P. acnes polypeptides,
CC   polynucleotides, antibodies, fusion proteins, T cell populations, or
CC   antigen-presenting cells that express the polypeptide); a method and kit
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 59 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
                ||||
Db         44 AQGV 47


RESULT 154
ABO54645
ID   ABO54645 standard; protein; 59 AA.
XX
AC   ABO54645;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human genome derived single exon protein #879.
XX
KW   Human; gene expression; single exon probe; microarray;
KW   alternative splicing event; genomic alteration.
XX
OS   Homo sapiens.
XX
```

PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 28279; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 59 AA;

Query Match 100.0%; Score 19; DB 8; Length 59;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 52 AQGV 55

RESULT 155
AAU48065
ID AAU48065 standard; protein; 60 AA.
XX
AC AAU48065;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #8961.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59541.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 9260; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 AA;

Query Match 100.0%; Score 19; DB 4; Length 60;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 57 AQGV 60

RESULT 156
ABP32165
ID ABP32165 standard; protein; 60 AA.

XX
AC ABP32165;
XX
DT 08-JUL-2002 (first entry)
XX
DE Human ORF1138 protein, SEQ ID NO:2276.
XX
KW Human; ORF; open reading frame; ORFX; drug screening; diagnosis;
KW disease monitoring; cytokine; cell proliferation; cell differentiation;
KW immune modulation; haematopoiesis regulation; tissue growth;
KW angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; tumour inhibition; bodily characteristic; fertility;
KW behaviour; cancer; proliferative disorder; neurological disorder;
KW cardiovascular disease; immune system disorder; organ transplantation;
KW tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
KW hypothyroidism; cholesterol ester storage disease; infection; vulnerary;
KW vasotropic; antipsoriatic; antidiabetic; cytostatic; nootropic;
KW neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
KW cardiant; hypotensive; antithyroid; antiinflammatory; immunomodulator;
KW dermatological; analgesic; virucide; antibacterial; fungicide.
XX
OS Homo sapiens.
XX
PN WO200190366-A2.
XX
PD 29-NOV-2001.
XX
PF 24-MAY-2001; 2001WO-US017076.
XX
PR 24-MAY-2000; 2000US-0206690P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Leach MD, Shimkets RA;
XX
DR WPI; 2002-106200/14.
DR N-PSDB; ABN76191.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and disorders related to organ
PT transplantation.
XX
PS Claim 10; Page 832; 2508pp; English.
XX
CC Sequences ABP31028-ABP35561 represent 4534 novel human proteins
CC designated ORF (open reading frame) 1-4534, and sequences ABN75054-
CC ABN79587 represent cDNAs encoding them. The invention also encompasses
CC polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
CC referred to as ORFX) proteins, polynucleotides at least 85% identical to
CC the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
CC polynucleotides, the recombinant production of ORFX proteins, antibodies
CC specific for ORFX proteins, methods of detecting ORFX polynucleotides and
CC polypeptides, methods of screening for modulators of ORFX expression or
CC activity, and methods of screening individuals for a predisposition to an
CC ORFX-associated disorder. The ORFX proteins of the invention have a wide
CC range of biological activities, such as cytokine, cell proliferation,
CC cell differentiation, immune modulation, haematopoiesis regulation,
CC tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
CC chemokinetic activity, haemostatic activity, thrombolytic activity,
CC receptor/ligand, antiinflammatory activity, tumour inhibition activity,
CC and antiinfective activity, and may also be involved in the determination
CC of bodily characteristics, fertility and behaviour. ORFX proteins,
CC nucleic acids and antibodies may be used in the treatment of cancers,
CC other proliferative disorders such as psoriasis and benign tumours,
CC neurological disorders such as epilepsy and Alzheimer's disease,
CC cardiovascular diseases, immune system disorders, disorders related to
CC organ transplantation, disorders of tissue growth and regeneration,
CC diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
CC storage disease, and infectious diseases caused by viral, bacterial,
CC fungal and other pathogens. ORFX nucleic acids may also be used as a
CC source of primers and probes, in the detection of ORFX genomic sequences
CC or transcripts, in the identification and cloning of homologous
CC sequences, in genetic diagnosis, and in forensic biology. The ORFX
CC nucleic acids may additionally be used to produce transgenic animals
CC which may be useful for studying the function and/or activity of ORFX
CC protein, and in drug screening. The ORFX proteins may also be used as
CC immunogens to generate specific antibodies, which are useful in the
CC diagnosis, treatment and monitoring of ORFX-associated diseases
XX
SQ Sequence 60 AA;

Query Match 100.0%; Score 19; DB 5; Length 60;
Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 20 AQGV 23

RESULT 157
ABM44584
ID ABM44584 standard; protein; 60 AA.
XX
AC ABM44584;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #9260.
XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64470.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 9260; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating acne

```
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 60 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 60;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         57 AQGV 60


RESULT 158
ABO78543
ID   ABO78543 standard; protein; 60 AA.
XX
AC   ABO78543;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Pseudomonas aeruginosa polypeptide #10718.
XX
KW   Bacterial infection; Pseudomonas aeruginosa infection; antibacterial.
XX
OS   Pseudomonas aeruginosa.
XX
PN   US6551795-B1.
XX
PD   22-APR-2003.
XX
PF   18-FEB-1999;   99US-00252991.
XX
PR   18-FEB-1998;   98US-0074788P.
PR   27-JUL-1998;   98US-0094190P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Rubenfield MJ,  Nolling J,  Deloughery C,  Bush D;
XX
DR   WPI; 2003-615309/58.
DR   N-PSDB; ABD12114.
XX
PT   Novel isolated nucleic acid encoding Pseudomonas aeruginosa polypeptide,
PT   useful as molecular targets for diagnostics, prophylaxis and treatment of
PT   pathological conditions resulting from bacterial infection.
XX
PS   Disclosure; SEQ ID NO 27289; 455pp; English.
XX
CC   The invention relates to Pseudomonas aeruginosa polypeptides and the
CC   polynucleotides encoding them. The sequences are useful in diagnosis and
CC   therapy of pathological conditions, as molecular targets for diagnostics,
CC   prophylaxis and treatment of pathological conditions resulting from a
CC   bacterial infection, for evaluating a compound, such as a polypeptide,
CC   for the ability to bind a P. aeruginosa nucleic acid, as components of
CC   effective antibacterial targets, as targets for antibacterial drugs,
CC   including anti-P. aeruginosa drugs, as templates for recombinant
CC   production of P. aeruginosa-derived peptides or polypeptides, as target
CC   components for diagnosis and/or treatment of P. aeruginosa-caused
CC   infection, and in detection of P. aeruginosa sequences or other sequences
CC   of Pseudomonas species using biochip technology. Sequences ABO67826-
CC   ABO84396 represent P. aeruginosa polypeptides of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification but was obtained in electronic format from USPTO at
CC   seqdata.uspto.gov/sequence.html
XX
SQ   Sequence 60 AA;

  Query Match             100.0%;  Score 19;  DB 7;  Length 60;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         24 AQGV 27


RESULT 159
AAU61564
ID   AAU61564 standard; protein; 61 AA.
XX
AC   AAU61564;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #22460.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59618.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 22759; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 61 AA;

Query Match 100.0%; Score 19; DB 4; Length 61;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 35 AQGV 38

RESULT 160
ABP04708
ID ABP04708 standard; protein; 61 AA.
XX
AC ABP04708;
XX
DT 25-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:9398.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN20460.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 9398; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 61 AA;

Query Match 100.0%; Score 19; DB 5; Length 61;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 54 AQGV 57

RESULT 161
ABM58083
ID ABM58083 standard; protein; 61 AA.
XX
AC ABM58083;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #22759.
XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64547.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 22759; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the

CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 61 AA;

Query Match 100.0%; Score 19; DB 6; Length 61;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 35 AQGV 38

RESULT 162
AAU64327
ID AAU64327 standard; protein; 62 AA.
XX
AC AAU64327;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #25223.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59641.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 25522; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 62 AA;

Query Match 100.0%; Score 19; DB 4; Length 62;
Best Local Similarity 100.0%; Pred. No. 2.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 163
ABM60846
ID ABM60846 standard; protein; 62 AA.
XX
AC ABM60846;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #25522.
XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64570.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 25522; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit

```
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 62 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 62;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 164
ABO62014
ID   ABO62014 standard; protein; 62 AA.
XX
AC   ABO62014;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Klebsiella pneumoniae polypeptide seqid 8531.
XX
KW   Recombinant expression vector; transcription regulatory element;
KW   Klebsiella pneumoniae protein; antibacterial; Vaccine.
XX
OS   Klebsiella pneumoniae.
XX
PN   US6610836-B1.
XX
PD   26-AUG-2003.
XX
PF   27-JAN-2000; 2000US-00489039.
XX
PR   29-JAN-1999;   99US-0117747P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Breton GL,  Osborne M;
XX
DR   WPI; 2003-895346/82.
DR   N-PSDB; ACH95565.
XX
PT   New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for
PT   preparing a vaccine composition against Klebsiella pneumoniae.
XX
PS   Disclosure; SEQ ID NO 8531; 932pp; English.
XX
CC   The invention describes a new isolated nucleic acid encoding a Klebsiella
CC   pneumoniae polypeptide. Also described are: a recombinant expression
CC   vector comprising the nucleic acid, operably linked to a transcription
CC   regulatory element; and a cell comprising the recombinant expression
CC   vector. The nucleic acid is useful for preparing a vaccine composition
CC   against Klebsiella pneumoniae. This is the amino acid sequence of a
CC   Klebsiella pneumoniae polypeptide of the invention
XX
SQ   Sequence 62 AA;

  Query Match             100.0%;  Score 19;  DB 7;  Length 62;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 165
ADY23472
ID   ADY23472 standard; protein; 62 AA.
XX
AC   ADY23472;
XX
DT   21-APR-2005  (first entry)
XX
DE   Plant full length insert polypeptide seqid 71256.
XX
KW   plant protectant; plant growth regulant; gene therapy; plant;
KW   recombinant DNA construct; physical array; plant breeding marker;
KW   cold tolerance; heat tolerance; drought tolerance; herbicide tolerance;
KW   extreme osmotic condition; pathogen tolerance; pest tolerance;
KW   growth rate; cell cycle pathway; disease resistance;
KW   galactomannan production; lignin production; plant growth regulator;
KW   yield; plant growth; plant development; seed oil; protein yield;
KW   protein content.
XX
OS   Unidentified.
XX
PN   US2004034888-A1.
XX
PD   19-FEB-2004.
XX
PF   28-APR-2003; 2003US-00425114.
XX
PR   06-MAY-1999;   99US-00304517.
PR   05-NOV-2001; 2001US-00985678.
XX
PA   (LIUJ/) LIU J.
PA   (ZHOU/) ZHOU Y.
PA   (KOVA/) KOVALIC D K.
PA   (SCRE/) SCREEN S E.
PA   (TABA/) TABASKA J E.
PA   (CAOY/) CAO Y.
XX
PI   Liu J,  Zhou Y,  Kovalic DK,  Screen SE,  Tabaska JE,  Cao Y;
XX
DR   WPI; 2004-180133/17.
XX
PT   New recombinant DNA construct, useful for improving plant tolerance to
PT   cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or
PT   pests, for conferring increased resistance to plant disease, or for
PT   improving yield.
XX
PS   Claim 1; SEQ ID NO 71256; 15pp; English.
XX
CC   The invention describes a recombinant DNA construct comprising a
CC   polynucleotide consisting of a sequence encoding an amino acid sequence
CC   available in electronic form from the US patent office at
CC   ftp.seqdata.uspto.gov/sequence.html?DocID:2004034888. The polynucleotide
CC   of the invention are also useful in physical arrays of molecules and as
CC   plant breeding markers. The recombinant DNA construct is useful for
CC   improving plant tolerance to cold, heat, drought, herbicides, extreme
CC   osmotic conditions, pathogens or pests, for manipulating growth rate in
CC   plant cells by modification of the cell cycle pathway, for conferring
CC   increased resistance to plant disease, for producing galactomannan,
CC   lignin or plant growth regulators, for increasing the rate of homologous
CC   recombination in plants, for improving yield by modification of
CC   photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake
CC   or by providing improved plant growth and development under at least one
CC   stress condition or for modifying seed oil or protein yield and/or
CC   content. This is the amino acid sequence of a plant full length insert
CC   polypeptide that can be used in the recombinant DNA construct of the
```

```
CC   invention.
XX
SQ   Sequence 62 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 62;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         13 AQGV 16


RESULT 166
AAG26814
ID   AAG26814 standard; protein; 63 AA.
XX
AC   AAG26814;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Zea mays protein fragment SEQ ID NO: 31409.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence; corn.
XX
OS   Zea mays subsp. mays.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-00301439.
XX
PR   25-FEB-1999;   99US-0121825P.
PR   05-MAR-1999;   99US-0123180P.
PR   09-MAR-1999;   99US-0123548P.
PR   23-MAR-1999;   99US-0125788P.
PR   25-MAR-1999;   99US-0126264P.
PR   29-MAR-1999;   99US-0126785P.
PR   01-APR-1999;   99US-0127462P.
PR   06-APR-1999;   99US-0128234P.
PR   08-APR-1999;   99US-0128714P.
PR   16-APR-1999;   99US-0129845P.
PR   19-APR-1999;   99US-0130077P.
PR   21-APR-1999;   99US-0130449P.
PR   23-APR-1999;   99US-0130510P.
PR   23-APR-1999;   99US-0130891P.
PR   28-APR-1999;   99US-0131449P.
PR   30-APR-1999;   99US-0132048P.
PR   30-APR-1999;   99US-0132407P.
PR   04-MAY-1999;   99US-0132484P.
PR   05-MAY-1999;   99US-0132485P.
PR   06-MAY-1999;   99US-0132486P.
PR   06-MAY-1999;   99US-0132487P.
PR   07-MAY-1999;   99US-0132863P.
PR   11-MAY-1999;   99US-0134256P.
PR   14-MAY-1999;   99US-0134218P.
PR   14-MAY-1999;   99US-0134219P.
PR   14-MAY-1999;   99US-0134221P.
PR   14-MAY-1999;   99US-0134370P.
PR   18-MAY-1999;   99US-0134768P.
PR   19-MAY-1999;   99US-0134941P.
PR   20-MAY-1999;   99US-0135124P.
PR   21-MAY-1999;   99US-0135353P.
PR   24-MAY-1999;   99US-0135629P.
PR   25-MAY-1999;   99US-0136021P.
PR   27-MAY-1999;   99US-0136392P.
PR   28-MAY-1999;   99US-0136782P.
PR   01-JUN-1999;   99US-0137222P.
PR   03-JUN-1999;   99US-0137528P.
PR   04-JUN-1999;   99US-0137502P.
PR   07-JUN-1999;   99US-0137724P.
PR   08-JUN-1999;   99US-0138094P.
PR   10-JUN-1999;   99US-0138540P.
PR   10-JUN-1999;   99US-0138847P.
PR   14-JUN-1999;   99US-0139119P.
PR   16-JUN-1999;   99US-0139452P.
PR   16-JUN-1999;   99US-0139453P.
PR   17-JUN-1999;   99US-0139492P.
PR   18-JUN-1999;   99US-0139454P.
PR   18-JUN-1999;   99US-0139455P.
PR   18-JUN-1999;   99US-0139456P.
PR   18-JUN-1999;   99US-0139457P.
PR   18-JUN-1999;   99US-0139458P.
PR   18-JUN-1999;   99US-0139459P.
PR   18-JUN-1999;   99US-0139460P.
PR   18-JUN-1999;   99US-0139461P.
PR   18-JUN-1999;   99US-0139462P.
PR   18-JUN-1999;   99US-0139463P.
PR   18-JUN-1999;   99US-0139750P.
PR   18-JUN-1999;   99US-0139763P.
PR   21-JUN-1999;   99US-0139817P.
PR   22-JUN-1999;   99US-0139899P.
PR   23-JUN-1999;   99US-0140353P.
PR   23-JUN-1999;   99US-0140354P.
PR   24-JUN-1999;   99US-0140695P.
PR   28-JUN-1999;   99US-0140823P.
PR   29-JUN-1999;   99US-0140991P.
PR   30-JUN-1999;   99US-0141287P.
PR   01-JUL-1999;   99US-0141842P.
PR   01-JUL-1999;   99US-0142154P.
PR   02-JUL-1999;   99US-0142055P.
PR   06-JUL-1999;   99US-0142390P.
PR   08-JUL-1999;   99US-0142803P.
PR   09-JUL-1999;   99US-0142920P.
PR   12-JUL-1999;   99US-0142977P.
PR   13-JUL-1999;   99US-0143542P.
PR   14-JUL-1999;   99US-0143624P.
PR   15-JUL-1999;   99US-0144005P.
PR   16-JUL-1999;   99US-0144085P.
PR   16-JUL-1999;   99US-0144086P.
PR   19-JUL-1999;   99US-0144325P.
PR   19-JUL-1999;   99US-0144331P.
PR   19-JUL-1999;   99US-0144332P.
PR   19-JUL-1999;   99US-0144333P.
PR   19-JUL-1999;   99US-0144334P.
PR   19-JUL-1999;   99US-0144335P.
PR   20-JUL-1999;   99US-0144352P.
PR   20-JUL-1999;   99US-0144632P.
PR   20-JUL-1999;   99US-0144884P.
PR   21-JUL-1999;   99US-0144814P.
PR   21-JUL-1999;   99US-0145086P.
PR   21-JUL-1999;   99US-0145088P.
PR   22-JUL-1999;   99US-0145085P.
PR   22-JUL-1999;   99US-0145087P.
PR   22-JUL-1999;   99US-0145089P.
PR   22-JUL-1999;   99US-0145192P.
PR   23-JUL-1999;   99US-0145145P.
PR   23-JUL-1999;   99US-0145218P.
PR   23-JUL-1999;   99US-0145224P.
PR   26-JUL-1999;   99US-0145276P.
PR   27-JUL-1999;   99US-0145913P.
PR   27-JUL-1999;   99US-0145918P.
PR   27-JUL-1999;   99US-0145919P.
PR   28-JUL-1999;   99US-0145951P.
PR   02-AUG-1999;   99US-0146386P.
PR   02-AUG-1999;   99US-0146388P.
PR   02-AUG-1999;   99US-0146389P.
PR   03-AUG-1999;   99US-0147038P.
PR   04-AUG-1999;   99US-0147204P.
PR   04-AUG-1999;   99US-0147302P.
PR   05-AUG-1999;   99US-0147192P.
PR   05-AUG-1999;   99US-0147260P.
PR   06-AUG-1999;   99US-0147303P.
```

PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 53 AQGV 56

RESULT 167
AAM83149
ID AAM83149 standard; protein; 63 AA.
XX
AC AAM83149;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:10742.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.

PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK55930.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
PS Claim 11; SEQ ID NO 10742; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 63 AA;

Query Match 100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 8 AQGV 11

RESULT 168
ABG26472
ID ABG26472 standard; protein; 63 AA.
XX
AC ABG26472;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #26463.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.

XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US008631.
XX
PR 31-MAR-2000; 2000US-00540217.
PR 23-AUG-2000; 2000US-00649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS90659.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.
XX
PS Claim 20; SEQ ID NO 56831; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC sequences. (I) is useful as hybridisation probes, polymerase chain
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC and in recombinant production of (II). The polynucleotides are also used
CC in diagnostics as expressed sequence tags for identifying expressed
CC genes. (I) is useful in gene therapy techniques to restore normal
CC activity of (II) or to treat disease states involving (II). (II) is
CC useful for generating antibodies against it, detecting or quantitating a
CC polypeptide in tissue, as molecular weight markers and as a food
CC supplement. (II) and its binding partners are useful in medical imaging
CC of sites expressing (II). (I) and (II) are useful for treating disorders
CC involving aberrant protein expression or biological activity. The
CC polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC amino acid sequences of the invention. Note: The sequence data for this
CC patent did not appear in the printed specification, but was obtained in
CC electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 63 AA;

Query Match 100.0%; Score 19; DB 4; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 34 AQGV 37

RESULT 169
ABO58146
ID ABO58146 standard; protein; 63 AA.
XX
AC ABO58146;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #4380.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 31780; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 63 AA;

Query Match 100.0%; Score 19; DB 8; Length 63;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 41 AQGV 44

RESULT 170
ABP29155
ID ABP29155 standard; protein; 64 AA.
XX

AC ABP29155;
XX
DT 02-JUL-2002 (first entry)
XX
DE Streptococcus polypeptide SEQ ID NO 7486.
XX
KW Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW group A streptococcus; Streptococcus pyogenes; antibacterial;
KW antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS Streptococcus pyogenes.
XX
PN WO200234771-A2.
XX
PD 02-MAY-2002.
XX
PF 29-OCT-2001; 2001WO-GB004789.
XX
PR 27-OCT-2000; 2000GB-00026333.
PR 24-NOV-2000; 2000GB-00028727.
PR 07-MAR-2001; 2001GB-00005640.
XX
PA (CHIR-) CHIRON SPA.
PA (GENO-) INST GENOMIC RES.
XX
PI Telford J, Masignani V, Margarit Y RosI, Grandi G, Fraser C;
PI Tettelin H;
XX
DR WPI; 2002-352536/38.
DR N-PSDB; ABN69786.
XX
PT New Streptococcus protein for the treatment or prevention of infection or
PT disease caused by Streptococcus bacteria, such as meningitis, and for
PT detecting a compound that binds to the protein.
XX
PS Claim 1; Page 3892; 4525pp; English.
XX
CC The invention relates to a protein (ABP25413-ABP30895) from group B
CC streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC the specification. The proteins have antibacterial and antiinflammatory
CC activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC antibodies that bind (I) are used in the manufacture of medicaments for
CC the treatment or prevention of infection or disease caused by
CC Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC Nucleic acids encoding (I) are used to detect Streptococcus in a
CC biological sample. (I) is used to determine whether a compound binds to
CC (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC used as a vaccine or diagnostic composition. The disease caused by
CC Streptococcus that is prevented or treated may be meningitis. Nucleic
CC acid encoding (I) may be used to recombinantly produce (I) and may be
CC used in gene therapy. Antibodies to (I) are used for affinity
CC chromatography, immunoassays, and distinguishing/identifying
CC Streptococcus proteins
XX
SQ Sequence 64 AA;

```
  Query Match             100.0%;  Score 19;  DB 5;  Length 64;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33
```

RESULT 171
AAG02408
ID AAG02408 standard; protein; 65 AA.
XX
AC AAG02408;
XX
DT 06-OCT-2000 (first entry)
XX
DE Human secreted protein, SEQ ID NO: 6489.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping.
XX
OS Homo sapiens.
XX
PN EP1033401-A2.
XX
PD 06-SEP-2000.
XX
PF 21-FEB-2000; 2000EP-00200610.
XX
PR 26-FEB-1999; 99US-0122487P.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR WPI; 2000-500381/45.
DR N-PSDB; AAC02414.
XX
PT New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT diagnostic, forensic, gene therapy and chromosome mapping procedures.
XX
PS Claim 13; SEQ ID NO 6489; 71pp + Sequence Listing; English.
XX
CC The present sequence is a polypeptide encoded by one of a large number of
CC 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs were
CC prepared from total human RNAs or polyA+ RNAs derived from 30 different
CC tissues. EST sequences usually correspond mainly to the 3' untranslated
CC region (UTR) of the mRNA because they are often obtained from oligo-dT
CC primed cDNA libraries. Such ESTs are not well suited for isolating cDNA
CC sequences derived from the 5' ends of mRNAs and even in those cases where
CC longer cDNA sequences have been obtained, the full 5' UTR is rarely
CC included. 5' ESTs are derived from mRNAs with intact 5' ends and can
CC therefore be used to obtain full length cDNAs and genomic DNAs. 5' ESTs
CC are also used in diagnostic, forensic, gene therapy and chromosome
CC mapping procedures. They are used to obtain upstream regulatory sequences
CC and to design expression and secretion vectors
XX
SQ Sequence 65 AA;

```
  Query Match             100.0%;  Score 19;  DB 3;  Length 65;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         48 AQGV 51
```

RESULT 172
AAG07706
ID AAG07706 standard; protein; 65 AA.
XX
AC AAG07706;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 4960.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.

XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.

PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 62 AQGV 65

RESULT 173
AAG26813
ID AAG26813 standard; protein; 65 AA.
XX
AC AAG26813;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 31408.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.

PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 55 AQGV 58

RESULT 174
ABO66725
ID ABO66725 standard; protein; 65 AA.
XX
AC ABO66725;
XX
DT 29-JUL-2004 (first entry)
XX
DE Klebsiella pneumoniae polypeptide seqid 13242.
XX
KW Recombinant expression vector; transcription regulatory element;
KW Klebsiella pneumoniae protein; antibacterial; Vaccine.
XX
OS Klebsiella pneumoniae.
XX
PN US6610836-B1.
XX
PD 26-AUG-2003.
XX
PF 27-JAN-2000; 2000US-00489039.
XX
PR 29-JAN-1999; 99US-0117747P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Breton GL, Osborne M;
XX
DR WPI; 2003-895346/82.
DR N-PSDB; ABD00296.
XX
PT New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for
PT preparing a vaccine composition against Klebsiella pneumoniae.
XX

PS Disclosure; SEQ ID NO 13242; 932pp; English.
XX
CC The invention describes a new isolated nucleic acid encoding a Klebsiella
CC pneumoniae polypeptide. Also described are: a recombinant expression
CC vector comprising the nucleic acid, operably linked to a transcription
CC regulatory element; and a cell comprising the recombinant expression
CC vector. The nucleic acid is useful for preparing a vaccine composition
CC against Klebsiella pneumoniae. This is the amino acid sequence of a
CC Klebsiella pneumoniae polypeptide of the invention
XX
SQ Sequence 65 AA;

Query Match 100.0%; Score 19; DB 7; Length 65;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 22 AQGV 25

RESULT 175
AAG07705
ID AAG07705 standard; protein; 66 AA.
XX
AC AAG07705;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 4959.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.

PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 63 AQGV 66

RESULT 176
AAM82556
ID AAM82556 standard; protein; 66 AA.
XX
AC AAM82556;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:10149.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.

PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK55337.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
PS Claim 11; SEQ ID NO 10149; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 66 AA;

Query Match 100.0%; Score 19; DB 4; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 52 AQGV 55

RESULT 177
AAU53135
ID AAU53135 standard; protein; 66 AA.
XX
AC AAU53135;
XX

DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #14031.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59558.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 14330; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 66 AA;

Query Match 100.0%; Score 19; DB 4; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 56 AQGV 59

RESULT 178
ABM49654
ID ABM49654 standard; protein; 66 AA.
XX
AC ABM49654;
XX

DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #14330.
XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64487.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 14330; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 66 AA;

Query Match 100.0%; Score 19; DB 6; Length 66;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 56 AQGV 59

RESULT 179
ABB71058

ID ABB71058 standard; protein; 67 AA.
XX
AC ABB71058;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 39966.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US009231.
XX
PR 23-MAR-2000; 2000US-0191637P.
PR 11-JUL-2000; 2000US-00614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL15161.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signaling and cell-cell
PT interactions.
XX
PS Disclosure; SEQ ID NO 39966; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 67 AA;

Query Match 100.0%; Score 19; DB 4; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 9 AQGV 12

RESULT 180
ADU04369
ID ADU04369 standard; protein; 67 AA.
XX
AC ADU04369;
XX
DT 13-JAN-2005 (first entry)
XX
DE MHV protein with homology to SARS coronavirus ORF1A.
XX
KW viral infection; virucide; autoimmune disease;
KW lymphoproliferative disorder; vaccine; gene therapy.
XX
OS Murine hepatitis virus.
XX
PN WO2004090544-A2.
XX
PD 21-OCT-2004.
XX
PF 13-APR-2004; 2004WO-CA000544.
XX
PR 09-APR-2003; 2003US-0461137P.
PR 30-SEP-2003; 2003US-0506779P.
XX
PA (CABL-) CANADIAN BLOOD SERVICES.
XX
PI Hu Y, Brown E;
XX
DR WPI; 2004-766498/75.
XX
PT Characterizing a viral infection in a host, for developing treatment for
PT severe acute respiratory syndrome-coronavirus (SARS-CoV), by determining
PT homology profile of a viral-based sequence element with an endogenous
PT host element.
XX
PS Claim 8; Fig 20A; 166pp; English.
XX
CC The invention relates to a novel method for characterising a viral
CC infection in a host. The method comprises identifying at least one viral-
CC based sequence element in a biological sample obtained from the host,
CC determining a homology profile of the viral-based sequence element with
CC at least one endogenous host element and characterising the viral
CC infection based on the homology profile, where the homology profile is
CC indicative of a viral behaviour of the viral infection in the host. The
CC method of the invention demonstrates virucide applications and may be
CC useful for preparing a medicament for detecting and/or treating a viral
CC infection or related condition, such as an autoimmune disease e.g. type
CC II cryoglobulinaemia, or lymphoproliferative disorder. The viral
CC infection may be due to HCV (Hepatitis C virus), HIV or a member of a
CC Retroviridae, Flaviviridae, Herpesviridae, Papillomaviridae or
CC Coronaviridae virus family. Treatment of the infection may utilise
CC vaccine or gene therapy. The target compound of the invention may be
CC useful for detecting the presence of a virus in a biological sample or
CC for manufacturing a medicament for treating SARS coronavirus (SARS-CoV)
CC and/or Human T-lymphotropic virus 1 (HTLV-I) infection. The methods are
CC further useful for developing treatment regimes to target genotype-
CC specific viral variants. The current sequence is that of the MHV protein
CC of the invention within homology to SARS coronavirus ORF1A.
XX
SQ Sequence 67 AA;

Query Match 100.0%; Score 19; DB 8; Length 67;
Best Local Similarity 100.0%; Pred. No. 2.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 38 AQGV 41

RESULT 181
AAG26016
ID AAG26016 standard; protein; 69 AA.
XX
AC AAG26016;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 30312.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.

XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.

PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 55 AQGV 58

RESULT 182
AAE01158
ID AAE01158 standard; protein; 69 AA.
XX
AC AAE01158;
XX
DT 17-JUL-2001 (first entry)
XX
DE Novel human cytokine 1 (NHC-1) protein.
XX
KW Novel human cytokine; NHC; cytostatic; antiinflammatory; neuroprotective;
KW immunosuppressive; gene therapy; cancer; infection; autoimmune disease;
KW trauma; cystic fibrosis; leukaemia; asthma; neurodegenerative disease;
KW allograft rejection; Alzheimer's disease; Parkinson's disease; pregnancy.
XX
OS Homo sapiens.
XX
PN US6204021-B1.
XX
PD 20-MAR-2001.
XX
PF 31-JAN-1997; 97US-00792013.
XX
PR 31-JAN-1997; 97US-00792013.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Bandman O, Hawkins PR, Murry LE, Goli SK;
XX
DR WPI; 2001-289513/30.
DR N-PSDB; AAD05034.
XX
PT New NHC-2 polynucleotides and polypeptides useful for diagnosing,
PT preventing, or treating cancers, inflammation, allograft rejection,
PT neurodegenerative diseases, and conditions affecting pregnancy, growth
PT and development.
XX
PS Example 6; Fig 1; 30pp; English.
XX
CC The present protein sequence is novel human cytokine 1 (NHC-1). NHC-1
CC cDNA was first identified in Incyte clone 1431384 from an ileum library
CC of a patient with irritable bowel syndrome (SINTBST01). The present
CC invention relates to novel human cytokines, NHC-1 and NHC-2 collectively
CC known as NHC. The antagonists or inhibitors NHC are useful for
CC diagnosing, preventing, or treating cancers, inflammations (caused by
CC viral, bacterial, fungal, helminthic or protozoal infection), trauma,
CC autoimmune diseases (e.g. Cystic fibrosis, leukaemia, asthma), allograft
CC rejection, neurodegenerative diseases (e.g. Alzheimer's disease,
CC Parkinson's disease), and conditions affecting pregnancy, growth and
CC development. NHC polynucleotides are used in recombinant DNA molecules to
CC direct expression of NHC in host cells, in the diagnosis of conditions or
CC diseases associated with NHC expression, in detecting altered NHC
CC expression and in assays that detect the activation or induction of
CC various cancers. They are also used to generate hybridisation probes for
CC mapping naturally occurring genomic sequence, to detect differences in
CC gene sequences between normal, carrier or affected individuals, for
CC screening libraries of compounds in various drug screening techniques,
CC and in molecular biology. NHC sequences are also used in gene therapy
XX
SQ Sequence 69 AA;

Query Match 100.0%; Score 19; DB 4; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 5 AQGV 8

RESULT 183
AAU76429
ID AAU76429 standard; protein; 69 AA.
XX
AC AAU76429;
XX
DT 21-MAY-2002 (first entry)
XX
DE Novel human cytokine-1 (NHC-1).
XX
KW Human; cytokine; NHC-1; cancer; inflammation; viral infection;
KW bacterial infection; fungal infection; helminthic infection;
KW protozoal infection; trauma; autoimmune disease; haemolytic anaemia;
KW arteriosclerosis; asthma; biliary cirrhosis; cystic fibrosis; diabetes;
KW glomerulonephritis; hyperthyroidism; pulmonary fibrosis;
KW systemic lupus erythematosus; myasthenia gravis; osteoporosis;
KW pancreatitis; Sjogren's syndrome; scleroderma; allograft rejection;
KW neurodegenerative disease; Alzheimer's disease; transplantation;
KW amyotropic lateral sclerosis; Huntington's disease; Parkinson's disease;
KW epilepsy; Down's syndrome; pregnancy; growth; development;
KW cell proliferation; bone marrow cell; tissue regeneration.
XX
OS Homo sapiens.
XX
PN US2002001827-A1.
XX
PD 03-JAN-2002.
XX
PF 12-FEB-2001; 2001US-00782142.

XX
PR 31-JAN-1997; 97US-00792013.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Bandman O, Hawkins PR, Murry LE, Goli SK;
XX
DR WPI; 2002-163701/21.
DR N-PSDB; ABK15586, ABK15588.
XX
PT New human cytokines and encoding polynucleotides, useful for treating,
PT diagnosing or preventing cancers, inflammation, allograft rejection,
PT neurodegenerative diseases and conditions affecting growth.
XX
PS Claim 1; Fig 1; 34pp; English.
XX
CC The invention describes a novel human cytokine, designated NHC (I). (I)
CC is useful for screening a compound for effectiveness as an agonist or
CC antagonist and preparing a polyclonal antibody or monoclonal antibody,
CC useful in a diagnostic test for a condition or a disease associated with
CC the expression of NHC in a biological sample, by combining the sample
CC with Ab and detecting the Ab-NHC complex. the sample. The polypeptide and
CC polynucleotide are useful from diagnosing, treating and preventing
CC cancers, inflammation (e.g. viral, bacterial, fungal, helminthic or
CC protozoal infection, trauma, autoimmune diseases such as haemolytic
CC anaemia, arteriosclerosis, asthma, biliary cirrhosis, cystic fibrosis,
CC diabetes, glomerulonephritis, hyperthyroidism, pulmonary fibrosis,
CC systemic lupus erythematosus, myasthenia gravis, osteoporosis,
CC pancreatitis, Sjogren's syndrome and scleroderma), allograft rejection,
CC neurodegenerative diseases (e.g. Alzheimer's disease, amyotropic lateral
CC sclerosis, Huntington's disease, Parkinson's disease, epilepsy and Down's
CC syndrome), and conditions affecting pregnancy, growth and development.
CC (I) is also useful for stimulating cell proliferation, and thus in ex
CC vivo therapies involving bone marrow cells, and for regenerating tissues
CC or organs for transplantation such as kidney, liver, pancreas and spleen.
CC (I) is also useful in drug screening techniques. This is the amino acid
CC sequence of novel human cytokine-1 (NHC-1), described in the method of
CC the invention
XX
SQ Sequence 69 AA;

Query Match 100.0%; Score 19; DB 5; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 5 AQGV 8

RESULT 184
ADA21106
ID ADA21106 standard; protein; 69 AA.
XX
AC ADA21106;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted protein SECP-11 SEQ ID NO:11.
XX
KW human; secreted protein; SECP; anti-HIV; antiallergic; antiinflammatory;
KW antianaemic; antiparkinsonian; nootropic; anticonvulsant;
KW antiarteriosclerotic; antiasthmatic; immunosuppressive; antithyroid;
KW cytostatic; hepatotropic; dermatological; antidiabetic; nephrotropic;
KW antigout; thyromimetic; neuroprotective; osteopathic; antiarthritic;
KW antiparasitic; antihelminthic; antipsoriatic; uropathic;
KW ophthalmological; antirheumatic; haemostatic; antibacterial; virucide;
KW protozoacide; fungicide; gene therapy; cell proliferative disorder;
KW arteriosclerosis; atherosclerosis; cirrhosis; hepatitis;
KW paroxysmal nocturnal haemoglobinuria; polycythaemia vera; psoriasis;
KW primary thrombocytopaenia; cancer; developmental disorder;
KW renal tubular acidosis; anaemia; mental retardation;
KW neurological disorder; Alzheimer's disease; Parkinson's disease;
KW epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergy;
KW asthma; autoimmune thyroiditis; contact dermatitis; Crohn's disease;
KW diabetes mellitus; glomerulonephritis; Goodpasture's syndrome; gout;
KW Graves' disease; Hashimoto's thyroiditis; irritable bowel syndrome;
KW multiple sclerosis; osteoarthritis; osteoporosis; pancreatitis;
KW Reiter's syndrome; rheumatoid arthritis; Sjogren's syndrome; uveitis;
KW infection.
XX
OS Homo sapiens.
XX
PN WO2003068943-A2.
XX
PD 21-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004712.
XX
PR 13-FEB-2002; 2002US-0357002P.
PR 06-MAR-2002; 2002US-0362439P.
PR 19-MAR-2002; 2002US-0366041P.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Lehr-Mason PM, Kable AE, Elliott VS, Marquis JP, Baughn MR;
PI Chawla NK, Tran UK, Jin P, Tang YT, Zebarjadian Y, Swarnakar A;
PI Hafalia AJA, Cocks BG, Warren BA, Emerling BM, Pearson CI, Chien D;
PI Peterson DP, Fu GK, Yue H, Jackson AA, Jiang X, Hawkins PR, Lal PG;
PI Khare R, Lee S, Lee SY, Richardson TW, Chang H;
XX
DR WPI; 2003-689669/65.
DR N-PSDB; ADA21157.
XX
PT New human secreted proteins and polynucleotides, useful for diagnosing,
PT treating or preventing autoimmune or inflammatory disorders (e.g. AIDS,
PT allergy, asthma or anemia), multiple sclerosis, osteoporosis, cancer or
PT hepatitis.
XX
PS Claim 1; Page 225; 295pp; English.
XX
CC The present sequence represents a human secreted protein (I) designated
CC SECP-11. (I) have anti-HIV, antiallergic, antiinflammatory, antianaemic,
CC antiparkinsonian, nootropic, anticonvulsant, antiarteriosclerotic,
CC antiasthmatic, immunosuppressive, antithyroid, cytostatic, hepatotropic,
CC dermatological, antidiabetic, nephrotropic, antigout, thyromimetic,
CC neuroprotective, osteopathic, antiarthritic, antiparasitic,
CC antihelminthic, antipsoriatic, uropathic, ophthalmological,
CC antirheumatic, haemostatic, antibacterial, virucide, protozoacide and
CC fungicide activities, and can be used in gene therapy. The human secreted
CC proteins (SECP), polynucleotides, agonists and antagonists of the present
CC invention are useful for diagnosing, treating or preventing disorders
CC associated with aberrant expression of SECP, particularly cell
CC proliferative disorders (e.g. arteriosclerosis, atherosclerosis,
CC cirrhosis, hepatitis, paroxysmal nocturnal haemoglobinuria, polycythaemia
CC vera, psoriasis, primary thrombocytopaenia or cancer), developmental
CC disorders (e.g. renal tubular acidosis, anaemia or mental retardation),
CC neurological disorders (e.g. Alzheimer's disease, Parkinson's disease or
CC epilepsy), autoimmune/inflammatory disorders (e.g. AIDS, allergies,
CC asthma, autoimmune thyroiditis, contact dermatitis, Crohn's disease,
CC diabetes mellitus, glomerulonephritis, Goodpasture's syndrome, gout,
CC Graves' disease, Hashimoto's thyroiditis, irritable bowel syndrome,
CC multiple sclerosis, osteoarthritis, osteoporosis, pancreatitis, Reiter's
CC syndrome, rheumatoid arthritis, Sjogren's syndrome, uveitis), or viral,
CC bacterial, fungal, parasitic, protozoan or helminthic infections. The
CC SECP and polynucleotides are also useful in assessing the effects of
CC exogenous compounds on the expression of nucleic acids secreted proteins.
CC The polynucleotides encoding SECP are useful for creating transgenic
CC animals to model human disease.
XX
SQ Sequence 69 AA;

Query Match 100.0%; Score 19; DB 6; Length 69;
Best Local Similarity 100.0%; Pred. No. 2.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              ||||
Db         19 AQGV 22
```

RESULT 185
ADA67726
ID ADA67726 standard; protein; 69 AA.
XX
AC ADA67726;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human cytokine 1, NHC-1.
XX
KW human; cytokine; neurodegenerative disorder; Parkinson's disease;
KW Alzheimer's disease; allograft rejection; inflammation; infection; viral;
KW bacterial; fungal; protozoal; autoimmune disease; diabetes;
KW haemolytic anaemia; arteriosclerosis; asthma; cystic fibrosis;
KW myasthenia gravis; allergy; osteoporosis; Grave's disease; cancer;
KW leukaemia; cervical cancer; breast cancer; pregnancy; growth;
KW development.
XX
OS Homo sapiens.
XX
PN US2003096371-A1.
XX
PD 22-MAY-2003.
XX
PF 19-NOV-2002; 2002US-00300257.
XX
PR 31-JAN-1997; 97US-00792013.
PR 12-FEB-2001; 2001US-00782142.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Bandman O, Hawkins PR, Murry LE, Goli SK;
XX
DR WPI; 2003-658246/62.
DR N-PSDB; ADA67730.
XX
PT New human cytokines, NHC-1 and NHC-2, and encoding polynucleotides,
PT useful for diagnosing, preventing, and treating diseases with abnormal
PT expression or activity of NHC, such as cancer, inflammatory and
PT neurodegenerative diseases.
XX
PS Claim 1; Fig 1; 35pp; English.
XX
CC The invention relates to an isolated novel human cytokine polypeptide.
CC The polypeptide or its fragments, and the polynucleotide encoding the
CC polypeptide are useful in diagnosing, preventing, and treating disorders
CC associated with an abnormal expression or activity of NHC, such as
CC neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's
CC disease), allograft rejection, inflammation caused by viral, bacterial,
CC fungal or protozoal infections, autoimmune diseases (e.g., diabetes,
CC haemolytic anaemia, arteriosclerosis, asthma, cystic fibrosis, myasthenia
CC gravis, allergies, osteoporosis and Grave's disease), cancers (e.g.
CC leukaemia, cervical or breast cancers) and conditions affecting
CC pregnancy, growth and development. The polynucleotides can be used to
CC create humanised animals or transgenic animals to model human disease.
CC The present sequence represents the amino acid sequence of novel human
CC cytokine 1, NHC-1.
XX
SQ Sequence 69 AA;

```
  Query Match             100.0%;  Score 19;  DB 7;  Length 69;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          5 AQGV 8
```

RESULT 186
AAY65387
ID AAY65387 standard; protein; 71 AA.
XX
AC AAY65387;
XX
DT 01-FEB-2000 (first entry)
XX
DE Human 5' EST related polypeptide SEQ ID NO:1548.
XX
KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;
KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;
KW location; development; protein synthesis; stability; regulation;
KW identification.
XX
OS Homo sapiens.
XX
PN WO9953051-A2.
XX
PD 21-OCT-1999.
XX
PF 09-APR-1999; 99WO-IB000712.
XX
PR 09-APR-1998; 98US-00057719.
PR 28-APR-1998; 98US-00069047.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR WPI; 2000-038446/03.
DR N-PSDB; AAZ43001.
XX
PT Novel secreted protein 5' expressed sequence tag sequences used in
PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.
XX
PS Claim 3; Page 816; 837pp; English.
XX
CC AAZ42265 to AAZ43075 represent novel 5' expressed sequence tag (EST)
CC sequences, corresponding to human secreted proteins. AAY64651 to AAY65438
CC represent the EST-related proteins corresponding to AAZ42265 to AAZ43052.
CC The 5' ESTs can be used for producing secreted human gene products. They
CC can be used to identify and isolate 5' untranslated regions (UTRs) and
CC upstream regulatory regions which control the location, development
CC stage, rate, and quantity of protein synthesis, as well as stability of
CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to
CC obtain full length cDNA clones. The ESTs can also be used in forensic
CC procedures to identify individuals, or in diagnostic procedures to
CC identify individuals having genetic diseases resulting from abnormal gene
CC expression. The products may also be used in gene therapy protocols. The
CC nucleic acids encoding signal peptides can be used for directing
CC extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell. The
CC proteins encoded by the EST sequences may be useful in treating a variety
CC of human conditions. Secreted proteins have therapeutic value, and the
CC identification of new secreted proteins is valuable. AAZ42249 to AAZ42264
CC and AAY64644 to AAY64650 represent sequences used in the exemplification
CC of the present invention
XX
SQ Sequence 71 AA;

```
  Query Match             100.0%;  Score 19;  DB 3;  Length 71;
  Best Local Similarity   100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         59 AQGV 62
```

RESULT 187
AAB63498

```
ID   AAB63498 standard; protein; 71 AA.
XX
AC   AAB63498;
XX
DT   26-MAR-2001  (first entry)
XX
DE   Human gastric cancer associated antigen protein sequence SEQ ID NO:860.
XX
KW   Human; breast cancer; gastric cancer; prostate cancer; diagnosis;
KW   cancer associated antigen; cytostatic; cancer vaccine.
XX
OS   Homo sapiens.
XX
PN   WO200073801-A2.
XX
PD   07-DEC-2000.
XX
PF   26-MAY-2000; 2000WO-US014749.
XX
PR   28-MAY-1999;   99US-0136526P.
PR   10-SEP-1999;   99US-0153454P.
XX
PA   (LUDW-) LUDWIG INST CANCER RES.
XX
PI   Obata Y;
XX
DR   WPI; 2001-025274/03.
XX
PT   Nucleic acids encoding breast, gastric and prostate cancer associated
PT   antigen precursors, useful for diagnosing and treating a condition
PT   characterized by expression of an abnormal amount of a protein, e.g.
PT   cancer.
XX
PS   Example 1; Page 589; 799pp; English.
XX
CC   AAF22422 to AAF22626, AAF22627 to AAF22773 and AAF22774 to AAF23014
CC   represent nucleotide sequences encoding human breast, gastric and
CC   prostate cancer associated antigen precursors (CAAP) respectively.
CC   AAB63232 to AAB63467, AAB63468 to AAB63721 and AAB63722 to AAB63970
CC   represent human breast, gastric and prostate CAAP protein sequence
CC   respectively. CAAPs have cytostatic activity and can be used in the
CC   production of cancer vaccines. The human CAAP proteins, peptides, nucleic
CC   acids or anti-CAAP antibodies are useful for diagnosing and treating a
CC   condition characterised by expression of an abnormal amount of a protein,
CC   e.g. cancer
XX
SQ   Sequence 71 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 71;
  Best Local Similarity   100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         20 AQGV 23


RESULT 188
ADU72951
ID   ADU72951 standard; protein; 71 AA.
XX
AC   ADU72951;
XX
DT   10-FEB-2005  (first entry)
XX
DE   Non-signal peptide-containing polypeptide fragment, SEQ ID NO:1548.
XX
KW   Protein secretion; recombinant protein; diagnosis; mapping; forensic;
KW   gene therapy.
XX
OS   Homo sapiens.
XX
PN   US6822072-B1.
XX
PD   23-NOV-2004.
XX
PF   21-DEC-1999;   99US-00471276.
XX
PR   09-APR-1998;   98US-00057719.
PR   28-APR-1998;   98US-00069047.
PR   09-APR-1999;   99WO-IB000712.
XX
PA   (GEST ) GENSET SA.
XX
PI   Edwards JDM,  Duclert A,  Giordano J;
XX
DR   WPI; 2004-812112/80.
DR   N-PSDB; ADU72163.
XX
PT   New expressed sequence tags and encoded human proteins useful for
PT   diagnosing, preventing or treating diseases such as autoimmune disorders,
PT   inflammation, wounds or infections, or in forensic or chromosome mapping
PT   procedures.
XX
PS   Example 15; SEQ ID NO 1548; 72pp; English.
XX
CC   The invention relates to an isolated or purified signal peptide
CC   consisting of residues 1-16 of ADU72234 (signal peptide given separately
CC   as ADU73026) which directs the extracellular secretion of a polypeptide
CC   to which it is oberably linked. The invention also relates to a method of
CC   producing the signal peptide. The invention further discloses: isolated,
CC   purified or enriched 5' expressed sequence tags (ESTs), many of which
CC   encode all or a part of a secretory signal peptide; polypeptides encoded
CC   by these ESTS (EST-related polypeptides); antibodies which recognize the
CC   EST-related polypeptides; vectors and host cells comprising EST-related
CC   nucleic acids of the invention; an array of ESTs; methods involving the
CC   use of signal peptides of the invention to target polypeptides; and
CC   methods involving the use of ESTs of the invention, for example, in
CC   identifying a promoter in genomic DNA. The EST-encoded signal peptides of
CC   the invention are useful for directing the secretion or import of a
CC   recombinant polypeptide via the generation of protein fusions comprising
CC   such signal peptides. The ESTs, EST-related polypeptides and methods of
CC   the invention can be used for forensic procedures, chromosome mapping,
CC   diagnostics, and therapeutic procedures, including gene therapy.
CC   Sequences ADU72920-ADU72956 represent incomplete polypeptides apparently
CC   lacking a signal peptide which are encoded by the 5' ESTs shown in
CC   ADU72132-ADU72168. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from the US patent office at
CC   seqdata.uspto.gov/sequence.html?DocID=US6822072.
XX
SQ   Sequence 71 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 71;
  Best Local Similarity   100.0%;  Pred. No. 3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         59 AQGV 62


RESULT 189
ADZ73942
ID   ADZ73942 standard; protein; 71 AA.
XX
AC   ADZ73942;
XX
DT   28-JUL-2005  (first entry)
XX
DE   Human incomplete polypeptide not including a signal peptide.
XX
KW   expressed sequence tag; EST; expression; protein secretion; diagnostic;
KW   forensic; gene therapy; haplotype mapping.
XX
OS   Homo sapiens.
```

XX
PN US2005106595-A1.
XX
PD 19-MAY-2005.
XX
PF 25-AUG-2004; 2004US-00926683.
XX
PR 09-APR-1998; 98US-00057719.
PR 28-APR-1998; 98US-00069047.
PR 09-APR-1999; 99WO-IB000712.
PR 21-DEC-1999; 99US-00471276.
XX
PA (GEST) GENSET SA.
XX
PI Dumas MEJ, Duclert A, Giordano J;
XX
DR WPI; 2005-384300/39.
DR N-PSDB; ADZ73154.
XX
PT New purified nucleic acid expressing secreted proteins useful in
PT forensic, gene therapy, and chromosome mapping procedures, and diagnosing
PT or treating cancer, atherosclerosis and autoimmune diseases, diabetes,
PT asthma and infections.
XX
PS Claim 1; SEQ ID NO 1548; 79pp; English.
XX
CC The invention relates to a novel purified nucleic acid (I) comprising any
CC of (ADZ72418-ADZ73205) or (ADZ73994-ADZ74016) and their complements; at
CC least 15 consecutive nucleotides of (I) and their complements; or any of
CC 788 nucleotide sequences encoding fully defined sequences of 16-255 amino
CC acids (ADZ73206-ADZ73993). The invention discloses 5' EST's derived from
CC mRNAs encoding secreted proteins. The 5' EST's may be used to obtain
CC cDNAs and genomic DNAs corresponding to the 5' ESTs. The methods and
CC compositions of the present invention are useful for expressing secreted
CC proteins or its portions (claimed) or to obtain antibodies capable of
CC specifically binding to the secreted proteins, and in diagnostic,
CC forensic, gene therapy, and chromosome mapping procedures, and for
CC designing expression vectors and secretion vectors. The present sequence
CC is used in the exemplification of the invention. Note: The sequence data
CC for this patent is not represented in the printed specification but is
CC based on sequence information supplied in electronic format from the
CC USPTO web site seqdata.uspto.gov/sequence.html; Document ID: 20050106595.
XX
SQ Sequence 71 AA;

Query Match 100.0%; Score 19; DB 9; Length 71;
Best Local Similarity 100.0%; Pred. No. 3e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 59 AQGV 62

RESULT 190
AAR58812
ID AAR58812 standard; protein; 72 AA.
XX
AC AAR58812;
XX
DT 16-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 14-OCT-1994 (first entry)
XX
DE E. coli multiple antibiotic resistance (Mar) enhancer.
XX
KW Cloned Mar operon; Mar regulatory region; MarO; MarA; MarR; MarB;
KW lacZ marker locus; Increased antibiotic sensitivity; Repression of Mar;
KW Multiple antibiotic resistance operon; Enhancer.
XX
OS Escherichia coli; (K12).
XX
PN WO9405810-A1.
XX
PD 17-MAR-1994.
XX
PF 27-AUG-1993; 93WO-US008115.
XX
PR 28-AUG-1992; 92US-00938085.
XX
PA (TUFT) TUFTS COLLEGE.
XX
PI Levy SB;
XX
DR WPI; 1994-101214/12.
DR N-PSDB; AAQ58707.
XX
PT Predicting antibiotic effectiveness of compositions - by cloning
PT fragments of the Mar operon, and antimicrobial compositions contg. these
PT fragments Multiple antibiotic resistance operon.
XX
PS Disclosure; Page 31-32; 55pp; English.
XX
CC This is an enhancer protein encoded by a wild-type multiple antibiotic
CC resistance (Mar) operon cloned from E.coli. It is operably linked to the
CC Mar repressor and activator. This is useful to test antibiotic
CC effectiveness, and can be used to enhance the effectiveness of known
CC antimicrobials or render ineffective antimicrobials effective. (Updated
CC on 25-MAR-2003 to correct PN field.) (Updated on 16-OCT-2003 to
CC standardise OS field)
XX
SQ Sequence 72 AA;

Query Match 100.0%; Score 19; DB 2; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 191
AAW71459
ID AAW71459 standard; protein; 72 AA.
XX
AC AAW71459;
XX
DT 25-MAR-2003 (revised)
DT 07-DEC-1998 (first entry)
XX
DE Protein encoded by ORF 72.
XX
KW Multiple antibiotic resistance operon; mar; antisense;
KW bacterial resistance; antibiotic; mar enhancer; marB.
XX
OS Escherichia coli.
XX
PN US5817793-A.
XX
PD 06-OCT-1998.
XX
PF 08-APR-1994; 94US-00225480.
XX
PR 28-AUG-1992; 92US-00938085.
XX
PA (TUFT) TUFTS COLLEGE.
XX
PI Levy SB;
XX
DR WPI; 1998-556472/47.
DR N-PSDB; AAV60383.
XX
PT DNA encoding activator of multiple antibiotic resistance operon - and
PT anti-sense molecule for lowering antibiotic resistance of bacteria.
XX

```
PS   Disclosure; Col 35-36; 22pp; English.
XX
CC   The present sequence represents the protein encoded by open reading frame
CC   (ORF) 72 of an Escherichia coli multiple antibiotic resistance (mar)
CC   operon. ORF 72 encodes the mar enhancer, which is neccessary for
CC   expression of the full mar phenotype. Antisense molecules directed
CC   against the mar operon can be used to lower the resistance of bacteria to
CC   antibiotics. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 72 AA;

  Query Match             100.0%;  Score 19;  DB 2;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         17 AQGV 20


RESULT 192
AAU07749
ID   AAU07749 standard; protein; 72 AA.
XX
AC   AAU07749;
XX
DT   04-DEC-2001  (first entry)
XX
DE   House dust mite allergenic protein Der p I variant e.
XX
KW   House dust mite; allergenic protein; Der p I; Der p II; Der f I;
KW   Der f II; antiallergenic; immunostimulant; house dust mite allergy;
KW   T-cell epitope; polymorphic variant.
XX
OS   Dermatophagoides pteronyssinus.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "The protein is deletion variant where residues 1-
FT                   150 of the wild-type mature Der p I have been deleted"
XX
PN   US6268491-B1.
XX
PD   31-JUL-2001.
XX
PF   07-JUN-1995;   95US-00484296.
XX
PR   16-OCT-1991;   91US-00777859.
PR   08-MAY-1992;   92US-00881396.
PR   14-APR-1993;   93WO-US003471.
PR   14-APR-1994;   94US-00227772.
PR   19-MAY-1995;   95US-00445307.
XX
PA   (IMMU-) IMMULOGIC PHARM CORP.
XX
PI   Garman RD,  Greenstein JL,  Kuo M,  Rogers BL,  Franzen HM,  Chen X;
PI   Evans S,  Shaked Z;
XX
DR   WPI; 2001-549074/61.
XX
PT   Peptides comprising T cell groups of the major allergens from
PT   Dermatophagoides (house dust mites), useful for treating house dust mite
PT   allergy in humans, and for diagnosing sensitivity to house dust mite
PT   protein allergens.
XX
PS   Disclosure; Fig 22; 158pp; English.
XX
CC   The invention relates to an isolated peptide of the major protein
CC   allergens of the genus Dermatophagoides, which comprises at least one T
CC   cell group of a protein allergen from Der p (DP) I, DP II, Der f (DF) I
CC   or DF II. The isolated peptide comprises at least two regions, each
CC   region comprising at least one T cell group of a protein allergen of the
CC   genus Dermatophagoides. The regions are derived from the same or
CC   different protein allergens of the genus Dermatophagoides. The peptides
CC   are useful for treating house dust mite allergy in humans. The peptides
CC   are also useful for detecting or diagnosing sensitivity to house dust
CC   mite protein allergens. The present peptides have similar or enhanced
CC   therapeutic properties as the naturally-occurring allergen, but have
CC   reduced side effects, and increased solubility and stability. The present
CC   sequence represents an allergenic protein from Dermatophagoides from
CC   which the T-cell epitope containing peptides are derived, a polymorphic
CC   variant of Der p I. Note: The present sequence is not shown in the
CC   specification but is derived from the Der p I sequence shown in figure 22
XX
SQ   Sequence 72 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 193
AAM87649
ID   AAM87649 standard; protein; 72 AA.
XX
AC   AAM87649;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:15242.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001354.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
```

PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK60430.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
PS Claim 11; SEQ ID NO 15242; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 72 AA;

Query Match 100.0%; Score 19; DB 4; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 7 AQGV 10

```
RESULT 194
AAU43630
ID   AAU43630 standard; protein; 72 AA.
XX
AC   AAU43630;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #4526.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59521.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 4825; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 72 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         51 AQGV 54
```

```
RESULT 195
ABU09526
ID   ABU09526 standard; protein; 72 AA.
XX
AC   ABU09526;
XX
DT   30-JUN-2003  (first entry)
XX
DE   E. coli multiple antibiotic resistance operon protein MarB.
XX
KW   Multiple antibiotic resistance; Mar; operon; infection; MarR; MarB; MarA;
KW   ORF157; ORF266; ORF64; antimicrobial.
XX
OS   Escherichia coli.
XX
PN   US2003013104-A1.
XX
PD   16-JAN-2003.
XX
PF   22-APR-2002; 2002US-00131406.
XX
PR   28-AUG-1992;   92US-00938085.
PR   08-APR-1994;   94US-00225480.
PR   17-JUL-1998;   98US-00118445.
XX
PA   (TUFT ) UNIV TUFTS.
XX
PI   Levy SB;
XX
DR   WPI; 2003-401595/38.
DR   N-PSDB; ABX95686.
XX
PT   Identifying bacterial loci which affect resistance to antibiotic
PT   compositions, by binding an activator of bacterial antibiotic resistance
PT   operon to bacterial DNA, and assaying for sites on DNA to which activator
PT   binds.
XX
PS   Claim 84; Page 19; 26pp; English.
XX
CC   The invention relates to identifying bacterial loci which affect
CC   resistance to antibiotic compositions, involves allowing an activator of
CC   a bacterial multiple antibiotic resistance (mar) operon to bind to a
CC   bacterial DNA molecule, and assaying for sites on the DNA to which the
CC   activator binds. The method alternatively involves introducing within the
CC   bacteria an operable nucleotide sequence encoding at least a functional
CC   fragment of an activator of a bacterial multiple-antibiotic resistance
CC   operon, where the fragment of the activator is capable of substantially
CC   increasing the expression of a bacterial mar phenotype, and assaying for
CC   changes in the levels of expression of the loci within the bacteria.
CC   Substitutively, the method involves subjecting bacteria to a first set of
CC   conditions such that the bacteria express or do not express a mar
CC   phenotype, introducing within the bacteria a nucleotide sequence
CC   including a marker locus and free of a regulatory region operably joined
CC   to the marker locus, permitting the sequence to integrate within a
CC   chromosome or at random sites within a chromosome of the bacteria,
CC   assaying for expression of the marker locus, subjecting a subset of the
CC   bacteria which express or do not express the marker locus to a second set
CC   of conditions such that the subset of bacteria do not express or express
CC   the phenotype, assaying for bacteria in the subset of bacteria which do
CC   not express or express the marker locus under the second set of
CC   conditions, and determining the site of integration of the marker locus
CC   in the subset of bacteria which express the marker locus under the first
CC   set of conditions and which express or do not express the marker locus
CC   under the second set of conditions. The method is useful for identifying
CC   bacterial loci which affect resistance to antibiotic compositions. An
CC   antibiotic composition is useful for inhibiting the growth of bacteria
CC   (e.g. a bacteria causing an infection), by exposing the bacteria to a
CC   composition including an amount of an antibiotic composition and an
CC   amount of substance which substantially decreases the expression of a mar
CC   phenotype by the bacteria. The substance is a nucleotide sequence
CC   comprising at least a functional fragment of a repressor locus of a
```

CC bacterial mar operon operably joined to a regulatory region such that the
CC expression of the repressor locus is substantially dependent upon the
CC regulatory region and the sequence is free from operable sequences
CC encoding an activator of a bacterial mar operon. The substance is a
CC nucleotide sequence having substantial homology to at least a fragment of
CC an activator locus of a bacterial multiple resistance operon and is an
CC inhibitor of the activity of an activator of a bacterial mar operon. The
CC E. coli mar operon encodes the MarR, MarB, MarA, ORF157, ORF266 and ORF64
CC proteins. The present sequence is the MarB protein
XX
SQ Sequence 72 AA;

Query Match 100.0%; Score 19; DB 6; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 196
ABM40149
ID ABM40149 standard; protein; 72 AA.
XX
AC ABM40149;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #4825.
XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64450.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 4825; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 72 AA;

Query Match 100.0%; Score 19; DB 6; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 51 AQGV 54

RESULT 197
AEA32550
ID AEA32550 standard; protein; 72 AA.
XX
AC AEA32550;
XX
DT 25-AUG-2005 (first entry)
XX
DE marC protein, SEQ ID 5.
XX
KW Multidrug-resistance; antibiotic-resistance; operon.
XX
OS Escherichia coli.
XX
PN US2005136460-A1.
XX
PD 23-JUN-2005.
XX
PF 15-NOV-2004; 2004US-00989992.
XX
PR 28-AUG-1992; 92US-00938085.
PR 08-APR-1994; 94US-00225480.
PR 17-JUL-1998; 98US-00118445.
PR 22-APR-2002; 2002US-00131406.
XX
PA (LEVY/) LEVY S B.
XX
PI Levy SB;
XX
DR WPI; 2005-457506/46.
DR N-PSDB; AEA32545.
XX
PT Method for predicting antibiotic effectiveness of a composition comprises
PT exposing a bacteria to the composition and assaying the effect of the
PT exposure on the expression of a genetic locus.
XX
PS Disclosure; SEQ ID NO 6; 23pp; English.
XX
CC The present invention relates to a method for predicting the antibiotic
CC effectiveness of a composition (A). The method comprises exposing a
CC bacteria to (A) and assaying the effect of the exposure on the expression
CC of a genetic locus, where the expression is regulated in part and
CC indirectly by at least a functional fragment of a regulatory region of a
CC bacterial multiple antibiotic resistance (mar) operon within the
CC bacteria. The present sequence is a protein encoded by the wild-type mar
CC operon of E. coli which was used to illustrate the invention.
XX
SQ Sequence 72 AA;

Query Match 100.0%; Score 19; DB 9; Length 72;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 17 AQGV 20

RESULT 198
ABP04492
ID ABP04492 standard; protein; 74 AA.
XX
AC ABP04492;
XX
DT 24-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:8966.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN20244.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 8966; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 74 AA;

Query Match 100.0%; Score 19; DB 5; Length 74;
Best Local Similarity 100.0%; Pred. No. 3.1e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 48 AQGV 51

RESULT 199
ABP32468
ID ABP32468 standard; protein; 74 AA.
XX
AC ABP32468;
XX
DT 08-JUL-2002 (first entry)
XX
DE Human ORF1441 protein, SEQ ID NO:2882.
XX
KW Human; ORF; open reading frame; ORFX; drug screening; diagnosis;
KW disease monitoring; cytokine; cell proliferation; cell differentiation;
KW immune modulation; haematopoiesis regulation; tissue growth;
KW angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; tumour inhibition; bodily characteristic; fertility;
KW behaviour; cancer; proliferative disorder; neurological disorder;
KW cardiovascular disease; immune system disorder; organ transplantation;
KW tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
KW hypothyroidism; cholesterol ester storage disease; infection; vulnerary;
KW vasotropic; antipsoriatic; antidiabetic; cytostatic; nootropic;
KW neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
KW cardiant; hypotensive; antithyroid; antiinflammatory; immunomodulator;
KW dermatological; analgesic; virucide; antibacterial; fungicide.
XX
OS Homo sapiens.
XX
PN WO200190366-A2.
XX
PD 29-NOV-2001.
XX
PF 24-MAY-2001; 2001WO-US017076.
XX
PR 24-MAY-2000; 2000US-0206690P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Leach MD, Shimkets RA;
XX
DR WPI; 2002-106200/14.
DR N-PSDB; ABN76494.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and disorders related to organ
PT transplantation.
XX
PS Claim 10; Page 980; 2508pp; English.
XX
CC Sequences ABP31028-ABP35561 represent 4534 novel human proteins
CC designated ORF (open reading frame) 1-4534, and sequences ABN75054-
CC ABN79587 represent cDNAs encoding them. The invention also encompasses
CC polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
CC referred to as ORFX) proteins, polynucleotides at least 85% identical to
CC the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
CC polynucleotides, the recombinant production of ORFX proteins, antibodies
CC specific for ORFX proteins, methods of detecting ORFX polynucleotides and
CC polypeptides, methods of screening for modulators of ORFX expression or

```
CC   activity, and methods of screening individuals for a predisposition to an
CC   ORFX-associated disorder. The ORFX proteins of the invention have a wide
CC   range of biological activities, such as cytokine, cell proliferation,
CC   cell differentiation, immune modulation, haematopoiesis regulation,
CC   tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
CC   chemokinetic activity, haemostatic activity, thrombolytic activity,
CC   receptor/ligand, antiinflammatory activity, tumour inhibition activity,
CC   and antiinfective activity, and may also be involved in the determination
CC   of bodily characteristics, fertility and behaviour. ORFX proteins,
CC   nucleic acids and antibodies may be used in the treatment of cancers,
CC   other proliferative disorders such as psoriasis and benign tumours,
CC   neurological disorders such as epilepsy and Alzheimer's disease,
CC   cardiovascular diseases, immune system disorders, disorders related to
CC   organ transplantation, disorders of tissue growth and regeneration,
CC   diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
CC   storage disease, and infectious diseases caused by viral, bacterial,
CC   fungal and other pathogens. ORFX nucleic acids may also be used as a
CC   source of primers and probes, in the detection of ORFX genomic sequences
CC   or transcripts, in the identification and cloning of homologous
CC   sequences, in genetic diagnosis, and in forensic biology. The ORFX
CC   nucleic acids may additionally be used to produce transgenic animals
CC   which may be useful for studying the function and/or activity of ORFX
CC   protein, and in drug screening. The ORFX proteins may also be used as
CC   immunogens to generate specific antibodies, which are useful in the
CC   diagnosis, treatment and monitoring of ORFX-associated diseases
XX
SQ   Sequence 74 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 74;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         48 AQGV 51


RESULT 200
ABP64192
ID   ABP64192 standard; protein; 75 AA.
XX
AC   ABP64192;
XX
DT   04-NOV-2002  (first entry)
XX
DE   Human ORF562.
XX
KW   Cytostatic; Cardiant; Anti-allergic; Immunosuppressive; Vulnerary;
KW   Antiinflammatory; gene therapy; human; ORFX; atherogenic; platelet;
KW   human umbilical vein endothelial cell; HUVEC; atherosclerotic plaque;
KW   cancer; cardiovascular disease; allergy; autoimmune disease;
KW   wound healing; blood coagulation disorder; inflammatory disorder.
XX
OS   Homo sapiens.
XX
PN   US2002082206-A1.
XX
PD   27-JUN-2002.
XX
PF   30-MAY-2001; 2001US-00867550.
XX
PR   30-MAY-2000; 2000US-0208427P.
XX
PA   (LEAC/) LEACH M D.
PA   (MEHR/) MEHRABAN F.
PA   (CONL/) CONLEY P B.
PA   (TOPP/) TOPPER J N.
PA   (LAWD/) LAW D.
XX
PI   Leach MD,  Mehraban F,  Conley PB,  Topper JN,  Law D;
XX
DR   WPI; 2002-626554/67.
DR   N-PSDB; ABQ98755.
XX
PT   New polypeptide designated ORFX are present in human atherogenic cells
PT   and are useful to prevent and treat ORFX-associated disorders including
PT   cancer, allergy, wound healing or autoimmune, cardiovascular or
PT   inflammatory disease.
XX
PS   Claim 10; SEQ ID NO 1124; 78pp; English.
XX
CC   The present invention relates to novel human ORFX polypeptides and their
CC   coding sequences (ABP63631-ABP64681 and ABQ98194-ABQ99267). The sequences
CC   were discovered in human atherogenic cells, in particular in platelets
CC   and human umbilical vein endothelial cells (HUVEC) and are expressed in
CC   many other tissues as well. Atherogenic cells are cells which have the
CC   potential to develop atherosclerotic plaques. The ORFX polypeptides and
CC   nucleic acids are useful for treating or preventing a pathological
CC   condition associated with an ORFX-associated disorder, e.g. cancer,
CC   cardiovascular disease, allergy, autoimmune disease, wound healing, blood
CC   coagulation disorders or inflammatory disorders. Note: The sequence data
CC   for this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from the USPTO web site at
CC   seqdata.uspto.gov/sequence.html?DocID=20020082206
XX
SQ   Sequence 75 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 75;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          4 AQGV 7


RESULT 201
AAW72051
ID   AAW72051 standard; protein; 76 AA.
XX
AC   AAW72051;
XX
DT   07-DEC-1998  (first entry)
XX
DE   HSV-2 strain SB5 Contig ID 38 ORF#1 protein.
XX
KW   HSV-2 strain SB5; immunological response induction; therapy;
KW   antiviral identification; viral protein inhibitor.
XX
OS   Herpes simplex virus 2.
XX
PN   WO9820016-A1.
XX
PD   14-MAY-1998.
XX
PF   31-OCT-1997;   97WO-US020016.
XX
PR   04-NOV-1996;   96US-0030279P.
PR   09-JUN-1997;   97US-0049018P.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Esser KM,  Chan JY,  Dabrowski-Amaral CE,  Delvecchio AM,  Dillon SB;
PI   Leary JJ;
XX
DR   WPI; 1998-286847/25.
DR   N-PSDB; AAV62136.
XX
PT   Herpes simplex virus type-2 sequences - useful in, e.g. prevention and
PT   treatment of infection or inducing immunological response in mammal.
XX
PS   Claim 10; Page 59; 748pp; English.
XX
CC   This sequence represents a Herpes simplex virus type-2 (HSV-2) protein
CC   sequence of the invention. This sequence was isolated from a HSV-2 strain
CC   SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 38.
```

CC Based on homology, this sequence is a minor capsid protein L2. The
CC proteins can be used for the treatment or prevention of disease, to
CC induce an immunological response in a mammal or to identify inhibitors;
CC activators or novel antivirals. Antagonists of the proteins can be used
CC to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC it can also be used to induce an immunological response in a mammal
XX
SQ Sequence 76 AA;

Query Match 100.0%; Score 19; DB 2; Length 76;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 6 AQGV 9

RESULT 202
ABO56564
ID ABO56564 standard; protein; 76 AA.
XX
AC ABO56564;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #2798.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 30198; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 76 AA;

Query Match 100.0%; Score 19; DB 8; Length 76;
Best Local Similarity 100.0%; Pred. No. 3.2e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 59 AQGV 62

RESULT 203
ADL05542
ID ADL05542 standard; protein; 77 AA.
XX
AC ADL05542;
XX
DT 06-MAY-2004 (first entry)
XX
DE M. catarrhalis protein #1308.
XX
KW Moraxella catarrhalis; infection.
XX
OS Moraxella catarrhalis.
XX
PN US6673910-B1.
XX
PD 06-JAN-2004.
XX
PF 04-APR-2000; 2000US-00540236.
XX
PR 08-APR-1999; 99US-0128416P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Breton GL;
XX
DR WPI; 2004-178127/17.
DR N-PSDB; ADL03622.
XX
PT New nucleic acid encoding a Moraxella catarrhalis polypeptide, useful for
PT preparing a composition for diagnosing, preventing or treating infection
PT caused by Moraxella catarrhalis.
XX
PS Disclosure; SEQ ID NO 3228; 429pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding an Moraxella
CC catarrhalis polypeptide. The nucleic acid is useful for preparing a
CC composition for diagnosing, preventing or treating infection caused by
CC Moraxella catarrhalis. The present sequence represents the amino acid
CC sequence of a M. catarrhalis protein.
XX
SQ Sequence 77 AA;

```
  Query Match           100.0%;  Score 19;  DB 8;  Length 77;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         47 AQGV 50
```

```
RESULT 204
AAU59277
ID   AAU59277 standard; protein; 78 AA.
XX
AC   AAU59277;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #20173.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59601.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 20472; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 78 AA;
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 78;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14
```

```
RESULT 205
ABG26469
ID   ABG26469 standard; protein; 78 AA.
XX
AC   ABG26469;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #26460.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US008631.
XX
PR   31-MAR-2000; 2000US-00540217.
PR   23-AUG-2000; 2000US-00649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS90656.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity.
XX
PS   Claim 20; SEQ ID NO 56828; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC   sequences. (I) is useful as hybridisation probes, polymerase chain
CC   reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC   and in recombinant production of (II). The polynucleotides are also used
CC   in diagnostics as expressed sequence tags for identifying expressed
CC   genes. (I) is useful in gene therapy techniques to restore normal
CC   activity of (II) or to treat disease states involving (II). (II) is
CC   useful for generating antibodies against it, detecting or quantitating a
CC   polypeptide in tissue, as molecular weight markers and as a food
CC   supplement. (II) and its binding partners are useful in medical imaging
CC   of sites expressing (II). (I) and (II) are useful for treating disorders
CC   involving aberrant protein expression or biological activity. The
CC   polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC   amino acid sequences of the invention. Note: The sequence data for this
CC   patent did not appear in the printed specification, but was obtained in
CC   electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 78 AA;
```

```
  Query Match           100.0%;  Score 19;  DB 4;  Length 78;
  Best Local Similarity  100.0%;  Pred. No. 3.3e+03;
```

```
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         55 AQGV 58


RESULT 206
ABM55796
ID   ABM55796 standard; protein; 78 AA.
XX
AC   ABM55796;
XX
DT   20-OCT-2003  (first entry)
XX
DE   Propionibacterium acnes predicted ORF-encoded polypeptide #20472.
XX
KW   Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW   immunostimulant; immune response; vaccine.
XX
OS   Propionibacterium acnes.
XX
PN   WO2003033515-A1.
XX
PD   24-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032727.
XX
PR   15-OCT-2001; 2001US-00978825.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Mitcham JL,  Skeiky YAW,  Persing DH,  Bhatia A,  Maisonneuve JL;
PI   Zhang Y,  Wang S,  Jen S,  Lodes MJ,  Benson DR,  Jones R,  Carter D;
PI   Barth B,  Vallieve-Douglass J;
XX
DR   WPI; 2003-381789/36.
DR   N-PSDB; ACF64530.
XX
PT   New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT   polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT   or for stimulating an immune response specific for a P. acnes protein.
XX
PS   Example 1; SEQ ID NO 20472; 1481pp; English.
XX
CC   The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC   encoding a Propionibacterium acnes protein. The invention also relates to
CC   polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC   immunogenic fragments of P. acnes polypeptides. The invention
CC   additionally encompasses expression vectors and host cells comprising a
CC   polynucleotide of the invention; antibodies against polypeptides of the
CC   invention; fusion proteins comprising a polypeptide of the invention; a
CC   method for stimulating an immune response specific for a P. acnes
CC   polypeptide and an isolated T cell population comprising T cells prepared
CC   via this method; a vaccine composition (comprising P. acnes polypeptides,
CC   polynucleotides, antibodies, fusion proteins, T cell populations, or
CC   antigen-presenting cells that express the polypeptide); a method and kit
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 78 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         11 AQGV 14


RESULT 207
ABP01669
ID   ABP01669 standard; protein; 79 AA.
XX
AC   ABP01669;
XX
DT   24-JUN-2002  (first entry)
XX
DE   Human ORFX protein sequence SEQ ID NO:3320.
XX
KW   Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW   hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW   degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW   cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW   hypertension; hypothyroidism; cholesterol ester storage disease;
KW   immune deficiency; immune disorder; infectious disease;
KW   autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW   myasthenia gravis.
XX
OS   Homo sapiens.
XX
PN   WO200192523-A2.
XX
PD   06-DEC-2001.
XX
PF   29-MAY-2001; 2001WO-US010836.
XX
PR   30-MAY-2000; 2000US-0206132P.
PR   29-AUG-2000; 2000US-0228716P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Leach MD;
XX
DR   WPI; 2002-106308/14.
DR   N-PSDB; ABN17421.
XX
PT   Novel human polypeptides and polynucleotides useful for diagnosing,
PT   preventing and treating cardiovascular disease, neurodegenerative,
PT   hyperproliferative disorders and autoimmune disorders.
XX
PS   Disclosure; SEQ ID NO 3320; 1037pp; English.
XX
CC   The present invention describes substantially purified human proteins
CC   (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC   in the specification). ABN15762 to ABN27252 encode the human ORFX
CC   proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC   treating or preventing a pathology associated with an ORFX-associated
CC   disorder in humans, and in the manufacture of a medicament for treating a
CC   syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC   sequences can be used in gene therapy. ORFX sequences can be used in the
CC   treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC   psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC   osteoarthritis, neurodegenerative disorders, disorders related to organ
CC   transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC   lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC   storage disease, various immune deficiencies and disorders, infectious
CC   diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC   arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC   disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC   useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC   bone degenerative disorders, or periodontal disease, and for gut
```

```
CC   protection or regeneration and treatment of lung or liver fibrosis,
CC   reperfusion injury in various tissues and conditions resulting from
CC   systemic cytokine damage. N.B. The sequence data for this patent did not
CC   form part of the printed specification, but was obtained in electronic
CC   format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 79 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 79;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         54 AQGV 57


RESULT 208
AAG19634
ID   AAG19634 standard; protein; 80 AA.
XX
AC   AAG19634;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID NO: 21509.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
XX
OS   Arabidopsis thaliana.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-00301439.
XX
PR   25-FEB-1999;   99US-0121825P.
PR   05-MAR-1999;   99US-0123180P.
PR   09-MAR-1999;   99US-0123548P.
PR   23-MAR-1999;   99US-0125788P.
PR   25-MAR-1999;   99US-0126264P.
PR   29-MAR-1999;   99US-0126785P.
PR   01-APR-1999;   99US-0127462P.
PR   06-APR-1999;   99US-0128234P.
PR   08-APR-1999;   99US-0128714P.
PR   16-APR-1999;   99US-0129845P.
PR   19-APR-1999;   99US-0130077P.
PR   21-APR-1999;   99US-0130449P.
PR   23-APR-1999;   99US-0130510P.
PR   23-APR-1999;   99US-0130891P.
PR   28-APR-1999;   99US-0131449P.
PR   30-APR-1999;   99US-0132048P.
PR   30-APR-1999;   99US-0132407P.
PR   04-MAY-1999;   99US-0132484P.
PR   05-MAY-1999;   99US-0132485P.
PR   06-MAY-1999;   99US-0132486P.
PR   06-MAY-1999;   99US-0132487P.
PR   07-MAY-1999;   99US-0132863P.
PR   11-MAY-1999;   99US-0134256P.
PR   14-MAY-1999;   99US-0134218P.
PR   14-MAY-1999;   99US-0134219P.
PR   14-MAY-1999;   99US-0134221P.
PR   14-MAY-1999;   99US-0134370P.
PR   18-MAY-1999;   99US-0134768P.
PR   19-MAY-1999;   99US-0134941P.
PR   20-MAY-1999;   99US-0135124P.
PR   21-MAY-1999;   99US-0135353P.
PR   24-MAY-1999;   99US-0135629P.
PR   25-MAY-1999;   99US-0136021P.
PR   27-MAY-1999;   99US-0136392P.
PR   28-MAY-1999;   99US-0136782P.
PR   01-JUN-1999;   99US-0137222P.
PR   03-JUN-1999;   99US-0137528P.
PR   04-JUN-1999;   99US-0137502P.
PR   07-JUN-1999;   99US-0137724P.
PR   08-JUN-1999;   99US-0138094P.
PR   10-JUN-1999;   99US-0138540P.
PR   10-JUN-1999;   99US-0138847P.
PR   14-JUN-1999;   99US-0139119P.
PR   16-JUN-1999;   99US-0139452P.
PR   16-JUN-1999;   99US-0139453P.
PR   17-JUN-1999;   99US-0139492P.
PR   18-JUN-1999;   99US-0139454P.
PR   18-JUN-1999;   99US-0139455P.
PR   18-JUN-1999;   99US-0139456P.
PR   18-JUN-1999;   99US-0139457P.
PR   18-JUN-1999;   99US-0139458P.
PR   18-JUN-1999;   99US-0139459P.
PR   18-JUN-1999;   99US-0139460P.
PR   18-JUN-1999;   99US-0139461P.
PR   18-JUN-1999;   99US-0139462P.
PR   18-JUN-1999;   99US-0139463P.
PR   18-JUN-1999;   99US-0139750P.
PR   18-JUN-1999;   99US-0139763P.
PR   21-JUN-1999;   99US-0139817P.
PR   22-JUN-1999;   99US-0139899P.
PR   23-JUN-1999;   99US-0140353P.
PR   23-JUN-1999;   99US-0140354P.
PR   24-JUN-1999;   99US-0140695P.
PR   28-JUN-1999;   99US-0140823P.
PR   29-JUN-1999;   99US-0140991P.
PR   30-JUN-1999;   99US-0141287P.
PR   01-JUL-1999;   99US-0141842P.
PR   01-JUL-1999;   99US-0142154P.
PR   02-JUL-1999;   99US-0142055P.
PR   06-JUL-1999;   99US-0142390P.
PR   08-JUL-1999;   99US-0142803P.
PR   09-JUL-1999;   99US-0142920P.
PR   12-JUL-1999;   99US-0142977P.
PR   13-JUL-1999;   99US-0143542P.
PR   14-JUL-1999;   99US-0143624P.
PR   15-JUL-1999;   99US-0144005P.
PR   16-JUL-1999;   99US-0144085P.
PR   16-JUL-1999;   99US-0144086P.
PR   19-JUL-1999;   99US-0144325P.
PR   19-JUL-1999;   99US-0144331P.
PR   19-JUL-1999;   99US-0144332P.
PR   19-JUL-1999;   99US-0144333P.
PR   19-JUL-1999;   99US-0144334P.
PR   19-JUL-1999;   99US-0144335P.
PR   20-JUL-1999;   99US-0144352P.
PR   20-JUL-1999;   99US-0144632P.
PR   20-JUL-1999;   99US-0144884P.
PR   21-JUL-1999;   99US-0144814P.
PR   21-JUL-1999;   99US-0145086P.
PR   21-JUL-1999;   99US-0145088P.
PR   22-JUL-1999;   99US-0145085P.
PR   22-JUL-1999;   99US-0145087P.
PR   22-JUL-1999;   99US-0145089P.
PR   22-JUL-1999;   99US-0145192P.
PR   23-JUL-1999;   99US-0145145P.
PR   23-JUL-1999;   99US-0145218P.
PR   23-JUL-1999;   99US-0145224P.
PR   26-JUL-1999;   99US-0145276P.
PR   27-JUL-1999;   99US-0145913P.
PR   27-JUL-1999;   99US-0145918P.
PR   27-JUL-1999;   99US-0145919P.
PR   28-JUL-1999;   99US-0145951P.
PR   02-AUG-1999;   99US-0146386P.
PR   02-AUG-1999;   99US-0146388P.
PR   02-AUG-1999;   99US-0146389P.
PR   03-AUG-1999;   99US-0147038P.
PR   04-AUG-1999;   99US-0147204P.
```

PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 80;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 60 AQGV 63

RESULT 209
ADH39815
ID ADH39815 standard; protein; 80 AA.
XX
AC ADH39815;
XX
DT 11-MAR-2004 (first entry)
XX
DE FarA amino acid sequence.
XX
KW actinomyces-originated plasmid; linear plasmid; pSLA2-L;
KW Streptomyces rochei; secondary metabolite; antibiotic; vitamin;
KW lankamycin; mithramycin-like substance; carotenoid; lankacidin.
XX
OS Unidentified.
XX
PN WO2004001039-A1.
XX
PD 31-DEC-2003.
XX
PF 19-JUN-2003; 2003WO-JP007767.
XX
PR 20-JUN-2002; 2002JP-00179345.
XX
PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI Kinashi H;
XX
DR WPI; 2004-082503/08.
XX
PT Actinomyces-originated plasmids for producing secondary metabolites e.g.
PT antibiotics and vitamins like lankamycins, lankacidins, mithramycin-like
PT substances and carotenoids.
XX
PS Disclosure; Fig 6A; 499pp; Japanese.
XX
CC The present invention describes an actinomyces-originated plasmid is a
CC linear plasmid (pSLA2-L) originating in Streptomyces rochei, which has a
CC base sequence capable of providing any of the protein sequences of SEQ ID
CC NO:1 to 143 (ADH39670 to ADH39812), or one based on these sequences but
CC with some amino acids deleted, substituted or added and capable of
CC producing a secondary metabolite. Also described is a process for
CC producing a secondary metabolite by using the plasmid. The plasmid can be
CC used for producing secondary metabolites e.g. antibiotics and vitamins
CC like lankamycins, mithramycin-like substances, carotenoids and
CC lankacidins. Such secondary metabolites are produced selectively and
CC efficiently. The present sequence represents an amino acid sequence given
CC in the exemplification of the present invention.
XX
SQ Sequence 80 AA;

Query Match 100.0%; Score 19; DB 8; Length 80;
Best Local Similarity 100.0%; Pred. No. 3.4e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 57 AQGV 60

RESULT 210
ABP10494
ID ABP10494 standard; protein; 81 AA.

```
XX
AC   ABP10494;
XX
DT   24-JUN-2002  (first entry)
XX
DE   Human ORFX protein sequence SEQ ID NO:20970.
XX
KW   Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW   hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW   degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW   cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW   hypertension; hypothyroidism; cholesterol ester storage disease;
KW   immune deficiency; immune disorder; infectious disease;
KW   autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW   myasthenia gravis.
XX
OS   Homo sapiens.
XX
PN   WO200192523-A2.
XX
PD   06-DEC-2001.
XX
PF   29-MAY-2001; 2001WO-US010836.
XX
PR   30-MAY-2000; 2000US-0206132P.
PR   29-AUG-2000; 2000US-0228716P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Leach MD;
XX
DR   WPI; 2002-106308/14.
DR   N-PSDB; ABN26246.
XX
PT   Novel human polypeptides and polynucleotides useful for diagnosing,
PT   preventing and treating cardiovascular disease, neurodegenerative,
PT   hyperproliferative disorders and autoimmune disorders.
XX
PS   Disclosure; SEQ ID NO 20970; 1037pp; English.
XX
CC   The present invention describes substantially purified human proteins
CC   (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC   in the specification). ABN15762 to ABN27252 encode the human ORFX
CC   proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC   treating or preventing a pathology associated with an ORFX-associated
CC   disorder in humans, and in the manufacture of a medicament for treating a
CC   syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC   sequences can be used in gene therapy. ORFX sequences can be used in the
CC   treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC   psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC   osteoarthritis, neurodegenerative disorders, disorders related to organ
CC   transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC   lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC   storage disease, various immune deficiencies and disorders, infectious
CC   diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC   arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC   disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC   useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC   bone degenerative disorders, or periodontal disease, and for gut
CC   protection or regeneration and treatment of lung or liver fibrosis,
CC   reperfusion injury in various tissues and conditions resulting from
CC   systemic cytokine damage. N.B. The sequence data for this patent did not
CC   form part of the printed specification, but was obtained in electronic
CC   format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 81 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 81;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         48 AQGV 51


RESULT 211
AAU52713
ID   AAU52713 standard; protein; 82 AA.
XX
AC   AAU52713;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #13609.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59557.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 13908; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 82 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 82;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
```

```
Db         66 AQGV 69


RESULT 212
ABM49232
ID   ABM49232 standard; protein; 82 AA.
XX
AC   ABM49232;
XX
DT   20-OCT-2003  (first entry)
XX
DE   Propionibacterium acnes predicted ORF-encoded polypeptide #13908.
XX
KW   Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW   immunostimulant; immune response; vaccine.
XX
OS   Propionibacterium acnes.
XX
PN   WO2003033515-A1.
XX
PD   24-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032727.
XX
PR   15-OCT-2001; 2001US-00978825.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Mitcham JL,  Skeiky YAW,  Persing DH,  Bhatia A,  Maisonneuve JL;
PI   Zhang Y,  Wang S,  Jen S,  Lodes MJ,  Benson DR,  Jones R,  Carter D;
PI   Barth B,  Vallieve-Douglass J;
XX
DR   WPI; 2003-381789/36.
DR   N-PSDB; ACF64486.
XX
PT   New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT   polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT   or for stimulating an immune response specific for a P. acnes protein.
XX
PS   Example 1; SEQ ID NO 13908; 1481pp; English.
XX
CC   The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC   encoding a Propionibacterium acnes protein. The invention also relates to
CC   polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC   immunogenic fragments of P. acnes polypeptides. The invention
CC   additionally encompasses expression vectors and host cells comprising a
CC   polynucleotide of the invention; antibodies against polypeptides of the
CC   invention; fusion proteins comprising a polypeptide of the invention; a
CC   method for stimulating an immune response specific for a P. acnes
CC   polypeptide and an isolated T cell population comprising T cells prepared
CC   via this method; a vaccine composition (comprising P. acnes polypeptides,
CC   polynucleotides, antibodies, fusion proteins, T cell populations, or
CC   antigen-presenting cells that express the polypeptide); a method and kit
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 82 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 82;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         66 AQGV 69


RESULT 213
AAG02108
ID   AAG02108 standard; protein; 83 AA.
XX
AC   AAG02108;
XX
DT   06-OCT-2000  (first entry)
XX
DE   Human secreted protein, SEQ ID NO: 6189.
XX
KW   Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW   gene therapy; chromosome mapping.
XX
OS   Homo sapiens.
XX
PN   EP1033401-A2.
XX
PD   06-SEP-2000.
XX
PF   21-FEB-2000; 2000EP-00200610.
XX
PR   26-FEB-1999;   99US-0122487P.
XX
PA   (GEST ) GENSET.
XX
PI   Dumas Milne Edwards J,  Duclert A,  Giordano J;
XX
DR   WPI; 2000-500381/45.
DR   N-PSDB; AAC02114.
XX
PT   New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT   obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT   diagnostic, forensic, gene therapy and chromosome mapping procedures.
XX
PS   Claim 13; SEQ ID NO 6189; 71pp + Sequence Listing; English.
XX
CC   The present sequence is a polypeptide encoded by one of a large number of
CC   5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs were
CC   prepared from total human RNAs or polyA+ RNAs derived from 30 different
CC   tissues. EST sequences usually correspond mainly to the 3' untranslated
CC   region (UTR) of the mRNA because they are often obtained from oligo-dT
CC   primed cDNA libraries. Such ESTs are not well suited for isolating cDNA
CC   sequences derived from the 5' ends of mRNAs and even in those cases where
CC   longer cDNA sequences have been obtained, the full 5' UTR is rarely
CC   included. 5' ESTs are derived from mRNAs with intact 5' ends and can
CC   therefore be used to obtain full length cDNAs and genomic DNAs. 5' ESTs
CC   are also used in diagnostic, forensic, gene therapy and chromosome
CC   mapping procedures. They are used to obtain upstream regulatory sequences
CC   and to design expression and secretion vectors
XX
SQ   Sequence 83 AA;

  Query Match             100.0%;  Score 19;  DB 3;  Length 83;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         75 AQGV 78


RESULT 214
AAM87125
ID   AAM87125 standard; protein; 83 AA.
XX
AC   AAM87125;
```

```
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:14718.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001354.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231968P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
PR   20-OCT-2000; 2000US-0241787P.
PR   20-OCT-2000; 2000US-0241808P.
PR   20-OCT-2000; 2000US-0241809P.
PR   20-OCT-2000; 2000US-0241826P.
PR   01-NOV-2000; 2000US-0244617P.
PR   08-NOV-2000; 2000US-0246474P.
PR   08-NOV-2000; 2000US-0246475P.
PR   08-NOV-2000; 2000US-0246476P.
PR   08-NOV-2000; 2000US-0246477P.
PR   08-NOV-2000; 2000US-0246478P.
PR   08-NOV-2000; 2000US-0246523P.
PR   08-NOV-2000; 2000US-0246524P.
PR   08-NOV-2000; 2000US-0246525P.
PR   08-NOV-2000; 2000US-0246526P.
PR   08-NOV-2000; 2000US-0246527P.
PR   08-NOV-2000; 2000US-0246528P.
PR   08-NOV-2000; 2000US-0246532P.
PR   08-NOV-2000; 2000US-0246609P.
PR   08-NOV-2000; 2000US-0246610P.
PR   08-NOV-2000; 2000US-0246611P.
PR   08-NOV-2000; 2000US-0246613P.
PR   17-NOV-2000; 2000US-0249207P.
PR   17-NOV-2000; 2000US-0249208P.
PR   17-NOV-2000; 2000US-0249209P.
PR   17-NOV-2000; 2000US-0249210P.
PR   17-NOV-2000; 2000US-0249211P.
PR   17-NOV-2000; 2000US-0249212P.
PR   17-NOV-2000; 2000US-0249213P.
PR   17-NOV-2000; 2000US-0249214P.
PR   17-NOV-2000; 2000US-0249215P.
PR   17-NOV-2000; 2000US-0249216P.
PR   17-NOV-2000; 2000US-0249217P.
PR   17-NOV-2000; 2000US-0249218P.
PR   17-NOV-2000; 2000US-0249244P.
PR   17-NOV-2000; 2000US-0249245P.
PR   17-NOV-2000; 2000US-0249264P.
PR   17-NOV-2000; 2000US-0249265P.
PR   17-NOV-2000; 2000US-0249297P.
PR   17-NOV-2000; 2000US-0249299P.
PR   17-NOV-2000; 2000US-0249300P.
PR   01-DEC-2000; 2000US-0250160P.
PR   01-DEC-2000; 2000US-0250391P.
PR   05-DEC-2000; 2000US-0251030P.
PR   05-DEC-2000; 2000US-0251988P.
PR   05-DEC-2000; 2000US-0256719P.
PR   06-DEC-2000; 2000US-0251479P.
PR   08-DEC-2000; 2000US-0251856P.
```

PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK59906.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
PS Claim 11; SEQ ID NO 14718; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 83 AA;

Query Match 100.0%; Score 19; DB 4; Length 83;
Best Local Similarity 100.0%; Pred. No. 3.5e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 38 AQGV 41

RESULT 215
AAG34308
ID AAG34308 standard; protein; 84 AA.
XX
AC AAG34308;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 41721.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.

PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 21 AQGV 24

RESULT 216
ABB65061
ID ABB65061 standard; protein; 84 AA.
XX
AC ABB65061;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 21975.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US009231.
XX
PR 23-MAR-2000; 2000US-0191637P.
PR 11-JUL-2000; 2000US-00614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL09164.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more

PT genes from Drosophila and for elucidating cell signaling and cell-cell
PT interactions.
XX
PS Disclosure; SEQ ID NO 21975; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 50 AQGV 53

RESULT 217
AAU61282
ID AAU61282 standard; protein; 84 AA.
XX
AC AAU61282;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #22178.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59615.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 22477; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 65 AQGV 68

RESULT 218
ABG05322
ID ABG05322 standard; protein; 84 AA.
XX
AC ABG05322;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #5313.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US008631.
XX
PR 31-MAR-2000; 2000US-00540217.
PR 23-AUG-2000; 2000US-00649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS69509.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.
XX
PS Claim 20; SEQ ID NO 35681; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC sequences. (I) is useful as hybridisation probes, polymerase chain
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC and in recombinant production of (II). The polynucleotides are also used
CC in diagnostics as expressed sequence tags for identifying expressed
CC genes. (I) is useful in gene therapy techniques to restore normal
CC activity of (II) or to treat disease states involving (II). (II) is
CC useful for generating antibodies against it, detecting or quantitating a

CC polypeptide in tissue, as molecular weight markers and as a food
CC supplement. (II) and its binding partners are useful in medical imaging
CC of sites expressing (II). (I) and (II) are useful for treating disorders
CC involving aberrant protein expression or biological activity. The
CC polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC amino acid sequences of the invention. Note: The sequence data for this
CC patent did not appear in the printed specification, but was obtained in
CC electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 39 AQGV 42

RESULT 219
AAG89210
ID AAG89210 standard; protein; 84 AA.
XX
AC AAG89210;
XX
DT 11-SEP-2001 (first entry)
XX
DE Human secreted protein, SEQ ID NO: 330.
XX
KW Human; secreted protein; gene therapy; vaccine; treatment; diagnosis;
KW GENSET.
XX
OS Homo sapiens.
XX
PN WO200142451-A2.
XX
PD 14-JUN-2001.
XX
PF 07-DEC-2000; 2000WO-IB001938.
XX
PR 08-DEC-1999; 99US-0169629P.
PR 06-MAR-2000; 2000US-0187470P.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Bougueleret L, Jobert S;
XX
DR WPI; 2001-367870/38.
DR N-PSDB; AAH64813.
XX
PT Full length GENSET human nucleic acids encoding potentially secreted
PT proteins, useful in gene therapy and vaccination against a variety of
PT diseases, and for diagnosis of those diseases.
XX
PS Claim 21; Page 848; 921pp; English.
XX
CC The invention relates to full length GENSET human nucleic acids encoding
CC potentially secreted proteins. The nucleic acids and the polypeptides
CC they encode may be used in the prevention, treatment and diagnosis of
CC diseases associated with inappropriate GENSET gene expression. For
CC example, they be used to treat disorders associated with decreased GENSET
CC gene expression by rectifying mutations or deletions in a patient's
CC genome that affect the activity of GENSET or by supplementing the
CC patients own production of GENSET polypeptides. Conversely, antisense
CC nucleic acid molecules may be administered to down regulate GENSET
CC expression by binding with the cells' own genes and preventing their
CC expression. The sense and antisense nucleic acids may also be used as DNA
CC probes in diagnostic assays to detect and quantitate the presence of
CC similar nucleic acid sequences in samples, and hence to determine which
CC patients may be in need of restorative therapy. The GENSET polypeptides
CC may be used as antigens in the production of antibodies and in assays to
CC identify modulators (agonists and antagonists) of GENSET polypeptide
CC expression and activity. The present sequence is a GENSET polypeptide of
CC the invention
XX
SQ Sequence 84 AA;

Query Match 100.0%; Score 19; DB 4; Length 84;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 30 AQGV 33

RESULT 220
ABM57801
ID ABM57801 standard; protein; 84 AA.
XX
AC ABM57801;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #22477.
XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64544.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 22477; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the

```
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 84 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 84;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         65 AQGV 68


RESULT 221
ABP76020
ID   ABP76020 standard; protein; 84 AA.
XX
AC   ABP76020;
XX
DT   21-FEB-2003  (first entry)
XX
DE   Human GENSET protein SEQ ID 227.
XX
KW   Cytostatic; antiinflammatory; nootropic; neuroprotective; cardiant;
KW   gastrointestinal; gene therapy; GENSET; heavy metal toxicity; cancer;
KW   inflammatory disease; immune disorder; neuromuscular; toxicity;
KW   central nervous system; cardiovascular; gastrointestinal.
XX
OS   Homo sapiens.
XX
PN   WO200283898-A1.
XX
PD   24-OCT-2002.
XX
PF   18-APR-2001; 2001WO-IB000914.
XX
PR   18-APR-2001; 2001WO-IB000914.
XX
PA   (GEST ) GENSET.
XX
PI   Bejanin S,  Tanaka H,  Dumas Milne Edwards J,  Jobert S,  Giordano J;
XX
DR   WPI; 2003-075548/07.
XX
PT   New GENSET polynucleotides and polypeptides, useful for treating heavy
PT   metal toxicity, cancer, inflammatory diseases, immune disorders, and the
PT   neuromuscular, CNS, cardiovascular or gastrointestinal effects of the
PT   toxicity.
XX
PS   Claim 14; Page 426-427; 735pp; English.
XX
CC   The present invention relates to novel GENSET polynucleotides (ABZ36404-
CC   ABZ36911) encoding polypeptides (ABP75963-ABP76368). The polynucleotides
CC   and polypeptides are useful in screening and diagnostic assays for
CC   abnormal GENSET expression and/or biological activity. They are also
CC   useful for screening of compounds for treating or preventing GENSET-
CC   related disorders, such as heavy metal toxicity, cancer, inflammatory
CC   diseases, immune disorders, and the neuromuscular, central nervous system
CC   (CNS), cardiovascular or gastrointestinal effects of the toxicity
XX
SQ   Sequence 84 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 84;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 222
ABP76176
ID   ABP76176 standard; protein; 84 AA.
XX
AC   ABP76176;
XX
DT   21-FEB-2003  (first entry)
XX
DE   Human GENSET protein SEQ ID 502.
XX
KW   Cytostatic; antiinflammatory; nootropic; neuroprotective; cardiant;
KW   gastrointestinal; gene therapy; GENSET; heavy metal toxicity; cancer;
KW   inflammatory disease; immune disorder; neuromuscular; toxicity;
KW   central nervous system; cardiovascular; gastrointestinal.
XX
OS   Homo sapiens.
XX
PN   WO200283898-A1.
XX
PD   24-OCT-2002.
XX
PF   18-APR-2001; 2001WO-IB000914.
XX
PR   18-APR-2001; 2001WO-IB000914.
XX
PA   (GEST ) GENSET.
XX
PI   Bejanin S,  Tanaka H,  Dumas Milne Edwards J,  Jobert S,  Giordano J;
XX
DR   WPI; 2003-075548/07.
XX
PT   New GENSET polynucleotides and polypeptides, useful for treating heavy
PT   metal toxicity, cancer, inflammatory diseases, immune disorders, and the
PT   neuromuscular, CNS, cardiovascular or gastrointestinal effects of the
PT   toxicity.
XX
PS   Claim 14; Page 553; 735pp; English.
XX
CC   The present invention relates to novel GENSET polynucleotides (ABZ36404-
CC   ABZ36911) encoding polypeptides (ABP75963-ABP76368). The polynucleotides
CC   and polypeptides are useful in screening and diagnostic assays for
CC   abnormal GENSET expression and/or biological activity. They are also
CC   useful for screening of compounds for treating or preventing GENSET-
CC   related disorders, such as heavy metal toxicity, cancer, inflammatory
CC   diseases, immune disorders, and the neuromuscular, central nervous system
CC   (CNS), cardiovascular or gastrointestinal effects of the toxicity
XX
SQ   Sequence 84 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 84;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         30 AQGV 33


RESULT 223
AAG27024
ID   AAG27024 standard; protein; 85 AA.
XX
AC   AAG27024;
XX
DT   17-OCT-2000  (first entry)
```

XX
DE Zea mays protein fragment SEQ ID NO: 31702.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.

PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 74 AQGV 77

RESULT 224
AAG32676
ID AAG32676 standard; protein; 85 AA.
XX
AC AAG32676;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 39466.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.

PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 100.0%; Score 19; DB 3; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              ||||
Db         74 AQGV 77
```

RESULT 225
AAG25324
ID AAG25324 standard; protein; 85 AA.
XX
AC AAG25324;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 29341.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.

XX

PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.

```
PR   29-SEP-1999;   99US-0156596P.
PR   04-OCT-1999;   99US-0157117P.
PR   05-OCT-1999;   99US-0157753P.
PR   06-OCT-1999;   99US-0157865P.
PR   07-OCT-1999;   99US-0158029P.
PR   08-OCT-1999;   99US-0158232P.
PR   12-OCT-1999;   99US-0158369P.
PR   13-OCT-1999;   99US-0159293P.
PR   13-OCT-1999;   99US-0159294P.
PR   13-OCT-1999;   99US-0159295P.
PR   14-OCT-1999;   99US-0159329P.
PR   14-OCT-1999;   99US-0159330P.
PR   14-OCT-1999;   99US-0159331P.
PR   14-OCT-1999;   99US-0159637P.
PR   14-OCT-1999;   99US-0159638P.
PR   18-OCT-1999;   99US-0159584P.
PR   21-OCT-1999;   99US-0160741P.
PR   21-OCT-1999;   99US-0160767P.
PR   21-OCT-1999;   99US-0160768P.
PR   21-OCT-1999;   99US-0160770P.
PR   21-OCT-1999;   99US-0160814P.
PR   21-OCT-1999;   99US-0160815P.
PR   22-OCT-1999;   99US-0160980P.
PR   22-OCT-1999;   99US-0160981P.
PR   22-OCT-1999;   99US-0160989P.
PR   25-OCT-1999;   99US-0161404P.
PR   25-OCT-1999;   99US-0161405P.
PR   25-OCT-1999;   99US-0161406P.
PR   26-OCT-1999;   99US-0161359P.
PR   26-OCT-1999;   99US-0161360P.
PR   26-OCT-1999;   99US-0161361P.
PR   28-OCT-1999;   99US-0161920P.
PR   28-OCT-1999;   99US-0161992P.
PR   28-OCT-1999;   99US-0161993P.
PR   29-OCT-1999;   99US-0162142P.

  Query Match           100.0%;  Score 19;  DB 3;  Length 85;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         74 AQGV 77


RESULT 226
AAU52346
ID   AAU52346 standard; protein; 85 AA.
XX
AC   AAU52346;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #13242.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59554.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 13541; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 85 AA;

  Query Match           100.0%;  Score 19;  DB 4;  Length 85;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         58 AQGV 61


RESULT 227
ABP62928
ID   ABP62928 standard; protein; 85 AA.
XX
AC   ABP62928;
XX
DT   14-OCT-2002  (first entry)
XX
DE   Human polypeptide SEQ ID NO 365.
XX
KW   Human; vulnerary; dermatological; neuroprotective; nootropic; cancer;
KW   antiparkinsonian; immunostimulant; cytostatic; immunosuppressive;
KW   antidiabetic; antiallergic; gene therapy; wound healing; tissue repair;
KW   burn; central nervous system disorder; Alzheimer's disease;
KW   Parkinson's disease; Huntington's disease; immune disorder;
KW   autoimmune disorder; multiple sclerosis; diabetes; allergy.
XX
OS   Homo sapiens.
XX
PN   WO200218424-A2.
XX
PD   07-MAR-2002.
XX
PF   31-AUG-2001; 2001WO-US027093.
XX
PR   01-SEP-2000; 2000US-00654935.
XX
PA   (HYSE-) HYSEQ INC.
```

```
XX
PI   Tang YT,  Asundi V,  Zhou P,  Xue AJ,  Ren F,  Zhang J,  Wang J;
PI   Zhao QA,  Wang D,  Liu C,  Drmanac RT,  Wehrman T;
XX
DR   WPI; 2002-583321/62.
DR   N-PSDB; ABQ93407.
XX
PT   New polynucleotide and polypeptides, useful for treatment and diagnosis
PT   of Alzheimer's, Parkinson's, Huntington's, amylotrophic lateral
PT   sclerosis, immune deficiencies, cancer, autoimmune disorders, multiple
PT   sclerosis, diabetes and allergies.
XX
PS   Claim 20; SEQ ID NO 365; 284pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated polynucleotide (I) comprising one of
CC   245 sequences (ABQ93288-ABQ93532). Treating a condition comprising
CC   administering to a mammalian subject a composition comprising the protein
CC   (II) encoded by (I) (ABP62809-ABP63053) or an antibody (III) to (II).
CC   (I), (II) and (III) are useful for diagnostic evaluation of disorders.
CC   (I) is useful for gene therapy of diseases and (II) can be used for
CC   therapeutic treatment. Diseases that may be treated include wound healing
CC   and tissue repair, burns, central nervous system disorders (e.g.
CC   Alzheimer's, Parkinson's, Huntington's and amylotrophic lateral
CC   sclerosis), immune deficiencies, cancer, autoimmune disorders, multiple
CC   sclerosis, diabetes and allergies. Note: The sequence data for this
CC   patent did not form part of the printed specification, but was obtained
CC   in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 85 AA;

  Query Match             100.0%;  Score 19;  DB 5;  Length 85;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47


RESULT 228
ABM48865
ID   ABM48865 standard; protein; 85 AA.
XX
AC   ABM48865;
XX
DT   20-OCT-2003  (first entry)
XX
DE   Propionibacterium acnes predicted ORF-encoded polypeptide #13541.
XX
KW   Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW   immunostimulant; immune response; vaccine.
XX
OS   Propionibacterium acnes.
XX
PN   WO2003033515-A1.
XX
PD   24-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032727.
XX
PR   15-OCT-2001; 2001US-00978825.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Mitcham JL,  Skeiky YAW,  Persing DH,  Bhatia A,  Maisonneuve JL;
PI   Zhang Y,  Wang S,  Jen S,  Lodes MJ,  Benson DR,  Jones R,  Carter D;
PI   Barth B,  Vallieve-Douglass J;
XX
DR   WPI; 2003-381789/36.
DR   N-PSDB; ACF64483.
XX
PT   New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT   polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT   or for stimulating an immune response specific for a P. acnes protein.
XX
PS   Example 1; SEQ ID NO 13541; 1481pp; English.
XX
CC   The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC   encoding a Propionibacterium acnes protein. The invention also relates to
CC   polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC   immunogenic fragments of P. acnes polypeptides. The invention
CC   additionally encompasses expression vectors and host cells comprising a
CC   polynucleotide of the invention; antibodies against polypeptides of the
CC   invention; fusion proteins comprising a polypeptide of the invention; a
CC   method for stimulating an immune response specific for a P. acnes
CC   polypeptide and an isolated T cell population comprising T cells prepared
CC   via this method; a vaccine composition (comprising P. acnes polypeptides,
CC   polynucleotides, antibodies, fusion proteins, T cell populations, or
CC   antigen-presenting cells that express the polypeptide); a method and kit
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 85 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 85;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         58 AQGV 61


RESULT 229
ADQ75906
ID   ADQ75906 standard; protein; 85 AA.
XX
AC   ADQ75906;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Lysine decarboxylase fragment used to create consensus protein #15.
XX
KW   amino acid production; threonine; lysine; food; animal feed; cosmetics;
KW   enzyme; lysine decarboxylase.
XX
OS   Unidentified.
XX
PN   WO2004057003-A2.
XX
PD   08-JUL-2004.
XX
PF   19-DEC-2003; 2003WO-EP014649.
XX
PR   20-DEC-2002; 2002DE-01061188.
XX
PA   (META-) METANOMICS GMBH & CO KGAA.
XX
PI   Schmitz O,  Puzio P,  Blau A,  Looser R,  Wendel B,  Kamlage B;
PI   Plesch G;
XX
DR   WPI; 2004-517685/49.
```

XX
PT Method for preparing amino acids, useful e.g. in foods, cosmetics and
PT pharmaceuticals, by growing transgenic organisms that express a protein
PT that degrades threonine and/or lysine.
XX
PS Disclosure; Fig 2; 110pp; German.
XX
CC The present invention relates to a method for preparing amino acids in
CC transgenic organisms by introducing and expressing a nucleic acid that
CC encodes a protein able to degrade Threonine (Thr) and/or Lysine (Lys), or
CC increases degradation of Thr and/or Lys in the organism. The amino acids,
CC preferably methionine, homoserine and lysine, or the organisms that
CC produce them, are used in preparation of foods, animal feeds, cosmetic or
CC pharmaceuticals (e.g. Met has antidepressant activity), also as synthetic
CC intermediates. The present sequence is a fragment of a lysine
CC decarboxylase enzyme used to create a consensus sequence for the protein.
XX
SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 8; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 12 AQGV 15

RESULT 230
ADQ75905
ID ADQ75905 standard; protein; 85 AA.
XX
AC ADQ75905;
XX
DT 23-SEP-2004 (first entry)
XX
DE Lysine decarboxylase fragment used to create consensus protein #14.
XX
KW amino acid production; threonine; lysine; food; animal feed; cosmetics;
KW enzyme; lysine decarboxylase.
XX
OS Unidentified.
XX
PN WO2004057003-A2.
XX
PD 08-JUL-2004.
XX
PF 19-DEC-2003; 2003WO-EP014649.
XX
PR 20-DEC-2002; 2002DE-01061188.
XX
PA (META-) METANOMICS GMBH & CO KGAA.
XX
PI Schmitz O, Puzio P, Blau A, Looser R, Wendel B, Kamlage B;
PI Plesch G;
XX
DR WPI; 2004-517685/49.
XX
PT Method for preparing amino acids, useful e.g. in foods, cosmetics and
PT pharmaceuticals, by growing transgenic organisms that express a protein
PT that degrades threonine and/or lysine.
XX
PS Disclosure; Fig 2; 110pp; German.
XX
CC The present invention relates to a method for preparing amino acids in
CC transgenic organisms by introducing and expressing a nucleic acid that
CC encodes a protein able to degrade Threonine (Thr) and/or Lysine (Lys), or
CC increases degradation of Thr and/or Lys in the organism. The amino acids,
CC preferably methionine, homoserine and lysine, or the organisms that
CC produce them, are used in preparation of foods, animal feeds, cosmetic or
CC pharmaceuticals (e.g. Met has antidepressant activity), also as synthetic
CC intermediates. The present sequence is a fragment of a lysine
CC decarboxylase enzyme used to create a consensus sequence for the protein.
XX
SQ Sequence 85 AA;

Query Match 100.0%; Score 19; DB 8; Length 85;
Best Local Similarity 100.0%; Pred. No. 3.6e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 12 AQGV 15

RESULT 231
ADY12627
ID ADY12627 standard; protein; 85 AA.
XX
AC ADY12627;
XX
DT 21-APR-2005 (first entry)
XX
DE Plant full length insert polypeptide seqid 68442.
XX
KW plant protectant; plant growth regulant; gene therapy; plant;
KW recombinant DNA construct; physical array; plant breeding marker;
KW cold tolerance; heat tolerance; drought tolerance; herbicide tolerance;
KW extreme osmotic condition; pathogen tolerance; pest tolerance;
KW growth rate; cell cycle pathway; disease resistance;
KW galactomannan production; lignin production; plant growth regulator;
KW yield; plant growth; plant development; seed oil; protein yield;
KW protein content.
XX
OS Unidentified.
XX
PN US2004034888-A1.
XX
PD 19-FEB-2004.
XX
PF 28-APR-2003; 2003US-00425114.
XX
PR 06-MAY-1999; 99US-00304517.
PR 05-NOV-2001; 2001US-00985678.
XX
PA (LIUJ/) LIU J.
PA (ZHOU/) ZHOU Y.
PA (KOVA/) KOVALIC D K.
PA (SCRE/) SCREEN S E.
PA (TABA/) TABASKA J E.
PA (CAOY/) CAO Y.
XX
PI Liu J, Zhou Y, Kovalic DK, Screen SE, Tabaska JE, Cao Y;
XX
DR WPI; 2004-180133/17.
XX
PT New recombinant DNA construct, useful for improving plant tolerance to
PT cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or
PT pests, for conferring increased resistance to plant disease, or for
PT improving yield.
XX
PS Claim 1; SEQ ID NO 68442; 15pp; English.
XX
CC The invention describes a recombinant DNA construct comprising a
CC polynucleotide consisting of a sequence encoding an amino acid sequence
CC available in electronic form from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID:2004034888. The polynucleotide
CC of the invention are also useful in physical arrays of molecules and as
CC plant breeding markers. The recombinant DNA construct is useful for
CC improving plant tolerance to cold, heat, drought, herbicides, extreme
CC osmotic conditions, pathogens or pests, for manipulating growth rate in
CC plant cells by modification of the cell cycle pathway, for conferring
CC increased resistance to plant disease, for producing galactomannan,
CC lignin or plant growth regulators, for increasing the rate of homologous
CC recombination in plants, for improving yield by modification of
CC photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake

```
CC   or by providing improved plant growth and development under at least one
CC   stress condition or for modifying seed oil or protein yield and/or
CC   content. This is the amino acid sequence of a plant full length insert
CC   polypeptide that can be used in the recombinant DNA construct of the
CC   invention.
XX
SQ   Sequence 85 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 85;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          8 AQGV 11


RESULT 232
ABM94141
ID   ABM94141 standard; protein; 85 AA.
XX
AC   ABM94141;
XX
DT   02-JUN-2005  (first entry)
XX
DE   M. xanthus protein sequence, seq id 13340.
XX
KW   Transgenic plant; DNA replication; gene regulation; gene expression.
XX
OS   Myxococcus xanthus.
XX
PN   US6833447-B1.
XX
PD   21-DEC-2004.
XX
PF   10-JUL-2001; 2001US-00902540.
XX
PR   10-JUL-2000; 2000US-0217883P.
XX
PA   (MONS ) MONSANTO TECHNOLOGY LLC.
XX
PI   Goldman BS,  Hinkle GJ,  Slater SC,  Wiegand RC;
XX
DR   WPI; 2005-028716/03.
XX
PT   New substantially purified Myxococcus xanthus nucleic acid molecule
PT   encoding a nitrite reductase, useful for determining gene expression,
PT   identifying mutations in a gene of interest, and for constructing
PT   mutations in a gene of interest.
XX
PS   Example 2; SEQ ID NO 13340; 25pp; English.
XX
CC   The invention relates to a substantially purified nucleic acid molecule
CC   encoding a nitrite reductase of SEQ ID NO. 11926. Further disclosed is a
CC   recombinant DNA construct for expression of a nitrite reductase gene in a
CC   plant cell, and a plant cell comprising the recombinant DNA construct.
CC   The nucleic acid is useful for determining gene expression, identifying
CC   mutations in a gene of interest, and for constructing mutations in a gene
CC   of interest. Sequences given in records for SEQ IDs 9692-16825 represent
CC   a group of 7134 Mxyococcus xanthus proteins and peptides. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from USPTO
XX
SQ   Sequence 85 AA;

  Query Match             100.0%;  Score 19;  DB 9;  Length 85;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         55 AQGV 58


RESULT 233
AAU47746
ID   AAU47746 standard; protein; 86 AA.
XX
AC   AAU47746;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #8642.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59539.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 8941; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 86 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          9 AQGV 12
```

RESULT 234
ABB78149
ID ABB78149 standard; protein; 86 AA.
XX
AC ABB78149;
XX
DT 05-NOV-2002 (first entry)
XX
DE Amino acid sequence of a YggX homologue.
XX
KW Superoxide damage; cell; YggX; Salmonella enterica serovar typhimurium;
KW hydroxyl radical; DNA damage; YggX homologue.
XX
OS Bordetella bronchiseptica.
XX
PN US2002072118-A1.
XX
PD 13-JUN-2002.
XX
PF 18-SEP-2001; 2001US-00955502.
XX
PR 22-SEP-2000; 2000US-0234588P.
XX
PA (DOWN/) DOWNS D.
PA (GRAL/) GRALNICK J A.
XX
PI Downs D, Gralnick JA;
XX
DR WPI; 2002-589476/63.
XX
PT Reducing superoxide damage to a cell, e.g. bacterial, mammalian or plant
PT cell, comprises engineering the cell to produce more YggX protein, a
PT protein identified from Salmonella enterica Serovar Typhimurium.
XX
PS Example; Fig 1A; 16pp; English.
XX
CC The specification describes a method for reducing superoxide damage to a
CC cell. The method comprises engineering the cell to produce more than the
CC native amount of YggX protein (a protein identified from Salmonella
CC enterica serovar typhimurium) or its homolog, where the cells are
CC rendered more resistant to superoxide damage. YggX reduces the oxidation
CC of (Fe-S) clusters, and thus reduces the loss of Fe(II) ions from
CC clusters. The resulting decrease in free-iron levels generates fewer
CC hydroxyl radicals and thus reduced DNA damage. The method is useful for
CC reducing superoxide damage in a bacterial, yeast, mammalian or plant
CC cell. ABB78147-78 represent YggX homologues
XX
SQ Sequence 86 AA;

Query Match 100.0%; Score 19; DB 5; Length 86;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 82 AQGV 85

RESULT 235
ABP32375
ID ABP32375 standard; protein; 86 AA.
XX
AC ABP32375;
XX
DT 08-JUL-2002 (first entry)
XX
DE Human ORF1348 protein, SEQ ID NO:2696.
XX
KW Human; ORF; open reading frame; ORFX; drug screening; diagnosis;
KW disease monitoring; cytokine; cell proliferation; cell differentiation;
KW immune modulation; haematopoiesis regulation; tissue growth;
KW angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; tumour inhibition; bodily characteristic; fertility;
KW behaviour; cancer; proliferative disorder; neurological disorder;
KW cardiovascular disease; immune system disorder; organ transplantation;
KW tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
KW hypothyroidism; cholesterol ester storage disease; infection; vulnerary;
KW vasotropic; antipsoriatic; antidiabetic; cytostatic; nootropic;
KW neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
KW cardiant; hypotensive; antithyroid; antiinflammatory; immunomodulator;
KW dermatological; analgesic; virucide; antibacterial; fungicide.
XX
OS Homo sapiens.
XX
PN WO200190366-A2.
XX
PD 29-NOV-2001.
XX
PF 24-MAY-2001; 2001WO-US017076.
XX
PR 24-MAY-2000; 2000US-0206690P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Leach MD, Shimkets RA;
XX
DR WPI; 2002-106200/14.
DR N-PSDB; ABN76401.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and disorders related to organ
PT transplantation.
XX
PS Claim 10; Page 934; 2508pp; English.
XX
CC Sequences ABP31028-ABP35561 represent 4534 novel human proteins
CC designated ORF (open reading frame) 1-4534, and sequences ABN75054-
CC ABN79587 represent cDNAs encoding them. The invention also encompasses
CC polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
CC referred to as ORFX) proteins, polynucleotides at least 85% identical to
CC the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
CC polynucleotides, the recombinant production of ORFX proteins, antibodies
CC specific for ORFX proteins, methods of detecting ORFX polynucleotides and
CC polypeptides, methods of screening for modulators of ORFX expression or
CC activity, and methods of screening individuals for a predisposition to an
CC ORFX-associated disorder. The ORFX proteins of the invention have a wide
CC range of biological activities, such as cytokine, cell proliferation,
CC cell differentiation, immune modulation, haematopoiesis regulation,
CC tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
CC chemokinetic activity, haemostatic activity, thrombolytic activity,
CC receptor/ligand, antiinflammatory activity, tumour inhibition activity,
CC and antiinfective activity, and may also be involved in the determination
CC of bodily characteristics, fertility and behaviour. ORFX proteins,
CC nucleic acids and antibodies may be used in the treatment of cancers,
CC other proliferative disorders such as psoriasis and benign tumours,
CC neurological disorders such as epilepsy and Alzheimer's disease,
CC cardiovascular diseases, immune system disorders, disorders related to
CC organ transplantation, disorders of tissue growth and regeneration,
CC diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
CC storage disease, and infectious diseases caused by viral, bacterial,
CC fungal and other pathogens. ORFX nucleic acids may also be used as a
CC source of primers and probes, in the detection of ORFX genomic sequences
CC or transcripts, in the identification and cloning of homologous
CC sequences, in genetic diagnosis, and in forensic biology. The ORFX
CC nucleic acids may additionally be used to produce transgenic animals
CC which may be useful for studying the function and/or activity of ORFX
CC protein, and in drug screening. The ORFX proteins may also be used as
CC immunogens to generate specific antibodies, which are useful in the
CC diagnosis, treatment and monitoring of ORFX-associated diseases
XX
SQ Sequence 86 AA;

Query Match 100.0%; Score 19; DB 5; Length 86;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;

```
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         75 AQGV 78


RESULT 236
ABM44265
ID   ABM44265 standard; protein; 86 AA.
XX
AC   ABM44265;
XX
DT   20-OCT-2003  (first entry)
XX
DE   Propionibacterium acnes predicted ORF-encoded polypeptide #8941.
XX
KW   Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW   immunostimulant; immune response; vaccine.
XX
OS   Propionibacterium acnes.
XX
PN   WO2003033515-A1.
XX
PD   24-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032727.
XX
PR   15-OCT-2001; 2001US-00978825.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Mitcham JL,  Skeiky YAW,  Persing DH,  Bhatia A,  Maisonneuve JL;
PI   Zhang Y,  Wang S,  Jen S,  Lodes MJ,  Benson DR,  Jones R,  Carter D;
PI   Barth B,  Vallieve-Douglass J;
XX
DR   WPI; 2003-381789/36.
DR   N-PSDB; ACF64468.
XX
PT   New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT   polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT   or for stimulating an immune response specific for a P. acnes protein.
XX
PS   Example 1; SEQ ID NO 8941; 1481pp; English.
XX
CC   The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC   encoding a Propionibacterium acnes protein. The invention also relates to
CC   polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC   immunogenic fragments of P. acnes polypeptides. The invention
CC   additionally encompasses expression vectors and host cells comprising a
CC   polynucleotide of the invention; antibodies against polypeptides of the
CC   invention; fusion proteins comprising a polypeptide of the invention; a
CC   method for stimulating an immune response specific for a P. acnes
CC   polypeptide and an isolated T cell population comprising T cells prepared
CC   via this method; a vaccine composition (comprising P. acnes polypeptides,
CC   polynucleotides, antibodies, fusion proteins, T cell populations, or
CC   antigen-presenting cells that express the polypeptide); a method and kit
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 86 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db          9 AQGV 12


RESULT 237
ADR87224
ID   ADR87224 standard; protein; 86 AA.
XX
AC   ADR87224;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Dust mite allergen Der p 1 fragment SEQ ID NO:13.
XX
KW   dust mite; allergen; Der p 1; T-cell response; IgE; immunoglobulin E;
KW   immune response; antiallergic; gene therapy; vaccine.
XX
OS   Dermatophagoides sp.
XX
PN   WO2004081028-A2.
XX
PD   23-SEP-2004.
XX
PF   15-MAR-2004; 2004WO-IB001300.
XX
PR   14-MAR-2003; 2003US-0455004P.
PR   12-MAR-2004; 2004US-00799514.
XX
PA   (UYLA-) UNIV LAUSANNE.
XX
PI   Spertini F;
XX
DR   WPI; 2004-668931/65.
XX
PT   New compositions including contiguous overlapping peptide fragments that
PT   form an entire amino acid sequence of an allergen (e.g. bee venom or
PT   birch pollen allergen), useful for preventing or treating IgE-mediated
PT   allergies.
XX
PS   Claim 4; SEQ ID NO 13; 82pp; English.
XX
CC   The invention relates to novel compositions including contiguous
CC   overlapping peptide fragments which together form an entire amino acid
CC   sequence of an allergen, where the fragments are capable of inducing a T-
CC   cell response in patients who are hypersensitive to the allergen. The
CC   contiguous overlapping peptide fragments further result in lower levels
CC   of IgE stimulation activity. The lower levels of IgE stimulation activity
CC   are zero or weak. The contiguous overlapping peptide fragments further
CC   result in a decrease in T-cell response upon subsequent exposure to the
CC   allergen, thus, modulating an immune response in the patients, who are
CC   hypersensitive to the allergen. A composition of the invention has
CC   antiallergic activity, and may have a use in gene therapy, and as a
CC   vaccine. The composition and methods are useful for preventing or
CC   treating IgE-mediated allergies. The present sequence represents a
CC   fragment of an allergen of the invention, dust mite Der p 1.
XX
SQ   Sequence 86 AA;

  Query Match             100.0%;  Score 19;  DB 8;  Length 86;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         44 AQGV 47
```

```
RESULT 238
AAU62248
ID   AAU62248 standard; protein; 87 AA.
XX
AC   AAU62248;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Propionibacterium acnes immunogenic protein #23144.
XX
KW   SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW   uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW   inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW   dermatological; osteopathic; neuroprotectant.
XX
OS   Propionibacterium acnes.
XX
PN   WO200181581-A2.
XX
PD   01-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US012865.
XX
PR   21-APR-2000; 2000US-0199047P.
PR   02-JUN-2000; 2000US-0208841P.
PR   07-JUL-2000; 2000US-0216747P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Skeiky YAW,  Persing DH,  Mitcham JL,  Wang SS,  Bhatia A;
PI   L'maisonneuve J,  Zhang Y,  Jen S,  Carter D;
XX
DR   WPI; 2001-616774/71.
DR   N-PSDB; AAS59624.
XX
PT   Propionibacterium acnes polypeptides and nucleic acids useful for
PT   vaccinating against and diagnosing infections, especially useful for
PT   treating acne vulgaris.
XX
PS   Example 1; SEQ ID NO 23443; 1069pp; English.
XX
CC   Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC   polypeptides. The proteins and their associated DNA sequences are used in
CC   the treatment, prevention and diagnosis of medical conditions caused by
CC   P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC   pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC   P. acnes is also involved in infections of bone, joints and the central
CC   nervous system, however it is particularly involved in the inflammatory
CC   lesions associated with acne vulgaris. A method for detecting the
CC   presence or absence of P. acnes in a patient comprises contacting a
CC   sample with a binding agent that binds to the proteins of the invention
CC   and determining the amount of bound protein in the sample. The
CC   polypeptides may be used as antigens in the production of antibodies
CC   specific for P. acnes proteins. These antibodies can be used to
CC   downregulate expression and activity of P. acnes polypeptides and
CC   therefore treat P. acnes infections. The antibodies may also be used as
CC   diagnostic agents for determining P. acnes presence, for example, by
CC   enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 87 AA;

  Query Match             100.0%;  Score 19;  DB 4;  Length 87;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         42 AQGV 45
```

```
RESULT 239
ABM58767
ID   ABM58767 standard; protein; 87 AA.
XX
AC   ABM58767;
XX
DT   20-OCT-2003  (first entry)
XX
DE   Propionibacterium acnes predicted ORF-encoded polypeptide #23443.
XX
KW   Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW   immunostimulant; immune response; vaccine.
XX
OS   Propionibacterium acnes.
XX
PN   WO2003033515-A1.
XX
PD   24-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032727.
XX
PR   15-OCT-2001; 2001US-00978825.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Mitcham JL,  Skeiky YAW,  Persing DH,  Bhatia A,  Maisonneuve JL;
PI   Zhang Y,  Wang S,  Jen S,  Lodes MJ,  Benson DR,  Jones R,  Carter D;
PI   Barth B,  Vallieve-Douglass J;
XX
DR   WPI; 2003-381789/36.
DR   N-PSDB; ACF64553.
XX
PT   New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT   polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT   or for stimulating an immune response specific for a P. acnes protein.
XX
PS   Example 1; SEQ ID NO 23443; 1481pp; English.
XX
CC   The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC   encoding a Propionibacterium acnes protein. The invention also relates to
CC   polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC   immunogenic fragments of P. acnes polypeptides. The invention
CC   additionally encompasses expression vectors and host cells comprising a
CC   polynucleotide of the invention; antibodies against polypeptides of the
CC   invention; fusion proteins comprising a polypeptide of the invention; a
CC   method for stimulating an immune response specific for a P. acnes
CC   polypeptide and an isolated T cell population comprising T cells prepared
CC   via this method; a vaccine composition (comprising P. acnes polypeptides,
CC   polynucleotides, antibodies, fusion proteins, T cell populations, or
CC   antigen-presenting cells that express the polypeptide); a method and kit
CC   for detecting or determining the presence or absence of P. acnes in a
CC   patient; and a method for inhibiting the development of P. acnes in a
CC   patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC   proteins, T cell populations or antigen-presenting cells that express the
CC   polypeptides are useful for diagnosing, preventing or treating acne
CC   vulgaris, or for stimulating an immune response specific for a P. acnes
CC   protein. The polynucleotides can also be used as probes or primers for
CC   nucleic acid hybridisation. The vaccine composition is useful for the
CC   stimulation of an immune response against P. acnes, or for treating acne,
CC   and the kit is useful for performing a diagnostic assay. The present
CC   sequence represents a polypeptide predicted to be encoded by an ORF (open
CC   reading frame) contained within the P. acnes polynucleotides of the
CC   invention. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 87 AA;

  Query Match             100.0%;  Score 19;  DB 6;  Length 87;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 AQGV 4
              ||||
Db         42 AQGV 45
```

RESULT 240
AAU54801
ID AAU54801 standard; protein; 88 AA.
XX
AC AAU54801;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #15697.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US012865.
XX
PR 21-APR-2000; 2000US-0199047P.
PR 02-JUN-2000; 2000US-0208841P.
PR 07-JUL-2000; 2000US-0216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59566.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris.
XX
PS Example 1; SEQ ID NO 15996; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA). Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 88 AA;

```
  Query Match             100.0%;  Score 19;  DB 4;  Length 88;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         82 AQGV 85
```

RESULT 241
ABU60929
ID ABU60929 standard; protein; 88 AA.
XX
AC ABU60929;
XX
DT 08-MAY-2003 (first entry)
XX
DE Lung specific protein (LSP) #32.
XX
KW Human; gene therapy; vaccine; lung specific antigen; cancer diagnosis;
KW cancer monitoring; cancer staging; cancer imaging; lung cancer;
KW non-cancerous diseases of the lung; transgenic animal.
XX
OS Homo sapiens.
XX
PN WO200268633-A2.
XX
PD 06-SEP-2002.
XX
PF 21-NOV-2001; 2001WO-US043612.
XX
PR 22-NOV-2000; 2000US-0252500P.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Macina RA, Recipon H, Chen S, Sun Y, Liu C;
XX
DR WPI; 2002-713376/77.
XX
PT New isolated human nucleic acid molecule and polypeptide, useful for
PT identifying, diagnosing, monitoring, staging, imaging and treating lung
PT cancer and non-cancerous diseases of the lung.
XX
PS Claim 11; Page 328; 389pp; English.
XX
CC The invention describes an isolated human nucleic acid (I) encoding any
CC of 120 10-1533 residue amino acid sequences (S1), given in the
CC specification, comprising any of 164 179-12421 base pair sequences (S2),
CC given in the specification. The methods and compositions of the present
CC invention are useful for identifying, diagnosing, monitoring, staging,
CC imaging and treating lung cancer and non-cancerous diseases of the lung.
CC They are also used for identifying lung tissue, monitoring and
CC identifying and/or designing antagonists of the polypeptide of the
CC invention, gene therapy, production of transgenic animals and production
CC of engineered lung tissue for treatment and research. This is the amino
CC acid sequence of a lung specific nucleic acid
XX
SQ Sequence 88 AA;

```
  Query Match             100.0%;  Score 19;  DB 5;  Length 88;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         69 AQGV 72
```

RESULT 242
ABM51320
ID ABM51320 standard; protein; 88 AA.
XX
AC ABM51320;
XX
DT 20-OCT-2003 (first entry)
XX
DE Propionibacterium acnes predicted ORF-encoded polypeptide #15996.

XX
KW Acne vulgaris; antiseborrhoeic; dermatological; antibacterial;
KW immunostimulant; immune response; vaccine.
XX
OS Propionibacterium acnes.
XX
PN WO2003033515-A1.
XX
PD 24-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032727.
XX
PR 15-OCT-2001; 2001US-00978825.
XX
PA (CORI-) CORIXA CORP.
XX
PI Mitcham JL, Skeiky YAW, Persing DH, Bhatia A, Maisonneuve JL;
PI Zhang Y, Wang S, Jen S, Lodes MJ, Benson DR, Jones R, Carter D;
PI Barth B, Vallieve-Douglass J;
XX
DR WPI; 2003-381789/36.
DR N-PSDB; ACF64495.
XX
PT New Propionibacterium acnes polypeptides and polynucleotides encoding the
PT polypeptide, useful for diagnosing, preventing or treating acne vulgaris,
PT or for stimulating an immune response specific for a P. acnes protein.
XX
PS Example 1; SEQ ID NO 15996; 1481pp; English.
XX
CC The invention relates to an isolated polynucleotide (ACF64435-ACF64733)
CC encoding a Propionibacterium acnes protein. The invention also relates to
CC polypeptides encoded by the polynucleotides (ABM35624-ABM64536) and to
CC immunogenic fragments of P. acnes polypeptides. The invention
CC additionally encompasses expression vectors and host cells comprising a
CC polynucleotide of the invention; antibodies against polypeptides of the
CC invention; fusion proteins comprising a polypeptide of the invention; a
CC method for stimulating an immune response specific for a P. acnes
CC polypeptide and an isolated T cell population comprising T cells prepared
CC via this method; a vaccine composition (comprising P. acnes polypeptides,
CC polynucleotides, antibodies, fusion proteins, T cell populations, or
CC antigen-presenting cells that express the polypeptide); a method and kit
CC for detecting or determining the presence or absence of P. acnes in a
CC patient; and a method for inhibiting the development of P. acnes in a
CC patient. The P. acnes polypeptides, polynucleotides, antibodies, fusion
CC proteins, T cell populations or antigen-presenting cells that express the
CC polypeptides are useful for diagnosing, preventing or treating acne
CC vulgaris, or for stimulating an immune response specific for a P. acnes
CC protein. The polynucleotides can also be used as probes or primers for
CC nucleic acid hybridisation. The vaccine composition is useful for the
CC stimulation of an immune response against P. acnes, or for treating acne,
CC and the kit is useful for performing a diagnostic assay. The present
CC sequence represents a polypeptide predicted to be encoded by an ORF (open
CC reading frame) contained within the P. acnes polynucleotides of the
CC invention. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 88 AA;

```
  Query Match             100.0%;  Score 19;  DB 6;  Length 88;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         82 AQGV 85
```

RESULT 243
AAY74147
ID AAY74147 standard; protein; 89 AA.
XX
AC AAY74147;
XX
DT 14-MAR-2000 (first entry)
XX
DE Human prostate tumor EST fragment derived protein #334.
XX
KW Pancreas; tumor; EST; expressed sequence tag; human; cytostatic;
KW treatment.
XX
OS Homo sapiens.
XX
PN DE19820190-A1.
XX
PD 04-NOV-1999.
XX
PF 28-APR-1998; 98DE-01020190.
XX
PR 28-APR-1998; 98DE-01020190.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-621386/54.
DR N-PSDB; AAZ52968.
XX
PT New human nucleic acid sequences from pancreatic tumors, and related
PT proteins.
XX
PS Claim 23; Page 448; 502pp; German.
XX
CC This invention describes novel polypeptides and their encoding nucleic
CC acids derived from human pancreatic tumor tissue which have cytostatic
CC activity. The sequences are also useful in producing pharmaceutical
CC compositions for treatment of pancreatic tumors. AAY73814-Y74252
CC represent protein fragments encoded by the human pancreatic tumor cDNA
CC library derived expressed sequence tag (EST) sequences represented in
CC AAZ52858-Z53014
XX
SQ Sequence 89 AA;

```
  Query Match             100.0%;  Score 19;  DB 2;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+03;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AQGV 4
              ||||
Db         32 AQGV 35
```

RESULT 244
AAY59139
ID AAY59139 standard; protein; 89 AA.
XX
AC AAY59139;
XX
DT 08-MAR-2000 (first entry)
XX
DE Mouse serine/threonine kinase, PAK4 partial protein seqeunce.
XX
KW PAK4; serine/threonine kinase; GTPase; intracellular signal cascade; Rac;
KW Cdc42H; morphogenesis; mitogenesis; JNK; p38 MAP kinase; mouse;
KW actin polymerization; filopodia; cancer; arthritis.
XX
OS Mus sp.
XX
PN WO9963073-A1.
XX
PD 09-DEC-1999.
XX
PF 21-MAY-1999; 99WO-US011341.
XX
PR 21-MAY-1998; 98US-00082737.
XX

PA (UYCO) UNIV COLUMBIA NEW YORK.
XX
PI Minden A;
XX
DR WPI; 2000-072881/06.
DR N-PSDB; AAZ40658.
XX
PT Novel mammalian nucleic acid useful for treating cancer and arthritis.
XX
PS Disclosure; Page 44; 95pp; English.
XX
CC The invention relates to an isolated mammalian nucleic acid that encodes
CC PAK4, a novel serine/threonine kinase or its mutant homolog. PAK4 is an
CC effector for the GTPases Rac and Cdc42Hs which are involved in
CC intracellular signal cascades, morphogenesis and mitogenesis, and
CC activate the JNK and p38 MAP kinase pathways. Inhibiting interaction of
CC PAK4 with these enzymes will thus result in inhibition of actin
CC polymerization and formation of filopodia. The PAK4 nucleic acid used for
CC recombinant production of the protein, and as a source of probes for
CC identifying homologous sequences and of (anti)sense oligonucleotides for
CC inhibiting PAK4 expression. The protein, or its fragments, are used to
CC raise specific antibodies and these are useful as ligands for therapeutic
CC inhibition of interaction between PAK4 and its native binding partners.
CC Inhibition of PAK4 activity or expression is used for treatment of cancer
CC and arthritis. The present sequence represents the partial sequence of
CC mouse PAK4
XX
SQ Sequence 89 AA;

Query Match 100.0%; Score 19; DB 3; Length 89;
Best Local Similarity 100.0%; Pred. No. 3.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 78 AQGV 81

RESULT 245
ADP56448
ID ADP56448 standard; protein; 89 AA.
XX
AC ADP56448;
XX
DT 18-NOV-2004 (first entry)
XX
DE Human PRO protein sequence SEQ ID NO:2424.
XX
KW human; PRO; immune related disease; inflammatory immune response;
KW immune response stimulation; antiallergic; antianaemic; antiarthritic;
KW antiasthmatic; antidiabetic; antiinflammatory; antipsoriatic;
KW antirheumatic; antithyroid; CNS; dermatological; gastrointestinal;
KW haemostatic; hepatotropic; immunostimulant; immunosuppressive; muscular;
KW nephrotropic; neuroprotective; osteopathic; respiratory; vasotropic;
KW virucide; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2004039956-A2.
XX
PD 13-MAY-2004.
XX
PF 28-OCT-2003; 2003WO-US034381.
XX
PR 29-OCT-2002; 2002US-0422472P.
XX
PA (GETH) GENENTECH INC.
XX
PI Aggarwal S, Clark H, Gurney AL, Schoenfeld J, Williams PM;
PI Wood WI, Wu TD;
XX
DR WPI; 2004-376182/35.
DR N-PSDB; ADP56447.
XX
PT New PRO polynucleotides and polypeptides, useful in useful in diagnosing
PT and treating an immune related disease, e.g. systemic lupus
PT erythematosus, rheumatoid arthritis, diabetes mellitus or asthma and in
PT stimulating an immune response.
XX
PS Claim 1; SEQ ID NO 2424; 3009pp; English.
XX
CC The present invention describes an isolated PRO nucleic acid (I). Also
CC described: (1) a vector comprising (I); (2) a host cell comprising the
CC vector of (1); (3) a process for producing a PRO polypeptides; (4) an
CC isolated PRO polypeptide; (5) a chimeric molecule comprising the
CC polypeptide of (4) fused to a heterologous amino acid sequence; (6) an
CC antibody which specifically binds to a polypeptide of (4); (7) a
CC composition of matter comprising a polypeptide of (4), an agonist or
CC antagonist of the polypeptide or an antibody that binds to the
CC polypeptide in combination with a carrier; (8) an article of manufacture
CC comprising a container, a label on the container and a composition of
CC matter of (7); (9) a method of treating an immune related disease in a
CC mammal; (10) a method for determining the presence of a PRO polypeptide
CC in a sample suspected of having the polypeptide; (11) a method of
CC diagnosing an immune related disease or an inflammatory immune response
CC in mammal; (12) a method of identifying a compound that inhibits or
CC mimics the activity of or expression of a gene encoding a PRO polypeptide
CC ; and (13) a method of stimulating the immune response in a mammal. The
CC PRO sequences have antiallergic, antianaemic, antiarthritic,
CC antiasthmatic, antidiabetic, antiinflammatory, antipsoriatic,
CC antirheumatic, antithyroid, CNS, dermatological, gastrointestinal,
CC haemostatic, hepatotropic, immunostimulant, immunosuppressive, muscular,
CC nephrotropic, neuroprotective, osteopathic, respiratory, vasotropic and
CC virucide activities, and can be used in gene therapy. The nucleic acid
CC (I) and the encoded polypeptides, compositions, kits and methods are
CC useful in diagnosing and treating an immune related disease and in
CC stimulating an immune response. The present sequence represents a human
CC PRO protein from the present invention.
XX
SQ Sequence 89 AA;

Query Match 100.0%; Score 19; DB 8; Length 89;
Best Local Similarity 100.0%; Pred. No. 3.8e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 62 AQGV 65

RESULT 246
AAU14672
ID AAU14672 standard; protein; 91 AA.
XX
AC AAU14672;
XX
DT 24-OCT-2001 (first entry)
XX
DE Novel bone marrow polypeptide #71.
XX
KW Bone marrow; diagnostic; therapeutic; gene therapy; antigenic;
KW haematopoiesis; myeloid; lymph cell disorder; tissue regeneration;
KW wound healing; nutritional supplement; immune disorder;
KW severe combined immunodeficiency; SCID.
XX
OS Homo sapiens.
XX
PN WO200157187-A2.
XX
PD 09-AUG-2001.
XX
PF 05-FEB-2001; 2001WO-US003782.
XX
PR 03-FEB-2000; 2000US-00496914.
PR 20-JUN-2000; 2000US-00598075.
PR 19-JUL-2000; 2000US-00620325.

PR 30-NOV-2000; 2000US-0250683P.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Ford JE, Boyle BJ, Tang YT, Liu C, Asundi V, Zhou P, Xue AJ;
PI Ren F, Drmanac RT;
XX
DR WPI; 2001-488875/53.
DR N-PSDB; AAS22977.
XX
PT Nucleic acids encoding bone marrow polypeptides, useful in diagnostic and
PT gene therapy.
XX
PS Claim 10; Page 245; 392pp; English.
XX
CC AAU14602-AAU14794 represent novel bone marrow polypeptides of the
CC invention. The proteins and corresponding coding sequences may be used in
CC the prevention, diagnosis and treatment of diseases associated with
CC inappropriate bone marrow polypeptide expression. For example, to treat
CC disorders associated with decreased expression by rectifying mutations or
CC deletions in a patient's genome that affect the activity of the
CC polypeptides by expressing inactive proteins or to supplement the
CC patient's own production of the polypeptide. Additionally, the nucleic
CC acids may be used to produce the polypeptides, by inserting the nucleic
CC acids into a host cell and culturing the cell to express the protein. The
CC nucleic acid and its complementary sequences may also be used as DNA
CC probes in diagnostic assays to detect and quantitate the presence of
CC similar nucleic acid sequences in samples, and therefore which patients
CC may be in need of restorative therapy. The proteins may also be used as
CC antigens in the production of antibodies against bone marrow proteins and
CC in assays to identify modulators of their expression and activity. The
CC anti-bone marrow protein antibodies and antagonists may also be used to
CC down regulate expression and activity. The antibodies may also be used as
CC diagnostic agents for detecting the presence of the protein in samples
CC (e.g. by enzyme linked immunosorbant assay (ELISA)). The proteins may be
CC used to regulate haematopoiesis activity, and consequently in the
CC treatment of myeloid or lymph cell disorders; in tissue regeneration,
CC such as wound healing; as a nutritional supplement; and in treatment of
CC immune disorders such as severe combined immunodeficiency (SCID)
XX
SQ Sequence 91 AA;

Query Match 100.0%; Score 19; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 9 AQGV 12

RESULT 247
ABG04651
ID ABG04651 standard; protein; 91 AA.
XX
AC ABG04651;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #4642.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US008631.
XX
PR 31-MAR-2000; 2000US-00540217.
PR 23-AUG-2000; 2000US-00649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS68838.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.
XX
PS Claim 20; SEQ ID NO 35010; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC sequences. (I) is useful as hybridisation probes, polymerase chain
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC and in recombinant production of (II). The polynucleotides are also used
CC in diagnostics as expressed sequence tags for identifying expressed
CC genes. (I) is useful in gene therapy techniques to restore normal
CC activity of (II) or to treat disease states involving (II). (II) is
CC useful for generating antibodies against it, detecting or quantitating a
CC polypeptide in tissue, as molecular weight markers and as a food
CC supplement. (II) and its binding partners are useful in medical imaging
CC of sites expressing (II). (I) and (II) are useful for treating disorders
CC involving aberrant protein expression or biological activity. The
CC polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC amino acid sequences of the invention. Note: The sequence data for this
CC patent did not appear in the printed specification, but was obtained in
CC electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 91 AA;

Query Match 100.0%; Score 19; DB 4; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 24 AQGV 27

RESULT 248
ABP09720
ID ABP09720 standard; protein; 91 AA.
XX
AC ABP09720;
XX
DT 24-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:19422.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.

XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN25472.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 19422; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 91 AA;

Query Match 100.0%; Score 19; DB 5; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 10 AQGV 13

RESULT 249
ABP11499
ID ABP11499 standard; protein; 91 AA.
XX
AC ABP11499;
XX
DT 24-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:22980.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US010836.
XX
PR 30-MAY-2000; 2000US-0206132P.
PR 29-AUG-2000; 2000US-0228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN27251.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders.
XX
PS Disclosure; SEQ ID NO 22980; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage. N.B. The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 91 AA;

Query Match 100.0%; Score 19; DB 5; Length 91;
Best Local Similarity 100.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AQGV 4
||||
Db 16 AQGV 19

RESULT 250
ABP79711
ID ABP79711 standard; protein; 92 AA.
XX
AC ABP79711;
XX
DT 07-MAR-2003 (first entry)
XX
DE N. gonorrhoeae amino acid sequence SEQ ID 5952.
XX
KW Antibacterial; infection; vaccine; gene therapy.
XX

OS Neisseria gonorrhoeae.
XX
PN WO200279243-A2.
XX
PD 10-OCT-2002.
XX
PF 12-FEB-2002; 2002WO-IB002069.
XX
PR 12-FEB-2001; 2001GB-00003424.
XX
PA (CHIR-) CHIRON SPA.
XX
PI Fontana MR, Pizza M, Masignani V, Monaci E;
XX
DR WPI; 2003-058415/05.
DR N-PSDB; ABZ40681.
XX
PT New protein from Neisseria gonorrheae, useful for the manufacture of a
PT medicament for treating or preventing N. gonorrheae infection.
XX
PS Disclosure; Page 622; 815pp; English.
XX
CC The present invention relates to proteins from Neisseria gonorrhoeae.
CC Also disclosed are the nucleic acid molecules encoding the proteins and
CC antibodies that specifically bind to the proteins. The composition
CC comprising the protein, nucleic acid or antibody is useful for the
CC manufacture of a medicament for treating or preventing N. gonorrhoeae
CC infection, this may be in the form of a vaccine or gene therapy.
CC Sequences given in records ABP76736-ABP81046 represent nucleic acid
CC molecules of the invention
XX
SQ Sequence 92 AA;

Query Match 100.0%; Score 19; DB 6; Length 92;
Best Local Similarity 100.0%; Pred. No. 3.9e+03;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AQGV 4
              ||||
Db         49 AQGV 52
```

Search completed: February 21, 2006, 09:02:39
Job time : 156 secs